299. 嚢胞性線維症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
/m2 dose
University of Washington
2010 Phase 1 NCT01093521 United States;
033841
Erasmus University Medical Centre
2012 - EUCTR2012-002503-17-NL Netherlands;
1,5 (Butylimino)-1,5-dideoxy-D-glucitol
Actelion Pharmaceuticals Ltd
2007 - EUCTR2006-002049-35-ES Spain;
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid
Bayer HealthCare AG
2007 - EUCTR2007-002912-24-DE Germany;
100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
100-mg ELX / 50-mg TEZ / 75 -mg IVA FDC
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC
VERTEX PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2019-000833-37-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-000833-37-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001735-31-GB Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000833-37-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2019-001735-31-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2019-000833-37-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
100-mg VX-445 /50-mg TEZ/75-mg
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2018-004652-38-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
100-mg VX-445/50-mg TEZ/75-mg IVA FDC
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
100g ELX / 50mg TEZ / 75mg IVA
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
129Xe Small and Large Human Lung Coil
Thunder Bay Regional Research Institute
2019 Early Phase 1 NCT02748798 Canada;
13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)
University of Miami
2022 - NCT05223881 United States;
150-mg IVACAFTOR
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2,3-dihydroxybutanedioic acid
University of LIverpool
2019 Phase 1;Phase 2 EUCTR2017-001259-29-GB United Kingdom;
2-aminoethanethiol
University of LIverpool
2019 Phase 1;Phase 2 EUCTR2017-001259-29-GB United Kingdom;
2622U90 Duramycin
AOP Orphan Pharmaceuticals AG
2008 - EUCTR2006-006693-24-CZ Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
2007 Phase 2;Phase 3 EUCTR2006-006693-24-DE Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
- Phase 2 EUCTR2006-006693-24-PL Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
291844
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
3He Human Lung Coil
Thunder Bay Regional Research Institute
2019 Early Phase 1 NCT02748798 Canada;
4D-710
4D Molecular Therapeutics
2022 Phase 1/Phase 2 NCT05248230 United States;
5-methyltetrahydrofolate and vitamin B12
Universita di Verona
2004 - NCT00730509 Italy;
5000 IU of cholecalciferol
St. Michael's Hospital, Toronto
2008 - NCT00685971 Canada;
552-02
Parion Sciences
2006 Phase 1/Phase 2 NCT00274313 United States;
75-mg IVACAFTOR
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)
University Hospital, Strasbourg, France
2020 Phase 4 NCT04381429 France;
AAC Hexal
Aarhus University Hospital
2016 Phase 2 EUCTR2016-000354-35-DK Denmark;
ABBV-119
AbbVie
2021 Phase 2 NCT04853368 Australia;Belgium;Czechia;Germany;Hungary;Netherlands;New Zealand;Slovakia;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-005805-25-NL Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
2021 Phase 2 EUCTR2020-005805-25-HU Hungary;
2021 Phase 2 EUCTR2020-005805-25-BE Belgium;Hungary;Netherlands;
ABBV-2222
AbbVie
2019 Phase 2 NCT03969888 Belgium;Canada;Czechia;France;Hungary;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
AbbVie Deutschland
2019 Phase 2 EUCTR2019-000750-63-NL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-HU Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-GB Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-FR Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-BE Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-005805-25-NL Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
2021 Phase 2 EUCTR2020-005805-25-HU Hungary;
2021 Phase 2 EUCTR2020-005805-25-BE Belgium;Hungary;Netherlands;
2020 Phase 2 EUCTR2019-000750-63-PL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
ABBV-3067
AbbVie
2019 Phase 2 NCT03969888 Belgium;Canada;Czechia;France;Hungary;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
AbbVie Deutschland
2019 Phase 2 EUCTR2019-000750-63-NL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-HU Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-GB Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-FR Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-BE Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-005805-25-NL Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
2021 Phase 2 EUCTR2020-005805-25-HU Hungary;
2021 Phase 2 EUCTR2020-005805-25-BE Belgium;Hungary;Netherlands;
2020 Phase 2 EUCTR2019-000750-63-PL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
ACC
Aarhus University Hospital
2014 Phase 2 EUCTR2013-005481-19-DK Denmark;
ACC600Tabs
Rigshospitalet
2010 Phase 4 EUCTR2007-001401-15-DK Denmark;
ACETYLCYSTEINE SODIUM
Aarhus University Hospital
2016 Phase 2 EUCTR2016-000354-35-DK Denmark;
ACIDE TRANEXAMIQUE MYLAN 0,5 g/ 5 mL, solution injectable
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2021 Phase 3 EUCTR2020-005931-58-FR France;
AER002
Aerovance Inc
2005 Phase 1;Phase 2 EUCTR2005-000313-35-GB United Kingdom;
AIR DNase
Protalix
2015 Phase 1 NCT02605590 Israel;
AIR DNase™
Protalix
2016 Phase 2 NCT02722122 Israel;
ALTU-135
ALTUS PHARMACEUTICALS INC
2007 - EUCTR2007-000178-21-IT Italy;
2007 - EUCTR2007-000171-41-IT Italy;
Altus Pharmaceuticals Inc
2007 Phase 3 EUCTR2007-000171-41-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000171-41-PL Italy;Poland;Slovakia;
Altus Pharmaceuticals Inc.
2007 Phase 3 EUCTR2007-000178-21-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000178-21-PL Italy;Poland;Slovakia;
ALTUS-135
ALTUS PHARMACEUTICALS INC
2007 - EUCTR2007-000171-41-IT Italy;
ALX-009
Alaxia SAS
2015 Phase 1 NCT02598999 France;
AMIKACIN SULFATE
INSMED INCORPORATED
2012 - EUCTR2011-000443-24-IT Australia;Austria;Belgium;Bulgaria;Canada;Denmark;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Spain;Sweden;United Kingdom;
2011 - EUCTR2011-000441-20-IT Austria;Bulgaria;Canada;Denmark;Greece;Hungary;Ireland;Italy;Netherlands;Spain;United Kingdom;
Insmed Incorporated
2013 - EUCTR2011-000443-24-NL Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000443-24-PL Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000443-24-BE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000441-20-BE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000443-24-SE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-000443-24-DK Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-000441-20-NL Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2012 - EUCTR2011-000441-20-IE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-DK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-BG Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-000443-24-SK Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-000443-24-GB Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-000443-24-FR Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2011 - EUCTR2011-000443-24-IE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000443-24-HU Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000443-24-GR Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2011 - EUCTR2011-000443-24-DE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;
2011 - EUCTR2011-000443-24-BG Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
2011 - EUCTR2011-000443-24-AT Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000441-20-SK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-HU Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-GR Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2011 - EUCTR2011-000441-20-GB Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-DE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-AT Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
Transave, Inc.
- Phase 2 EUCTR2006-006980-22-PL Belgium;Hungary;Poland;Slovakia;
AMILASA
ANTHERA Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2016-002851-92-ES Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
AMYLASE
ANTHERA Pharmaceuticals, Inc.
2017 Phase 3 EUCTR2017-000571-85-LT Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-HU Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-GB Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000571-85-ES Hungary;Israel;Lithuania;Poland;Spain;United States;
2016 Phase 4 EUCTR2016-002851-92-CZ Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
2016 Phase 3 EUCTR2016-002851-92-HU Canada;Hungary;Israel;Spain;United States;
- Phase 3 EUCTR2017-000571-85-PL Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-002851-92-PL Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
AP-PA02
Armata Pharmaceuticals, Inc.
2020 Phase 1/Phase 2 NCT04596319 United States;
ARD-3150
Aradigm Corporation
2015 Phase 3 EUCTR2013-005366-19-PL Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005366-19-FR Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005348-28-PL Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-RO Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-IT Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-HU Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-GB Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-ES Australia;Canada;France;Germany;Hungary;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-RO Australia;Canada;Georgia;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-LV Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-IT Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-IE Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-HU Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-GB Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-ES Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
ARIKACE™
Insmed Incorporated
2007 Phase 1/Phase 2 NCT00777296 Belgium;Bulgaria;Hungary;Macedonia, The Former Yugoslav Republic of;North Macedonia;Poland;Serbia;Slovakia;Ukraine;
ARO-ENaC
Arrowhead Pharmaceuticals
2020 Phase 1/Phase 2 NCT04375514 Australia;New Zealand;
AZD1236
AstraZeneca
2009 Phase 2 NCT00812045 Canada;Netherlands;Poland;Spain;
AstraZeneca AB
2008 - EUCTR2008-004699-34-NL Netherlands;Spain;
2008 - EUCTR2008-004699-34-ES Netherlands;Spain;
AZD5634
AstraZeneca
2017 Phase 1 NCT02950805 United States;
AZD5634 for infusion
AstraZeneca
2016 Phase 1 NCT02679729 United States;
AZD5634 for inhalation
AstraZeneca
2016 Phase 1 NCT02679729 United States;
AZD7986
Insmed Incorporated
2021 Phase 3 EUCTR2020-003688-25-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-LT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-IE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2017-002533-32-BE Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-SE Australia;Belgium;Bulgaria;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-PL Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-NL Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-GB Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-ES Australia;Belgium;Bulgaria;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-DK Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-DE Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-BG Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
AZD9668
AstraZeneca
2008 Phase 2 NCT00757848 Denmark;Germany;Poland;Russian Federation;Sweden;United Kingdom;
AstraZeneca AB
2009 - EUCTR2008-001530-27-GB Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-001530-27-DK Denmark;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-001530-27-SE Denmark;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-001530-27-DE Denmark;Germany;Sweden;United Kingdom;
AZITHROMYCIN DIHYDRATE
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
- Phase 3 EUCTR2014-003023-22-FR France;
AZLI
Gilead Sciences, Inc.
2012 Phase 3 EUCTR2011-001362-18-ES France;Germany;Italy;Poland;Spain;United States;
Gilead Sciences
2017 Phase 3 NCT03219164 Austria;Belgium;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2012 Phase 3 NCT01641822 United States;
2011 Phase 3 NCT01404234 France;Germany;Italy;Poland;Spain;United States;
2011 Phase 3 NCT01314716 Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2011 Phase 3 NCT01313624 Australia;Canada;United States;
2010 Phase 3 NCT01059565 Canada;United States;
Gilead Sciences Inc
2010 - EUCTR2007-004277-26-AT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-004277-26-GB Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-FR Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-ES Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-BE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-PT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-NL Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DK Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Gilead Sciences, Inc.
2018 Phase 3 EUCTR2016-002749-42-NL Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2016-002749-42-GR Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-IT Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-GB Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-FR Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-ES Austria;Belgium;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-DK Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-DE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-BE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-AT Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2012 Phase 2 EUCTR2011-001255-36-BE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001362-18-DE France;Germany;Italy;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-NL Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-IE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-DE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-AT Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2011 Phase 2 EUCTR2011-001255-36-ES Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- Phase 3 EUCTR2016-002749-42-IE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2011-001362-18-FR France;Germany;Italy;Poland;Spain;United States;
- Phase 2 EUCTR2011-001255-36-FR Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- - EUCTR2011-001362-18-Outside-EU/EEA United States;
- - EUCTR2011-001255-36-Outside-EU/EEA United States;
AZLI 75 mg three times a day (TID)
Gilead Sciences
2005 Phase 3 NCT00112359 Australia;Canada;New Zealand;United States;
AZLI 75 mg three times daily (TID)
Gilead Sciences
2008 Phase 3 NCT00712166 Australia;Canada;United States;
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Gilead Sciences
2005 Phase 3 NCT00128492 Australia;Canada;New Zealand;United States;
AZLI 75 mg two times a day (BID)/three times a day (TID)
Gilead Sciences
2005 Phase 3 NCT00104520 United States;
AZTREONAM LYSINE
Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
2014 Phase 4 EUCTR2013-004295-35-AT Austria;
Acebilustat
Celtaxsys Inc.
2016 Phase 2 EUCTR2015-002677-38-IT Belgium;France;Germany;Italy;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-GB Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-DE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-BE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
Acetylcysteine
University Hospital, Ghent
2010 Phase 4 NCT00996424 Belgium;
West China Hospital, Sichuan University
2020 Phase 4 ChiCTR2000031817 China;
Active Treatment Group Hypertonic Saline
University of Washington, the Collaborative Health Studies Coordinating Center
2015 Phase 2/Phase 3 NCT02950883 Australia;Belgium;Canada;Denmark;France;Italy;Netherlands;Spain;United States;
Actrapid 100 IU/ml, Solution for injection in a vial
St George's, University of London
2008 - EUCTR2007-004956-35-GB United Kingdom;
Actrapid Penfill 100UI/ml
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2006 - EUCTR2006-001254-27-FR France;
Acute Antioxidant
Augusta University
2015 - NCT02690064 United States;
Ad26.COV2-S.02
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
Adempas
Bayer AG
2015 Phase 2 EUCTR2013-004595-35-BE Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2014 Phase 2 EUCTR2013-004595-35-GB Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2014 Phase 2 EUCTR2013-004595-35-DE Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
Bayer HealthCare AG
2015 Phase 2 EUCTR2013-004595-35-NL Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States;
Adeno-associated virus-CFTR vector
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1999 Phase 1 NCT00004533 -
Adrenalina
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
Advagraf prolonged-release hard capsules
Hopital Erasme - Chest service
2009 - EUCTR2009-014050-15-BE Belgium;
AeroVanc
Savara Inc.
2011 Phase 1 NCT01537666 Australia;
Aeroquin
Mpex Pharmaceuticals, Inc.
2011 Phase 3 EUCTR2010-019634-26-GB Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-IE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-DE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
- Phase 3 EUCTR2010-019634-26-FR France;Germany;Ireland;United Kingdom;
Aerosolized, human, plasma-derived Alpha-1 Antitrypsin
Kamada, Ltd.
2007 Phase 2 NCT00499837 Israel;
Aerosoltherapy
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2018 - NCT03655249 Belgium;
Air
Assistance Publique - Hôpitaux de Paris
2012 - NCT01586728 France;
Airway clearance technique
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2012 - NCT02201082 Belgium;
Albuterol
National Center for Research Resources (NCRR)
2000 - NCT00005110 United States;
University of Arizona
2009 - NCT01880723 United States;
Albuterol inhaler.
University of Florida
2007 - NCT01851642 United States;
Alendronate
Istituto Auxologico Italiano
2002 Phase 3 NCT01812551 Holy See (Vatican City State);Italy;
McMaster University
2003 Phase 4 NCT00157690 Canada;
Alendronate sodium
University of North Carolina
1998 - NCT00004489 United States;
Alginate oligosaccharide
AlgiPharma AS
2015 Phase 2 NCT02453789 Germany;
2014 Phase 2 NCT02157922 Denmark;Germany;Norway;Sweden;United Kingdom;
Allo-hMSCs
Joshua M Hare
2020 Phase 1 NCT03058068 United States;
Alpha-1 HC
Grifols Therapeutics Inc.
2012 Phase 2 NCT01684410 United States;
Alpha1-Proteinase Inhibitor (Human)
Grifols Therapeutics Inc.
2003 Phase 2 NCT00486837 -
Amikacin
Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine
2015 - ChiCTR-IPC-15005915 -
Qilu Hospital of Shandong University
2014 Phase 4 NCT02081963 China;
The Leeds Teaching Hospitals NHS Trust
2015 - NCT02489955 United Kingdom;
Amikacin Sulfate
Insmed Incorporated
2011 - EUCTR2011-000442-38-ES Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-000442-38-BG Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
- Phase 3 EUCTR2011-000442-38-PL Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
Amikacin nebulization
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2012 - NCT02201082 Belgium;
Amikacin sulfate
Transave, Inc.
2007 - EUCTR2006-006980-22-BE Belgium;Hungary;
Amikacina liposomal (Arikace?)
Insmed Incorporated
2011 Phase 3 EUCTR2011-000441-20-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
Amikacine nebulization
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2015 - NCT02535130 Belgium;
Amikin, amiklin, amicacin, BB-K8, Biklin, Fabianol, Kaminax, Mikavir, Novamin, Pierami
Transave, Inc
2005 - EUCTR2005-004389-17-HU Hungary;
Amikin®, amiklin, amicacin, BB-K8, Biklin®, Fabianol®, Kaminax, Mikavir, Novamin®, Pierami
Transave, Inc.
2005 - EUCTR2005-004899-21-BE Belgium;
Amiloride
FDA Office of Orphan Products Development
1996 - NCT00004705 -
Amiloride HCl
University of North Carolina
2001 Phase 2 NCT00274391 United States;
Amiloride Solution for Inhalation
Children's Hospital Boston
2006 Phase 1 NCT00547053 United States;
Amitriptylin-CT
PSKS
- Phase 2 EUCTR2008-002673-13-DE Germany;
Amitriptylin-ct Tabletten
Paediatrisches Sekretariat fuer Klinische Studien
2006 Phase 2 EUCTR2006-002259-33-DE Germany;
Amitriptyline
PSKS
- Phase 2 EUCTR2008-002673-13-DE Germany;
University Children’s Hospital Tuebingen
2009 Phase 2 NCT01309178 Germany;
University Hospital Tuebingen
2006 Phase 2 NCT00515229 Germany;
Amoxicillin and Clavulanic acid
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Amphotericin B
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
2010 - EUCTR2010-019194-15-IT Italy;
Amylase
Altus Pharmaceuticals Inc
2007 Phase 3 EUCTR2007-000171-41-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000171-41-PL Italy;Poland;Slovakia;
Altus Pharmaceuticals Inc.
2007 Phase 3 EUCTR2007-000178-21-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000178-21-PL Italy;Poland;Slovakia;
Anakinra
Heidelberg University
2021 Phase 2 NCT03925194 Germany;
Andecaliximab
Gilead Sciences
2016 Phase 2 NCT02759562 Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
Anti-pseudomonas IgY gargle
Immunsystem AB
2003 Phase 1/Phase 2 NCT00633191 Sweden;
Anti-reflux pharmacotherapy
Bayside Health
2001 - NCT00164021 Australia;
Antibiotic
Aradigm Corporation
2010 - NCT01090908 -
Antioxidant Cocktail
Augusta University
2011 Phase 2 NCT01772758 United States;
Antistaminici H1 - H2
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
AquADEK
University of Colorado, Denver
2007 Phase 1/Phase 2 NCT01018303 United States;
AquADEKs-2
University of Colorado, Denver
2013 Phase 2 NCT01859390 United States;
Arginine
Children's Hospital of Philadelphia
2013 - NCT01852448 United States;
Aridol or Osmohale
Pharmaxis Pharmaceuticals Limited
- Phase 3 EUCTR2007-001412-23-DE Germany;Ireland;United Kingdom;
Arikayce™
Insmed Incorporated
2009 Phase 2 NCT03905642 Belgium;Hungary;Macedonia, The Former Yugoslav Republic of;North Macedonia;Poland;Serbia;Slovakia;Ukraine;
2008 Phase 1/Phase 2 NCT00558844 United States;
Ataluren
PTC THERAPEUTICS, INC.
2010 - EUCTR2010-019692-30-IT Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC Therapeutics
2015 Phase 3 NCT02456103 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 NCT02107859 Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2010 Phase 3 NCT01140451 Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 Phase 3 NCT00803205 Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2007 Phase 2 NCT00458341 Belgium;France;Israel;
2005 Phase 2 NCT00237380 Israel;
PTC Therapeutics, Inc
2011 Phase 3 EUCTR2010-019692-30-GB Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019692-30-ES Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-019692-30-DE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2010 - EUCTR2010-019692-30-SE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 - EUCTR2010-019692-30-NL Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 - EUCTR2010-019692-30-BE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-BE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC Therapeutics, Inc.
2016 Phase 3 EUCTR2014-005355-83-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-GR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-FR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005449-35-FR Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2015 Phase 3 EUCTR2013-004581-34-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-GR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005449-35-SE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-IT Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-ES Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-DE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-BE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-004581-34-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
University of Alabama at Birmingham
2017 Phase 4 NCT03256968 United States;
Ataluren (PTC124®)
PTC Therapeutics
2014 Phase 3 NCT02139306 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Atorvastatin
NHS Lothian
2010 Phase 4 EUCTR2010-022042-24-GB United Kingdom;
2010 Phase 4 EUCTR2010-022040-20-GB United Kingdom;
University of Edinburgh
2010 Phase 4 NCT01299181 United Kingdom;
Atropina
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
Augmentin
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Aurexis® (tefibazumab)
Bristol-Myers Squibb
2005 Phase 2 NCT00198289 United States;
Avian polyclonal IgY antibody against PA
MUKOVISZIDOSE E.V.
2012 Phase 3 EUCTR2011-000801-39-IT Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
Mukoviszidose Institute gGmbH
2014 Phase 3 EUCTR2011-000801-39-HU Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2014 Phase 3 EUCTR2011-000801-39-ES Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2014 Phase 3 EUCTR2011-000801-39-AT Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2013 Phase 3 EUCTR2011-000801-39-IE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2012 Phase 3 EUCTR2011-000801-39-SE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2012 Phase 3 EUCTR2011-000801-39-BE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2011 Phase 3 EUCTR2011-000801-39-DE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
Azithromycin
Assistance Publique Hopitaux De Marseille
2015 Phase 3 NCT02531984 -
Bonnie Ramsey
2014 Phase 3 NCT02054156 United States;
Hospices Civils de Lyon
2014 - NCT02803944 France;
Instituto de Investigacion Sanitaria La Fe
2006 - NCT01463371 Spain;
Seattle Children's Hospital
2016 Phase 4 NCT02677701 United States;
St. Michael's Hospital, Toronto
2006 Phase 2 NCT00298922 Canada;
The University of Queensland
2012 Phase 3 NCT01270074 Australia;New Zealand;
University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)
2012 Phase 4 NCT03045198 -
University of Colorado, Denver
2014 - NCT02372383 United States;
Azithromycin 250 mg tablets
CF Therapeutics Development Network Coordinating Center
2007 Phase 4 NCT00431964 Canada;United States;
Azithromycin 500 mg film-coated tablet
university medical center utrecht
2018 Phase 4 EUCTR2016-001440-18-NL Netherlands;
Aztreonam
Gilead Sciences Inc
2008 - EUCTR2007-004277-26-IT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Liverpool Heart & Chest Hospital
2016 Phase 4 EUCTR2016-002832-34-GB United Kingdom;
Liverpool Heart and Chest Hospital NHS Foundation Trust
2017 Phase 4 NCT02894684 United Kingdom;
Aztreonam Lysine for Inhalation
Gilead Sciences
2003 - NCT00499720 Puerto Rico;United States;
Aztreonam for Inhalation (AI)
Gilead Sciences
2003 Phase 2 NCT01055847 United States;
Aztreonam for Inhalation Solution
Gilead Sciences, Inc.
2012 Phase 2 EUCTR2011-001255-36-BE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001362-18-DE France;Germany;Italy;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-NL Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-IE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-DE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-AT Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2011 Phase 2 EUCTR2011-001255-36-ES Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- Phase 3 EUCTR2011-001362-18-FR France;Germany;Italy;Poland;Spain;United States;
- Phase 2 EUCTR2011-001255-36-FR Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- - EUCTR2011-001362-18-Outside-EU/EEA United States;
- - EUCTR2011-001255-36-Outside-EU/EEA United States;
Aztreonam for Inhalation Solution (AZLI)
Gilead Sciences
2011 Phase 2 NCT01375049 Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2008 Phase 3 NCT00757237 Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Aztreonam lysine
Gilead Sciences
2009 - NCT00989807 Canada;
Gilead Sciences Inc
2010 - EUCTR2007-004277-26-AT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-004277-26-GB Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-FR Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-ES Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-BE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-PT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-NL Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DK Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Aztreonam lysine for inhalation
Novartis Pharmaceuticals
2010 - NCT01460836 -
Aztreonam solución para inhalación
Gilead Sciences, Inc.
2012 Phase 3 EUCTR2011-001362-18-ES France;Germany;Italy;Poland;Spain;United States;
Aztreonan lysine
Gilead Sciences Inc
2008 - EUCTR2007-004277-26-IT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
BAY 85-8501
Bayer HealthCare AG
2013 Phase 2 EUCTR2012-004491-18-IT Italy;United Kingdom;
2013 Phase 2 EUCTR2012-004491-18-GB Italy;Spain;United Kingdom;
2013 - EUCTR2012-004491-18-ES Spain;United Kingdom;
BAY q 3939
Bayer HealthCare AG
2007 - EUCTR2007-002912-24-DE Germany;
BAY63-2521
Bayer AG
2015 Phase 2 EUCTR2013-004595-35-BE Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2014 Phase 2 EUCTR2013-004595-35-GB Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2014 Phase 2 EUCTR2013-004595-35-DE Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
Bayer HealthCare AG
2015 Phase 2 EUCTR2013-004595-35-NL Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States;
BAY85-8501
Bayer
2013 Phase 2 NCT01818544 France;Germany;Italy;Spain;United Kingdom;
BAYQ3939
Bayer AG
2014 Phase 3 EUCTR2013-004659-19-BG Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Bayer AG
2014 Phase 3 EUCTR2013-004659-19-NL Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-LT Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-DE Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-CZ Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-AT Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Bayer Healthcare AG, D-51368 Leverkusen, Germany
2014 Phase 3 EUCTR2013-004659-19-SK Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-PT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-LV Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
BAYq3939
BAYER HEALTHCARE AG
2013 Phase 3 EUCTR2011-004208-39-IT Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
Bayer HealthCare AG
2014 Phase 3 EUCTR2011-004208-39-SK Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2014 - EUCTR2011-004208-39-LV Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-GB Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-FR Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-ES Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-DE Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 - EUCTR2011-004208-39-DK Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2009 Phase 2 EUCTR2009-009869-34-ES Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-SE Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-GB Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-DE Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008314-40-SE Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-008314-40-DK Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-008314-40-DE Denmark;Germany;Sweden;United Kingdom;
Bayer Healthcare AG
2009 - EUCTR2008-008314-40-GB Denmark;Germany;Sweden;United Kingdom;
BCG TICE Vaccine
Johns Hopkins University
2021 Phase 2 NCT04884308 United States;
BH4
Augusta University
2011 Phase 2 NCT01772758 United States;
BI 1265162
Boehringer Ingelheim
2019 Phase 2 NCT04059094 Belgium;Canada;France;Germany;Spain;Sweden;United Kingdom;United States;
BI 1265162 10 µg
Boehringer Ingelheim
2019 Phase 2 EUCTR2019-000261-21-SE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim France
2019 Phase 2 EUCTR2019-000261-21-FR Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Limited
2019 Phase 2 EUCTR2019-000261-21-IE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000261-21-GB Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2019 Phase 2 EUCTR2019-000261-21-DE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim, S.A.
2019 Phase 2 EUCTR2019-000261-21-ES Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2019 Phase 2 EUCTR2019-000261-21-BE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1265162 100 µg
Boehringer Ingelheim
2019 Phase 2 EUCTR2019-000261-21-SE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim France
2019 Phase 2 EUCTR2019-000261-21-FR Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Limited
2019 Phase 2 EUCTR2019-000261-21-IE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000261-21-GB Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2019 Phase 2 EUCTR2019-000261-21-DE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim, S.A.
2019 Phase 2 EUCTR2019-000261-21-ES Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2019 Phase 2 EUCTR2019-000261-21-BE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1265162 25 µg
Boehringer Ingelheim
2019 Phase 2 EUCTR2019-000261-21-SE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim France
2019 Phase 2 EUCTR2019-000261-21-FR Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Limited
2019 Phase 2 EUCTR2019-000261-21-IE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000261-21-GB Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2019 Phase 2 EUCTR2019-000261-21-DE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim, S.A.
2019 Phase 2 EUCTR2019-000261-21-ES Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2019 Phase 2 EUCTR2019-000261-21-BE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1265162 50 µg
Boehringer Ingelheim
2019 Phase 2 EUCTR2019-000261-21-SE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim France
2019 Phase 2 EUCTR2019-000261-21-FR Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Limited
2019 Phase 2 EUCTR2019-000261-21-IE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000261-21-GB Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2019 Phase 2 EUCTR2019-000261-21-DE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim, S.A.
2019 Phase 2 EUCTR2019-000261-21-ES Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2019 Phase 2 EUCTR2019-000261-21-BE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1323495
Boehringer Ingelheim
2021 Phase 1 NCT04656275 Germany;United Kingdom;
BI 443651
Boehringer Ingelheim
2017 Phase 1 NCT02976519 Germany;United Kingdom;
BIIL 283 BS (Amelubent)
Boehringer Ingelheim
2003 Phase 2 NCT00060801 United States;
BIIL 284 BS, high dose
Boehringer Ingelheim
2002 Phase 1 NCT02269189 -
BIIL 284 BS, high dose, adult patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BIIL 284 BS, high dose, pediatric patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BIIL 284 BS, low dose
Boehringer Ingelheim
2002 Phase 1 NCT02269189 -
BIIL 284 BS, low dose, adult patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BIIL 284 BS, low dose, pediatric patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BIIL 284 BS, medium dose, adult patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BIIL 284 BS, medium dose, pediatric patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BLF
Alaxia SAS
2015 Phase 1 NCT02598999 France;
BRAMICIL - 100 MG/ 2 ML SOLUZIONE INIETTABILE 10 FIALE DA 2 ML
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML
ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
- Phase 4 EUCTR2014-001401-41-IT Italy;Netherlands;
BRAMITOB*NEBUL 28F 300MG/4ML
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
2011 - EUCTR2011-001821-26-IT Italy;
BRAMITOB*NEBUL 56F 300MG/4ML
AZIENDA OSPEDALIERA MEYER
2011 - EUCTR2011-006171-19-IT Italy;
BX004-A
BiomX, Inc.
2021 Phase 1/Phase 2 NCT05010577 -
Bactrim
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Balance
Hacettepe University
2019 - NCT03902236 Turkey;
University of Alabama at Birmingham
2008 - NCT01759342 United States;
Benralizumab
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
AstraZeneca
2021 Phase 3 NCT05006573 Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
AstraZeneca AB
2021 Phase 3 EUCTR2020-004068-24-DK Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
2021 Phase 3 EUCTR2020-004068-24-DE Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Viet Nam;
Beta-Adrenergic cocktail
Richard Barry Moss
2015 - NCT02310789 United States;
Bethkis
Mylan Inc.
2015 - NCT02449031 United States;
Biaxin ( clarithromycin)
Wake Forest University
2000 Phase 2 NCT00205634 United States;
Bio-25 probiotic
Sheba Medical Center
2010 - NCT01201434 -
Bisphosphonate treatment
Gilles Boire
2001 Phase 4 NCT01882400 Canada;
Blood draw
Emory University
2015 - NCT02589444 United States;
Blood draw.
University of Florida
2007 - NCT01851642 United States;
Blood or Saliva Sample Collection
Children's Hospital of Philadelphia
2013 - NCT01852448 United States;
Blood sample
Hopital Foch
2016 - NCT02850692 France;
Blood sampling for determination of serum Zn
University Hospital, Ghent
2004 - NCT00221559 Belgium;
Blood test
Assistance Publique - Hôpitaux de Paris
2018 - NCT03492567 France;
Boost VHC
Virginia Commonwealth University
2022 - NCT03931252 United States;
Boots High Strength Garlic Odour Controlled
University of Nottingham
2005 Phase 2 EUCTR2005-000311-98-GB United Kingdom;
Bramitob
Erasmus University Medical Centre
2012 - EUCTR2012-002503-17-NL Netherlands;
Haga Hospital
2014 - EUCTR2013-004488-30-NL Netherlands;
Bramitob 300mg/4ml Nebuliser Solution
Bramitob® administered by PARI LC® PLUS nebulizer
Chiesi Farmaceutici S.p.A.
2010 Phase 1 NCT01116089 Czech Republic;Czechia;Moldova, Republic of;Russian Federation;Slovakia;
Bramitob® administered by PARI eFlow® rapid electronic nebulizer
Chiesi Farmaceutici S.p.A.
2010 Phase 1 NCT01116089 Czech Republic;Czechia;Moldova, Republic of;Russian Federation;Slovakia;
Brensocatib
Fernandez C
2021 Phase 3 JPRN-jRCT2031210048 Australia;Canada;Germany;Japan;New Zealand;Taiwan;United States;
INSMED INCORPORATED
2021 Phase 3 EUCTR2020-003688-25-IT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Insmed Incorporated
2021 Phase 3 EUCTR2020-003688-25-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-LT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-IE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2 NCT05090904 United States;
2020 Phase 3 NCT04594369 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Broccoli sprouts
University Hospitals Cleveland Medical Center
2011 - NCT01315665 United States;
Bronchial mucus collection
University Hospital, Grenoble
2021 - NCT04687319 -
Bronchitol
PHARMAXIS LTD
2014 Phase 3 EUCTR2013-005357-79-SK Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
Pharmaxis Limited
2016 Phase 3 EUCTR2013-005357-79-SE Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;European Union;Greece;Hungary;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2013-005357-79-GR Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2013-005357-79-BG Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005357-79-IT Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005357-79-HU Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005357-79-CZ Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005357-79-BE Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Pharmaxis Ltd.
2014 - EUCTR2012-002699-14-NL Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;
2014 - EUCTR2012-002699-14-IT Argentina;Belgium;Canada;Italy;Netherlands;United Kingdom;
2013 Phase 2 EUCTR2012-002699-14-GB Argentina;Belgium;Canada;France;Italy;Netherlands;United Kingdom;
2013 - EUCTR2012-002699-14-BE Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
- Phase 2 EUCTR2012-002699-14-FR Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Bronchoscopy with BAL
National Center for Research Resources (NCRR)
2001 - NCT00023465 United States;
Bucelipase alfa
Biovitrum AB
2008 - EUCTR2007-004063-21-NL Netherlands;
Budesonide-formoterol single inhaler
Hospital General de Requena
2004 - NCT00728715 Spain;
Burlulipase
Nordmark Arzneimittel GmbH & Co. KG
2013 Phase 1/Phase 2 NCT01710644 United States;
C01CA04 - Dopamina
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
CAYSTON aztreonam 75 mg powder and solvent for nebuliser solution
GILEAD SCIENCES INC.
2012 Phase 3 EUCTR2011-001362-18-IT France;Germany;Italy;Spain;United States;
CB-280
Calithera Biosciences, Inc
2020 Phase 1 NCT04279769 Canada;United States;
CEFTAZIDIMA PENTAIDRATO
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
CEFTAZIDIME PENTAHYDRATE
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
CF patients with a G551D mutation and treated with Ivacaftor
Assistance Publique - Hôpitaux de Paris
2014 - NCT02194881 France;
CFTR Modulators
Children's Hospital Medical Center, Cincinnati
2022 - NCT04580368 -
Societe Francaise de la Mucoviscidose
2020 - NCT04301856 France;
Universidad Europea de Madrid
2020 - NCT04415268 Spain;
CFTR potentiator
Novartis Pharma AG
2021 Phase 2 EUCTR2019-002840-26-DE China;Germany;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002840-26-GB China;Germany;Spain;United Kingdom;
CHF 6333
Chiesi Farmaceutici S.p.A.
2019 Phase 1 NCT04010799 Germany;
CHF6333 (Part 1 - SAD)
Chiesi Farmaceutici S.p.A.
2016 Phase 1 NCT03056326 Belgium;
CHF6333 (Part 2 - MAD)
Chiesi Farmaceutici S.p.A.
2016 Phase 1 NCT03056326 Belgium;
CIPROFLOXACIN HYDROCHLORIDE
AZIENDA OSPEDALIERA MEYER
2011 - EUCTR2011-006171-19-IT Italy;
Aradigm Corporation
2010 Phase 2 EUCTR2009-014412-35-DE Germany;United Kingdom;
2010 - EUCTR2009-014412-35-GB Germany;United Kingdom;
CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE
COP:TRIN Region Hovedstaden (Gentofte hospital)
2017 Phase 4 EUCTR2015-003399-58-DK Denmark;
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
CIPROFLOXACINA CLORIDRATO
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
CIPROXIN - 500 MG COMPRESSE RIVESTITE 14 COMPRESSE
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
CIPROXIN*6CPR RIV
AZIENDA OSPEDALIERA MEYER
2011 - EUCTR2011-006171-19-IT Italy;
CLORURO SODICO
ADELAIDA LAMAS FERREIRO
2009 - EUCTR2008-001284-11-ES Spain;
COLIMICINA - 1000000 U/4 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 4 ML
AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER
2016 Phase 3 EUCTR2015-003881-96-IT Italy;
COLIMYCINE inhalation
Poitiers University Hospital
2011 Phase 1 NCT01537614 France;
COLIMYCINE injectable
Poitiers University Hospital
2011 Phase 1 NCT01537614 France;
COLISTIMETATO SODICO
AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER
2016 Phase 3 EUCTR2015-003881-96-IT Italy;
COLISTIMETHATE SODIUM
Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
2014 Phase 4 EUCTR2013-004295-35-AT Austria;
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
COLISTIMETHATE SODIUM (A COMPONENT)
CUB - Hôpital Erasme
2014 - EUCTR2013-004987-80-BE Belgium;
COLISTIN MESILATE SODIUM
AZIENDA OSPEDALIERA MEYER
2011 - EUCTR2011-006171-19-IT Italy;
COLISTINEB 2MUI
CUB - Hôpital Erasme
2014 - EUCTR2013-004987-80-BE Belgium;
COVID-19 Vaccine (ChAdOx1-S [recombinant])
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant])
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 Vaccine Moderna dispersion for injection
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 mRNA vaccine (nucleoside-modified)
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 mRNA vaccine Moderna (CX-024414)
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 vaccine (Ad26.COV2-S [recombinant])
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19)
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
CPX
FDA Office of Orphan Products Development
1997 Phase 1 NCT00004428 -
CR002 Liquid API
CSL Behring
2011 Phase 1 NCT01347190 Bulgaria;Hungary;Poland;United Kingdom;
CRC3357, ZK-355322, Leukoton
Celtaxsys Inc.
2016 Phase 2 EUCTR2015-002677-38-IT Belgium;France;Germany;Italy;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-GB Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-DE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-BE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
CREON
AbbVie
2021 Phase 4 NCT05069597 United States;
2020 Phase 4 NCT04315311 United States;
2012 - NCT01652157 United States;
CREON 10000 Capsules
EURAND SPA
2010 - EUCTR2009-012842-21-IT Bulgaria;Germany;Hungary;Italy;United Kingdom;
CREON IR
Abbott Laboratories GmbH
2015 - EUCTR2014-004519-35-HU Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-GB Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-CZ Czech Republic;Hungary;Spain;United Kingdom;
CREON N 25000
Abbott Laboratories GmbH
2013 - EUCTR2013-002819-10-HU Hungary;Russian Federation;Spain;
CSL787
CSL Behring
2020 Phase 1 NCT04643587 United Kingdom;
CTX-4430
Celtaxsys Inc.
2016 Phase 2 EUCTR2015-002677-38-IT Belgium;France;Germany;Italy;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-GB Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-DE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-BE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
Celtaxsys, Inc.
2015 Phase 2 NCT02443688 Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2013 Phase 1 NCT01944735 United Kingdom;
CYC202
CHRU de Brest
2015 Phase 2 EUCTR2015-002911-13-FR France;
CYCLO[L-ALANYL-L-SERYL-L-ISOLEUCYL-L-PROLYL-L-PROLYL-L-GLUTAMINYL-L-LYSYL-L-TYROSYL-D-PROLYL-L-PROLYL-(2S)-2-AMINODECANOYL-L-ALPHA-GLUTAMYL-L-THREONYL]
Santhera Pharmaceuticals (Switzerland) Ltd
2018 Phase 1;Phase 2 EUCTR2018-002550-71-DE Germany;
Calcium carbonate
University of North Carolina
1998 - NCT00004489 United States;
Calfactant
University of Pittsburgh
2008 - NCT00628134 United States;
Cavosonstat
Nivalis Therapeutics, Inc.
2016 Phase 2 NCT02724527 United States;
2016 Phase 1 NCT02934139 United States;
2015 Phase 2 NCT02589236 United States;
Cayston
Gilead Sciences, Inc.
2012 Phase 3 EUCTR2011-001362-18-ES France;Germany;Italy;Poland;Spain;United States;
Gilead Sciences Inc
2010 - EUCTR2007-004277-26-AT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-004277-26-GB Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
- - EUCTR2007-004277-26-Outside-EU/EEA United States;
Gilead Sciences, Inc.
2018 Phase 3 EUCTR2016-002749-42-NL Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2016-002749-42-GR Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-IT Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-GB Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-FR Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-ES Austria;Belgium;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-DK Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-DE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-BE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-AT Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2012 Phase 2 EUCTR2011-001255-36-BE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001362-18-DE France;Germany;Italy;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-NL Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-IE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-DE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-AT Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2011 Phase 2 EUCTR2011-001255-36-ES Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- Phase 3 EUCTR2016-002749-42-IE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2011-001362-18-FR France;Germany;Italy;Poland;Spain;United States;
- Phase 2 EUCTR2011-001255-36-FR Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- - EUCTR2015-000398-11-Outside-EU/EEA United States;
- - EUCTR2015-000397-36-Outside-EU/EEA Canada;
- - EUCTR2015-000396-26-Outside-EU/EEA United States;
- - EUCTR2015-000395-97-Outside-EU/EEA Australia;Canada;United States;
- - EUCTR2011-001362-18-Outside-EU/EEA United States;
- - EUCTR2011-001255-36-Outside-EU/EEA United States;
- - EUCTR2009-011740-19-Outside-EU/EEA Canada;United States;
Liverpool Heart & Chest Hospital
2016 Phase 4 EUCTR2016-002832-34-GB United Kingdom;
Mylan Inc.
2015 - NCT02449031 United States;
Cayston 75 mg Pulver und Lösungsmittel zur Herstellung einer Lösung für einen Vernebler
Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
2014 Phase 4 EUCTR2013-004295-35-AT Austria;
Cayston Aztreonam 75 mg powder and solvent for nebuliser solution
GILEAD SCIENCES INC.
2012 - EUCTR2011-001255-36-IT Austria;Germany;Ireland;Italy;Netherlands;Spain;United States;
Ceftaroline
Children's Hospital Medical Center, Cincinnati
2017 Phase 4 NCT03771313 United States;
Ceftazidim Fresenius Kabi 2000 mg poeder voor oplossing voor injectie of infusie
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
Ceftazidime
Association Nationale pour le Traitement à Domicile de l'Insuffisance Respiratoire
2001 Phase 4 NCT00333385 France;
Imperial College London
2010 Phase 4 NCT01044719 United Kingdom;
Imperial College, London
2009 - EUCTR2009-014042-28-GB United Kingdom;
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
University College Cork
2015 - NCT02526004 Ireland;
University Ghent
2016 - NCT02840136 Belgium;
University Hospitals Bristol NHS Foundation Trust
2016 Phase 4 EUCTR2009-012575-10-SE Sweden;United Kingdom;
2009 Phase 4 EUCTR2009-012575-10-GB Sweden;United Kingdom;
Ceftazidime and tobramycin
University of North Carolina, Chapel Hill
2004 Phase 1 NCT00823238 United States;
Ceftazidime/avibactam
University of Southern California
2015 Phase 4 NCT02504827 United States;
Ceftolozane/Tazobactam
Joseph L. Kuti, PharmD
2015 Phase 4 NCT02421120 United States;
Cefuroxim
Västra Götalandsregionen
2021 Phase 4 EUCTR2019-003501-10-DK Denmark;Norway;Sweden;
2020 Phase 4 EUCTR2019-003501-10-SE Denmark;Norway;Sweden;
Cephalexin
University of British Columbia
2020 Phase 3 NCT04553419 Canada;
Cftr Modulators
Indiana University
2019 - NCT04206436 United States;
Chlorhexidine Gluconate
University of North Carolina, Chapel Hill
2018 Phase 2 NCT03489629 United States;
Chlorhexidine gluconate oral rinse
University of North Carolina, Chapel Hill
2011 Phase 2 NCT01349192 United States;
Chlorhexidine solution wipes
University of North Carolina, Chapel Hill
2011 Phase 2 NCT01349192 United States;
Chloride
Milton S. Hershey Medical Center
2018 - NCT03367494 United States;
Cholecalciferol
Children's Hospital of Philadelphia
2008 Phase 3 NCT00762918 United States;
Emory University
2011 Phase 3 NCT01426256 United States;
Shanghai Pulmonary Hospital, Shanghai, China
2015 Phase 4 NCT02507843 China;
University of North Carolina
1998 - NCT00004489 United States;
Cholecalciferol (Vitamin D3)
University of Pittsburgh
2010 - NCT01222273 United States;
Cholecalciferol (vitaminD3)
Heba Omara
2018 Phase 2/Phase 3 NCT04411901 Egypt;
Cholecalciferol Pill
Hospital Infantil de Mexico Federico Gomez
2022 Phase 4 NCT05276960 Mexico;
Choline Chloride
University Hospital Tuebingen
2014 - NCT03312140 -
Choline supplementation
University of British Columbia
2007 - NCT00686361 Canada;
Chronic Antioxidant
Augusta University
2015 - NCT02690064 United States;
Cipro (Ciprofloxacin, BAYQ3939)
Bayer
2016 - NCT02555059 Japan;
Cipro Inhale
Bayer HealthCare AG
2009 Phase 2 EUCTR2009-009869-34-ES Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-SE Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-GB Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-DE Germany;Spain;Sweden;United Kingdom;
Ciprofloxacin
AZIENDA OSPEDALIERA MEYER
2008 - EUCTR2008-006502-42-IT Italy;
Bayer
2016 - NCT02661438 United States;
Bayer HealthCare AG
2009 Phase 2 EUCTR2009-009869-34-ES Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-SE Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-GB Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-DE Germany;Spain;Sweden;United Kingdom;
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
University Hospitals Bristol NHS Foundation Trust
2016 Phase 4 EUCTR2009-012575-10-SE Sweden;United Kingdom;
2009 Phase 4 EUCTR2009-012575-10-GB Sweden;United Kingdom;
Vertex Pharmaceuticals Incorporated
2014 Phase 1 NCT02015507 -
2013 Phase 1 NCT01768663 United States;
Ciprofloxacin (BAYQ3939) dry powder for inhalation
Bayer
2014 Phase 3 NCT02106832 Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Czechia;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Ciprofloxacin (Cipro Inhale, BAYQ3939)
Bayer
2008 Phase 2 NCT00645788 Australia;Canada;Denmark;Germany;Israel;Norway;Sweden;United Kingdom;United States;
Ciprofloxacin (Cipro, BAYQ3939)
Bayer
2009 Phase 2 NCT00930982 Australia;Germany;Spain;Sweden;United Kingdom;United States;
2009 Phase 1 NCT00910351 United States;
Ciprofloxacin (ciproxin)
Belfast City Hospital Trust
2005 Phase 4 EUCTR2005-003837-42-GB United Kingdom;
Ciprofloxacin DPI
BAYER HEALTHCARE AG
2013 Phase 3 EUCTR2011-004208-39-IT Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
Bayer AG
2014 Phase 3 EUCTR2013-004659-19-BG Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Bayer AG
2014 Phase 3 EUCTR2013-004659-19-NL Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-LT Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-DE Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-CZ Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-AT Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Bayer HealthCare AG
2014 Phase 3 EUCTR2011-004208-39-SK Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2014 - EUCTR2011-004208-39-LV Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-GB Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-FR Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-ES Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-DE Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 - EUCTR2011-004208-39-DK Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
Bayer Healthcare AG, D-51368 Leverkusen, Germany
2014 Phase 3 EUCTR2013-004659-19-SK Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-PT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-LV Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Ciprofloxacin DPI (BAYQ3939)
Bayer
2013 Phase 3 NCT01764841 Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
Ciprofloxacin Inhale
Bayer HealthCare AG
2009 - EUCTR2008-008314-40-SE Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-008314-40-DK Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-008314-40-DE Denmark;Germany;Sweden;United Kingdom;
Bayer Healthcare AG
2009 - EUCTR2008-008314-40-GB Denmark;Germany;Sweden;United Kingdom;
Ciprofloxacin dispersion for inhalation
Aradigm Corporation
2014 Phase 3 NCT02104245 Australia;Canada;Former Serbia and Montenegro;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 NCT01515007 Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;New Zealand;Poland;Romania;South Africa;Spain;Taiwan;United Kingdom;United States;
Ciprofloxacin for Inhalation
Aradigm Corporation
2010 Phase 2 NCT00889967 Canada;Germany;United Kingdom;United States;
2010 Phase 2 EUCTR2009-014412-35-DE Germany;United Kingdom;
2010 - EUCTR2009-014412-35-GB Germany;United Kingdom;
Ciproxin
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Ciproxin Suspension
Southampton University Hospital Trust
2008 - EUCTR2008-001769-27-GB United Kingdom;
Clarithromycin
Chinese University of Hong Kong
2020 - NCT04658277 Hong Kong;
Claritromycin 500mg film coated tablets
university medical center utrecht
2018 Phase 4 EUCTR2016-001440-18-NL Netherlands;
Cobamamide
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
2010 - EUCTR2010-020516-11-IT Italy;
Colistimethat-Natrium
University of Jena
2009 - EUCTR2008-007877-19-DE Germany;
Colistimethate
Novartis Pharmaceuticals
2013 Phase 4 NCT01844778 Germany;Ireland;Spain;Switzerland;United Kingdom;
Colistimethate 75 mg inhaled two times daily
Dartmouth-Hitchcock Medical Center
2014 - NCT02113397 United States;
Colistimethate Sodium
Zambon SpA
2017 Phase 3 NCT03093974 Australia;Belgium;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Colistimethate sodium
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-DK Belgium;Denmark;
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
Profile Pharma Ltd
2010 - EUCTR2008-005045-34-IE Ireland;United Kingdom;
2008 Phase 3 EUCTR2008-005045-34-GB Ireland;Russian Federation;Ukraine;United Kingdom;
University of Colorado, Denver
2013 - NCT02288429 United States;
Zambon SpA
2018 Phase 3 NCT03460704 Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
Colistimethate sodium (BAN, USAN), Colistimethatum natricum, Colistin sodium methanesulfonate
Forest Laboratories UK Ltd.
2011 - EUCTR2011-000192-13-PL Germany;Poland;Ukraine;United Kingdom;
2011 - EUCTR2011-000192-13-GB Germany;Poland;United Kingdom;
2011 - EUCTR2011-000192-13-DE Germany;Poland;Ukraine;United Kingdom;
Colistimethate sodium (promixin)
Aarhus University Hospital, Department of Respiratory Medicine
2015 Phase 2 EUCTR2015-003662-87-DK Denmark;
Colistin
AZIENDA OSPEDALIERA MEYER
2008 - EUCTR2008-006502-42-IT Italy;
National Jewish Health
2016 Phase 4 NCT02918409 United States;
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
University Hospital Tuebingen
2014 Phase 3 NCT03341741 -
University of Jena
2009 Phase 2 NCT01035853 Germany;
Colistin CF
University of Jena
2009 - EUCTR2008-007877-19-DE Germany;
Colistin Forest - Trockenstechampullen mit Lösungsmittel
Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
2014 Phase 4 EUCTR2013-004295-35-AT Austria;
Colobreathe
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-DK Belgium;Denmark;
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
Forest Laboratories UK Ltd.
2011 - EUCTR2011-000192-13-PL Germany;Poland;Ukraine;United Kingdom;
2011 - EUCTR2011-000192-13-GB Germany;Poland;United Kingdom;
2011 - EUCTR2011-000192-13-DE Germany;Poland;Ukraine;United Kingdom;
Colomycin
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-DK Belgium;Denmark;
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
The Leeds Teaching Hospitals NHS Trust
2015 - NCT02489955 United Kingdom;
Comirnaty concentrate for dispersion for injection
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
Compound 1a
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Continuous Glucose Monitoring
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Continuous Glucose Monitoring System (CGMS)
University Hospital, Strasbourg, France
2008 - NCT00476281 France;
Continuous glucose monitor (CGM)
Jagdeesh Ullal
2021 Phase 4 NCT04533646 United States;
Continuous infusion Cefepime
The Alfred
2012 Phase 4 NCT01667094 Australia;
Continuous infusion Ceftazidime
The Alfred
2012 Phase 4 NCT01667094 Australia;
Continuous infusion Meropenem
The Alfred
2012 Phase 4 NCT01667094 Australia;
Continuous infusion Piperacillin tazobactam
The Alfred
2012 Phase 4 NCT01667094 Australia;
Continuous infusion Ticarcillin-clavulanate
The Alfred
2012 Phase 4 NCT01667094 Australia;
Control
University Hospital Southampton NHS Foundation Trust.
2011 Phase 2 NCT02295566 United Kingdom;
Control Group Isotonic Saline
University of Washington, the Collaborative Health Studies Coordinating Center
2015 Phase 2/Phase 3 NCT02950883 Australia;Belgium;Canada;Denmark;France;Italy;Netherlands;Spain;United States;
Control multivitamin
University of Colorado, Denver
2013 Phase 2 NCT01859390 United States;
Creon 10.000, hårde enterokapsler
Terese Katzenstein
2020 Phase 4 EUCTR2019-004940-31-DK Denmark;
Creon 10000
Solvay Pharmaceuticals GmbH
2008 - EUCTR2007-004004-12-BG Bulgaria;
Creon 25.000, hårde enterokapsler
Terese Katzenstein
2020 Phase 4 EUCTR2019-004940-31-DK Denmark;
Creon 25000
Abbott Laboratories GmbH
2013 - EUCTR2013-002819-10-HU Hungary;Russian Federation;Spain;
Solvay Pharmaceuticals GmbH
2008 - EUCTR2007-004004-12-BG Bulgaria;
Creon 40.000, hårde enterokapsler
Terese Katzenstein
2020 Phase 4 EUCTR2019-004940-31-DK Denmark;
Creon IR
Abbott
2015 Phase 2 NCT02415959 Czech Republic;Hungary;Poland;Spain;
Creon N
Abbott
2014 Phase 3 NCT02137382 Hungary;Russian Federation;Spain;
Creon®
Abbott
2014 Phase 3 NCT02137382 Hungary;Russian Federation;Spain;
Creon® (DR/GR)
Abbott
2015 Phase 2 NCT02415959 Czech Republic;Hungary;Poland;Spain;
Creon® 25,000
Abbott Laboratories GmbH
2015 - EUCTR2014-004519-35-HU Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-GB Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-CZ Czech Republic;Hungary;Spain;United Kingdom;
Crestor
University of Liverpool
2014 Phase 2 EUCTR2014-002387-32-GB United Kingdom;
Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm
University Medical Centre Utrecht
2014 Phase 2 EUCTR2014-000817-30-NL Netherlands;
Cystagon
University of LIverpool
2019 Phase 1;Phase 2 EUCTR2017-001259-29-GB United Kingdom;
Cystagon (cysteamine bitartrate) immediate-release capsules
University of Aberdeen
2014 Phase 1;Phase 2 EUCTR2014-000284-40-GB United Kingdom;
Cysteamine
NovaBiotics Ltd.
2016 Phase 2 NCT03000348 Italy;United Kingdom;United States;
University of Aberdeen
2014 Phase 1/Phase 2 NCT02212431 United Kingdom;
Cysteamine bitartrate
NovaBiotics, Ltd
2017 Phase 2 EUCTR2015-004986-99-IT Italy;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004986-99-GB Italy;Netherlands;United Kingdom;United States;
University of LIverpool
2019 Phase 1;Phase 2 EUCTR2017-001259-29-GB United Kingdom;
Cysteamine bitartrate (Cystagon)
European Institute for Cystic Fibrosis Research (IERFC)
2013 - EUCTR2013-001258-82-IT Italy;
Cystic Fibrosis Ready to Use Supplemental Food
Washington University School of Medicine
2018 Phase 1/Phase 2 NCT03462056 United States;
D-a-tocopheryl PEG 1000 succinate
ORPHAN
2007 - EUCTR2007-001007-38-FR France;
D6-25-hydroxyvitamin D3
University of Washington
2017 Phase 1 NCT03104855 United States;
DCI 1020
Digestive Care, Inc.
2009 - NCT00663975 United States;
DEPELESTAT
DEBIOPHARM S.A.
2005 - EUCTR2004-002341-12-IT Belgium;Germany;Italy;United Kingdom;
DORIPENEM HYDRATE
Johnson & Johnson Pharmaceutical Research & Development L.L.C
- - EUCTR2015-001225-16-Outside-EU/EEA United States;
DP Mannitol
Pharmaxis Ltd
2004 Phase 2 EUCTR2004-001888-21-GB United Kingdom;
DTPA
University of Pittsburgh
2007 - NCT00541190 United States;
DX-890
DEBIOPHARM S.A.
2005 - EUCTR2004-002341-12-IT Belgium;Germany;Italy;United Kingdom;
De-activated smart device
Vertex Pharmaceuticals Incorporated
2016 Phase 4 NCT02823470 Canada;United States;
Decolonization
State University of New York - Upstate Medical University
2011 - NCT01229553 United States;
Denosumab
University of Texas Southwestern Medical Center
2022 Phase 4 NCT03921060 United States;
Denufosol Tetrasodium (INS37217) Inhalation Solution
Merck Sharp & Dohme Corp.
2008 Phase 3 NCT00625612 Australia;Canada;New Zealand;United States;
Denufosol tetrasodium (INS37217)
Merck Sharp & Dohme Corp.
2005 Phase 2 NCT00130182 United States;
2005 Phase 2 NCT00103714 United States;
2003 Phase 2 NCT00056147 United States;
Denufosol tetrasodium (INS37217) Inhalation Solution
Merck Sharp & Dohme Corp.
2007 Phase 2 NCT00425165 United States;
2006 Phase 3 NCT00357279 Canada;United States;
2001 Phase 1/Phase 2 NCT00034515 United States;
Denufosol tetrasodium Inhalation Solution
Merck Sharp & Dohme Corp.
2010 Phase 2 NCT01181622 United States;
2009 Phase 3 NCT00846781 Australia;Canada;New Zealand;United States;
Depelestat
Debiopharm SA
2005 Phase 2 EUCTR2004-002341-12-GB Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-DE Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-BE Belgium;Germany;Italy;United Kingdom;
Detoxifying agents for antineoplastic treatment
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
2010 - EUCTR2010-020516-11-IT Italy;
Deuterated Ivacaftor
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
Dexamethasone
ISTITUTO GIANNINA GASLINI
2008 - EUCTR2007-001782-15-IT Italy;
Dexamethasone sodium phosphate 250 mg/10 ml solution
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
2011 - EUCTR2011-000130-11-IT Italy;
Diet
Hospital de Clinicas de Porto Alegre
2016 - NCT03205904 Brazil;
Digitoxin
National Jewish Health
2010 Phase 2 NCT00782288 United States;
Docosahexaenoic acid
Hospices Civils de Lyon
2010 Phase 2 NCT02690857 -
Docosahexaenoic acid (DHA)
University of Massachusetts, Worcester
2003 - NCT00530244 United States;
Docosahexaenoic acid administration: 50 mg/kg/day during 12 months
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
2011 - NCT01783613 Spain;
Docosahexanoic Acid Supplement
Vanderbilt University
2013 Phase 2 NCT00924547 United States;
Dornase alfa
David Nichols, MD
2020 - NCT04378153 United States;
Genentech, Inc.
2008 Phase 4 NCT00680316 United States;
2007 Phase 4 NCT00434278 United States;
University of Jena
- Phase 3 EUCTR2007-001548-36-DE Germany;
Dornase alfa (Pulmozyme)
University of Jena
2007 Phase 3 NCT00534079 Germany;
Dornase alfa [Pulmozyme®]
Genentech, Inc.
2012 Phase 4 NCT01712334 United States;
Dornase alpha
Pharmaxis
2005 Phase 2 NCT00117208 United Kingdom;
University of Oklahoma
2006 - NCT00671723 United States;
Doxycyclin
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Doxycycline
Johns Hopkins University
2012 Phase 2 NCT01594827 United States;
University of Alabama at Birmingham
2008 - NCT01112059 United States;
University of Southern California
2008 Phase 4 NCT01323101 United States;
Dry powder tobramycin
University Medical Center Groningen
2013 - EUCTR2012-004437-16-NL Netherlands;
- Phase 2 EUCTR2016-005014-21-NL Netherlands;
Dual Energy X-ray Absorptiometry (DEXA)
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
2006 - NCT00287430 -
Dulaglutide 0.75Mg/0.5Ml Inj Pen
University of Pennsylvania
2021 Phase 2 NCT04731272 United States;
Duramycin, 2622U90
AOP Orphan Pharmaceuticals AG
2006 Phase 2;Phase 3 EUCTR2005-005594-29-SK Czech Republic;Hungary;Slovakia;
2006 - EUCTR2005-005594-29-HU Czech Republic;Hungary;
2006 - EUCTR2005-005594-29-CZ Czech Republic;Hungary;
2006 - EUCTR2005-004344-30-HU Hungary;
2005 - EUCTR2005-004344-30-AT Austria;Hungary;
ECGC
Hadassah Medical Organization
2011 - NCT00889434 Israel;
EGCG + Tocotrienol
Hadassah Medical Organization
2011 - NCT00889434 Israel;
ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
ELX (VX-445)/TEZ (VX-661)/IVA (VX-770)
VERTEX PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2020-003170-44-IT Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2020-003170-44-CZ Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-NL Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-FR Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-BE Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
ELX / 40mg TEZ / 60mg IVA
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
ELX /50 mg TEZ /75 mg IVA FDC
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
ELX-02
Eloxx Pharmaceuticals Inc
2019 Phase 2 EUCTR2018-000966-12-DE Australia;Germany;Israel;
Eloxx Pharmaceuticals, Inc.
2019 Phase 2 NCT04135495 Canada;United States;
2019 Phase 2 NCT04126473 Australia;Germany;Israel;
ELX/25 mg TEZ/37.5 mg IVA
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
ELX/25 mg TEZ/37.5 mg IVA fixed dose combination
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
ELX/50 mg TEZ /75 mg IVA FDC
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
ELX/50 mg TEZ/75 mg IVA fixed dose combination
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2021-001628-16-ES Australia;Belgium;Canada;Spain;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2021-001628-16-BE Australia;Belgium;Canada;Spain;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
ELX/50mg TEZ /75mg IVA
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
ELX/TEZ/IVA
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 NCT05274269 -
2022 Phase 3 NCT05153317 United States;
2022 Phase 3 NCT05111145 Australia;Spain;
2022 Phase 3 EUCTR2021-000712-31-SE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-DE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 NCT05076149 Australia;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2021 Phase 3 NCT05033080 Czechia;Germany;United Kingdom;United States;
2021 Phase 3 NCT04969224 Australia;Belgium;Canada;Spain;
2021 Phase 3 NCT04599465 Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
2021 Phase 3 NCT04545515 Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2021-000694-85-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NO Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-GR Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
2021 - NCT04702360 -
2020 Phase 3 NCT04537793 Australia;Canada;Germany;United Kingdom;United States;
2020 Phase 3 NCT04362761 Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 NCT04353817 Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 NCT04183790 Australia;Canada;Ireland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 - NCT04058210 -
2019 Phase 3 NCT04105972 Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 NCT04058366 Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 NCT04058353 Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 NCT04043806 Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-CZ Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
EMEA/H/C/000125
European Institute for Cystic Fibrosis Research (IERFC)
2013 - EUCTR2013-001258-82-IT Italy;
EPI-hNE4 DX-890
Debiopharm SA
2005 Phase 2 EUCTR2004-002341-12-GB Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-DE Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-BE Belgium;Germany;Italy;United Kingdom;
ETD001 multiple once daily doses
Enterprise Therapeutics Ltd
2021 Phase 1 NCT04926701 United Kingdom;
ETD001 multiple twice daily doses
Enterprise Therapeutics Ltd
2021 Phase 1 NCT04926701 United Kingdom;
ETD001 single dose
Enterprise Therapeutics Ltd
2021 Phase 1 NCT04926701 United Kingdom;
EU Orphan Designation Number EU/3/02/120
AOP Orphan Pharmaceuticals AG
2006 - EUCTR2005-004344-30-HU Hungary;
2005 - EUCTR2005-004344-30-AT Austria;Hungary;
EUR-1008
Aptalis Pharma US Inc.
2013 - EUCTR2009-012842-21-HU Bulgaria;Germany;Hungary;Italy;United Kingdom;
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-DE Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-BG Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
EUR-1008 (APT-1008)
Forest Laboratories
2010 Phase 4 NCT01131507 United States;
2010 Phase 4 NCT01100606 United States;
2006 Phase 3 NCT00981214 United States;
2006 Phase 3 NCT00297167 United States;
EUR-1008 25,000 Units
Aptalis Pharma
2012 Phase 3 NCT01641393 Belgium;Bulgaria;France;Germany;Italy;Poland;United Kingdom;
EZ-2053
Neovii Biotech
2005 Phase 3 NCT00105183 Australia;Austria;Canada;United States;
Elasomeran
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
Elexacaftor
VERTEX PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2020-003170-44-IT Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
2019 Phase 3 EUCTR2019-000833-37-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
2021 Phase 3 EUCTR2021-001628-16-ES Australia;Belgium;Canada;Spain;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-003170-44-CZ Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-001827-11-IE Australia;Canada;Ireland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001695-38-GB Australia;Canada;Ireland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-001628-16-BE Australia;Belgium;Canada;Spain;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-NL Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-FR Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-BE Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-001827-11-GB Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2019-000833-37-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-001695-38-IE Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Elexacaftor-tezacaftor-ivacaftor exposure
Jennifer Taylor-Cousar
2019 - NCT04056702 United States;
Elexacaftor/tezacaftor/ivacaftor
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-000712-31-SE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-DE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NO Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-GR Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-CZ Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Engineerd Protein Inhibitor of human Neutrophil Elastase
Debiopharm SA
2005 Phase 2 EUCTR2004-002341-12-GB Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-DE Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-BE Belgium;Germany;Italy;United Kingdom;
Engineered Protein Inhibitor of human Neutrophil Elastase
Debiopharm SA
2005 Phase 2 EUCTR2004-002341-12-GB Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-DE Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-BE Belgium;Germany;Italy;United Kingdom;
Ensure High Protein
Virginia Commonwealth University
2022 - NCT03931252 United States;
Ensure plus
Texas A&M University
2011 - NCT01494909 United States;
Ergocalciferol (vitamin D2)
Atlanta VA Medical Center
2006 - NCT00450073 United States;
Esomeprazole
Biovitrum AB
2008 - EUCTR2007-004063-21-NL Netherlands;
Columbia University
2008 Phase 2 NCT01983774 United States;
Essential amino acid intake + Leucine vs total AA supplement
Texas A&M University
2008 - NCT01172301 United States;
Estradiol
Emory University
2019 Phase 4 NCT03724955 United States;
Ethambutol
University of Colorado, Denver
2014 - NCT02372383 United States;
Exercise
University of Kansas Medical Center
2022 Phase 2 NCT05239611 United States;
Exhaled Nitric Oxide
The Hospital for Sick Children
2010 - NCT01155115 Canada;
F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)
University Hospital, Strasbourg, France
2020 Phase 4 NCT04381429 France;
FDG-PET
National Center for Research Resources (NCRR)
2001 - NCT00023465 United States;
FDL169
Flatley Discovery Lab LLC
2018 Phase 1/Phase 2 NCT03756922 United Kingdom;
2018 Phase 1 NCT03527095 United Kingdom;
2017 Phase 1 NCT03424252 United Kingdom;
2017 Phase 1 NCT03093714 Australia;Czechia;Germany;United Kingdom;
2016 Phase 1/Phase 2 NCT02767297 United Kingdom;
2015 Phase 1 NCT02680418 United Kingdom;
2015 Phase 1 NCT02359357 United Kingdom;
FDL176
Flatley Discovery Lab LLC
2018 Phase 1/Phase 2 NCT03756922 United Kingdom;
2017 Phase 1 NCT03173573 Australia;
FDL176 & FDL169 coadministration
Flatley Discovery Lab LLC
2018 Phase 1 NCT03516331 United Kingdom;
FLUCLOXACILLIN SODIUM
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
FORLAX 4 g, poudre pour solution buvable en sachet
CHU de Bordeaux
2020 Phase 2 EUCTR2019-004958-29-FR France;
FTI, AZLI
Gilead Sciences
2008 Phase 2 NCT00794586 United States;
Fasenra
AstraZeneca AB
2021 Phase 3 EUCTR2020-004068-24-DK Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
2021 Phase 3 EUCTR2020-004068-24-DE Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Viet Nam;
Fenretinide
Elias Matouk
2014 Phase 1 NCT02141958 Canada;
Ferinject
University of Oxford / Clinical Trials and Research Governance
2018 Phase 4 EUCTR2018-002366-39-GB United Kingdom;
Ferric carboxymaltose
University of Oxford
2019 Phase 4 NCT03632525 United Kingdom;
University of Oxford / Clinical Trials and Research Governance
2018 Phase 4 EUCTR2018-002366-39-GB United Kingdom;
Ferrous sulfate
Dartmouth-Hitchcock Medical Center
2011 - NCT01755455 United States;
Finely ground flaxseed powder
University of Pennsylvania
2012 Phase 1 NCT02014181 United States;
Fish oil
Nestlé
2016 - NCT02646995 Switzerland;
Flucloxacillin 250mg/5ml Sugar-Free Powder for Oral Solution
Alder Hey Children's NHS Foundation Trust
2016 Phase 4 EUCTR2016-002578-11-GB United Kingdom;
Flucloxicillin
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
Flumist®
McGill University Health Center
2013 - NCT01885169 Canada;
Fluticasone
Royal Brompton & Harefield NHS Foundation Trust
2001 - NCT00220259 United Kingdom;
Fortum
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
Frequently Sampled Oral Glucose Tolerance Test and CGM
University Hospitals Cleveland Medical Center
2019 - NCT03961516 United States;
Fucidin Tablets
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Fusidin
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
G1117337
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002181-42-DE Germany;
G914167
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
G957389
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-NL Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-GB Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-ES Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-BE Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002837-31-CZ Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-IE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-GB Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-DE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-BE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
GIP
University of Pennsylvania
2013 - NCT01851694 United States;
GLP-1
University of Pennsylvania
2013 - NCT01851694 United States;
GLPG1837
Galapagos NV
2016 Phase 2 EUCTR2015-003292-30-NL Belgium;Netherlands;
2016 Phase 2 EUCTR2015-003292-30-BE Belgium;Netherlands;
2016 Phase 2 EUCTR2015-003291-77-IE Australia;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2015-003291-77-GB Australia;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2015-003291-77-DE Australia;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2015-003291-77-CZ Australia;Czech Republic;Germany;Ireland;United Kingdom;
GLPG1837 dose 1
Galapagos NV
2016 Phase 2 NCT02707562 Australia;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 NCT02690519 Belgium;Netherlands;
GLPG1837 dose 2
Galapagos NV
2016 Phase 2 NCT02707562 Australia;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 NCT02690519 Belgium;Netherlands;
GLPG1837 dose 3
Galapagos NV
2016 Phase 2 NCT02707562 Australia;Czech Republic;Germany;Ireland;United Kingdom;
GLPG2222
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
2018 Phase 1 NCT03540524 Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
2017 Phase 2 NCT03119649 Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-NL Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-GB Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-ES Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-BE Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002837-31-CZ Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-IE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-GB Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-DE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-BE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
GLPG2222 150 mg q.d.
Galapagos NV
2017 Phase 2 NCT03045523 Australia;Belgium;Czechia;Germany;Ireland;United Kingdom;
GLPG2222 300 mg q.d.
Galapagos NV
2017 Phase 2 NCT03045523 Australia;Belgium;Czechia;Germany;Ireland;United Kingdom;
GLPG2451 dose regimen A
Galapagos NV
2018 Phase 1 NCT03540524 Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
GLPG2451 dose regimen B
Galapagos NV
2018 Phase 1 NCT03540524 Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
GLPG2737
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
2018 Phase 1 NCT03540524 Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
2017 Phase 2 NCT03474042 Germany;
2017 Phase 2 EUCTR2017-002181-42-DE Germany;
GLPG2737 single dose
Galapagos NV
2017 Phase 1 NCT03450720 Belgium;
GLPG3067
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
GLPG3067 single dose
Galapagos NV
2018 Phase 1 NCT03589313 Belgium;
GLUTATHIONE SODIUM
Aarhus University Hospital
2014 Phase 2 EUCTR2013-005481-19-DK Denmark;
GLYPRESSINE 1 mg/5 mL, poudre et solvant pour solution injectable (I.V.)
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2021 Phase 3 EUCTR2020-005931-58-FR France;
GS-5737
Gilead Sciences
2013 Phase 1 NCT01840735 United States;
2012 Phase 1 NCT01793649 United States;
GS-5745
Gilead Sciences, Inc.
2016 Phase 2 EUCTR2015-002192-23-ES Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002192-23-DE Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002192-23-BE Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
GS-9411
Gilead Sciences
2009 Phase 1 NCT01025713 Australia;
2009 Phase 1 NCT00999531 Australia;
2009 Phase 1 NCT00951522 Australia;
2008 Phase 1 NCT00800579 Australia;
GSH (Glutathione)
Mukoviszidose Institut gGmbH i. G.
2006 - EUCTR2005-003870-88-DE Germany;
Galicaftor
AbbVie
2021 Phase 2 NCT04853368 Australia;Belgium;Czechia;Germany;Hungary;Netherlands;New Zealand;Slovakia;
AbbVie Deutschland
2019 Phase 2 EUCTR2019-000750-63-NL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-HU Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-GB Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-FR Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-BE Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2020 Phase 2 EUCTR2019-000750-63-PL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
Gallium nitrate
Chris Goss
2021 Phase 1 NCT04294043 United States;
University of Washington
2016 Phase 2 NCT02354859 United States;
Genistein (Unconjugated Isoflavones 100)
Children's Hospital of Philadelphia
2003 Phase 1/Phase 2 NCT00590538 United States;
Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm
University Medical Centre Utrecht
2014 Phase 2 EUCTR2014-000817-30-NL Netherlands;
Gentamicin
Assistance Publique - Hôpitaux de Paris
2003 Phase 2 NCT00376428 France;
Gernebcin
University of Jena
2008 - EUCTR2008-000164-17-DE Germany;
Ghrelin
Papworth Hospital
2010 - NCT00763477 United Kingdom;
Giving DHA-rich supplement
University Hospital, Ghent
2007 Phase 2 NCT00221546 Belgium;
Glargine
Federico II University
2006 Phase 4 NCT00483769 Italy;
Glargine insulin
University of Minnesota - Clinical and Translational Science Institute
2003 Phase 3 NCT00222521 United States;
Glucose
Children's Hospital of Philadelphia
2013 - NCT01852448 United States;
Christoph Saner
2015 - NCT02569229 Switzerland;
Emory University
2014 - NCT02202876 United States;
Hospices Civils de Lyon
2009 - NCT02723968 -
Imperial College London
2009 - NCT01091025 United Kingdom;
Katie Larson Ode
2019 - NCT03650712 United States;
Liverpool Heart and Chest Hospital NHS Foundation Trust
2011 - NCT03644199 United Kingdom;
Mayo Clinic
2021 - NCT04579939 United States;
National Center for Research Resources (NCRR)
2001 - NCT00014768 United States;
Royal Brompton & Harefield NHS Foundation Trust
2013 - NCT01883037 United Kingdom;
Yale University
2015 Early Phase 1 NCT02398383 United States;
Glutamine
Emory University
2010 Phase 2 NCT01051999 United States;
Glutathione
AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI
2009 - EUCTR2008-005080-33-IT Italy;
Glycine
Instituto Nacional de Enfermedades Respiratorias
2012 Phase 2 NCT01417481 Mexico;
Glycine Buffer
University Hospitals Cleveland Medical Center
2018 Phase 1/Phase 2 NCT03617718 United States;
GlycosBio Nutritional Supplement
GlycosBio, Inc.
2018 - NCT04966897 United States;
Gold
The Alfred
2016 - NCT02717650 Australia;
Growth Hormone Stimulation Test
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
Growth hormone
University of Utah
2001 Phase 2 NCT00016445 United States;
H02 - Corticosteroidi Sistemici
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
HEPARIN SODIUM
Vectura Limited
2008 - EUCTR2007-006276-11-IE Ireland;Italy;
2008 - EUCTR2007-006276-11-GB Ireland;Italy;United Kingdom;
- Phase 2 EUCTR2007-006276-11-PL Ireland;Italy;Poland;United Kingdom;
HFNT during exercise
The Leeds Teaching Hospitals NHS Trust
2019 - NCT03965832 United Kingdom;
HGPIV diagnosis test
Hospices Civils de Lyon
2009 - NCT02723968 -
HMSCs
Marilyn Glassberg
2016 Phase 1 NCT02625246 United States;
HOMAR-IR diagnosis test
Hospices Civils de Lyon
2009 - NCT02723968 -
HP 129Xe
Thunder Bay Regional Research Institute
2019 Early Phase 1 NCT02748798 Canada;
HP 3He
Thunder Bay Regional Research Institute
2019 Early Phase 1 NCT02748798 Canada;
Heparin 25mg inhalation powder, hard capsule
VECTURA LIMITED
2010 - EUCTR2007-006276-11-IT Ireland;Italy;
Vectura Limited
2008 - EUCTR2007-006276-11-IE Ireland;Italy;
2008 - EUCTR2007-006276-11-GB Ireland;Italy;United Kingdom;
- Phase 2 EUCTR2007-006276-11-PL Ireland;Italy;Poland;United Kingdom;
Heracillin
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
High dose of budesonide
Hospital General de Requena
2004 - NCT00728715 Spain;
High flow nasal oxygen cannula
St. Michael's Hospital, Toronto
2014 - NCT02262871 Canada;
High-Dose Vitamin D3
Emory University
2015 - NCT02589444 United States;
History and physical exam.
University of Florida
2007 - NCT01851642 United States;
Home Oral Glucose Tolerance Test kit
Great Ormond Street Hospital for Children NHS Foundation Trust
2015 - NCT02703155 United Kingdom;
Human recombinant growth hormone
National Center for Research Resources (NCRR)
2000 Phase 3 NCT00005112 United States;
Hyaluronan
Ospedale Civile Ca' Foncello
2009 - NCT01658449 Italy;
Hydrocortisone
Birmingham Children's Hospital NHS Foundation Trust
2012 - EUCTR2011-005790-23-GB United Kingdom;
Hydroxychloroquine
Vanderbilt University
2006 Phase 1 NCT00311883 United States;
Hyperglycemic Clamp with concurrent GIP infusion
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Hyperglycemic clamp with concurrent GLP-1 infusion
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Hyperpolarized Helium-3
University of Massachusetts, Worcester
2008 - NCT00846573 United States;
Hyperpolarized Helium-3 MRI of the chest
University of Virginia
2011 - NCT02163681 United States;
Hyperpolarized Xe129
Mario Castro, MD, MPH
2020 Phase 1 NCT04624490 United States;
Hyperpolarized Xenon
Children's Hospital Medical Center, Cincinnati
2016 - NCT02848560 United States;
Hyperpolarized Xenon 129
Children's Hospital Medical Center, Cincinnati
2020 Phase 4 NCT04467957 -
Hyperpolarized Xenon gas
Children's Hospital Medical Center, Cincinnati
2018 - NCT03593434 United States;
University of North Carolina, Chapel Hill
2018 Early Phase 1 NCT03482960 United States;
Hyperpolarized xenon-129
The University of Nottingham
- Phase 2 EUCTR2019-003052-36-GB United Kingdom;
Hypertonic Saline
Parion Sciences
2015 Phase 2 NCT02343445 United States;
The Hospital for Sick Children
2011 Phase 2 NCT02276898 Canada;
2006 Phase 2 NCT00721071 Canada;
2006 Phase 1 NCT00753987 Canada;
Tim Corcoran
2017 Phase 1 NCT02947126 United States;
University of North Carolina, Chapel Hill
2009 - NCT01031706 United States;
University of Oklahoma
2006 - NCT00671723 United States;
Hypertonic Saline (HS)
CF Therapeutics Development Network Coordinating Center
2009 - NCT00709280 Canada;United States;
University of Washington, the Collaborative Health Studies Coordinating Center
2015 - NCT02378467 Canada;United States;
Hypertonic Saline (HS), 4mL
Heidelberg University
2012 Phase 2 NCT01619657 Germany;
Hypertonic bicarbonate
Joseph Pilewski
2014 Phase 1 NCT03391414 United States;
Hypertonic saline
Adelaida Lamas Ferreiro
2009 Phase 4 NCT01377792 Spain;
Erasmus MC
2018 Phase 3 EUCTR2015-004143-39-IT Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2017 Phase 3 EUCTR2015-004143-39-DK Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-NL Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-BE Australia;Belgium;Denmark;Netherlands;Spain;United States;
- Phase 3 EUCTR2015-004143-39-FR Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
Joseph Zabner
2011 Phase 1/Phase 2 NCT01355796 United States;
Royal Prince Alfred Hospital, Sydney, Australia
2000 Phase 3 NCT00271310 -
The Hospital for Sick Children
2008 - NCT00700050 Canada;
Hypertonic saline ()
University of Pittsburgh
2010 Phase 1 NCT01223183 United States;
Hypertonic saline () and isotonic saline ()
The Hospital for Sick Children
2008 Phase 3 NCT00635141 Canada;
Hypertonic saline -
The Alfred
2007 Phase 3 NCT00484263 Australia;
Hypertonic saline solution
University Hospital Ghent
2007 - EUCTR2007-002707-40-BE Belgium;
ICS+LABA
Shanghai Pulmonary Hospital, Shanghai, China
2011 Phase 4 NCT02782312 China;
IDPM
Pharmaxis Pharmaceuticals Limited
2009 Phase 3 EUCTR2008-002740-42-FR Belgium;France;Germany;Netherlands;
2009 - EUCTR2008-002740-42-NL Belgium;France;Germany;Netherlands;
2009 - EUCTR2008-002740-42-BE Belgium;France;Germany;Netherlands;
2008 - EUCTR2008-002740-42-DE Belgium;France;Germany;Netherlands;
2007 - EUCTR2007-001412-23-IE Ireland;United Kingdom;
- Phase 3 EUCTR2007-001412-23-DE Germany;Ireland;United Kingdom;
IDPM: Inhaled Dry Powder Mannitol
Pharmaxis Ltd
2009 - EUCTR2008-008228-34-GB United Kingdom;
Pharmaxis Pharmaceuticals Limited
2009 - EUCTR2007-001412-23-GB Ireland;United Kingdom;
Pharmaxis UK Limited
2007 Phase 3 EUCTR2006-004078-28-GB United Kingdom;
IGE025
Novartis Pharma Services AG
2008 - EUCTR2007-006648-23-DE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
INCRELEX*SC 1FL 4ML 10MG/ML
AZIENDA OSPEDALIERA DI PARMA
2011 - EUCTR2011-002719-27-IT Italy;
INDUSIL*OS GTT FL 30MG+FL 15ML
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
2010 - EUCTR2010-020516-11-IT Italy;
INOmax 400ppm mol/mol inhalation gas
Southampton University Hopsitals NHS Trust
2011 - EUCTR2010-023529-39-GB United Kingdom;
INS1007
INSMED INCORPORATED
2021 Phase 3 EUCTR2020-003688-25-IT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-IT Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
Insmed Incorporated
2021 Phase 3 EUCTR2020-003688-25-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-LT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-IE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2017-002533-32-BE Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-SE Australia;Belgium;Bulgaria;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-PL Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-NL Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-GB Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-ES Australia;Belgium;Bulgaria;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-DK Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-DE Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-BG Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
INS1007 10 mg oral tablet
Insmed Incorporated
2017 Phase 2 NCT03218917 Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
INS1007 25 mg oral tablet
Insmed Incorporated
2017 Phase 2 NCT03218917 Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
IONIS-ENaCRx
Ionis Pharmaceuticals, Inc.
2018 Phase 1 NCT03647228 Germany;United Kingdom;
IV amikacin
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV ceftazidime
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV glucose tolerance test
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
IV meropenem
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV piperacillin-tazobactam
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV ticarcillin-clavulanate
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV tobramycin
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV vancomycin hydrochloride
Savara Inc.
2011 Phase 1 NCT01537666 Australia;
IVA
Vertex Pharmaceuticals Incorporated
2019 Phase 2 NCT03911713 Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 3 NCT03691779 Australia;Ireland;United Kingdom;United States;
2018 Phase 3 NCT03601637 Canada;United States;
2018 Phase 3 NCT03537651 Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 NCT03525574 Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 NCT03447262 Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 2 NCT03625466 Germany;
2016 Phase 2 NCT02971839 United States;
2016 Phase 2 NCT02951182 Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;United Kingdom;United States;
2016 Phase 1 NCT03486236 United Kingdom;
IVACAFTOR 59,
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
Ibuprofen
FDA Office of Orphan Products Development
1996 - NCT00004440 -
Ramsey, Bonnie, MD
2004 - NCT00219895 United States;
University Hospitals Cleveland Medical Center
2007 - NCT00531882 United States;
Icenticaftor
Novartis Pharma AG
2021 Phase 2 EUCTR2019-002840-26-DE China;Germany;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002840-26-GB China;Germany;Spain;United Kingdom;
IgY
Mukoviszidose Institut gGmbH
2011 Phase 3 NCT01455675 Austria;Belgium;Germany;Hungary;Ireland;Italy;Poland;Spain;Sweden;
Impact
Alcresta Therapeutics, Inc.
2016 - NCT02750501 United States;
Impact-Nutridrink
University Hospital, Motol
2013 Phase 4 NCT02048592 Czech Republic;
Indirect Calorimetry
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
Indium
University of Pittsburgh
2007 - NCT00541190 United States;
Indium-DTPA
Tim Corcoran
2017 Phase 1 NCT02947126 United States;
Influenza vaccination
Assistance Publique - Hôpitaux de Paris
2009 Phase 4 NCT01499914 France;
Inhaled AR-501
Aridis Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03669614 United States;
Inhaled Mannitol
Pharmaxis
2013 Phase 2 NCT01883531 United Kingdom;
Inhaled Reduced Glutathione
Serafino A. Marsico
2010 Phase 3 NCT01450267 Italy;
Inhaled SNSP113
Synspira, Inc.
2017 Phase 1 NCT03309358 United Kingdom;
Inhaled Sodium Pyruvate
University of Minnesota - Clinical and Translational Science Institute
2006 Phase 1 NCT00332215 United States;
Inhaled Vancomycin
Johns Hopkins University
2012 Phase 2 NCT01594827 United States;
Inhaled dry powder mannitol
Pharmaxis Pharmaceuticals Limited
2007 - EUCTR2007-001412-23-IE Ireland;United Kingdom;
- Phase 3 EUCTR2007-001412-23-DE Germany;Ireland;United Kingdom;
Inhaled hypertonic saline ()
Tim Corcoran
2013 Phase 1 NCT01887197 United States;
University of Pittsburgh
2014 Phase 1 NCT02141191 United States;
Inhaled hypertonic saline (HS)
CF Therapeutics Development Network Coordinating Center
2007 - NCT00546663 Canada;United States;
Inhaled mannitol
Pharmaxis
2014 Phase 3 NCT02134353 Argentina;Australia;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Israel;Italy;Mexico;New Zealand;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
2008 Phase 3 NCT00630812 Argentina;Belgium;Canada;France;Germany;Netherlands;United States;
2004 Phase 2 NCT00455130 Australia;New Zealand;
Inhaled tobramycin
Seattle Children's Hospital
2016 Phase 4 NCT02677701 United States;
University of North Carolina, Chapel Hill
2004 Phase 1 NCT00823238 United States;
Initiation of CFTR Modulator
Children's Hospital Medical Center, Cincinnati
2020 Phase 4 NCT04467957 -
2020 Phase 4 NCT04259970 Canada;United States;
Insulin
Fondazione per la ricerca sulla Fibrosi Cistica
2005 Phase 3 NCT00687466 Italy;
Jagdeesh Ullal
2021 Phase 4 NCT04533646 United States;
National Center for Research Resources (NCRR)
2001 - NCT00014768 United States;
Insulin Asparte
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2001 Phase 3 NCT00072904 Canada;United States;
Insulin Pump
University of Texas Southwestern Medical Center
2006 - NCT00287456 United States;
Insulin detemir [rDNA origin] injection
Nationwide Children's Hospital
2008 Phase 2/Phase 3 NCT00639626 United States;
Insulin glargine
ISTITUTO GIANNINA GASLINI
2005 - EUCTR2005-002135-27-IT Italy;
Insuline humaine recombinante
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2006 - EUCTR2006-001254-27-FR France;
Interferon gamma-1b
InterMune
2002 Phase 1/Phase 2 NCT00043342 United States;
2001 Phase 1/Phase 2 NCT00043316 United States;
Intermittent, short infusion Cefepime
The Alfred
2012 Phase 4 NCT01667094 Australia;
Intermittent, short infusion Ceftazidime
The Alfred
2012 Phase 4 NCT01667094 Australia;
Intermittent, short infusion Meropenem
The Alfred
2012 Phase 4 NCT01667094 Australia;
Intermittent, short infusion Piperacillin tazobactam
The Alfred
2012 Phase 4 NCT01667094 Australia;
Intermittent, short infusion Ticarcillin-clavulanate
The Alfred
2012 Phase 4 NCT01667094 Australia;
Inulin
Emory University
2020 Phase 4 NCT04118010 United States;
Isotonic Saline
Tim Corcoran
2017 Phase 1 NCT02947126 United States;
Isotonic Saline (IS)
CF Therapeutics Development Network Coordinating Center
2009 - NCT00709280 Canada;United States;
University of Washington, the Collaborative Health Studies Coordinating Center
2015 - NCT02378467 Canada;United States;
Isotonic Saline (IS), 4mL
Heidelberg University
2012 Phase 2 NCT01619657 Germany;
Isotonic saline
Erasmus MC
2018 Phase 3 EUCTR2015-004143-39-IT Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2017 Phase 3 EUCTR2015-004143-39-DK Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-NL Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-BE Australia;Belgium;Denmark;Netherlands;Spain;United States;
- Phase 3 EUCTR2015-004143-39-FR Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
University of Jena
2007 Phase 3 NCT00534079 Germany;
University of Pittsburgh
2010 Phase 1 NCT01223183 United States;
2008 - NCT00628134 United States;
Itraconazole
Novartis Pharmaceuticals
2008 Phase 4 NCT00787917 Belgium;Germany;Italy;Netherlands;United Kingdom;
Ottawa Hospital Research Institute
2007 Phase 4 NCT00528190 Canada;
Vertex Pharmaceuticals Incorporated
2013 Phase 1 NCT01768663 United States;
Itraconazole/voriconazole
Rennes University Hospital
2014 Phase 2 NCT01576315 France;United Kingdom;
Ivacaftor
Children's Hospital of Philadelphia
2019 - NCT03783286 United States;
Eloxx Pharmaceuticals Inc
2019 Phase 2 EUCTR2018-000966-12-DE Australia;Germany;Israel;
Eloxx Pharmaceuticals, Inc.
2019 Phase 2 NCT04135495 Canada;United States;
Medical University of South Carolina
2016 Phase 3 NCT02934698 -
Richard Barry Moss
2015 - NCT02310789 United States;
The Alfred
2014 Phase 4 NCT01937325 Australia;
University of California, San Francisco
2013 - NCT01784419 United States;
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2019 Phase 2 EUCTR2018-003970-28-NL Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-GB Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 3 NCT03277196 Australia;Canada;Germany;Ireland;United Kingdom;United States;
2017 Phase 3 NCT03068312 Israel;
2016 Phase 3 NCT02742519 Australia;Canada;United Kingdom;
2016 Phase 3 NCT02725567 Australia;Canada;Ireland;United Kingdom;United States;
2016 Phase 2 NCT02951195 United States;
2016 Phase 1 NCT03029455 United Kingdom;
2015 Phase 3 NCT02390219 United States;
2015 - NCT02445053 Italy;Netherlands;United Kingdom;
2014 Phase 2 NCT02070744 United States;
2014 Phase 1 NCT02015507 -
2013 Phase 3 NCT01946412 Canada;United Kingdom;United States;
2013 Phase 3 NCT01897233 Canada;United States;
2013 Phase 3 NCT01707290 Belgium;France;Ireland;United Kingdom;United States;
2013 Phase 3 NCT01705145 Canada;United Kingdom;United States;
2013 Phase 1 NCT01910415 Netherlands;
2013 Phase 1 NCT01899105 United States;
2013 Phase 1 NCT01768663 United States;
2012 Phase 3 NCT01614470 Belgium;France;United States;
2012 Phase 3 NCT01614457 Ireland;United Kingdom;United States;
2012 Phase 2 NCT01685801 United States;
2012 Phase 2 NCT01531673 Canada;Germany;United Kingdom;United States;
2011 Phase 2 NCT01262352 Canada;Ireland;United Kingdom;United States;
2010 Phase 3 NCT01117012 Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 Phase 3 EUCTR2009-012997-11-GB Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 Phase 2 NCT01225211 Australia;Belgium;France;Germany;Ireland;New Zealand;United Kingdom;United States;
2010 - EUCTR2010-020546-96-GB Canada;United Kingdom;United States;
2010 - EUCTR2009-012997-11-IE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2009-012997-11-DE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2009-012997-11-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 NCT00909727 Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 NCT00909532 Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-007479-26-GB Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-007416-15-GB Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 2 NCT00953706 United States;
2009 - EUCTR2008-007479-26-IE Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 - EUCTR2008-007479-26-DE Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 - EUCTR2008-007416-15-IE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- - EUCTR2008-007416-15-DE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
university medical center utrecht
2018 Phase 4 EUCTR2016-001440-18-NL Netherlands;
Ivacaftor (proposed INN)
Vertex Pharmaceuticals Incorporated
- - EUCTR2009-010261-23-Outside-EU/EEA United States;
Ivacaftor 125mg tablet
Vertex Pharmaceuticals Incorporated
2014 Phase 3 EUCTR2013-000604-41-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-IT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 - EUCTR2013-000604-41-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-SE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-GB Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003990-24-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003989-40-NL Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IT Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-DE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
Ivacaftor 150 mg or
Vertex Pharmaceuticals Incorporated
2007 Phase 2 NCT00457821 Canada;Germany;United States;
Ivacaftor 25 mg/
Vertex Pharmaceuticals Incorporated
2007 Phase 2 NCT00457821 Canada;Germany;United States;
Ivacaftor 75 mg/
Vertex Pharmaceuticals Incorporated
2007 Phase 2 NCT00457821 Canada;Germany;United States;
Ivacaftor Exposed
Vertex Pharmaceuticals Incorporated
2013 - NCT01863238 United States;
Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Sonya Heltshe
2020 - NCT04509050 United States;
Ivacaftor+lumacaftor
Assistance Publique - Hôpitaux de Paris
2016 - NCT03475381 France;
Ivacaftor/Ataluren
University of Alabama at Birmingham
2017 Phase 4 NCT03256799 United States;
Ivacaftor/Kalydeco
University Medical Centre Utrecht
2014 Phase 2 EUCTR2014-000817-30-NL Netherlands;
Ivacaftor/Trikafta
University of Alabama at Birmingham
2018 Phase 4 NCT03624101 United States;
J01GB01
University Medical Center Groningen
2013 - EUCTR2012-004437-16-NL Netherlands;
- Phase 2 EUCTR2016-005014-21-NL Netherlands;
JBT-101
CORBUS PHARMACEUTICALS, INC
2018 Phase 2 EUCTR2017-003723-29-IT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Corbus Pharmaceuticals, Inc.
2020 Phase 2;Phase 3 EUCTR2020-001762-11-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2020-001762-11-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003723-29-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003723-29-NL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-SK Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-PT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-GR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002581-23-DE Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
2015 Phase 2 EUCTR2015-002581-23-GB Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
2015 Phase 2 EUCTR2015-002581-23-FR Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
2015 Phase 2 EUCTR2015-002581-23-BE Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2017-003723-29-FR Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
JBT-101 (lenabasum)
Corbus Pharmaceuticals Inc.
2015 Phase 2 NCT02465450 Belgium;France;Germany;Italy;Poland;United Kingdom;United States;
KB001
KaloBios Pharmaceuticals
2008 Phase 1/Phase 2 NCT00638365 United States;
KB001-A
KaloBios Pharmaceuticals
2012 Phase 2 NCT01695343 Australia;Israel;New Zealand;United States;
KREON 25000
Aptalis Pharma US Inc.
2013 - EUCTR2009-012842-21-HU Bulgaria;Germany;Hungary;Italy;United Kingdom;
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-DE Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-BG Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
Axcan Pharma Inc.
- - EUCTR2010-019267-11-DE Germany;
KREON N 25000
Abbott Laboratories GmbH
2013 - EUCTR2013-002819-10-ES Hungary;Russian Federation;Spain;
KREON de Liberación Inmediata
Abbott Laboratories GmbH
2015 Phase 2 EUCTR2014-004519-35-ES Czech Republic;Hungary;Spain;United Kingdom;
Kaftrio
Haga Teaching Hospital
2021 Phase 4 EUCTR2020-005224-12-NL Netherlands;
Royal College of Surgeons, Ireland
2020 Phase 4 NCT04602468 Ireland;United Kingdom;
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
Kalydeco
Eloxx Pharmaceuticals Inc
2019 Phase 2 EUCTR2018-000966-12-DE Australia;Germany;Israel;
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-PL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2016-004479-35-GB Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2017-001379-21-GB Canada;Germany;Ireland;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001997-16-IE Canada;Germany;Ireland;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001267-39-GB Australia;Canada;France;United Kingdom;
2016 Phase 3 EUCTR2014-004838-25-DE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-AT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004788-18-BE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-BE Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-SE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-NL Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IT Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-GB Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-ES Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DK Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-NL Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-IT Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-GB Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-DE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004787-37-ES Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-DE Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-AT Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 - EUCTR2014-004827-29-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2014 Phase 2 EUCTR2010-020413-90-GB Australia;Belgium;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2010-020413-90-IE Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
2013 Phase 3 EUCTR2012-000386-20-GB Canada;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000389-39-GB Belgium;France;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000389-39-BE Belgium;France;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000388-26-BE Belgium;France;United States;
2012 - EUCTR2012-000387-19-GB United Kingdom;United States;
2011 - EUCTR2010-020413-90-DE Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
2011 - EUCTR2010-020413-90-BE Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
2010 Phase 3 EUCTR2009-012997-11-GB Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2009-012997-11-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-001379-21-IE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2017-001379-21-DE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001997-16-GB Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001997-16-DE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001267-39-FR Australia;Canada;France;United Kingdom;
- Phase 2 EUCTR2017-000673-37-Outside-EU/EEA United States;
- Phase 2 EUCTR2017-000672-28-Outside-EU/EEA United States;
Kalydeco 150 mg film-c
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Kalydeco 150 mg film-coated tablets
VERTEX PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2019-000833-37-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-IT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2021-001628-16-ES Australia;Belgium;Canada;Spain;
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-001827-11-IE Australia;Canada;Ireland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004652-38-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001735-31-GB Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000833-37-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001695-38-GB Australia;Canada;Ireland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004134-29-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-NL Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-GB Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-DE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-BE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-IE Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-GB Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-ES Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-000126-55-NL Netherlands;
2017 Phase 3 EUCTR2017-000540-18-DE France;Germany;United States;
2017 Phase 2 EUCTR2017-000797-11-NL Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-NL Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-GB Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-ES Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-DE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-BE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-AT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000454-36-DK Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-001628-16-BE Australia;Belgium;Canada;Spain;
- Phase 3 EUCTR2019-001827-11-GB Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2019-001735-31-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2019-000833-37-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-001695-38-IE Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-004133-82-DE Australia;Germany;Ireland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-004132-11-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000540-18-FR France;Germany;United States;
Ketone Monoester
University of Alabama at Birmingham
2021 - NCT04938726 -
Kineret
Ruprecht-Karls-University Heidelberg, Medical Faculty
- Phase 2 EUCTR2016-004786-80-DE Germany;
Klacid
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Kreon 25 000
Abbott Laboratories GmbH
2015 Phase 2 EUCTR2014-004519-35-ES Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-HU Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-GB Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-CZ Czech Republic;Hungary;Spain;United Kingdom;
Aptalis Pharma US Inc.
2013 - EUCTR2009-012842-21-HU Bulgaria;Germany;Hungary;Italy;United Kingdom;
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-DE Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-BG Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
Kreon 25,000 Units
Aptalis Pharma
2012 Phase 3 NCT01641393 Belgium;Bulgaria;France;Germany;Italy;Poland;United Kingdom;
Kreon 25000
Abbott Laboratories GmbH
2013 - EUCTR2013-002819-10-ES Hungary;Russian Federation;Spain;
Kreon® 25,000
Abbott Laboratories GmbH
2015 Phase 2 EUCTR2014-004519-35-ES Czech Republic;Hungary;Spain;United Kingdom;
Forest Laboratories
2011 Phase 4 NCT01327703 Germany;Poland;
L-Glutamine
University of Nottingham
2008 Phase 4 EUCTR2007-006204-37-GB United Kingdom;
L-Lysine N acetylcysteinate
LABORATOIRES SMB S.A.
2010 - EUCTR2010-018454-13-IT Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine N-acetylcysteinate
LABORATOIRES SMB S.A.
2010 - EUCTR2010-018454-13-IT Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine- N-acetylcysteinate
Laboratoires SMB S.A.
2010 Phase 3 EUCTR2010-018454-13-ES Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine-N-acetyl-L-cysteinate
Laboratoires SMB S.A.
- Phase 3 EUCTR2010-018454-13-BE Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine-N-acetylcysteinate
Laboratoires SMB S.A.
2010 Phase 3 EUCTR2010-018454-13-FR Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018454-13-DK Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-HU Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-GB Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-DE Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-CZ Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-alanine
Emory University
2010 Phase 2 NCT01051999 United States;
L-arginine
The Hospital for Sick Children
2006 Phase 2 NCT00405665 Canada;
LABA/LAMA
Shanghai Pulmonary Hospital, Shanghai, China
2020 Phase 4 NCT04509661 -
LANTUS*SC 5CAR3ML100UI/ML
ISTITUTO GIANNINA GASLINI
2005 - EUCTR2005-002135-27-IT Italy;
LAU-7b
Laurent Pharmaceuticals Inc.
2018 Phase 2 NCT03265288 Australia;Canada;United States;
LEVOFLOXACIN HEMIHYDRATE
Medical University of Vienna
2020 Phase 4 EUCTR2019-000955-16-AT Austria;
LIPASA
ANTHERA Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2016-002851-92-ES Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
LIPASE
ANTHERA Pharmaceuticals, Inc.
2017 Phase 3 EUCTR2017-000571-85-LT Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-HU Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-GB Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000571-85-ES Hungary;Israel;Lithuania;Poland;Spain;United States;
2016 Phase 4 EUCTR2016-002851-92-CZ Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
2016 Phase 3 EUCTR2016-002851-92-HU Canada;Hungary;Israel;Spain;United States;
2016 Phase 3 EUCTR2015-002739-17-CZ Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-HU Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-ES Canada;Czech Republic;Hungary;Israel;Spain;United States;
- Phase 3 EUCTR2017-000571-85-PL Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-002851-92-PL Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
LU 70274
Nordmark Arzneimittel GmbH
2006 - EUCTR2006-005180-25-DE Germany;
LUM
Vertex Pharmaceuticals Incorporated
2018 Phase 3 NCT03601637 Canada;United States;
2018 Phase 2 NCT03625466 Germany;
LUM/IVA
Vertex Pharmaceuticals Incorporated
2020 Phase 3 NCT04235140 Canada;United States;
2017 Phase 3 NCT03125395 Canada;United States;
2017 Phase 2 NCT03061331 Netherlands;
2016 Phase 4 NCT02875366 Australia;United Kingdom;
2016 Phase 4 NCT02823470 Canada;United States;
2016 Phase 3 NCT02797132 Canada;United States;
2015 Phase 3 NCT02544451 Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
LUM/IVA fixed-dose combination
Vertex Pharmaceuticals Incorporated
2018 Phase 2 EUCTR2017-003761-99-DE Germany;
2016 Phase 2 EUCTR2016-001585-29-NL Netherlands;
Lactic acid producing organisms
UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
2009 - EUCTR2009-015875-28-IT Italy;
2009 - EUCTR2009-011289-27-IT Italy;
Lactizole nebulization
Medical Universtity of Lodz
2019 - NCT04058340 Poland;
Lactobacillus reuteri
Azienda Policlinico Umberto I
2009 Phase 4 NCT01737983 Italy;
Lactobacillus rhamnosus
Cantonal Hospital of St. Gallen
2013 - NCT01837355 Switzerland;
Lactobacillus rhamnosus GG
Federico II University
2010 Phase 3 NCT01956916 Italy;
2009 Phase 3 NCT01961661 Italy;
Lansoprazole
Arkansas Children's Hospital Research Institute
2006 Phase 1 NCT00458614 United States;
Lantus 100 units/ml solution for injection in a cartridge
HagaZiekenhuis, pulmonary department
2012 - EUCTR2011-001916-69-NL Netherlands;
Lantus® 100 Units/ml solution for injection in a vial. Lantus® 100 Units/ml solution for injection in a cartridge. Lantus® 100 Units/ml solution for injection in a pre-filled pen
St George's, University of London
2008 - EUCTR2007-004956-35-GB United Kingdom;
Lefamulin
Nabriva Therapeutics AG
2022 Phase 1 NCT05225805 -
Lenabasum
CORBUS PHARMACEUTICALS, INC
2018 Phase 2 EUCTR2017-003723-29-IT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Corbus Pharmaceuticals Inc.
2017 Phase 2 NCT03451045 Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Corbus Pharmaceuticals, Inc.
2020 Phase 2;Phase 3 EUCTR2020-001762-11-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2020-001762-11-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003723-29-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-SK Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-GR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2017-003723-29-FR Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Leucine
National Center for Research Resources (NCRR)
2001 - NCT00014768 United States;
Levemir 100 U/ml solution for injection in a cartridge, Levemir 100 U/ml solution for injection in a pre-filled pen
St George's, University of London
2008 - EUCTR2007-004956-35-GB United Kingdom;
Levemir FlexPen
Liverpool Heart and Chest Hospital NHS Trust
2013 - EUCTR2012-002880-86-GB United Kingdom;
Levemir Penfill
Sheffield Children's NHS Trust
2006 Phase 4 EUCTR2005-002997-31-GB United Kingdom;
Levemir insulin
University of Minnesota
2015 Phase 2/Phase 3 NCT02496780 United States;
Levofloxacin
Mpex Pharmaceuticals, Inc.
2008 - EUCTR2008-001728-30-NL Germany;Netherlands;
2008 - EUCTR2008-001728-30-DE Germany;Netherlands;
Levofloxacin Kabi
Medical University of Vienna
2020 Phase 4 EUCTR2019-000955-16-AT Austria;
Levofloxacin hemihydrate
Mpex Pharmaceuticals, Inc.
2011 Phase 3 EUCTR2010-019634-26-GB Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-IE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-DE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
- Phase 3 EUCTR2010-019634-26-FR France;Germany;Ireland;United Kingdom;
Linez
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Linezolid
University of Texas Southwestern Medical Center
2010 Phase 2 NCT00625703 United States;
Linoleic acid supplementation
Karolinska Institutet
2021 - NCT04531410 Italy;Norway;Poland;Sweden;
Lipase CLEC
Altus Pharmaceuticals Inc
2007 Phase 3 EUCTR2007-000171-41-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000171-41-PL Italy;Poland;Slovakia;
Altus Pharmaceuticals Inc.
2007 Phase 3 EUCTR2007-000178-21-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000178-21-PL Italy;Poland;Slovakia;
Lipase Lip2 from Yarrowia lipolytica
AzurRx
2020 Phase 2 EUCTR2018-003831-31-ES Hungary;Poland;Spain;
AzurRx SAS
- Phase 2 EUCTR2018-003831-31-PL Hungary;Poland;Spain;Turkey;
Lipitor
NHS Lothian
2010 Phase 4 EUCTR2010-022042-24-GB United Kingdom;
2010 Phase 4 EUCTR2010-022040-20-GB United Kingdom;
Liposomal Amikacin
INSMED INCORPORATED
2012 - EUCTR2011-000443-24-IT Australia;Austria;Belgium;Bulgaria;Canada;Denmark;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Spain;Sweden;United Kingdom;
Liposomal Amikacin (Arikace TM)
Insmed Incorporated
2011 Phase 3 EUCTR2011-000443-24-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
Liposomal Amikacin (Arikace™)
INSMED INCORPORATED
2011 - EUCTR2011-000441-20-IT Austria;Bulgaria;Canada;Denmark;Greece;Hungary;Ireland;Italy;Netherlands;Spain;United Kingdom;
Insmed Incorporated
2013 - EUCTR2011-000443-24-NL Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000443-24-PL Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000443-24-BE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000441-20-BE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000443-24-SE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-000443-24-DK Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-000441-20-NL Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2012 - EUCTR2011-000441-20-IE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-DK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-BG Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-000443-24-SK Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-000443-24-GB Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-000443-24-FR Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2011 - EUCTR2011-000443-24-IE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000443-24-HU Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000443-24-GR Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2011 - EUCTR2011-000443-24-DE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;
2011 - EUCTR2011-000443-24-BG Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
2011 - EUCTR2011-000443-24-AT Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000442-38-ES Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-000442-38-BG Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-000441-20-SK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-HU Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-GR Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2011 - EUCTR2011-000441-20-GB Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-DE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-AT Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
- Phase 3 EUCTR2011-000442-38-PL Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
Transave, Inc.
2007 Phase 2 EUCTR2006-006980-22-SK Belgium;Hungary;Poland;Slovakia;
2007 - EUCTR2006-006980-22-HU Belgium;Hungary;
2007 - EUCTR2006-006980-22-BE Belgium;Hungary;
- Phase 2 EUCTR2006-006980-22-PL Belgium;Hungary;Poland;Slovakia;
Liposomal amikacin for inhalation
Insmed Incorporated
2012 Phase 3 NCT01316276 Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2012 Phase 3 NCT01315691 -
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
Insmed Incorporated
2012 Phase 3 NCT01315678 Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
Liposomal amphotericin B (Ambisome®)
Poitiers University Hospital
2014 Phase 2 NCT02273661 France;
Liprotamasa
ANTHERA Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2016-002851-92-ES Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
Liprotamase
ANTHERA Pharmaceuticals, Inc.
2017 Phase 3 EUCTR2017-000571-85-LT Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-HU Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-GB Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000571-85-ES Hungary;Israel;Lithuania;Poland;Spain;United States;
2016 Phase 4 EUCTR2016-002851-92-CZ Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
2016 Phase 3 EUCTR2016-002851-92-HU Canada;Hungary;Israel;Spain;United States;
2016 Phase 3 EUCTR2015-002739-17-CZ Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-HU Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-ES Canada;Czech Republic;Hungary;Israel;Spain;United States;
- Phase 3 EUCTR2017-000571-85-PL Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-002851-92-PL Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
Anthera Pharmaceuticals
2017 Phase 3 NCT03051490 Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2016 Phase 4 NCT02823964 Czech Republic;Czechia;Hungary;Israel;Poland;Spain;United States;
2015 Phase 3 NCT02279498 Canada;Czech Republic;Czechia;Hungary;Israel;Poland;Spain;United States;
2007 Phase 3 NCT00449904 United States;
2007 Phase 3 NCT00449878 United States;
2004 Phase 2 NCT00095732 United States;
Liprotamase Powder for Oral Solution
Anthera Pharmaceuticals
2016 Phase 3 NCT02734810 United States;
Loestrin (norethindrone acetate and ethinyl estradiol)
University of Texas Southwestern Medical Center
2014 Early Phase 1 NCT02036879 United States;
Lonodelestat
Santhera Pharmaceuticals (Switzerland) Ltd
2018 Phase 1;Phase 2 EUCTR2018-002550-71-DE Germany;
Losartan
University of Kansas Medical Center
2022 Early Phase 1 NCT03435939 United States;
University of Miami
2017 Phase 2 NCT03206788 United States;
Lubiprostone
University of Arkansas
2008 - NCT00706004 United States;
Lucinactant first
University of North Carolina, Chapel Hill
2008 Phase 2 NCT00934362 United States;
Lumacaftor
Vertex Pharmaceuticals Incorporated
2015 Phase 3 NCT02390219 United States;
2013 Phase 3 NCT01897233 Canada;United States;
2013 Phase 1 NCT01910415 Netherlands;
2013 Phase 1 NCT01899105 United States;
2013 Phase 1 NCT01768663 United States;
2010 Phase 2 NCT01225211 Australia;Belgium;France;Germany;Ireland;New Zealand;United Kingdom;United States;
Lumacaftor / ivacaftor
Vertex Pharmaceuticals Incorporated
2018 Phase 2 EUCTR2017-003761-99-DE Germany;
Lumacaftor Plus Ivacaftor Combination
Vertex Pharmaceuticals Incorporated
2013 Phase 3 NCT01931839 Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 NCT01807949 Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 NCT01807923 Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
Lumacaftor plus Ivacaftor
Hannover Medical School
2016 - NCT02807415 Germany;
Lumacaftor, Ivacaftor Drug Combination
Carmel Medical Center
2016 - NCT04623879 -
Lumacaftor-Ivacaftor treatment
University Hospital, Strasbourg, France
2016 - NCT03512119 France;
Lumacaftor-ivacaftor
Massachusetts General Hospital
2018 - NCT02653027 -
2016 - NCT02858843 -
Lumacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
2014 Phase 2 EUCTR2010-020413-90-GB Australia;Belgium;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2010-020413-90-IE Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
2011 - EUCTR2010-020413-90-DE Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
2011 - EUCTR2010-020413-90-BE Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
Lumacaftor/ivacaftor
Vertex Pharmaceuticals Incorporated
2016 Phase 4 EUCTR2016-000066-34-GB Australia;United Kingdom;
- Phase 3 EUCTR2017-001309-34-Outside-EU/EEA United States;
- Phase 3 EUCTR2017-001078-41-Outside-EU/EEA Canada;United States;
Lumacaftor/ivacaftor 100mg/125mg tablets
Vertex Pharmaceuticals Incorporated
2016 Phase 3 EUCTR2015-001644-11-GB Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-FR Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DK Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-BE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-SE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-GB Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-DK Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-DE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-BE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2015-001644-11-SE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2015-000543-16-FR Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
Lumacaftor/ivacaftor 200mg/
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
Lumacaftor/ivacaftor 200mg/125mg tablets
Vertex Pharmaceuticals Inc.
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2016 Phase 3 EUCTR2015-001644-11-GB Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-FR Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DK Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-BE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-IT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 - EUCTR2013-000604-41-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-SE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-GB Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003990-24-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003989-40-NL Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IT Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-DE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2015-001644-11-SE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
Lumacaftor/ivacaftor 200mg/83mg tablet
Vertex Pharmaceuticals Incorporated
2014 Phase 3 EUCTR2013-000604-41-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-IT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 - EUCTR2013-000604-41-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-SE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-GB Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003990-24-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003989-40-NL Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IT Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-DE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
Lung Clearance Index
The Hospital for Sick Children
2015 Phase 2 NCT02740868 Canada;
University of North Carolina, Chapel Hill
2015 Early Phase 1 NCT03497117 United States;
Lym-X-Sorb powder
Avanti Polar Lipids, Inc.
2007 Phase 2 NCT00406536 United States;
Lysomucil
University Hospital Ghent
2009 - EUCTR2008-008317-20-BE Belgium;
MAG-DHA
SCF Pharma
2015 Phase 2 NCT02518672 Canada;
MEDI-563
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
AstraZeneca AB
2021 Phase 3 EUCTR2020-004068-24-DK Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
2021 Phase 3 EUCTR2020-004068-24-DE Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Viet Nam;
MEROPENEM TRIHYDRATE
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
MINOCYCLINE HYDROCHLORIDE
AOU Meyer
2013 Phase 3 EUCTR2013-000219-25-IT Italy;
MOLI 1901
AOP ORPHAN PHARMACEUTICALS
2008 - EUCTR2006-006693-24-IT Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
MP-376
Horizon Pharma USA, Inc.
2008 Phase 2 NCT00677365 Germany;Netherlands;United States;
Mpex Pharmaceuticals, Inc.
2011 Phase 3 EUCTR2010-019634-26-GB Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-IE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-DE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2008 - EUCTR2008-001728-30-NL Germany;Netherlands;
2008 - EUCTR2008-001728-30-DE Germany;Netherlands;
- Phase 3 EUCTR2010-019634-26-FR France;Germany;Ireland;United Kingdom;
MP-376 (Levofloxacin Solution for Inhalation)
Horizon Pharma USA, Inc.
2011 Phase 3 NCT01270347 France;Germany;Ireland;Israel;United Kingdom;United States;
MP-376 (Levofloxacin solution for Inhalation)
Horizon Pharma USA, Inc.
2010 Phase 3 NCT01180634 Australia;Canada;Israel;New Zealand;United States;
2009 Phase 1 NCT00840333 United States;
2007 Phase 1 NCT00503490 United States;
MRI with PFP
University of North Carolina, Chapel Hill
2015 Early Phase 1 NCT03497117 United States;
MRT5005
Translate Bio, Inc.
2018 Phase 1/Phase 2 NCT03375047 United States;
MS1819
AzurRx BioPharma, Inc.
2020 Phase 2 NCT04375878 Poland;United States;
MS1819-SD
AzurRx
2020 Phase 2 EUCTR2018-003831-31-ES Hungary;Poland;Spain;
2019 Phase 2 EUCTR2018-003831-31-HU Hungary;Poland;Spain;
AzurRx BioPharma, Inc.
2019 Phase 2 NCT03746483 Poland;United States;
AzurRx SAS
2019 Phase 2 NCT04302662 Hungary;Turkey;
- Phase 2 EUCTR2018-003831-31-PL Hungary;Poland;Spain;Turkey;
MSI-1995
Genaera Corporation
2005 Phase 2 EUCTR2004-004334-13-IE Ireland;
MTT
Pharmaxis Pharmaceuticals Limited
2009 Phase 3 EUCTR2008-002740-42-FR Belgium;France;Germany;Netherlands;
2009 - EUCTR2008-002740-42-NL Belgium;France;Germany;Netherlands;
2009 - EUCTR2008-002740-42-BE Belgium;France;Germany;Netherlands;
2008 - EUCTR2008-002740-42-DE Belgium;France;Germany;Netherlands;
Macroduct sweat stimulator
Richard Barry Moss
2015 - NCT02310789 United States;
Magnetic Resonance Imaging
The Hospital for Sick Children
2015 Phase 2 NCT02740868 Canada;
Mannite
University Children’s Hospital Tuebingen
2009 Phase 2 NCT01309178 Germany;
Mannitol
Pharmaxis
2008 Phase 1 NCT00792714 Australia;United Kingdom;
2007 Phase 3 NCT00446680 Australia;Ireland;United Kingdom;
2005 Phase 2 NCT00251056 Argentina;Canada;
Pharmaxis Ltd.
2014 - EUCTR2012-002699-14-NL Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;
2014 - EUCTR2012-002699-14-IT Argentina;Belgium;Canada;Italy;Netherlands;United Kingdom;
2013 Phase 2 EUCTR2012-002699-14-GB Argentina;Belgium;Canada;France;Italy;Netherlands;United Kingdom;
2013 - EUCTR2012-002699-14-BE Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
- Phase 2 EUCTR2012-002699-14-FR Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Mannitol + pulmozyme
Pharmaxis
2005 Phase 2 NCT00117208 United Kingdom;
Mannitol inhalation powder
Tim Corcoran
2013 Phase 1 NCT01887197 United States;
Manuka honey sinus rinse
Swansea University
2019 - NCT04589897 United Kingdom;
Matched isoglycemic clamp
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Medical Grade Oxygen
Hal C Charles
2012 Phase 1 NCT01731015 United States;
Melphalan
Federal State Budgetary Institution, Pulmonology Scientific Research Institute
2018 Phase 2 NCT04278040 Russian Federation;
Menadiol sodium diphosphate
Barts and the London NHS Trust
2006 Phase 3 EUCTR2006-000945-20-GB United Kingdom;
Meropenem
Imperial College London
2010 Phase 4 NCT01044719 United Kingdom;
Imperial College, London
2009 - EUCTR2009-014042-28-GB United Kingdom;
Joseph Kuti
2012 Phase 4 NCT01429259 United States;
University Ghent
2016 - NCT02840136 Belgium;
Meropenem Fresenius Kabi 1 g poeder voor oplossing voor injectie of infusie
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
Meropenem Infusion
St. Michael's Hospital, Toronto
2010 - NCT01158937 Canada;
Mesenchymal Stem Cells
Erica Roesch
2016 Phase 1 NCT02866721 United States;
Metformin Hydrochloride
University of Kansas Medical Center
2022 Phase 2 NCT04530383 United States;
Metformine HCL 500 PCH
Staf Longziekten
2009 - EUCTR2009-009875-37-NL Netherlands;
Miglustat
Actelion
2008 Phase 2 NCT00742092 Belgium;
2007 Phase 2 NCT00537602 Spain;
Actelion Pharmaceuticals Ltd
2008 - EUCTR2008-002352-20-BE Belgium;
2007 - EUCTR2006-002049-35-ES Spain;
Assistance Publique - Hôpitaux de Paris
2015 Phase 2/Phase 3 NCT02325362 France;
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2009 Phase 2 NCT00945347 Belgium;
Minocycline
University of North Carolina, Chapel Hill
2018 Phase 2 NCT03489629 United States;
2011 Phase 2 NCT01349192 United States;
Modified Oral Glucose Tolerance Test (50g 4-hours)
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Modified lipid formulation
Nestlé
2016 - NCT02646995 Switzerland;
Molgramostim
Savara Inc.
2015 Phase 1 NCT02468908 United Kingdom;
Molgramostim nebulizer solution
Savara Inc.
2019 Phase 2 NCT03597347 United States;
Moli 1901 (2622U90, duramycin)
AOP Orphan Pharmaceuticals AG
2007 Phase 2;Phase 3 EUCTR2006-006693-24-FR Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
Moli1901
AOP Orphan Pharmaceuticals AG
2007 Phase 2 NCT00671736 Austria;
2006 Phase 2;Phase 3 EUCTR2005-005594-29-SK Czech Republic;Hungary;Slovakia;
2006 - EUCTR2005-005594-29-HU Czech Republic;Hungary;
2006 - EUCTR2005-005594-29-CZ Czech Republic;Hungary;
Moli1901 (2622U90, duramycin)
AOP Orphan Pharmaceuticals AG
2008 Phase 2;Phase 3 EUCTR2006-006693-24-ES Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
2008 - EUCTR2006-006693-24-CZ Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
2007 Phase 2;Phase 3 EUCTR2006-006693-24-DE Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
2007 - EUCTR2006-006693-24-SE Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
2007 - EUCTR2006-006693-24-HU Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
2007 - EUCTR2006-006693-24-AT Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
2006 - EUCTR2005-004344-30-HU Hungary;
2005 - EUCTR2005-004344-30-AT Austria;Hungary;
- Phase 2 EUCTR2006-006693-24-PL Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
Moxifloxacin hydrochloride
Vertex Pharmaceuticals Incorporated
2013 Phase 1 NCT01910415 Netherlands;
Mucoid exopolysaccharide P. aeruginosa immune globulin IV
National Center for Research Resources (NCRR)
1995 Phase 2 NCT00004747 -
Mucolysin
Aarhus University Hospital
2016 Phase 2 EUCTR2016-000354-35-DK Denmark;
2014 Phase 2 EUCTR2013-005481-19-DK Denmark;
Mucomyst
Aarhus University Hospital
2014 Phase 2 EUCTR2013-005481-19-DK Denmark;
Multienzymes (lipase, protease etc.)
ALTUS PHARMACEUTICALS INC
2007 - EUCTR2007-000178-21-IT Italy;
2007 - EUCTR2007-000171-41-IT Italy;
EURAND SPA
2010 - EUCTR2009-012842-21-IT Bulgaria;Germany;Hungary;Italy;United Kingdom;
Mupirocin
University of North Carolina, Chapel Hill
2018 Phase 2 NCT03489629 United States;
2011 Phase 2 NCT01349192 United States;
Mupirocin Intranasal Creme
Johns Hopkins University
2012 Phase 2 NCT01594827 United States;
N-(5-hydroxy-2,4- bis(trimethylsilyl)phenyl)-4-oxo- 1,4-dihydroquinoline-3-carboxamide
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
N-acetylcystein
Rigshospitalet
2010 Phase 4 EUCTR2007-001401-15-DK Denmark;
N-acetylcysteine
Qilu Hospital of Shandong University
2014 - NCT02088216 China;
University Hospital Ghent
2009 - EUCTR2008-008317-20-BE Belgium;
N-acetylcysteine (NAC)
Stanford University
2008 Phase 2 NCT00809094 United States;
N6022
Nivalis Therapeutics, Inc.
2014 Phase 1 NCT01746784 United States;
N91115
Nivalis Therapeutics, Inc.
2015 Phase 1 NCT02275936 United States;
2014 Phase 1 NCT02227888 United States;
NAL
LABORATOIRES SMB S.A.
2010 - EUCTR2010-018454-13-IT Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
Laboratoires SMB S.A.
2010 Phase 3 EUCTR2010-018454-13-FR Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018454-13-ES Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018454-13-DK Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-HU Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-GB Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-DE Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-CZ Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
- Phase 3 EUCTR2010-018454-13-BE Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
NEB/01-07
Laboratoire Erempharma
2008 - EUCTR2007-003868-22-FR France;
NEBCINE
CHRU de Lille
- Phase 2 EUCTR2014-003882-10-FR France;
NO
Southampton University Hopsitals NHS Trust
2011 - EUCTR2010-023529-39-GB United Kingdom;
NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
2020 Phase 2;Phase 3 EUCTR2019-004511-31-IT Czech Republic;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
NOXAFIL - 40 mg/ml oral suspension
Bambino Gesù Children's Hospital
- Phase 2;Phase 3 EUCTR2019-004511-31-IE Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
NOXAFIL - oral suspension 40 mg/ml
Bambino Gesù Children's Hospital
2022 Phase 2;Phase 3 EUCTR2019-004511-31-NL Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
2022 Phase 2;Phase 3 EUCTR2019-004511-31-DE Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
2021 Phase 2;Phase 3 EUCTR2019-004511-31-PT Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
2021 Phase 2;Phase 3 EUCTR2019-004511-31-GR Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
- Phase 2;Phase 3 EUCTR2019-004511-31-FR Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
Bambino Gesù Children´s Hospital
2022 Phase 2;Phase 3 EUCTR2019-004511-31-ES Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
NR
Virginia Commonwealth University
2020 - NCT04166396 United States;
NaCl
University of North Carolina
2001 Phase 2 NCT00274391 United States;
NaCl/Inhalation solution
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
NaCl/inhalation solution
Vertex Pharmaceuticals Inc.
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
Nacystelyn
LABORATOIRES SMB S.A.
2010 - EUCTR2010-018454-13-IT Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
Nacystelyn®
Laboratoires SMB S.A.
2010 Phase 3 EUCTR2010-018454-13-FR Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018454-13-ES Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018454-13-DK Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-HU Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-GB Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-DE Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-CZ Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
- Phase 3 EUCTR2010-018454-13-BE Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
Nasal Aztreonam
Virginia Commonwealth University
2017 Phase 2 NCT02730793 United States;
Navocaftor
AbbVie
2021 Phase 2 NCT04853368 Australia;Belgium;Czechia;Germany;Hungary;Netherlands;New Zealand;Slovakia;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-005805-25-NL Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
2021 Phase 2 EUCTR2020-005805-25-HU Hungary;
2021 Phase 2 EUCTR2020-005805-25-BE Belgium;Hungary;Netherlands;
Nebcin
University Hospital, Lille
2017 Phase 3 NCT03066453 France;
Nebcin (tobramycin)
The Univeristy of Nottingham
2010 Phase 4 EUCTR2010-023030-23-GB United Kingdom;
Nebcinal
EREMPHARMA SAS
- Phase 1 EUCTR2010-023533-34-FR France;
Erempharma SAS
2009 - EUCTR2009-013660-39-FR France;
Nebcinal Tobi
Erempharma
2010 - NCT01288170 France;
Nebulization of Amikacin during NIV (RR: 15 cycles/minute)
University Hospital St Luc, Brussels
2014 - NCT02084043 Belgium;Switzerland;
Nebulization of Amikacin during NIV (RR: 25 cycles/minute)
University Hospital St Luc, Brussels
2014 - NCT02084043 Belgium;Switzerland;
Nebulization tobramycin
University Medical Center Groningen
- Phase 2 EUCTR2016-005014-21-NL Netherlands;
Nexium 20
Biovitrum AB
2008 - EUCTR2007-004063-21-NL Netherlands;
Nitric Oxide
Southampton University Hopsitals NHS Trust
2011 - EUCTR2010-023529-39-GB United Kingdom;
University Hospital Southampton NHS Foundation Trust.
2011 Phase 2 NCT02295566 United Kingdom;
Nitric Oxide 160 ppm
Novoteris, LLC
2017 Phase 2 NCT02498535 Canada;United States;
Nitric Oxide for Inhalation
Mallinckrodt
2004 Phase 1/Phase 2 NCT00570349 United States;
Nitrogen
Mallinckrodt
2004 Phase 1/Phase 2 NCT00570349 United States;
Nocturnal oxygen , nocturnal bi-level positive pressure ventilation
Bayside Health
2003 Phase 1/Phase 2 NCT00157183 Australia;
Non invasive ventilation
Karolinska University Hospital
2016 - NCT02684552 Sweden;
None
AstraZeneca AB
2009 - EUCTR2008-001530-27-GB Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-001530-27-DK Denmark;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-001530-27-SE Denmark;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-001530-27-DE Denmark;Germany;Sweden;United Kingdom;
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
University of Nottingham
2008 Phase 4 EUCTR2007-006204-37-GB United Kingdom;
None assigned
Aradigm Corporation
2010 Phase 2 EUCTR2009-014412-35-DE Germany;United Kingdom;
2010 - EUCTR2009-014412-35-GB Germany;United Kingdom;
Noninvasive ventilation
St. Michael's Hospital, Toronto
2014 - NCT02262871 Canada;
Normal Saline
University of Washington
2016 Phase 2 NCT02354859 United States;
Normal saline
Nivalis Therapeutics, Inc.
2014 Phase 1 NCT01746784 United States;
Qilu Hospital of Shandong University
2014 Phase 4 NCT02081963 China;
Translate Bio, Inc.
2018 Phase 1/Phase 2 NCT03375047 United States;
University Hospital, Ghent
2010 Phase 4 NCT00996424 Belgium;
Normal saline IV, salt tablets
Bayside Health
2004 Phase 2/Phase 3 NCT00163852 Australia;
Normal saline solution
University Hospital Ghent
2007 - EUCTR2007-002707-40-BE Belgium;
Normal saline:
University of Oklahoma
2006 - NCT00671723 United States;
Norvir 100 mg film-coated tablets
university medical center utrecht
2018 Phase 4 EUCTR2016-001440-18-NL Netherlands;
Novo Rapid
Papworth Hospital NHS Foundation Trust
2005 Phase 4 EUCTR2004-005019-28-GB United Kingdom;
Novo Rapid Insulin (Novonordisk)
Hadassah Medical Organization
2010 - NCT01149005 Israel;
NovoNorm
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2006 - EUCTR2006-001254-27-FR France;
NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen.
St George's, University of London
2008 - EUCTR2007-004956-35-GB United Kingdom;
NovoRapid Aspartate
Papworth Hospital NHS Foundation Trust
2005 Phase 4 EUCTR2004-005019-28-GB United Kingdom;
Novolog insulin
University of Minnesota
2015 Phase 2/Phase 3 NCT02496780 United States;
Novorapid / humalog short acting insulin
Hadassah Medical Organization
2010 - NCT01149005 Israel;
Noxafil
MSD
2012 - EUCTR2012-003140-68-GB United Kingdom;
Noxafil - oral suspension 40 mg/ml
Bambino Gesù Children's Hospital
- Phase 2;Phase 3 EUCTR2019-004511-31-GB Czech Republic;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
Noxafil 100 mg Tablets Gastro-Resistant
Bambino Gesù Children's Hospital
- Phase 2;Phase 3 EUCTR2019-004511-31-IE Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
Noxafil®
Karolinska University Hospital, Stockholm CF center
2018 Phase 2 EUCTR2018-002579-16-SE Sweden;
Nutridrink-Impact
University Hospital, Motol
2013 Phase 4 NCT02048592 Czech Republic;
Nutropin AQ
University of Massachusetts, Worcester
2008 Phase 1 NCT00803179 United States;
University of Texas Southwestern Medical Center
2000 Phase 2/Phase 3 NCT00256555 -
Nutropin AQ [somatropin (DNA origin) injection]
Genentech, Inc.
2003 Phase 2 NCT00079742 United States;
OGT 918
Actelion Pharmaceuticals Ltd
2007 - EUCTR2006-002049-35-ES Spain;
OSCN-
Alaxia SAS
2015 Phase 1 NCT02598999 France;
Oleic acid supplementation
Karolinska Institutet
2021 - NCT04531410 Italy;Norway;Poland;Sweden;
OligoG (60 mg/ml)
AlgiPharma AS
2011 Phase 2 EUCTR2010-023090-19-GB Ireland;United Kingdom;
2011 - EUCTR2010-023090-19-IE Ireland;United Kingdom;
OligoG CF-5/20
AlgiPharma AS
2011 Phase 1/Phase 2 NCT01465529 Ireland;United Kingdom;
2009 Phase 1 NCT00970346 United Kingdom;
OligoG CF-5/20 -
AlgiPharma AS
2020 Phase 2 EUCTR2018-000378-30-GB Austria;Germany;Ireland;Poland;United Kingdom;
- Phase 2 EUCTR2018-000378-30-IE Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF-5/20, 17,5 mg, Hartkapsel mit Pulver zur Inhalation
AlgiPharma AS
2020 Phase 2 EUCTR2018-000378-30-DE Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF/20 -
AlgiPharma AS
2020 Phase 2 EUCTR2018-000378-30-GB Austria;Germany;Ireland;Poland;United Kingdom;
- Phase 2 EUCTR2018-000378-30-IE Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF/20, 27,5 mg, Hartkapsel mit Pulver zur Inhalation
AlgiPharma AS
2020 Phase 2 EUCTR2018-000378-30-DE Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF/20, 37,5 mg, Hartkapsel mit Pulver zur Inhalation
AlgiPharma AS
2020 Phase 2 EUCTR2018-000378-30-DE Austria;Germany;Ireland;Poland;United Kingdom;
OligoG DPI
AlgiPharma AS
2019 Phase 2 NCT03822455 Australia;
OligoG Dry powder for inhalation
AlgiPharma AS
2020 Phase 2/Phase 3 NCT03698448 Germany;
OligoG-CF5/20, Alginate oligosaccharide (G-block) fragment
AlgiPharma AS
2011 Phase 2 EUCTR2010-023090-19-GB Ireland;United Kingdom;
Oligomer of Sodium Alginate
Algipharma AS
2014 Phase 2 EUCTR2014-002125-35-DE Germany;
2014 Phase 2 EUCTR2014-000844-13-SE Denmark;Germany;Sweden;
2014 Phase 2 EUCTR2014-000844-13-DK Denmark;Germany;Sweden;
Omadacycline Injection [Nuzyra]
Paul Beringer
2021 Phase 4 NCT04460586 United States;
Omadacycline Oral Tablet [Nuzyra]
Paul Beringer
2021 Phase 4 NCT04460586 United States;
Omalizumab
NOVARTIS FARMA
2009 - EUCTR2007-006648-23-IT Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Novartis Pharma Services AG
2009 - EUCTR2007-006648-23-GB Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-006648-23-DE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-006648-23-BE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Novartis Pharmaceuticals
2008 Phase 4 NCT00787917 Belgium;Germany;Italy;Netherlands;United Kingdom;
Omega 3 Premium
Hôpital Universitaire Des Enfants Reine Fabiola (H.U.D.E.R.F.)
2008 - EUCTR2006-004155-38-BE Belgium;
Omega-3 triglycerides
Queen Fabiola Children's University Hospital
2008 Phase 3 NCT00959010 Belgium;
Omeprazole 40mg Capsule
Children's Hospital of Philadelphia
2018 Phase 2 NCT03551691 United States;
Once-daily insulin detemir
Sydney Children's Hospitals Network
2010 Phase 3 NCT01100892 Australia;United States;
Oral Aztreonam
Virginia Commonwealth University
2017 Phase 2 NCT02730793 United States;
Oral Glucose Tolerance Test
University of Texas Southwestern Medical Center
2006 - NCT00287456 United States;
Oral Glucose Tolerance test (75g 2-hour)
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Oral Glucose tolerance test
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
Oral Glutathione
University of Minnesota
2017 Phase 2 NCT03020719 United States;
Oral ciprofloxacin
Seattle Children's Hospital
2004 Phase 2 NCT00097773 United States;
Oral ciprofloxacin plus inhaled colistin
Universitaire Ziekenhuizen Leuven
2001 Phase 4 NCT01400750 Belgium;
Oral reduced l-glutathione
Clark Bishop
2011 - NCT02029521 Italy;
Oral roflumilast
The University of Hong Kong
2018 Phase 2 NCT03428334 Hong Kong;
Orkambi
Antwerp University Hospital
2018 Phase 4 EUCTR2018-001573-24-BE Belgium;
Assistance Publique - Hôpitaux de Paris
2019 - NCT03894657 France;
Children's Hospital of Philadelphia
2019 - NCT03795363 United States;
Parion Sciences
2016 Phase 2 NCT02709109 France;Ireland;United Kingdom;United States;
University Hospital, Antwerp
2018 Phase 4 NCT03956589 Belgium;
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incoporated
2017 Phase 4 EUCTR2016-004996-33-ES Australia;Canada;Spain;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
2016 Phase 4 EUCTR2016-000066-34-GB Australia;United Kingdom;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
Orkambi 100 mg/125 mg film-coated tablets
Vertex Pharmaceuticals Incorporated
2018 Phase 2 EUCTR2017-003761-99-DE Germany;
Orkambi 200 mg/125 mg film-coated tablets
Vertex Pharmaceuticals Incorporated
2016 Phase 2 EUCTR2016-001585-29-NL Netherlands;
Orkambi: contains lumacaftor and ivacaftor
Orkambi®
ASSISTANC-PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
- Phase 4 EUCTR2018-002624-16-FR France;
Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/
University of Pennsylvania
2014 Phase 1 NCT02144246 United States;
Oseltamivir
Inserm
2009 - EUCTR2009-016662-90-FR France;
Other non-sponsor pancreatic enzyme replacement therapy
AbbVie
2012 - NCT01652157 United States;
Other respiratory system products
DEBIOPHARM S.A.
2005 - EUCTR2004-002341-12-IT Belgium;Germany;Italy;United Kingdom;
Oxygen
Assistance Publique - Hôpitaux de Paris
2012 - NCT01586728 France;
Karolinska University Hospital
2016 - NCT02684552 Sweden;
P-1037
Parion Sciences
2015 Phase 2 NCT02343445 United States;
PAAG15
Synspira Therapeutics, Inc.
2019 Phase 2 EUCTR2019-003178-25-HU Hungary;
PANCREASE MT
Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
- - EUCTR2015-001219-11-Outside-EU/EEA Canada;United States;
PANCREASLIPASE
Aptalis Pharma US Inc.
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
PANCREATIN (PAncreas Powder)
Abbott Laboratories GmbH
2015 - EUCTR2014-004519-35-GB Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-CZ Czech Republic;Hungary;Spain;United Kingdom;
PANCREATIN (Pancreas Powder)
Abbott Laboratories GmbH
2015 - EUCTR2014-004519-35-HU Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-GB Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-CZ Czech Republic;Hungary;Spain;United Kingdom;
PANCREATINA
Abbott Laboratories GmbH
2013 - EUCTR2013-002819-10-ES Hungary;Russian Federation;Spain;
PANCREATINA (Páncreas Polvo)
Abbott Laboratories GmbH
2015 Phase 2 EUCTR2014-004519-35-ES Czech Republic;Hungary;Spain;United Kingdom;
PANCREAZE
AbbVie
2012 - NCT01652157 United States;
PANCREAZE®
ANTHERA Pharmaceuticals, Inc.
2017 Phase 3 EUCTR2017-000571-85-LT Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-HU Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-GB Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000571-85-ES Hungary;Israel;Lithuania;Poland;Spain;United States;
2016 Phase 3 EUCTR2015-002739-17-CZ Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-HU Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-ES Canada;Czech Republic;Hungary;Israel;Spain;United States;
- Phase 3 EUCTR2017-000571-85-PL Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
PANCRECARB® (pancrelipase)
Digestive Care, Inc.
2007 Phase 3 NCT00432861 United States;
PANZYTRAT 25000
Axcan Pharma Inc.
- - EUCTR2010-019267-11-DE Germany;
PARI eFlow nebulizer system
Savara Inc.
2019 Phase 2 NCT03597347 United States;
PBI4050
Liminal BioSciences Ltd.
2017 Phase 2 NCT02955888 Canada;
PC945
Pulmocide Ltd
2019 Phase 2 NCT03870841 United Kingdom;
2018 Phase 2 EUCTR2018-000243-87-GB United Kingdom;
PERTZYE
AbbVie
2012 - NCT01652157 United States;
PFP
University of North Carolina, Chapel Hill
2018 Early Phase 1 NCT03482960 United States;
2015 Early Phase 1 NCT03489590 United States;
PFP and SF6 Human Lung Coil
Thunder Bay Regional Research Institute
2019 Early Phase 1 NCT02748798 Canada;
PFT
Indiana University
2018 - NCT03579173 United States;
PGM169/GL67A
Imperial College
2012 Phase 2 EUCTR2011-004761-33-GB United Kingdom;
2008 - EUCTR2007-004050-85-GB United Kingdom;
Imperial College London
2012 Phase 2 NCT01621867 United Kingdom;
2008 Phase 1/Phase 2 NCT00789867 United Kingdom;
PIPERACILLIN SODIUM
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
PL 0010/0211
Southampton University Hospital Trust
2008 - EUCTR2008-001769-27-GB United Kingdom;
PO azithromycin
Seattle Children's Hospital
2004 - NCT00153634 United States;
PO ciprofloxacin
Seattle Children's Hospital
2004 - NCT00153634 United States;
POL6014
Santhera Pharmaceuticals
2018 Phase 1/Phase 2 NCT03748199 Germany;
Santhera Pharmaceuticals (Switzerland) Ltd
2018 Phase 1;Phase 2 EUCTR2018-002550-71-DE Germany;
2017 Phase 1;Phase 2 EUCTR2016-005110-22-DE Germany;
POL7080
Polyphor Ltd.
2014 Phase 2 EUCTR2013-002202-31-DE Germany;Spain;United Kingdom;
2013 Phase 2 NCT02096315 Spain;United Kingdom;
2013 Phase 2 EUCTR2013-002202-31-GB Germany;Spain;United Kingdom;
2013 - EUCTR2013-002202-31-ES Germany;Spain;United Kingdom;
PPI treatment
University of Colorado, Denver
2017 - NCT02769637 United States;
PREFOLIC*30CPR GASTROR
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
2010 - EUCTR2010-020516-11-IT Italy;
PROMIXIN*NEBUL 30MONOD 1MUI
AZIENDA OSPEDALIERA MEYER
2011 - EUCTR2011-006171-19-IT Italy;
PROTEASA
ANTHERA Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2016-002851-92-ES Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
PROTEASE
ANTHERA Pharmaceuticals, Inc.
2017 Phase 3 EUCTR2017-000571-85-LT Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-HU Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-GB Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000571-85-ES Hungary;Israel;Lithuania;Poland;Spain;United States;
2016 Phase 4 EUCTR2016-002851-92-CZ Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
2016 Phase 3 EUCTR2016-002851-92-HU Canada;Hungary;Israel;Spain;United States;
2016 Phase 3 EUCTR2015-002739-17-CZ Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-HU Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-ES Canada;Czech Republic;Hungary;Israel;Spain;United States;
- Phase 3 EUCTR2017-000571-85-PL Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-002851-92-PL Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
PTC-0161480
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC-124
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC-C124
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC124
PTC THERAPEUTICS, INC.
2010 - EUCTR2010-019692-30-IT Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-IT Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC Therapeutics
2006 Phase 2 NCT00351078 Israel;
2005 Phase 2 NCT00234663 United States;
PTC Therapeutics, Inc
2011 Phase 3 EUCTR2010-019692-30-GB Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019692-30-ES Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-019692-30-DE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2010 - EUCTR2010-019692-30-SE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 - EUCTR2010-019692-30-NL Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 - EUCTR2010-019692-30-BE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-BE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC Therapeutics, Inc.
2016 Phase 3 EUCTR2014-005355-83-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-GR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-FR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005449-35-FR Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2015 Phase 3 EUCTR2013-004581-34-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-GR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005449-35-SE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-IT Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-ES Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-DE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-BE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-004581-34-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2007 - EUCTR2007-000724-40-BE Belgium;
PTI-428
Proteostasis Therapeutics
2017 Phase 1;Phase 2 EUCTR2016-001214-24-DK Canada;Czech Republic;Denmark;France;Germany;Italy;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2016-001214-24-DE Canada;Czech Republic;Denmark;France;Germany;Italy;United Kingdom;United States;
Proteostasis Therapeutics, Inc.
2018 Phase 2 NCT03591094 United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1/Phase 2 NCT03500263 United Kingdom;
2017 Phase 1/Phase 2 NCT03251092 Australia;Belgium;Canada;Denmark;France;Germany;New Zealand;United Kingdom;United States;
2017 Phase 1 NCT03258424 United Kingdom;
2016 Phase 1/Phase 2 NCT02718495 Canada;Czechia;Denmark;France;Germany;United Kingdom;United States;
PTI-801
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1/Phase 2 NCT03500263 United Kingdom;
2017 Phase 1/Phase 2 NCT03251092 Australia;Belgium;Canada;Denmark;France;Germany;New Zealand;United Kingdom;United States;
2017 Phase 1 NCT03140527 Canada;Denmark;Germany;Portugal;Sweden;United States;
PTI-808
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1/Phase 2 NCT03500263 United Kingdom;
2017 Phase 1/Phase 2 NCT03251092 Australia;Belgium;Canada;Denmark;France;Germany;New Zealand;United Kingdom;United States;
2017 Phase 1 NCT03140527 Canada;Denmark;Germany;Portugal;Sweden;United States;
PUR118
Pulmatrix Inc.
2012 Phase 1 NCT01543191 United Kingdom;
Pancreas Powder
Aptalis Pharma US Inc.
2013 - EUCTR2009-012842-21-HU Bulgaria;Germany;Hungary;Italy;United Kingdom;
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-DE Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-BG Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
Axcan Pharma Inc.
- - EUCTR2010-019267-11-DE Germany;
Pancrease MT 10.5, or MT 21
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008 Phase 3 NCT00662675 Canada;United States;
Pancreatin
Abbott Products
2012 Phase 3 NCT01747330 Russian Federation;
McNeil Consumer and Specialty Pharmaceuticals
- Phase 2 EUCTR2005-001438-34-BE Belgium;
Pancrelipase
AbbVie
2019 Phase 4 NCT03924947 Spain;United States;
Digestive Care, Inc.
2008 Phase 4 NCT00744250 United States;
University of Colorado, Denver
2014 - NCT02372383 United States;
Pancrelipase Delayed Release
Solvay Pharmaceuticals
2009 Phase 3 NCT00775528 United States;
2008 Phase 3 NCT00690820 United States;
2007 Phase 3 NCT00510484 Hungary;Israel;South Africa;Spain;United States;
Pancrelipase Delayed Release Capsule
Solvay Pharmaceuticals GmbH
2008 - EUCTR2007-004004-12-BG Bulgaria;
Pancrelipase Microtablets
McNeil Consumer and Specialty Pharmaceuticals
- Phase 2 EUCTR2005-001438-34-BE Belgium;
Pancrelipase microtablets
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
2005 Phase 2 NCT00217204 Belgium;Netherlands;
Pancrelipase with bicarbonate
National Center for Research Resources (NCRR)
1999 - NCT00006063 -
Pancrelipase/Pancreas Powder
Solvay Pharmaceuticals GmbH
2008 - EUCTR2007-004004-12-BG Bulgaria;
Pankreatin
Terese Katzenstein
2020 Phase 4 EUCTR2019-004940-31-DK Denmark;
Panzytrat® 25,000
Forest Laboratories
2011 Phase 4 NCT01327703 Germany;Poland;
Panzytrat® ok
McNeil Consumer and Specialty Pharmaceuticals
- Phase 2 EUCTR2005-001438-34-BE Belgium;
Perfluorinated gas/oxygen mixture
Hal C Charles
2009 Phase 1 NCT01710449 United States;
Perform three multiple breath nitrogen washout tests (N2-MBW-test)
Universitair Ziekenhuis Brussel
2017 - NCT02950116 Belgium;
Physiologic serum nebulized nasally
Virginie ESCABASSE
2017 Phase 3 NCT02888730 France;
Physiological solution
Serafino A. Marsico
2010 Phase 3 NCT01450267 Italy;
Physiotherapy, exercise, percutaneous gastrostomy feeds
Bayside Health
2001 - NCT00164021 Australia;
Pilocarpine
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2017 - NCT03584841 Belgium;
Pilocarpine Iontophoresis
Emory University
2022 - NCT04732195 United States;
Pilocarpine Nitrate
Richard Barry Moss
2015 - NCT02310789 United States;
Pilocarpine microneedle patch
Emory University
2022 - NCT04732195 United States;
Pioglitazone
Paul Beringer
2008 Phase 1 NCT00719381 United States;
University Hospitals Cleveland Medical Center
2007 - NCT00531882 United States;
2006 - NCT00322868 United States;
Piperacillin sodium , tazobactam sodium
COP:TRIN Region Hovedstaden (Gentofte hospital)
2017 Phase 4 EUCTR2015-003399-58-DK Denmark;
Piperacillin with Tazobactam (tazocin)
Aarhus University Hospital, Department of Respiratory Medicine
2015 Phase 2 EUCTR2015-003662-87-DK Denmark;
Piperacillin-tazobactam combination product
University Ghent
2016 - NCT02840136 Belgium;
West Virginia University
2012 Phase 4 NCT01694069 United States;
Piperacillin/Tazobactam
COP:TRIN Region Hovedstaden (Gentofte hospital)
2017 Phase 4 EUCTR2015-003399-58-DK Denmark;
Piperacillin/Tazobactam Kabi - Fresenius Kabi Austria
Medical University of Vienna
2020 Phase 4 EUCTR2019-000955-16-AT Austria;
Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
Plerixafor mobilization of autologous CD117 stem cells
University of Colorado, Denver
2013 Phase 1 NCT01916577 United States;
Polyethylene Glycol 3350
St. Louis University
2019 Phase 4 NCT04210427 United States;
Porcine (pig) PERT
Anthera Pharmaceuticals
2015 Phase 3 NCT02279498 Canada;Czech Republic;Czechia;Hungary;Israel;Poland;Spain;United States;
Porcine PERT
Anthera Pharmaceuticals
2017 Phase 3 NCT03051490 Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
AzurRx BioPharma, Inc.
2020 Phase 2 NCT04375878 Poland;United States;
2019 Phase 2 NCT03746483 Poland;United States;
Posaconazole
Bambino Gesù Children's Hospital
2022 Phase 2;Phase 3 EUCTR2019-004511-31-DE Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
Bayside Health
2018 - NCT03421366 Australia;
MSD
2012 - EUCTR2012-003140-68-GB United Kingdom;
Posaconazole 100 MG [Noxafil]
Bambino Gesù Hospital and Research Institute
2021 Phase 2/Phase 3 NCT04966234 Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Switzerland;United Kingdom;
Posaconazole 40 MG/ML
Bambino Gesù Hospital and Research Institute
2021 Phase 2/Phase 3 NCT04966234 Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Switzerland;United Kingdom;
Positive expiratory pressure
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2015 - NCT02535130 Belgium;
Prednisolone
Birmingham Children's Hospital NHS Foundation Trust
2012 - EUCTR2011-005790-23-GB United Kingdom;
Prednisone
The Hospital for Sick Children
2017 Phase 3 NCT03070522 Canada;
Prograft capsules
Hopital Erasme - Chest service
2009 - EUCTR2009-014050-15-BE Belgium;
Prolastin (drug)
Université de Sherbrooke
2004 Phase 2 NCT02010411 Canada;
Promixin
ZAMBON SPA
2020 Phase 3 EUCTR2016-004558-13-IT Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
Promixin 1 million International Units (IU) Powder for Nebuliser Solution
Profile Pharma Ltd
2010 - EUCTR2008-005045-34-IE Ireland;United Kingdom;
2008 Phase 3 EUCTR2008-005045-34-GB Ireland;Russian Federation;Ukraine;United Kingdom;
Promixin, 1 million International Units (IU) Powder for Nebuliser Solution
Zambon S.p.A.
2020 Phase 3 EUCTR2016-004558-13-PT Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
2020 Phase 3 EUCTR2016-004558-13-GR Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
2020 Phase 3 EUCTR2016-004558-13-DE Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
2017 Phase 3 EUCTR2016-004558-13-PL Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
2017 Phase 3 EUCTR2016-004558-13-FR Canada;France;Poland;United States;
Promixin,1 millón de Unidades Internacionales,polvo para solución para inhalación por nebulizador
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-001565-33-ES Germany;Ireland;Spain;Switzerland;United Kingdom;
Promixin/Tadim
ZAMBON SPA
2017 Phase 3 EUCTR2015-002743-33-IT Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Zambon S.p.A.
2018 Phase 3 EUCTR2015-002743-33-NL Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2015-002743-33-GR Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2015-002743-33-PT Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2015-002743-33-GB Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2015-002743-33-ES Belgium;Germany;Italy;Portugal;Spain;United Kingdom;
2017 Phase 3 EUCTR2015-002743-33-DE Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Protease
Altus Pharmaceuticals Inc
2007 Phase 3 EUCTR2007-000171-41-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000171-41-PL Italy;Poland;Slovakia;
Altus Pharmaceuticals Inc.
2007 Phase 3 EUCTR2007-000178-21-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000178-21-PL Italy;Poland;Slovakia;
PsAer IgY
MUKOVISZIDOSE E.V.
2012 Phase 3 EUCTR2011-000801-39-IT Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
Mukoviszidose Institute gGmbH
2014 Phase 3 EUCTR2011-000801-39-HU Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2014 Phase 3 EUCTR2011-000801-39-ES Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2014 Phase 3 EUCTR2011-000801-39-AT Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2013 Phase 3 EUCTR2011-000801-39-IE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2012 Phase 3 EUCTR2011-000801-39-SE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2012 Phase 3 EUCTR2011-000801-39-BE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2011 Phase 3 EUCTR2011-000801-39-DE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
Pulmaquin®
Aradigm Corporation
2015 Phase 3 EUCTR2013-005366-19-PL Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005366-19-FR Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005348-28-PL Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-RO Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-IT Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-HU Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-GB Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-ES Australia;Canada;France;Germany;Hungary;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-RO Australia;Canada;Georgia;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-LV Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-IT Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-IE Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-HU Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-GB Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-ES Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
Pulmonary Function Testing
The Hospital for Sick Children
2010 - NCT01155115 Canada;
Pulmonary function testing.
University of Florida
2007 - NCT01851642 United States;
Pulmozyme
F. Hoffmann-La Roche AG
- Phase 4 EUCTR2015-003537-99-Outside-EU/EEA United States;
University Hospital, Tours
2009 Phase 4 NCT00843817 France;
University of Jena
2005 Phase 3 NCT00265434 Germany;
- Phase 3 EUCTR2007-001548-36-DE Germany;
Pulmozyme (Dornase alpha)
ErasmusMC - Sophia Children's Hospital
- - EUCTR2007-000935-25-NL Netherlands;
Pulmozyme (dornase alfa)
Pharmaxis Ltd
2004 Phase 2 EUCTR2004-001888-21-GB United Kingdom;
University of Vermont
2006 Phase 2 NCT00416182 United States;
Pulmozyme single use ampule
Milton S. Hershey Medical Center
2013 Phase 3 NCT01155752 United States;
Pulmozyme®
AO GENERIUM
2017 Phase 3 NCT04468100 Russian Federation;
QAU145
Novartis Pharmaceuticals
2007 Phase 2 NCT00506792 United States;
QBW251
Novartis Pharma AG
2021 Phase 2 EUCTR2019-002840-26-DE China;Germany;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002840-26-GB China;Germany;Spain;United Kingdom;
Novartis Pharma Services AG
2015 - EUCTR2011-005085-37-FR Belgium;France;Germany;Ireland;United Kingdom;United States;
2015 - EUCTR2011-005085-37-BE Belgium;France;Ireland;United Kingdom;United States;
2014 Phase 1;Phase 2 EUCTR2011-005085-37-DE Belgium;France;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2011-005085-37-IE Belgium;France;Ireland;United Kingdom;United States;
2012 Phase 1;Phase 2 EUCTR2011-005085-37-GB Belgium;France;Germany;Ireland;Netherlands;Romania;United Kingdom;United States;
Novartis Pharmaceuticals
2012 Phase 1/Phase 2 NCT02190604 Belgium;France;Germany;Ireland;Netherlands;Romania;United Kingdom;United States;
QBW276
Novartis Pharmaceuticals
2017 Phase 1/Phase 2 NCT02566044 Germany;United Kingdom;United States;
QBW276 1500mcg
Novartis Pharma AG
2017 Phase 1;Phase 2 EUCTR2014-004915-35-DE Germany;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2014-004915-35-GB Germany;United Kingdom;United States;
QBW276 300mcg
Novartis Pharma AG
2017 Phase 1;Phase 2 EUCTR2014-004915-35-DE Germany;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2014-004915-35-GB Germany;United Kingdom;United States;
QBW276 Succinate
Novartis Pharma AG
2017 Phase 1;Phase 2 EUCTR2014-004915-35-DE Germany;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2014-004915-35-GB Germany;United Kingdom;United States;
QR-010
ProQR Therapeutics
2015 Phase 1/Phase 2 NCT02532764 Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2015 Phase 1 NCT02564354 Belgium;France;United States;
Quercetin
University of Alabama at Birmingham
2010 Phase 2 NCT01348204 United States;
R03AC02
University Medical Centre Utrecht
2014 Phase 2 EUCTR2014-000057-37-NL Netherlands;
R03CC02
University Medical Centre Utrecht
2014 Phase 2 EUCTR2014-000057-37-NL Netherlands;
R05C B01
Rigshospitalet
2010 Phase 4 EUCTR2007-001401-15-DK Denmark;
RELiZORB (immobilized lipase) cartridge
Alcresta Therapeutics, Inc.
2016 - NCT02750501 United States;
RPL554
Verona Pharma plc
2017 Phase 2 NCT02919995 United Kingdom;
2017 Phase 2 EUCTR2015-004263-36-DE Germany;United Kingdom;
2016 Phase 2 EUCTR2015-004263-36-GB Germany;United Kingdom;
RPS 2505
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Radiolabelled OligoG CF-5/20 DPI
Bio-Images Research Ltd
2014 Phase 2 NCT01991028 United Kingdom;
Radiolabelled OligoG CF-5/20 Dry Powder for Inhalation (DPI)
AlgiPharma AS
2014 Phase 2 EUCTR2013-003774-27-GB United Kingdom;
Radiolabelled OligoG CF-5/20 Solution
Bio-Images Research Ltd
2014 Phase 2 NCT01991028 United Kingdom;
Radiolabelled OligoG CF-5/20 Solution for Nebulisation
AlgiPharma AS
2014 Phase 2 EUCTR2013-003774-27-GB United Kingdom;
Rapeglinide
Papworth Hospital NHS Foundation Trust
2005 Phase 4 EUCTR2004-005019-28-GB United Kingdom;
Ravicti high dose
National Jewish Health
2018 Phase 1/Phase 2 NCT02323100 United States;
Ravicti low dose
National Jewish Health
2018 Phase 1/Phase 2 NCT02323100 United States;
Recombiant human Desoxyribonuclease ( rhDNase)
University of Jena
- Phase 3 EUCTR2007-001548-36-DE Germany;
Recombinant Human DNase (Pulmozyme)
Nationwide Children's Hospital
2005 Phase 2 NCT00179998 United States;
Recombinant human IGF-1
Stony Brook University
2008 Phase 1 NCT00566241 United States;
Recombinant humanized monoclonal antibody omalizumab to IgE
Novartis Pharma Services AG
2009 - EUCTR2007-006648-23-NL Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Recombinant truncated SPINT2 protease inhibitor
Aerovance Inc
2005 Phase 1;Phase 2 EUCTR2005-000313-35-GB United Kingdom;
Red Blood Cell Zn
Indiana University
2019 - NCT04302428 United States;
Reduced glutathione
Mukoviszidose Institut gGmbH i. G.
2006 - EUCTR2005-003870-88-DE Germany;
Reduced glutathione sodium salt
Mukoviszidose Institut gGmbH
2007 Phase 2 NCT00506688 Germany;
Repaglinide
Arbelaez, Ana Maria
2006 - NCT00763412 United States;
Mukoviszidose Institut gGmbH
2001 Phase 3 NCT00662714 Austria;France;Germany;Italy;
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2001 Phase 3 NCT00072904 Canada;United States;
Repaglinide and Insulin
Children's Hospital of Philadelphia
2005 - NCT00231192 United States;
Reparixin
IST. DI RICERCHE FARMACOLOG. M. NEGRI
2010 - EUCTR2009-013340-36-IT Italy;
Resunab, ajulemic acid, anabasum
Corbus Pharmaceuticals, Inc.
2020 Phase 2;Phase 3 EUCTR2020-001762-11-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2020-001762-11-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003723-29-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003723-29-NL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-SK Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-PT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-GR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2017-003723-29-FR Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Resveratrol
Virginia Commonwealth University
2020 - NCT04166396 United States;
RhBSSL
Biovitrum AB
2008 - EUCTR2007-004063-21-NL Netherlands;
Swedish Orphan Biovitrum
2008 Phase 2 NCT00743483 Netherlands;Poland;
RhDNAse
Pharmaxis Ltd
2004 Phase 2 EUCTR2004-001888-21-GB United Kingdom;
The Hospital for Sick Children
2008 Phase 4 NCT00557089 Canada;
Rifampin
AOU Meyer
2013 Phase 3 EUCTR2013-000219-25-IT Italy;
Johns Hopkins University
2020 Phase 4 NCT02547116 United States;
2012 Phase 2 NCT01594827 United States;
University of Colorado, Denver
2014 - NCT02372383 United States;
University of North Carolina, Chapel Hill
2011 Phase 2 NCT01349192 United States;
Vertex Pharmaceuticals Incorporated
2013 Phase 1 NCT01768663 United States;
2009 Phase 1 NCT01018368 United States;
Rimactan
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Riociguat (Adempas, BAY63-2521)
Bayer
2014 Phase 2 NCT02170025 Belgium;Canada;France;Germany;Greece;Italy;Netherlands;United Kingdom;United States;
Roflumilast
Assiut University
2019 Early Phase 1 NCT04090294 -
Prince of Songkla University
2015 Phase 3 NCT04122547 Thailand;
University of Sao Paulo General Hospital
2019 Phase 2 NCT03988816 Brazil;
Roflumilast Oral Tablet
The University of Hong Kong
2020 Phase 2 NCT04322929 Hong Kong;
Roscovitine
University Hospital, Brest
2016 Phase 2 NCT02649751 France;
Rosuvastatin calcium
University of Liverpool
2014 Phase 2 EUCTR2014-002387-32-GB United Kingdom;
Roxithromycin
First Affiliated Hospital of Guangxi Medical University
2009 - ChiCTR-TRC-13003979 China;
Répaglinide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2006 - EUCTR2006-001254-27-FR France;
S-1226
SolAeroMed Inc.
2019 Phase 2 NCT03903913 Canada;
SB-656933 Tablets
GlaxoSmithKline Research & Development Limited
2010 - EUCTR2010-018738-27-DE Germany;
SB-656933-AAA
GlaxoSmithKline Research & Development Limited
2010 - EUCTR2010-018738-27-DE Germany;
SB656933
GlaxoSmithKline
2009 Phase 2 NCT00903201 Canada;France;Germany;Israel;United States;
2008 Phase 1 NCT00605761 United States;
SE10599
University of Nottingham
2005 Phase 2 EUCTR2005-000311-98-GB United Kingdom;
SIN ASIGNAR
ANTHERA Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2016-002851-92-ES Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
SLIT Amikacin
Transave, Inc
2005 - EUCTR2005-004389-17-HU Hungary;
SLIT(TM) Amikacin
Transave, Inc.
2005 - EUCTR2005-004899-21-BE Belgium;
SNSP113
Synspira Therapeutics, Inc.
2019 Phase 2 EUCTR2019-003178-25-HU Hungary;
SODIUM BICARBONATE BP
Fundació Parc Taulí
2017 Phase 2 EUCTR2016-004033-25-ES Spain;
SODIUM CHLORIDE PH. EUR.
Erasmus MC
- Phase 3 EUCTR2015-004143-39-FR Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
SODIUM CHLORIDE SOLUTION
Erasmus MC
2018 Phase 3 EUCTR2015-004143-39-IT Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2017 Phase 3 EUCTR2015-004143-39-DK Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-NL Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-BE Australia;Belgium;Denmark;Netherlands;Spain;United States;
SPI-1005 Ebselen 200mg Capsule x1
Sound Pharmaceuticals, Incorporated
2017 Phase 2 NCT02819856 United States;
SPI-1005 Ebselen 200mg Capsule x2
Sound Pharmaceuticals, Incorporated
2017 Phase 2 NCT02819856 United States;
SPI-1005 Ebselen 200mg Capsule x3
Sound Pharmaceuticals, Incorporated
2017 Phase 2 NCT02819856 United States;
SPX-101
SPYRYX BIOSCIENCES, INC.
2017 Phase 2 EUCTR2016-005230-30-IT Australia;Canada;France;Italy;Portugal;United Kingdom;
Spyryx Biosciences, Inc.
2017 Phase 2 NCT03229252 Canada;France;Italy;Portugal;United Kingdom;
2017 Phase 2 EUCTR2016-005230-30-PT Australia;Canada;France;Italy;Portugal;United Kingdom;
2017 Phase 2 EUCTR2016-005230-30-GB Australia;Canada;France;Italy;Portugal;United Kingdom;
2017 Phase 1 NCT03056989 Canada;
STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE ( W / V)
Erasmus MC
2017 Phase 3 EUCTR2015-004143-39-ES Australia;Denmark;Netherlands;Spain;United States;
SUB185183
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
Salbutamol
UMC Utrecht
2015 Phase 2 EUCTR2015-001317-28-NL Netherlands;
University of British Columbia
2018 - NCT03522831 Canada;
Salbutamol-ratiopharm® N metered-dose aerosol inhaler
ZAMBON SPA
2020 Phase 3 EUCTR2016-004558-13-IT Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
Salbutamol-ratiopharm® N metereddose aerosol inhaler
ZAMBON SPA
2020 Phase 3 EUCTR2016-004558-13-IT Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
Salbutamolo
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
Saline
AlgiPharma AS
2011 Phase 1/Phase 2 NCT01465529 Ireland;United Kingdom;
Joseph Zabner
2013 Phase 1/Phase 2 NCT00928135 United States;
Lakshmi Durairaj
2017 Phase 1 NCT03078088 United States;
Parion Sciences
2016 Phase 2 NCT02709109 France;Ireland;United Kingdom;United States;
Saline Solution
Zambon SpA
2018 Phase 3 NCT03460704 Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
2017 Phase 3 NCT03093974 Australia;Belgium;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Saline inhalation solution
Medical Center Alkmaar
2016 Phase 2/Phase 3 NCT02657473 Netherlands;
Salmeterol
National Center for Research Resources (NCRR)
2000 - NCT00005110 United States;
Saxagliptin
Ram Weiss
2015 - NCT02239458 Israel;
2014 - NCT02148978 Israel;
Serum Zn
Indiana University
2019 - NCT04302428 United States;
Short-acting Insulin (Actrapid)
Mukoviszidose Institut gGmbH
2001 Phase 3 NCT00662714 Austria;France;Germany;Italy;
Sildenafil
Children's Hospital Medical Center, Cincinnati
2012 Phase 1/Phase 2 NCT01194232 United States;
National Jewish Health
2015 Phase 2 NCT01132482 United States;
2015 Phase 1/Phase 2 NCT02626182 United States;
2008 Phase 1/Phase 2 NCT00659529 United States;
Sildenafil (Acute-1 hour)
Augusta University
2014 Phase 2 NCT02057458 United States;
Sildenafil (Subchronic-4 weeks)
Augusta University
2014 Phase 2 NCT02057458 United States;
Sildenafil 40mg oral capsule
National Jewish Health
2019 Phase 2/Phase 3 NCT04039087 United States;
Simvastatin
University Hospitals Cleveland Medical Center
2007 - NCT00531882 United States;
University of British Columbia
2010 Phase 1/Phase 2 NCT01092572 Canada;
Simvastatin treatment for 28 days
Akron Children's Hospital
2004 Phase 1 NCT00255242 United States;
Sitagliptin
Emory University
2010 Phase 3 NCT00967798 Canada;United States;
Nemours Children's Clinic
2012 Phase 1 NCT01721382 United States;
University of British Columbia
2010 Phase 2 NCT01257464 Canada;
University of Pennsylvania
2013 - NCT01879228 United States;
SmartPill Motility System & PillCam Patency Capsule
St. Louis University
2019 Phase 4 NCT04210427 United States;
Snack beverage
Institut de Recherches Cliniques de Montreal
2019 - NCT03710538 Canada;
Sodium (R)-8-methyl-2-(3-methylbenzofuran-2-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)ethoxy)quinoline-4-ca
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
Sodium 4-Phenylbutyrate
Children's Hospital of Philadelphia
2003 Phase 1/Phase 2 NCT00590538 United States;
Sodium 4-Phenylbutyrate (4PBA)
Children's Hospital of Philadelphia
2001 Phase 1/Phase 2 NCT00016744 United States;
Sodium Pyruvate in Sodium Chloride Solution
Emphycorp
2006 Phase 1 NCT00308243 United States;
Sodium bicarbonate
University of Pittsburgh
2002 Phase 1 NCT00177645 United States;
Sodium chloride
Joseph Pilewski
2014 Phase 1 NCT03391414 United States;
Sodium chloride ()
University of North Carolina, Chapel Hill
2009 Phase 1 NCT01094704 United States;
Sodium chloride 0,
University of Jena
2010 - NCT01086839 Germany;
Sodium nitrite
Schmidhofer, Mark, MD
2016 Phase 1/Phase 2 NCT02694393 United States;
Soluble fiber supplementation
Institut de Recherches Cliniques de Montreal
2016 - NCT02810691 Canada;
Somalgen
Genaera Corporation
2005 Phase 2 EUCTR2004-004334-13-IE Ireland;
Sperti Del Sol Lamp
Atlanta VA Medical Center
2006 - NCT00450073 United States;
Spiriva Respimat 2.5 mcg
Boehringer Ingelheim
2010 Phase 3 EUCTR2010-019802-17-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim España, S.A
2010 - EUCTR2010-019802-17-ES Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France
2010 - EUCTR2010-019802-17-PT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Limited
2010 - EUCTR2010-019802-17-IE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019802-17-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2010 - EUCTR2010-019802-17-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2010 - EUCTR2010-019802-17-AT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH&Co KG
2010 Phase 3 EUCTR2010-019802-17-SK Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2010 Phase 3 EUCTR2010-019802-17-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Spiriva Respimat 2.5 microgram, solution for inhalation
BOEHRINGER ING.
2010 - EUCTR2010-019802-17-IT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2009 - EUCTR2008-001156-43-IT Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim
2010 Phase 3 EUCTR2010-019802-17-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim España, S.A
2010 - EUCTR2010-019802-17-ES Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France
2010 - EUCTR2010-019802-17-PT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-001156-43-FR Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim Limited
2010 - EUCTR2010-019802-17-IE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019802-17-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2008 - EUCTR2008-001156-43-GB Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2010 - EUCTR2010-019802-17-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co.KG
2008 - EUCTR2008-001156-43-DE Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim Pharmaceuticals, Inc.
2009 - EUCTR2008-001156-43-PT Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2010 - EUCTR2010-019802-17-HU Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-AT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH&Co KG
2010 Phase 3 EUCTR2010-019802-17-SK Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
Boehringer Ingelheim bv
2009 - EUCTR2008-001156-43-NL Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2010 Phase 3 EUCTR2010-019802-17-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2008 - EUCTR2008-001156-43-BE Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Spirometry
National Center for Research Resources (NCRR)
2001 - NCT00023465 United States;
Sporanox 10 mg/ml Oral Solution
CHU de Rennes (Rennes University Hospital Centre)
2012 - EUCTR2011-005799-41-GB United Kingdom;
Sputum
University of Miami
2010 - NCT02198079 United States;
Sputum Collection
The Hospital for Sick Children
2010 - NCT01155115 Canada;
Ss-Adrenergic cocktail
Richard Barry Moss
2015 - NCT02310789 United States;
Standard Care
Liverpool Heart and Chest Hospital NHS Foundation Trust
2017 Phase 4 NCT02894684 United Kingdom;
Standard Dose YPT-01
Yale University
2021 Phase 1/Phase 2 NCT04684641 United States;
Standard Formula
Laboratorios Ordesa
2012 - NCT02128984 Peru;Spain;
Standard Nutritional Supplement + PERT
GlycosBio, Inc.
2018 - NCT04966897 United States;
Standard formula (Enfamil)
University of Massachusetts, Worcester
2003 - NCT00530244 United States;
Standard of care IV antibiotic(s)
Chris Goss
2016 Phase 4 NCT02781610 Canada;United States;
Standard oxygen therapy/RA
The Leeds Teaching Hospitals NHS Trust
2019 - NCT03965832 United Kingdom;
Standard sinus rinse
Swansea University
2019 - NCT04589897 United Kingdom;
Standardized turmeric root extract
Ramsey, Bonnie, MD
2005 Phase 1 NCT00219882 United States;
Study medication, azithromycin
Rigshospitalet, Denmark
2008 Phase 4 NCT00411736 Denmark;Norway;Sweden;
Sulfato de amikacina
Insmed Incorporated
2011 Phase 3 EUCTR2011-000443-24-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2011-000441-20-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
Supplementation with vitamin D2/D3
Karolinska Institutet
2010 Phase 2 NCT01321905 Sweden;
Symbiotic Formula with DHA and antioxidants
Laboratorios Ordesa
2012 - NCT02128984 Peru;Spain;
Symdeko
University of Alabama at Birmingham
2019 Early Phase 1 NCT03587961 United States;
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
Symdeko/Trikafta
University of Alabama at Birmingham
2018 Phase 4 NCT03624101 United States;
Symkevi
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
Symkevi 100mg/150mg Film-coated tablets
VERTEX PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001735-31-GB Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
- Phase 3 EUCTR2019-001735-31-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
Synrinse
University of Washington
2017 Phase 1/Phase 2 NCT03154541 United States;
T 100 PARI
PARI GmbH
- Phase 1 EUCTR2005-004103-10-PL Germany;Poland;
T100
PARI Pharma GmbH
- Phase 1 EUCTR2010-023235-41-PL Poland;
T100 PARI
PARI GmbH
2007 - EUCTR2007-000959-33-DE Germany;
PARI Pharma GmbH
2006 - EUCTR2005-004103-10-DE Germany;
TAD 600
AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI
2009 - EUCTR2008-005080-33-IT Italy;
Mukoviszidose Institut gGmbH i. G.
2006 - EUCTR2005-003870-88-DE Germany;
TAZOBACTAM SODIUM
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
TBD
AbbVie Deutschland
2019 Phase 2 EUCTR2019-000750-63-NL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
TBM100
NOVARTIS PHARMA SERVICES AG
2016 Phase 2 EUCTR2015-003040-39-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Novartis Pharma GmbH
2008 - EUCTR2007-004507-36-DE Germany;
Novartis Pharma Services AG
2017 Phase 2 EUCTR2015-003040-39-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-IE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-GB Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-BE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2010 - EUCTR2009-016590-15-DE Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;
2009 - EUCTR2009-016590-15-HU Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
- Phase 4 EUCTR2011-002000-32-FR Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Pharmaceuticals
2013 Phase 4 NCT01775137 Argentina;Australia;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
2012 Phase 4 NCT01519661 Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TBM100C
NOVARTIS FARMA
2012 - EUCTR2011-002000-32-IT Argentina;Australia;Brazil;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Farmaceutica S. A
2011 Phase 4 EUCTR2011-002000-32-ES Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-003532-23-ES Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2013 - EUCTR2012-001565-33-ES Germany;Ireland;Spain;Switzerland;United Kingdom;
Novartis Pharma GmbH
2014 Phase 4 EUCTR2014-001204-21-DE Germany;
Novartis Pharma Services AG
2015 - EUCTR2012-001565-33-IE Germany;Ireland;Spain;Switzerland;United Kingdom;
2013 Phase 4 EUCTR2012-001565-33-GB Germany;Ireland;Spain;Switzerland;United Kingdom;
2013 - EUCTR2012-003532-23-DE Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2013 - EUCTR2012-001565-33-DE Germany;Ireland;Spain;Switzerland;United Kingdom;
2012 - EUCTR2012-003532-23-HU Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2011 Phase 3 EUCTR2005-003772-37-IE Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2011 - EUCTR2011-002000-32-HU Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2011 - EUCTR2011-002000-32-DE Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2010 - EUCTR2009-016734-26-LV Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-LT Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-EE Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-BG Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-LV Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-LT Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-EE Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-BG Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-LV Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-LT Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-EE Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-BG Bulgaria;Estonia;Latvia;Lithuania;
2008 Phase 3 EUCTR2005-003772-37-GR Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2007 - EUCTR2005-003772-37-HU Germany;Greece;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-003772-37-GB Germany;Greece;Hungary;Italy;Spain;United Kingdom;
TEZ
Vertex Pharmaceuticals Incorporated
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 3 NCT03691779 Australia;Ireland;United Kingdom;United States;
2018 Phase 3 NCT03537651 Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 NCT03525574 Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 NCT03447262 Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2016 Phase 2 NCT02951182 Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;United Kingdom;United States;
2016 Phase 1 NCT03486236 United Kingdom;
TEZ/150 mg IVA FDC
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
TEZ/IVA
Vertex Pharmaceuticals Incorporated
2019 Phase 2 NCT03912233 Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 3 NCT03559062 Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 1/Phase 2 NCT03768089 Netherlands;United Kingdom;
2017 Phase 2 NCT03224351 Ireland;Israel;United Kingdom;United States;
2017 Phase 1/Phase 2 NCT03227471 Australia;Belgium;Netherlands;United States;
2016 Phase 3 NCT02953314 Canada;United States;
2015 Phase 3 NCT02565914 Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
THA
Children's Hospital of Philadelphia
2006 Phase 4 NCT00572975 United States;
TIOTROPIUM BROMIDE MONOHYDRATE
Boehringer Ingelheim
2010 Phase 3 EUCTR2010-019802-17-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim España, S.A
2010 - EUCTR2010-019802-17-ES Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France
2010 - EUCTR2010-019802-17-PT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Limited
2010 - EUCTR2010-019802-17-IE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019802-17-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2010 - EUCTR2010-019802-17-HU Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-AT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH&Co KG
2010 Phase 3 EUCTR2010-019802-17-SK Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2010 Phase 3 EUCTR2010-019802-17-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
TIP
Chiron Corporation Ltd
2006 - EUCTR2005-003772-37-ES Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Novartis Pharma Services AG
2005 - EUCTR2005-002035-28-LT Lithuania;
- - EUCTR2005-003772-37-DE Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Novartis Pharmaceuticals
2017 Phase 2 NCT02712983 Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
TIP (Tobramycin inhalation powder)
Novartis Farmaceutica S. A
2011 Phase 4 EUCTR2011-002000-32-ES Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Pharma Services AG
2011 - EUCTR2011-002000-32-HU Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2010 - EUCTR2009-016734-26-LV Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-LT Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-EE Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-BG Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-LV Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-LT Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-EE Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-BG Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-LV Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-LT Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-EE Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-BG Bulgaria;Estonia;Latvia;Lithuania;
- Phase 4 EUCTR2011-002000-32-FR Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TIS (Tobramycin Inhalation Solution)
Horizon Pharma USA, Inc.
2011 Phase 3 NCT01270347 France;Germany;Ireland;Israel;United Kingdom;United States;
TIS or TIP
Novartis Pharmaceuticals
2015 Phase 4 NCT02248922 Germany;
TNSE
ECUPHARMA S.R.L.
2007 - EUCTR2007-003628-39-IT Italy;
TOBI
CHRU de Lille
- Phase 2 EUCTR2014-003882-10-FR France;
Gilead Sciences Inc
2010 - EUCTR2007-004277-26-AT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-004277-26-GB Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-FR Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-ES Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-BE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-PT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-NL Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DK Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
- - EUCTR2007-004277-26-Outside-EU/EEA United States;
Mpex Pharmaceuticals, Inc.
2011 - EUCTR2010-019634-26-IE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
Novartis Pharma Services AG
2011 Phase 3 EUCTR2005-003772-37-IE Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2005-003772-37-GR Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2007 - EUCTR2005-003772-37-HU Germany;Greece;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-003772-37-GB Germany;Greece;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2005-003772-37-DE Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Novartis Pharmaceuticals
2010 Phase 3 NCT01082367 Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;United States;
PARI GmbH
- Phase 1 EUCTR2005-004103-10-PL Germany;Poland;
St. Michael's Hospital, Toronto
2014 Phase 1 NCT02212587 Canada;
Universitaire Ziekenhuizen Leuven
2001 Phase 4 NCT01400750 Belgium;
TOBI (tobramycin)
Pari Pharma GmbH
2013 Phase 1 NCT01953367 Germany;
TOBI 300 mg / 5 mL nebuliser solution
Novartis Pharma Services AG
2013 - EUCTR2009-016590-15-PL Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;United States;
2009 - EUCTR2009-016590-15-HU Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
TOBI 300 mg/5 ml Lösung für einen
Mpex Pharmaceuticals, Inc.
2011 - EUCTR2010-019634-26-DE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
TOBI 300 mg/5 ml Lösung für einen Vernebler
Novartis Pharma Services AG
2010 - EUCTR2009-016590-15-DE Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;
TOBI 300 mg/5 ml Nebuliser Solution
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
TOBI 300 mg/5 ml solución para inhalación por nebulizador
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-001565-33-ES Germany;Ireland;Spain;Switzerland;United Kingdom;
TOBI 300 mg/5 ml, solution pour inhalation par nébuliseur
Mpex Pharmaceuticals, Inc.
- Phase 3 EUCTR2010-019634-26-FR France;Germany;Ireland;United Kingdom;
TOBI 300mg/ 5ml solución para inhalación con nebulizador
Insmed Incorporated
2011 Phase 3 EUCTR2011-000441-20-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
TOBI 300mg/5mL Nebuliser Solution
Chiron Corporation Ltd
2006 - EUCTR2005-003772-37-ES Germany;Greece;Hungary;Italy;Spain;United Kingdom;
TOBI 300mg/5mL nebuliser solution
Novartis Pharma Services AG
2010 Phase 3 EUCTR2009-016590-15-FR France;Germany;Greece;Hungary;Italy;Poland;
2010 - EUCTR2009-016590-15-GR France;Germany;Greece;Hungary;Italy;Poland;
TOBI 300mg/5ml Nebuliser solution
Insmed Incorporated
2012 Phase 3 EUCTR2011-000441-20-BE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-NL Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2012 - EUCTR2011-000441-20-IE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-DK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-BG Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-SK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-HU Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-GR Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2011 - EUCTR2011-000441-20-GB Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-DE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-AT Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
TOBI PODHALER
Novartis Farmaceutica S. A
2011 Phase 4 EUCTR2011-002000-32-ES Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI PODHALER - 28 MG POLVERE PER INALAZIONE CAPSULA RIGIDA USO INALATORIO BLISTER(ALU/ALU) 56 CAPSULE + 1 INALATORE
NOVARTIS PHARMA SERVICES AG
2016 Phase 2 EUCTR2015-003040-39-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
TOBI PODHALER*448CPS 28MG+10IN
NOVARTIS FARMA
2013 - EUCTR2012-003532-23-IT Argentina;Australia;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI Podhaler
Mylan Inc.
2015 - NCT02449031 United States;
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-003532-23-ES Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2013 - EUCTR2012-001565-33-ES Germany;Ireland;Spain;Switzerland;United Kingdom;
Novartis Pharma GmbH
2014 Phase 4 EUCTR2014-001204-21-DE Germany;
Novartis Pharma Services AG
2017 Phase 2 EUCTR2015-003040-39-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-IE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-GB Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-BE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2015 - EUCTR2012-001565-33-IE Germany;Ireland;Spain;Switzerland;United Kingdom;
2013 Phase 4 EUCTR2012-001565-33-GB Germany;Ireland;Spain;Switzerland;United Kingdom;
2013 - EUCTR2012-003532-23-DE Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2013 - EUCTR2012-001565-33-DE Germany;Ireland;Spain;Switzerland;United Kingdom;
2012 - EUCTR2012-003532-23-HU Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
- Phase 4 EUCTR2011-002000-32-FR Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Pharmaceuticals Corporation
- Phase 4 EUCTR2016-004318-82-Outside-EU/EEA United States;
- Phase 4 EUCTR2016-001840-20-Outside-EU/EEA United States;
TOBI Podhaler 28 mg Hartkapseln mit Pulver zur Inhalation
Novartis Pharma Services AG
2011 - EUCTR2011-002000-32-DE Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI Podhaler 28 mg inhalációs por, kemény kapszula
Novartis Pharma Services AG
2011 - EUCTR2011-002000-32-HU Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI*NEBUL 56F 1D 300MG/5ML
AZIENDA OSPEDALIERA MEYER
2008 - EUCTR2008-006502-42-IT Italy;
Gilead Sciences Inc
2008 - EUCTR2007-004277-26-IT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
NOVARTIS FARMA
2011 - EUCTR2009-016590-15-IT Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
TOBI®
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-DK Belgium;Denmark;
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
Gilead Sciences, Inc.
- - EUCTR2015-000398-11-Outside-EU/EEA United States;
PARI GmbH
2007 - EUCTR2007-000959-33-DE Germany;
PARI Pharma GmbH
2006 - EUCTR2005-004103-10-DE Germany;
- Phase 1 EUCTR2010-023235-41-PL Poland;
TOBI™ Podhaler™ 112 mg inhaled twice daily
Dartmouth-Hitchcock Medical Center
2014 - NCT02113397 United States;
TOBRAMICINA SOLFATO
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
TOBRAMYCIN SULFATE
Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
2014 Phase 4 EUCTR2013-004295-35-AT Austria;
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
TOTTIZIM - 1 G/10 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO ENDOVENOSO 1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 10 ML
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
TR02
Transave, Inc
2005 - EUCTR2005-004389-17-HU Hungary;
Transave, Inc.
2005 - EUCTR2005-004899-21-BE Belgium;
Ta1
SciClone Pharmaceuticals Limited Ltd
2019 Phase 2 EUCTR2019-001441-40-IT Italy;
Tacrolimus and MMF
University Hospital, Limoges
2009 Phase 4 NCT00975663 Belgium;France;
Tacrolimus capsules
Hopital Erasme - Chest service
2009 - EUCTR2009-014050-15-BE Belgium;
Tacrolimus prolonged-release hard capsules
Hopital Erasme - Chest service
2009 - EUCTR2009-014050-15-BE Belgium;
Tad
Aarhus University Hospital
2014 Phase 2 EUCTR2013-005481-19-DK Denmark;
Talniflumate
Genaera Corporation
2005 Phase 2 EUCTR2004-004334-13-IE Ireland;
Tauroursodeoxycholic acid
Children's Hospital Medical Center, Cincinnati
1997 - NCT00004441 Italy;United States;
Technetium Sulfur Colloid
Tim Corcoran
2017 Phase 1 NCT02947126 United States;
Tedizolid IV
University of Southern California
2015 Phase 4 NCT02444234 United States;
Tedizolid PO
University of Southern California
2015 Phase 4 NCT02444234 United States;
Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.
Neupharma Srl
2019 Phase 1 NCT04176328 Italy;
Telavancin Injection
Joseph L. Kuti, PharmD
2017 Phase 4 NCT03172793 United States;
Terlipressin acetate
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2021 Phase 3 EUCTR2020-005931-58-FR France;
Tezacaftor
VERTEX PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2020-003170-44-IT Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
2021 Phase 3 EUCTR2021-001628-16-ES Australia;Belgium;Canada;Spain;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-003170-44-CZ Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 2 NCT02951195 United States;
2016 Phase 1 NCT03029455 United Kingdom;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-001628-16-BE Australia;Belgium;Canada;Spain;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-NL Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-FR Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-BE Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Tezacaftor (TEZ)
VERTEX PHARMACEUTICALS INCORPORATED
2017 Phase 2 EUCTR2016-000454-36-IT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-000454-36-NL Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-GB Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-ES Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-DE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-BE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-AT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000454-36-DK Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Tezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
2017 Phase 3 NCT03150719 France;Germany;United States;
2016 Phase 2 NCT02730208 Australia;
2016 Phase 2 NCT02508207 United States;
2015 Phase 3 NCT02412111 Australia;Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
Tezacaftor/Ivacaftor + Ivacaftor
Nottingham University Hospitals NHS Trust
2019 Phase 2 NCT04006873 United Kingdom;
Tezacaftor/Ivacaftor 100mg/
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
Tezacaftor/Ivacaftor/100mg/
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-004133-82-IE Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-GB Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-ES Australia;Germany;Ireland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-004133-82-DE Australia;Germany;Ireland;Spain;United Kingdom;United States;
Tezacaftor/ivacaftor
Vertex Pharmaceuticals Incorporated
2017 - NCT03278314 -
Tezacaftor/ivacaftor 100mg/
VERTEX PHARMACEUTICALS INCORPORATED
2017 Phase 2 EUCTR2016-000454-36-IT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-000126-55-NL Netherlands;
2017 Phase 3 EUCTR2017-000540-18-DE France;Germany;United States;
2017 Phase 2 EUCTR2017-000797-11-NL Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-000454-36-NL Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-GB Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-ES Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-DE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-BE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-AT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000454-36-DK Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-000540-18-FR France;Germany;United States;
Tham
Lakshmi Durairaj
2017 Phase 1 NCT03078088 United States;
The gut mycobiota and microbiota profile
University Hospital, Bordeaux
2018 - NCT03565692 France;
The lung mycobiota and microbiota profile
University Hospital, Bordeaux
2018 - NCT03565692 France;
Theophylline
The First Affiliated Hospital of Guangzhou Medical University
2012 Phase 4 NCT01684683 China;
The first affiliated hospital of Guangzhou Medical University
2012 - ChiCTR-TRC-12002470 China;
Thymosin alpha 1
SciClone Pharmaceuticals Limited Ltd
2019 Phase 2 EUCTR2019-001441-40-IT Italy;
Tigerase®
AO GENERIUM
2017 Phase 3 NCT04468100 Russian Federation;
Tiotropium Bromide (monohydrate)
Boehringer Ingelheim Pharma GmbH & Co. KG
2010 - EUCTR2010-019802-17-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Tiotropium Respimat
Boehringer Ingelheim
2010 Phase 3 EUCTR2010-019802-17-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim España, S.A
2010 - EUCTR2010-019802-17-ES Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France
2010 - EUCTR2010-019802-17-PT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Limited
2010 - EUCTR2010-019802-17-IE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019802-17-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2010 - EUCTR2010-019802-17-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2010 - EUCTR2010-019802-17-HU Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-AT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH&Co KG
2010 Phase 3 EUCTR2010-019802-17-SK Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2010 Phase 3 EUCTR2010-019802-17-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Tiotropium Respimat 1.25 microgram solution for inhalation
Boehringer Ingelheim France
2008 Phase 2 EUCTR2008-001156-43-FR Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim Limited
2008 - EUCTR2008-001156-43-GB Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim Pharmaceuticals, Inc.
2009 - EUCTR2008-001156-43-PT Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim bv
2009 - EUCTR2008-001156-43-NL Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2008 - EUCTR2008-001156-43-BE Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium Respimat 1.25 microgram, solution for inhalation
Boehringer Ingelheim Pharma GmbH & Co.KG
2008 - EUCTR2008-001156-43-DE Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium Respimat 1.25 micrograms solution for inhalation
BOEHRINGER ING.
2009 - EUCTR2008-001156-43-IT Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium Respimat® inhaler
Boehringer Ingelheim
2010 Phase 3 NCT01179347 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Tiotropium bromide
BOEHRINGER ING.
2010 - EUCTR2010-019802-17-IT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2009 - EUCTR2008-001156-43-IT Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium bromide 5 mcg
Boehringer Ingelheim
2008 Phase 2 NCT00737100 Australia;Belgium;France;Germany;Italy;Netherlands;New Zealand;Portugal;Russian Federation;United Kingdom;United States;
Tiotropium bromide high
Boehringer Ingelheim
2006 Phase 1 NCT02172534 -
Tiotropium bromide low
Boehringer Ingelheim
2006 Phase 1 NCT02172534 -
Tiotropium bromide medium
Boehringer Ingelheim
2006 Phase 1 NCT02172534 -
Tiotropium bromide monohydrate
Boehringer Ingelheim Pharma GmbH & Co.KG
2008 - EUCTR2008-001156-43-DE Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium bromide-low dose-2.5mcg
Boehringer Ingelheim
2008 Phase 2 NCT00737100 Australia;Belgium;France;Germany;Italy;Netherlands;New Zealand;Portugal;Russian Federation;United Kingdom;United States;
Tobacco
University Hospital, Toulouse
2019 - NCT04437641 France;
University of Alabama at Birmingham
2021 - NCT04777344 United States;
Tobi
EREMPHARMA SAS
- Phase 1 EUCTR2010-023533-34-FR France;
Erempharma SAS
2009 - EUCTR2009-013660-39-FR France;
INSMED INCORPORATED
2011 - EUCTR2011-000441-20-IT Austria;Bulgaria;Canada;Denmark;Greece;Hungary;Ireland;Italy;Netherlands;Spain;United Kingdom;
Novartis Pharma GmbH
2008 - EUCTR2007-004507-36-DE Germany;
Tobi 300 mg/5 ml Nebuliser Solution
Leeds Teaching Hospitals NHS Trust
2007 - EUCTR2007-005346-20-GB United Kingdom;
Mpex Pharmaceuticals, Inc.
2011 Phase 3 EUCTR2010-019634-26-GB Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
Tobi 300mg/5ml Nebuliser solution.
Chiesi Farmaceutici S.p.A
2009 Phase 3 EUCTR2006-006215-68-FR Czech Republic;France;Germany;Hungary;Spain;
2008 Phase 3 EUCTR2006-006215-68-CZ Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-HU Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-DE Czech Republic;France;Germany;Hungary;Spain;
Tobi 300mg/5ml Solución para inhalación por nebulizador.
Chiesi Farmaceutici S.p.A
2008 Phase 3 EUCTR2006-006215-68-ES Czech Republic;France;Germany;Hungary;Spain;
Tobi Inhalant Product
University Hospital, Lille
2017 Phase 3 NCT03066453 France;
Tobi Nebcinal
Erempharma
2010 - NCT01288170 France;
Tobi Podhaler
Mylan Inc.
2018 Phase 4 NCT03502070 United States;
Novartis Pharmaceuticals
2014 Phase 4 NCT02178540 United States;
Tobramcyin
The Univeristy of Nottingham
2010 Phase 4 EUCTR2010-023030-23-GB United Kingdom;
Tobramicina
Chiesi Farmaceutici S.p.A
2008 Phase 3 EUCTR2006-006215-68-ES Czech Republic;France;Germany;Hungary;Spain;
Insmed Incorporated
2011 Phase 3 EUCTR2011-000441-20-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
Tobramicina polvere inalatoria
NOVARTIS PHARMA SERVICES AG
2016 Phase 2 EUCTR2015-003040-39-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Tobramicyn
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
Tobramycin
AZIENDA OSPEDALIERA MEYER
2008 - EUCTR2008-006502-42-IT Italy;
Chiesi Farmaceutici S.p.A
2009 Phase 3 EUCTR2006-006215-68-FR Czech Republic;France;Germany;Hungary;Spain;
2008 Phase 3 EUCTR2006-006215-68-ES Czech Republic;France;Germany;Hungary;Spain;
2008 Phase 3 EUCTR2006-006215-68-CZ Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-HU Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-DE Czech Republic;France;Germany;Hungary;Spain;
Chiesi Farmaceutici S.p.A.
2009 Phase 3 NCT01111383 France;Poland;Ukraine;
Erempharma
2011 Phase 1/Phase 2 NCT01337219 France;
FDA Office of Orphan Products Development
1995 Phase 3 NCT00004829 -
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-DK Belgium;Denmark;
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
Gilead Sciences Inc
2010 - EUCTR2007-004277-26-AT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-004277-26-GB Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-FR Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-ES Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-BE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-PT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-NL Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DK Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Imperial College London
2010 Phase 4 NCT01044719 United Kingdom;
Imperial College, London
2009 - EUCTR2009-014042-28-GB United Kingdom;
Leeds Teaching Hospitals NHS Trust
2007 - EUCTR2007-005346-20-GB United Kingdom;
NOVARTIS FARMA
2013 - EUCTR2012-003532-23-IT Argentina;Australia;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
National Jewish Health
2016 Phase 4 NCT02918409 United States;
Novartis
2008 Phase 3 NCT00634192 Germany;
2006 Phase 1 NCT00420836 -
2006 Phase 1 NCT00399945 United Kingdom;
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-003532-23-ES Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Pharma GmbH
2008 - EUCTR2007-004507-36-DE Germany;
Novartis Pharma Services AG
2013 - EUCTR2012-003532-23-DE Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2013 - EUCTR2009-016590-15-PL Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;United States;
2012 - EUCTR2012-003532-23-HU Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2011 - EUCTR2011-002000-32-DE Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2010 Phase 3 EUCTR2009-016590-15-FR France;Germany;Greece;Hungary;Italy;Poland;
2010 - EUCTR2009-016590-15-GR France;Germany;Greece;Hungary;Italy;Poland;
2010 - EUCTR2009-016590-15-DE Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;
2009 - EUCTR2009-016590-15-HU Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
The Leeds Teaching Hospitals NHS Trust
2015 - NCT02489955 United Kingdom;
University College Cork
2015 - NCT02526004 Ireland;
University Hospitals Bristol NHS Foundation Trust
2016 Phase 4 EUCTR2009-012575-10-SE Sweden;United Kingdom;
2009 Phase 4 EUCTR2009-012575-10-GB Sweden;United Kingdom;
University Medical Center Groningen
2019 Phase 1/Phase 2 NCT03485456 Netherlands;
University Medical Centre Groningen
2013 Phase 1/Phase 2 NCT02035488 Netherlands;
University of Jena
2008 - EUCTR2008-000164-17-DE Germany;
University of Milan
2012 Phase 4 NCT01608555 Italy;
University of Nottingham
2011 Phase 4 NCT01207245 United Kingdom;
Tobramycin (Gernebcin®)
University of Jena
2008 Phase 2 NCT00774072 Germany;
Tobramycin / Bramitob
Chiesi Farmaceutici S.p.A.
2009 Phase 3 NCT00885365 Czech Republic;Czechia;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
Tobramycin / TOBI
Chiesi Farmaceutici S.p.A.
2009 Phase 3 NCT00885365 Czech Republic;Czechia;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
Tobramycin 100 PARI
PARI GmbH
2007 - EUCTR2007-000959-33-DE Germany;
- Phase 1 EUCTR2005-004103-10-PL Germany;Poland;
PARI Pharma GmbH
2006 - EUCTR2005-004103-10-DE Germany;
Tobramycin Inhalation Powder
Chiron Corporation Ltd
2006 - EUCTR2005-003772-37-ES Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Novartis
2005 Phase 3 NCT00125346 Argentina;Brazil;Bulgaria;Canada;Chile;Former Serbia and Montenegro;Lithuania;Mexico;United States;
Novartis Pharma Services AG
2005 - EUCTR2005-002035-28-LT Lithuania;
- - EUCTR2005-003772-37-DE Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Novartis Pharmaceuticals
2014 Phase 4 NCT02015663 United States;
2013 Phase 4 NCT01844778 Germany;Ireland;Spain;Switzerland;United Kingdom;
2009 Phase 3 NCT00918957 Bulgaria;Egypt;Estonia;India;Latvia;Lithuania;Romania;Russian Federation;South Africa;
2006 Phase 3 NCT00388505 Australia;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Spain;United Kingdom;United States;
Tobramycin Inhalation Powder (TIP)
Novartis Pharma Services AG
2011 Phase 3 EUCTR2005-003772-37-IE Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2005-003772-37-GR Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2007 - EUCTR2005-003772-37-HU Germany;Greece;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-003772-37-GB Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Tobramycin Inhalation Powder TIP delivered by the T-326 Inhaler
CHIRON CORPORATION LIMITED
2006 - EUCTR2005-003772-37-IT Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Tobramycin Inhalation Solution (TIS)
Gilead Sciences
2008 Phase 3 NCT00757237 Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Tobramycin Powder
University Hospital Tuebingen
2014 Phase 3 NCT03341741 -
Tobramycin Solution for Inhalation
Novartis Pharmaceuticals
2006 Phase 3 NCT00388505 Australia;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Spain;United Kingdom;United States;
Tobramycin Steri-Neb 300 mg/5 ml, inhalation solution
Noordwest Ziekenhuisgroep
2016 Phase 2;Phase 3 EUCTR2016-000166-35-NL Netherlands;
Tobramycin dry powder
University Medical Center Groningen
2013 - EUCTR2012-004437-16-NL Netherlands;
Tobramycin for Inhalation
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2000 Phase 2 NCT00006280 United States;
Tobramycin inhalation powder
NOVARTIS FARMA
2012 - EUCTR2011-002000-32-IT Argentina;Australia;Brazil;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Pharma Services AG
2017 Phase 2 EUCTR2015-003040-39-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-IE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-GB Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-BE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Novartis Pharmaceuticals
2010 Phase 3 NCT01069705 Bulgaria;Estonia;Latvia;Lithuania;Romania;Russian Federation;South Africa;
2009 Phase 3 NCT00982930 Estonia;Russian Federation;
Tobramycin inhalation solution
Gilead Sciences
2012 Phase 3 NCT01641822 United States;
Medical Center Alkmaar
2016 Phase 2/Phase 3 NCT02657473 Netherlands;
Novartis Pharmaceuticals
2013 Phase 4 NCT01844778 Germany;Ireland;Spain;Switzerland;United Kingdom;
Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
Insmed Incorporated
2012 Phase 3 NCT01315678 Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
Tobramycin injection 40mg/1ml
The Univeristy of Nottingham
2010 Phase 4 EUCTR2010-023030-23-GB United Kingdom;
Tobramycin nebulized nasally
Virginie ESCABASSE
2017 Phase 3 NCT02888730 France;
Tobramycin solution for inhalation
Bonnie Ramsey
2014 Phase 3 NCT02054156 United States;
Novartis
2003 Phase 3 NCT00391976 -
Novartis Pharmaceuticals
2010 - NCT01460836 -
Tobramycin solution for inhalation (TOBI)
Seattle Children's Hospital
2004 Phase 2 NCT00097773 United States;
Tobramycine
Erempharma SAS
2009 - EUCTR2009-013660-39-FR France;
Novartis Pharma Services AG
2005 - EUCTR2005-002035-28-LT Lithuania;
Tobramycinum
PARI GmbH
- Phase 1 EUCTR2005-004103-10-PL Germany;Poland;
PARI Pharma GmbH
- Phase 1 EUCTR2010-023235-41-PL Poland;
Tobrineb/Bramitob
Chiesi Farmaceutici S.p.A
2009 Phase 3 EUCTR2006-006215-68-FR Czech Republic;France;Germany;Hungary;Spain;
2008 Phase 3 EUCTR2006-006215-68-ES Czech Republic;France;Germany;Hungary;Spain;
2008 Phase 3 EUCTR2006-006215-68-CZ Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-HU Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-DE Czech Republic;France;Germany;Hungary;Spain;
Tozinameran
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
Treatment
Johns Hopkins All Children's Hospital
2016 Phase 2 NCT02613884 United States;
Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor
Charite University, Berlin, Germany
2018 - NCT04732910 Germany;
Treatment with polyethylene glycol (Macrogol 4000)
University Hospital, Bordeaux
2020 Phase 2 NCT04458129 -
Trifakta
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Trikafta
Emory University
2019 Phase 2 NCT03506061 United States;
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Trimethoprim Sulfamethoxazole (TMP/SMX)
University of North Carolina, Chapel Hill
2018 Phase 2 NCT03489629 United States;
Trimethoprim and Sulfamethoxazole
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Trimethoprim-sulfamethoxazole
AOU Meyer
2013 Phase 3 EUCTR2013-000219-25-IT Italy;
Trimethoprim/Sulfamethoxazole
University of North Carolina, Chapel Hill
2011 Phase 2 NCT01349192 United States;
Trimethoprim/Sulfamethoxazole (TMP/SMX)
Johns Hopkins University
2012 Phase 2 NCT01594827 United States;
Trimetoprim
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Västra Götalandsregionen
2021 Phase 4 EUCTR2019-003501-10-DK Denmark;Norway;Sweden;
2020 Phase 4 EUCTR2019-003501-10-SE Denmark;Norway;Sweden;
Triple combination therapy
National Jewish Health
2019 - NCT04038710 United States;
ULTRESA
AbbVie
2012 - NCT01652157 United States;
Ultrase® MT12
Forest Laboratories
2009 Phase 3 NCT00880100 United States;
Ultrase® MT20
Forest Laboratories
2007 Phase 3 NCT00513682 United States;
2006 Phase 3 NCT00408317 United States;
Unconjugated Isoflavones 100 (PTI G-4660, Genistein)
Children's Hospital of Philadelphia
2001 Phase 1/Phase 2 NCT00016744 United States;
Uridine
FDA Office of Orphan Products Development
1996 - NCT00004705 -
Urinary collect
University Hospital, Strasbourg, France
2008 - NCT00476281 France;
Urinary levels of PIIINP as a marker of changes in renal function
Nantes University Hospital
2012 - NCT01572194 France;
Ursodiol
Children's Hospital Medical Center, Cincinnati
1997 - NCT00004441 Italy;United States;
National Center for Research Resources (NCRR)
1995 Phase 2 NCT00004315 United States;
V-Fend
CHU de Rennes (Rennes University Hospital Centre)
2012 - EUCTR2011-005799-41-GB United Kingdom;
VFEND 40 mg/ml powder for oral suspension
CHU de Rennes (Rennes University Hospital Centre)
2012 - EUCTR2011-005799-41-GB United Kingdom;
VITAMIN E - TGPS
ORPHAN
2007 - EUCTR2007-001007-38-FR France;
VR496
VECTURA LIMITED
2010 - EUCTR2007-006276-11-IT Ireland;Italy;
VRT-813077
Vertex Pharmaceuticals Incorporated
2010 Phase 3 EUCTR2009-012997-11-FR Czech Republic;France;Germany;Ireland;United Kingdom;
- - EUCTR2009-010261-23-Outside-EU/EEA United States;
VRT-826809
Vertex Pharmaceuticals Incorporated
2009 - EUCTR2008-006446-25-NL Belgium;Germany;Netherlands;
2009 - EUCTR2008-006446-25-DE Belgium;Germany;Netherlands;
2009 - EUCTR2008-006446-25-BE Belgium;Germany;Netherlands;
VRT-893661
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002968-40-PL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2016-004479-35-PL Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-GB Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-FR Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DK Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-BE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-004827-29-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 - EUCTR2014-004827-29-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-004479-35-IE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
VRT-893661 VRT-0893661
Vertex Pharmaceuticals Incorporated
2016 Phase 3 EUCTR2014-004838-25-DE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-AT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004788-18-BE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-BE Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-SE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-NL Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IT Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-GB Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-ES Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DK Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-NL Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-IT Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-GB Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-DE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004787-37-ES Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-DE Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-AT Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
VX-121
Vertex Pharmaceuticals Incorporated
2019 Phase 2 NCT03912233 Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-000126-55-NL Netherlands;
2018 Phase 1/Phase 2 NCT03768089 Netherlands;United Kingdom;
VX-121/TEZ/D-IVA
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-000712-31-SE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-DE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 NCT05076149 Australia;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2021 Phase 3 NCT05033080 Czechia;Germany;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NO Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-GR Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-CZ Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
VX-121/tezacaftor/deutivacaftor
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-000712-31-SE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-DE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NO Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-GR Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-CZ Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
VX-152
Vertex Pharmaceuticals Incorporated
2016 Phase 2 NCT02951195 United States;
VX-371
Parion Sciences
2016 Phase 2 NCT02709109 France;Ireland;United Kingdom;United States;
VX-371 in hypertonic saline
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
VX-371 in saline
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
VX-440
VERTEX PHARMACEUTICALS INCORPORATED
2017 Phase 2 EUCTR2016-000454-36-IT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2016-000454-36-NL Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-GB Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-ES Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-DE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-BE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-AT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 NCT02951182 Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000454-36-DK Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 1 NCT03486236 United Kingdom;
VX-445
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 NCT03691779 Australia;Ireland;United Kingdom;United States;
2018 Phase 3 NCT03525574 Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000797-11-NL Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 1/Phase 2 NCT03227471 Australia;Belgium;Netherlands;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-445 / TEZ / IVA
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
VX-445 / TEZ / IVA FDC
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-001827-11-IE Australia;Canada;Ireland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001695-38-GB Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2019-001827-11-GB Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-001695-38-IE Australia;Canada;Ireland;United Kingdom;United States;
VX-445 /50 mg TEZ/75 mg IVA FDC
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
VX-445 /TEZ/IVA
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2018-004652-38-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
VX-445/50 mg TEZ /75 mg IVA FDC
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-445/50mg TEZ /75mg IVA FDC
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
VX-445/TEZ/IVA
VERTEX PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2019-000833-37-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
2020 Phase 3 EUCTR2019-000833-37-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001735-31-GB Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000833-37-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001695-38-GB Australia;Canada;Ireland;United Kingdom;United States;
2018 Phase 3 NCT03525548 Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 NCT03525444 Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2019-001735-31-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2019-000833-37-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-001695-38-IE Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-561
Vertex Pharmaceuticals Incorporated
2019 Phase 2 NCT03912233 Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 NCT03911713 Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-NL Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-GB Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-DE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-BE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
2017 Phase 2 NCT03224351 Ireland;Israel;United Kingdom;United States;
2017 Phase 1/Phase 2 NCT03227471 Australia;Belgium;Netherlands;United States;
2016 Phase 2 NCT02971839 United States;
VX-561 (CTP-656)
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
VX-659
Vertex Pharmaceuticals Incorporated
2018 Phase 3 NCT03447262 Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 2 NCT03224351 Ireland;Israel;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
2016 Phase 1 NCT03029455 United Kingdom;
VX-659/ TEZ/IVA
Vertex Pharmaceuticals Incorporated
2019 Phase 3 EUCTR2017-004134-29-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
VX-659/TEZ/IVA
Vertex Pharmaceuticals Incorporated
2018 Phase 3 NCT03633526 United States;
2018 Phase 3 NCT03460990 Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 NCT03447249 Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-IE Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-GB Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-ES Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-004133-82-DE Australia;Germany;Ireland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-004132-11-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
VX-659/Tezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
2019 Phase 3 EUCTR2017-004134-29-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-IE Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-GB Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-ES Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-004133-82-DE Australia;Germany;Ireland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-004132-11-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
VX-661
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2018-004652-38-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2014 Phase 2 NCT02070744 United States;
2014 Phase 1 NCT02015507 -
2012 Phase 2 NCT01531673 Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-661 / VX-770
VERTEX PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001735-31-GB Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2019-001735-31-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
VX-661 Plus Ivacaftor Combination
Vertex Pharmaceuticals Incorporated
2015 Phase 3 NCT02347657 Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
VX-661 plus ivacaftor combination
Vertex Pharmaceuticals Incorporated
2015 Phase 3 NCT02516410 Australia;Austria;Canada;France;Israel;Spain;United States;
VX-661, VRT-893661
Vertex Pharmaceuticals Incorporated
2013 Phase 2 EUCTR2011-003821-93-DE Canada;Germany;United Kingdom;United States;
2012 Phase 2 EUCTR2011-003821-93-GB Canada;Germany;United Kingdom;United States;
VX-661/Ivacaftor
Vertex Pharmaceuticals Incorporated
2015 Phase 3 NCT02392234 Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
VX-661/VX-770
VERTEX PHARMACEUTICALS INCORPORATED
2017 Phase 2 EUCTR2016-000454-36-IT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-000126-55-NL Netherlands;
2017 Phase 3 EUCTR2017-000540-18-DE France;Germany;United States;
2017 Phase 2 EUCTR2017-000797-11-NL Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-NL Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-GB Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-ES Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-DE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-BE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-AT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-DE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-AT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004788-18-BE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000454-36-DK Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-BE Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-SE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-NL Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IT Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-GB Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-ES Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DK Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-NL Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-IT Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-GB Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-DE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004787-37-ES Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-DE Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-AT Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 - EUCTR2014-004827-29-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000540-18-FR France;Germany;United States;
VX-661/VX-770 (TEZ/IVA)
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-004133-82-IE Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-GB Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-ES Australia;Germany;Ireland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-004133-82-DE Australia;Germany;Ireland;Spain;United Kingdom;United States;
VX-661/ivacaftor (VX-770) 100mg/
Vertex Pharmaceuticals Incorporated
2016 Phase 3 EUCTR2014-004827-29-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 - EUCTR2014-004827-29-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
VX-661/ivacaftor 100 mg/
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002968-40-PL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2016-004479-35-PL Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-GB Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-FR Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DK Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-BE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
- Phase 3 EUCTR2017-002968-40-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-004479-35-IE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
VX-661/ivacaftor 100mg/
Vertex Pharmaceuticals Incorporated
2016 Phase 3 EUCTR2014-004838-25-DE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-AT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004788-18-BE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-BE Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-SE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-NL Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IT Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-GB Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-ES Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DK Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-NL Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-IT Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-GB Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-DE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004787-37-ES Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-DE Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-AT Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
VX-661/ivacaftor 50 mg/
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002968-40-PL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2016-004479-35-PL Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-GB Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-FR Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DK Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-BE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
- Phase 3 EUCTR2017-002968-40-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-004479-35-IE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
VX-77
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
VX-770
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
2022 Phase 3 EUCTR2021-000712-31-SE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-DE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-001628-16-ES Australia;Belgium;Canada;Spain;
2021 Phase 3 EUCTR2021-000694-85-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NO Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-GR Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-001827-11-IE Australia;Canada;Ireland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004652-38-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001695-38-GB Australia;Canada;Ireland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004134-29-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-NL Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-GB Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-DE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-BE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-001379-21-GB Canada;Germany;Ireland;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001997-16-IE Canada;Germany;Ireland;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001267-39-GB Australia;Canada;France;United Kingdom;
2015 Phase 3 NCT02514473 Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-000386-20-GB Canada;United Kingdom;United States;
2013 Phase 3 EUCTR2012-000204-15-GB Canada;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000389-39-GB Belgium;France;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000389-39-BE Belgium;France;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000388-26-BE Belgium;France;United States;
2012 - EUCTR2012-000387-19-GB United Kingdom;United States;
2011 - NCT01381289 -
2010 Phase 2 NCT01161537 United States;
2010 Phase 1 NCT01216046 United States;
2010 Phase 1 NCT01208285 Czech Republic;Slovakia;
2010 Phase 1 NCT01153542 United States;
2010 Phase 1 NCT01060566 United States;
2009 Phase 1 NCT01018368 United States;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-001628-16-BE Australia;Belgium;Canada;Spain;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-CZ Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-001827-11-GB Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2019-000833-37-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-001695-38-IE Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-004132-11-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-001379-21-IE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2017-001379-21-DE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001997-16-GB Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001997-16-DE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001267-39-FR Australia;Canada;France;United Kingdom;
- Phase 2 EUCTR2017-000673-37-Outside-EU/EEA United States;
- Phase 2 EUCTR2017-000672-28-Outside-EU/EEA United States;
- - EUCTR2009-010261-23-Outside-EU/EEA United States;
VX-770, VRT-8130077
Vertex Pharmaceuticals Incorporated
2010 Phase 3 EUCTR2009-012997-11-FR Czech Republic;France;Germany;Ireland;United Kingdom;
VX-770, VRT-813077
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002968-40-PL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2016-004479-35-PL Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-GB Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-FR Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DK Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-BE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-004838-25-DE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-AT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004788-18-BE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-BE Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-SE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-NL Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IT Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-GB Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-ES Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DK Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-NL Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-IT Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-GB Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-DE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004787-37-ES Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-DE Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-AT Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 - EUCTR2014-004827-29-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2014 Phase 2 EUCTR2010-020413-90-GB Australia;Belgium;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2010-020413-90-IE Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
2013 Phase 2 EUCTR2011-003821-93-DE Canada;Germany;United Kingdom;United States;
2012 Phase 2 EUCTR2011-003821-93-GB Canada;Germany;United Kingdom;United States;
2011 - EUCTR2010-020413-90-DE Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
2011 - EUCTR2010-020413-90-BE Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
2010 Phase 3 EUCTR2009-012997-11-GB Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2010-020546-96-GB Canada;United Kingdom;United States;
2010 - EUCTR2009-012997-11-IE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2009-012997-11-DE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2009-012997-11-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-007479-26-GB Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-007479-26-FR France;Germany;Ireland;United Kingdom;
2009 Phase 3 EUCTR2008-007416-15-GB Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-007416-15-FR Czech Republic;France;Germany;Ireland;United Kingdom;
2009 - EUCTR2008-007479-26-IE Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 - EUCTR2008-007479-26-DE Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 - EUCTR2008-007416-15-IE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 - EUCTR2008-007416-15-CZ Czech Republic;France;Germany;Ireland;United Kingdom;
2007 - EUCTR2007-002657-23-DE Germany;
- Phase 3 EUCTR2017-002968-40-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-004479-35-IE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
- - EUCTR2008-007416-15-DE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
VX-809
Vertex Pharmaceuticals Incorporated
2015 Phase 3 NCT02514473 Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2010 Phase 1 NCT01216046 United States;
2009 Phase 2 NCT00865904 Belgium;Canada;Germany;Netherlands;United States;
2009 - EUCTR2008-006446-25-NL Belgium;Germany;Netherlands;
2009 - EUCTR2008-006446-25-DE Belgium;Germany;Netherlands;
2009 - EUCTR2008-006446-25-BE Belgium;Germany;Netherlands;
VX-809 & VX-770
Vertex Pharmaceuticals Incorporated
2009 Phase 1 NCT00966602 Netherlands;
VX-809 / VX-770
Vertex Pharmaceuticals Incorporated
2018 Phase 2 EUCTR2017-003761-99-DE Germany;
2016 Phase 3 EUCTR2015-001644-11-GB Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-FR Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DK Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-BE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-SE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-GB Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-DK Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-DE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-BE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-IT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 - EUCTR2013-000604-41-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-SE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-GB Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003990-24-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003989-40-NL Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IT Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-DE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2015-001644-11-SE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2015-000543-16-FR Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
VX-809, VRT-826809
Vertex Pharmaceuticals Incorporated
2014 Phase 2 EUCTR2010-020413-90-GB Australia;Belgium;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2010-020413-90-IE Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
2011 - EUCTR2010-020413-90-DE Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
2011 - EUCTR2010-020413-90-BE Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
VX-809/VX-770
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
2016 Phase 4 EUCTR2016-000066-34-GB Australia;United Kingdom;
2014 Phase 2 EUCTR2010-020413-90-GB Australia;Belgium;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2010-020413-90-IE Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
2011 - EUCTR2010-020413-90-DE Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
2011 - EUCTR2010-020413-90-BE Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
- Phase 3 EUCTR2017-001309-34-Outside-EU/EEA United States;
- Phase 3 EUCTR2017-001078-41-Outside-EU/EEA Canada;United States;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
Vaccin grippal pandémique H1N1
Inserm
2009 - EUCTR2009-016662-90-FR France;
Vaccination with vaccine against hepatitis A and B
Karolinska University Hospital
2015 - NCT02605538 Sweden;
Valganciclovir [Valcyte]
Hoffmann-La Roche
2004 Phase 1 NCT00377741 United States;
Vancomycin
Case Western Reserve University
2012 Phase 1 NCT01509339 United States;
Vancomycin hydrochloride inhalation powder
Savara Inc.
2013 Phase 2 NCT01746095 United States;
Vancomycin inhalation powder
Savara Inc.
2017 Phase 3 NCT03181932 Canada;United States;
Vantobra (tobramycin)
Pari Pharma GmbH
2013 Phase 1 NCT01953367 Germany;
Vardenafil
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2011 Phase 2 NCT01002534 Belgium;
Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
Ventolin® Evohaler
ZAMBON SPA
2017 Phase 3 EUCTR2015-002743-33-IT Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Ventolin¿ Evohaler¿
ZAMBON SPA
2017 Phase 3 EUCTR2015-002743-33-IT Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Vfend
Leeds Teaching Hospital NHS Trust
2007 Phase 4 EUCTR2006-006362-41-GB United Kingdom;
Vitamin D
Hadassah Medical Organization
2014 - NCT02043717 Israel;
Vitamin D Oil
Emory University
2013 Phase 4 NCT01880346 United States;
Vitamin D Powder
Emory University
2013 Phase 4 NCT01880346 United States;
Vitamin D3
Atlanta VA Medical Center
2006 - NCT00450073 United States;
Emory University
2020 Phase 4 NCT04118010 United States;
2008 - NCT00788138 United States;
University of Southern California
2019 - NCT03734744 United States;
Vitamin K supplementation, dose #1
Institut de Recherches Cliniques de Montreal
2020 - NCT04496921 Canada;
Vitamin K supplementation, dose #2
Institut de Recherches Cliniques de Montreal
2020 - NCT04496921 Canada;
Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1
University of British Columbia
2007 - NCT01070446 Canada;
Voriconazole
CHU de Rennes (Rennes University Hospital Centre)
2012 - EUCTR2011-005799-41-GB United Kingdom;
WATER FOR INJECTIONS, EP
Fundació Parc Taulí
2017 Phase 2 EUCTR2016-004033-25-ES Spain;
Whole body Protein Turnover
University of Texas Southwestern Medical Center
2006 - NCT00287456 United States;
Whole body Protein Turnover Study
University of Texas Southwestern Medical Center
2006 - NCT00287430 -
Whole body protein turnover
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
Xenon
Children's Hospital Medical Center, Cincinnati
2021 - NCT04793867 United States;
Papworth Hospital NHS Foundation Trust
2016 - NCT02912637 United Kingdom;
Xenon-129
The Hospital for Sick Children
2015 Phase 2 NCT02740868 Canada;
Xolair
Novartis Pharma Services AG
2009 Phase 4 EUCTR2007-006648-23-IE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
2009 - EUCTR2007-006648-23-NL Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
2009 - EUCTR2007-006648-23-GB Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-006648-23-BE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Xolair 150 mg Pulver und Injektionslösung zur Herstellung einer Injektionslösung
Novartis Pharma Services AG
2008 - EUCTR2007-006648-23-DE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Xylitol
Joseph Zabner
2013 Phase 1/Phase 2 NCT00928135 United States;
2011 Phase 1/Phase 2 NCT01355796 United States;
ZENPEP
AbbVie
2012 - NCT01652157 United States;
EURAND SPA
2010 - EUCTR2009-012842-21-IT Bulgaria;Germany;Hungary;Italy;United Kingdom;
ZITHOMAX 40 mg/ml ENFANTS
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
- Phase 3 EUCTR2014-003023-22-FR France;
Zadaxin
SciClone Pharmaceuticals Limited Ltd
2019 Phase 2 EUCTR2019-001441-40-IT Italy;
Zavesca
Actelion Pharmaceuticals Ltd
2008 - EUCTR2008-002352-20-BE Belgium;
2007 - EUCTR2006-002049-35-ES Spain;
Zenpep
Aptalis Pharma US Inc.
2013 - EUCTR2009-012842-21-HU Bulgaria;Germany;Hungary;Italy;United Kingdom;
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-BG Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
Zinc acetate (20mg/d)
Cystic Fibrosis Foundation Therapeutics
2004 - NCT00104494 United States;
Zitromax
Copenhagen CF-centre
2009 Phase 4 EUCTR2006-003275-12-NO Denmark;Norway;Sweden;
2007 Phase 4 EUCTR2006-003275-12-DK Denmark;
- Phase 4 EUCTR2006-003275-12-SE Denmark;Norway;Sweden;
Zoledronic acid
Papworth Hospital NHS Foundation Trust
2013 Phase 4 NCT01702415 United Kingdom;
chlorhexidine gluconate liquid skin cleanser
Johns Hopkins University
2012 Phase 2 NCT01594827 United States;
normal saline (control)
Mukoviszidose Institut gGmbH
2007 Phase 2 NCT00506688 Germany;
saline
Johns Hopkins University
2007 Phase 2 NCT01293084 -
w/v sodium chloride solution
Merck Sharp & Dohme Corp.
2010 Phase 2 NCT01181622 United States;
University of Washington
2010 Phase 1 NCT01093521 United States;
033841
Erasmus University Medical Centre
2012 - EUCTR2012-002503-17-NL Netherlands;
1,5 (Butylimino)-1,5-dideoxy-D-glucitol
Actelion Pharmaceuticals Ltd
2007 - EUCTR2006-002049-35-ES Spain;
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid
Bayer HealthCare AG
2007 - EUCTR2007-002912-24-DE Germany;
100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
100-mg ELX / 50-mg TEZ / 75 -mg IVA FDC
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC
VERTEX PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2019-000833-37-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-000833-37-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001735-31-GB Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000833-37-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2019-001735-31-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2019-000833-37-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
100-mg VX-445 /50-mg TEZ/75-mg
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2018-004652-38-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
100-mg VX-445/50-mg TEZ/75-mg IVA FDC
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
100g ELX / 50mg TEZ / 75mg IVA
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
129Xe Small and Large Human Lung Coil
Thunder Bay Regional Research Institute
2019 Early Phase 1 NCT02748798 Canada;
13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)
University of Miami
2022 - NCT05223881 United States;
150-mg IVACAFTOR
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2,3-dihydroxybutanedioic acid
University of LIverpool
2019 Phase 1;Phase 2 EUCTR2017-001259-29-GB United Kingdom;
2-aminoethanethiol
University of LIverpool
2019 Phase 1;Phase 2 EUCTR2017-001259-29-GB United Kingdom;
2622U90 Duramycin
AOP Orphan Pharmaceuticals AG
2008 - EUCTR2006-006693-24-CZ Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
2007 Phase 2;Phase 3 EUCTR2006-006693-24-DE Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
- Phase 2 EUCTR2006-006693-24-PL Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
291844
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
3He Human Lung Coil
Thunder Bay Regional Research Institute
2019 Early Phase 1 NCT02748798 Canada;
4D-710
4D Molecular Therapeutics
2022 Phase 1/Phase 2 NCT05248230 United States;
5-methyltetrahydrofolate and vitamin B12
Universita di Verona
2004 - NCT00730509 Italy;
5000 IU of cholecalciferol
St. Michael's Hospital, Toronto
2008 - NCT00685971 Canada;
552-02
Parion Sciences
2006 Phase 1/Phase 2 NCT00274313 United States;
75-mg IVACAFTOR
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)
University Hospital, Strasbourg, France
2020 Phase 4 NCT04381429 France;
AAC Hexal
Aarhus University Hospital
2016 Phase 2 EUCTR2016-000354-35-DK Denmark;
ABBV-119
AbbVie
2021 Phase 2 NCT04853368 Australia;Belgium;Czechia;Germany;Hungary;Netherlands;New Zealand;Slovakia;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-005805-25-NL Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
2021 Phase 2 EUCTR2020-005805-25-HU Hungary;
2021 Phase 2 EUCTR2020-005805-25-BE Belgium;Hungary;Netherlands;
ABBV-2222
AbbVie
2019 Phase 2 NCT03969888 Belgium;Canada;Czechia;France;Hungary;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
AbbVie Deutschland
2019 Phase 2 EUCTR2019-000750-63-NL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-HU Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-GB Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-FR Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-BE Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-005805-25-NL Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
2021 Phase 2 EUCTR2020-005805-25-HU Hungary;
2021 Phase 2 EUCTR2020-005805-25-BE Belgium;Hungary;Netherlands;
2020 Phase 2 EUCTR2019-000750-63-PL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
ABBV-3067
AbbVie
2019 Phase 2 NCT03969888 Belgium;Canada;Czechia;France;Hungary;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
AbbVie Deutschland
2019 Phase 2 EUCTR2019-000750-63-NL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-HU Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-GB Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-FR Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-BE Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-005805-25-NL Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
2021 Phase 2 EUCTR2020-005805-25-HU Hungary;
2021 Phase 2 EUCTR2020-005805-25-BE Belgium;Hungary;Netherlands;
2020 Phase 2 EUCTR2019-000750-63-PL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
ACC
Aarhus University Hospital
2014 Phase 2 EUCTR2013-005481-19-DK Denmark;
ACC600Tabs
Rigshospitalet
2010 Phase 4 EUCTR2007-001401-15-DK Denmark;
ACETYLCYSTEINE SODIUM
Aarhus University Hospital
2016 Phase 2 EUCTR2016-000354-35-DK Denmark;
ACIDE TRANEXAMIQUE MYLAN 0,5 g/ 5 mL, solution injectable
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2021 Phase 3 EUCTR2020-005931-58-FR France;
AER002
Aerovance Inc
2005 Phase 1;Phase 2 EUCTR2005-000313-35-GB United Kingdom;
AIR DNase
Protalix
2015 Phase 1 NCT02605590 Israel;
AIR DNase™
Protalix
2016 Phase 2 NCT02722122 Israel;
ALTU-135
ALTUS PHARMACEUTICALS INC
2007 - EUCTR2007-000178-21-IT Italy;
2007 - EUCTR2007-000171-41-IT Italy;
Altus Pharmaceuticals Inc
2007 Phase 3 EUCTR2007-000171-41-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000171-41-PL Italy;Poland;Slovakia;
Altus Pharmaceuticals Inc.
2007 Phase 3 EUCTR2007-000178-21-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000178-21-PL Italy;Poland;Slovakia;
ALTUS-135
ALTUS PHARMACEUTICALS INC
2007 - EUCTR2007-000171-41-IT Italy;
ALX-009
Alaxia SAS
2015 Phase 1 NCT02598999 France;
AMIKACIN SULFATE
INSMED INCORPORATED
2012 - EUCTR2011-000443-24-IT Australia;Austria;Belgium;Bulgaria;Canada;Denmark;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Spain;Sweden;United Kingdom;
2011 - EUCTR2011-000441-20-IT Austria;Bulgaria;Canada;Denmark;Greece;Hungary;Ireland;Italy;Netherlands;Spain;United Kingdom;
Insmed Incorporated
2013 - EUCTR2011-000443-24-NL Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000443-24-PL Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000443-24-BE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000441-20-BE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000443-24-SE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-000443-24-DK Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-000441-20-NL Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2012 - EUCTR2011-000441-20-IE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-DK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-BG Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-000443-24-SK Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-000443-24-GB Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-000443-24-FR Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2011 - EUCTR2011-000443-24-IE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000443-24-HU Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000443-24-GR Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2011 - EUCTR2011-000443-24-DE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;
2011 - EUCTR2011-000443-24-BG Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
2011 - EUCTR2011-000443-24-AT Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000441-20-SK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-HU Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-GR Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2011 - EUCTR2011-000441-20-GB Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-DE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-AT Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
Transave, Inc.
- Phase 2 EUCTR2006-006980-22-PL Belgium;Hungary;Poland;Slovakia;
AMILASA
ANTHERA Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2016-002851-92-ES Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
AMYLASE
ANTHERA Pharmaceuticals, Inc.
2017 Phase 3 EUCTR2017-000571-85-LT Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-HU Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-GB Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000571-85-ES Hungary;Israel;Lithuania;Poland;Spain;United States;
2016 Phase 4 EUCTR2016-002851-92-CZ Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
2016 Phase 3 EUCTR2016-002851-92-HU Canada;Hungary;Israel;Spain;United States;
- Phase 3 EUCTR2017-000571-85-PL Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-002851-92-PL Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
AP-PA02
Armata Pharmaceuticals, Inc.
2020 Phase 1/Phase 2 NCT04596319 United States;
ARD-3150
Aradigm Corporation
2015 Phase 3 EUCTR2013-005366-19-PL Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005366-19-FR Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005348-28-PL Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-RO Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-IT Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-HU Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-GB Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-ES Australia;Canada;France;Germany;Hungary;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-RO Australia;Canada;Georgia;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-LV Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-IT Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-IE Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-HU Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-GB Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-ES Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
ARIKACE™
Insmed Incorporated
2007 Phase 1/Phase 2 NCT00777296 Belgium;Bulgaria;Hungary;Macedonia, The Former Yugoslav Republic of;North Macedonia;Poland;Serbia;Slovakia;Ukraine;
ARO-ENaC
Arrowhead Pharmaceuticals
2020 Phase 1/Phase 2 NCT04375514 Australia;New Zealand;
AZD1236
AstraZeneca
2009 Phase 2 NCT00812045 Canada;Netherlands;Poland;Spain;
AstraZeneca AB
2008 - EUCTR2008-004699-34-NL Netherlands;Spain;
2008 - EUCTR2008-004699-34-ES Netherlands;Spain;
AZD5634
AstraZeneca
2017 Phase 1 NCT02950805 United States;
AZD5634 for infusion
AstraZeneca
2016 Phase 1 NCT02679729 United States;
AZD5634 for inhalation
AstraZeneca
2016 Phase 1 NCT02679729 United States;
AZD7986
Insmed Incorporated
2021 Phase 3 EUCTR2020-003688-25-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-LT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-IE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2017-002533-32-BE Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-SE Australia;Belgium;Bulgaria;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-PL Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-NL Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-GB Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-ES Australia;Belgium;Bulgaria;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-DK Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-DE Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-BG Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
AZD9668
AstraZeneca
2008 Phase 2 NCT00757848 Denmark;Germany;Poland;Russian Federation;Sweden;United Kingdom;
AstraZeneca AB
2009 - EUCTR2008-001530-27-GB Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-001530-27-DK Denmark;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-001530-27-SE Denmark;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-001530-27-DE Denmark;Germany;Sweden;United Kingdom;
AZITHROMYCIN DIHYDRATE
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
- Phase 3 EUCTR2014-003023-22-FR France;
AZLI
Gilead Sciences, Inc.
2012 Phase 3 EUCTR2011-001362-18-ES France;Germany;Italy;Poland;Spain;United States;
Gilead Sciences
2017 Phase 3 NCT03219164 Austria;Belgium;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2012 Phase 3 NCT01641822 United States;
2011 Phase 3 NCT01404234 France;Germany;Italy;Poland;Spain;United States;
2011 Phase 3 NCT01314716 Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2011 Phase 3 NCT01313624 Australia;Canada;United States;
2010 Phase 3 NCT01059565 Canada;United States;
Gilead Sciences Inc
2010 - EUCTR2007-004277-26-AT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-004277-26-GB Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-FR Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-ES Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-BE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-PT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-NL Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DK Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Gilead Sciences, Inc.
2018 Phase 3 EUCTR2016-002749-42-NL Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2016-002749-42-GR Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-IT Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-GB Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-FR Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-ES Austria;Belgium;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-DK Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-DE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-BE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-AT Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2012 Phase 2 EUCTR2011-001255-36-BE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001362-18-DE France;Germany;Italy;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-NL Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-IE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-DE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-AT Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2011 Phase 2 EUCTR2011-001255-36-ES Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- Phase 3 EUCTR2016-002749-42-IE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2011-001362-18-FR France;Germany;Italy;Poland;Spain;United States;
- Phase 2 EUCTR2011-001255-36-FR Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- - EUCTR2011-001362-18-Outside-EU/EEA United States;
- - EUCTR2011-001255-36-Outside-EU/EEA United States;
AZLI 75 mg three times a day (TID)
Gilead Sciences
2005 Phase 3 NCT00112359 Australia;Canada;New Zealand;United States;
AZLI 75 mg three times daily (TID)
Gilead Sciences
2008 Phase 3 NCT00712166 Australia;Canada;United States;
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Gilead Sciences
2005 Phase 3 NCT00128492 Australia;Canada;New Zealand;United States;
AZLI 75 mg two times a day (BID)/three times a day (TID)
Gilead Sciences
2005 Phase 3 NCT00104520 United States;
AZTREONAM LYSINE
Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
2014 Phase 4 EUCTR2013-004295-35-AT Austria;
Acebilustat
Celtaxsys Inc.
2016 Phase 2 EUCTR2015-002677-38-IT Belgium;France;Germany;Italy;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-GB Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-DE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-BE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
Acetylcysteine
University Hospital, Ghent
2010 Phase 4 NCT00996424 Belgium;
West China Hospital, Sichuan University
2020 Phase 4 ChiCTR2000031817 China;
Active Treatment Group Hypertonic Saline
University of Washington, the Collaborative Health Studies Coordinating Center
2015 Phase 2/Phase 3 NCT02950883 Australia;Belgium;Canada;Denmark;France;Italy;Netherlands;Spain;United States;
Actrapid 100 IU/ml, Solution for injection in a vial
St George's, University of London
2008 - EUCTR2007-004956-35-GB United Kingdom;
Actrapid Penfill 100UI/ml
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2006 - EUCTR2006-001254-27-FR France;
Acute Antioxidant
Augusta University
2015 - NCT02690064 United States;
Ad26.COV2-S.02
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
Adempas
Bayer AG
2015 Phase 2 EUCTR2013-004595-35-BE Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2014 Phase 2 EUCTR2013-004595-35-GB Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2014 Phase 2 EUCTR2013-004595-35-DE Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
Bayer HealthCare AG
2015 Phase 2 EUCTR2013-004595-35-NL Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States;
Adeno-associated virus-CFTR vector
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1999 Phase 1 NCT00004533 -
Adrenalina
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
Advagraf prolonged-release hard capsules
Hopital Erasme - Chest service
2009 - EUCTR2009-014050-15-BE Belgium;
AeroVanc
Savara Inc.
2011 Phase 1 NCT01537666 Australia;
Aeroquin
Mpex Pharmaceuticals, Inc.
2011 Phase 3 EUCTR2010-019634-26-GB Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-IE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-DE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
- Phase 3 EUCTR2010-019634-26-FR France;Germany;Ireland;United Kingdom;
Aerosolized, human, plasma-derived Alpha-1 Antitrypsin
Kamada, Ltd.
2007 Phase 2 NCT00499837 Israel;
Aerosoltherapy
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2018 - NCT03655249 Belgium;
Air
Assistance Publique - Hôpitaux de Paris
2012 - NCT01586728 France;
Airway clearance technique
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2012 - NCT02201082 Belgium;
Albuterol
National Center for Research Resources (NCRR)
2000 - NCT00005110 United States;
University of Arizona
2009 - NCT01880723 United States;
Albuterol inhaler.
University of Florida
2007 - NCT01851642 United States;
Alendronate
Istituto Auxologico Italiano
2002 Phase 3 NCT01812551 Holy See (Vatican City State);Italy;
McMaster University
2003 Phase 4 NCT00157690 Canada;
Alendronate sodium
University of North Carolina
1998 - NCT00004489 United States;
Alginate oligosaccharide
AlgiPharma AS
2015 Phase 2 NCT02453789 Germany;
2014 Phase 2 NCT02157922 Denmark;Germany;Norway;Sweden;United Kingdom;
Allo-hMSCs
Joshua M Hare
2020 Phase 1 NCT03058068 United States;
Alpha-1 HC
Grifols Therapeutics Inc.
2012 Phase 2 NCT01684410 United States;
Alpha1-Proteinase Inhibitor (Human)
Grifols Therapeutics Inc.
2003 Phase 2 NCT00486837 -
Amikacin
Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine
2015 - ChiCTR-IPC-15005915 -
Qilu Hospital of Shandong University
2014 Phase 4 NCT02081963 China;
The Leeds Teaching Hospitals NHS Trust
2015 - NCT02489955 United Kingdom;
Amikacin Sulfate
Insmed Incorporated
2011 - EUCTR2011-000442-38-ES Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-000442-38-BG Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
- Phase 3 EUCTR2011-000442-38-PL Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
Amikacin nebulization
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2012 - NCT02201082 Belgium;
Amikacin sulfate
Transave, Inc.
2007 - EUCTR2006-006980-22-BE Belgium;Hungary;
Amikacina liposomal (Arikace?)
Insmed Incorporated
2011 Phase 3 EUCTR2011-000441-20-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
Amikacine nebulization
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2015 - NCT02535130 Belgium;
Amikin, amiklin, amicacin, BB-K8, Biklin, Fabianol, Kaminax, Mikavir, Novamin, Pierami
Transave, Inc
2005 - EUCTR2005-004389-17-HU Hungary;
Amikin®, amiklin, amicacin, BB-K8, Biklin®, Fabianol®, Kaminax, Mikavir, Novamin®, Pierami
Transave, Inc.
2005 - EUCTR2005-004899-21-BE Belgium;
Amiloride
FDA Office of Orphan Products Development
1996 - NCT00004705 -
Amiloride HCl
University of North Carolina
2001 Phase 2 NCT00274391 United States;
Amiloride Solution for Inhalation
Children's Hospital Boston
2006 Phase 1 NCT00547053 United States;
Amitriptylin-CT
PSKS
- Phase 2 EUCTR2008-002673-13-DE Germany;
Amitriptylin-ct Tabletten
Paediatrisches Sekretariat fuer Klinische Studien
2006 Phase 2 EUCTR2006-002259-33-DE Germany;
Amitriptyline
PSKS
- Phase 2 EUCTR2008-002673-13-DE Germany;
University Children’s Hospital Tuebingen
2009 Phase 2 NCT01309178 Germany;
University Hospital Tuebingen
2006 Phase 2 NCT00515229 Germany;
Amoxicillin and Clavulanic acid
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Amphotericin B
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
2010 - EUCTR2010-019194-15-IT Italy;
Amylase
Altus Pharmaceuticals Inc
2007 Phase 3 EUCTR2007-000171-41-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000171-41-PL Italy;Poland;Slovakia;
Altus Pharmaceuticals Inc.
2007 Phase 3 EUCTR2007-000178-21-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000178-21-PL Italy;Poland;Slovakia;
Anakinra
Heidelberg University
2021 Phase 2 NCT03925194 Germany;
Andecaliximab
Gilead Sciences
2016 Phase 2 NCT02759562 Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
Anti-pseudomonas IgY gargle
Immunsystem AB
2003 Phase 1/Phase 2 NCT00633191 Sweden;
Anti-reflux pharmacotherapy
Bayside Health
2001 - NCT00164021 Australia;
Antibiotic
Aradigm Corporation
2010 - NCT01090908 -
Antioxidant Cocktail
Augusta University
2011 Phase 2 NCT01772758 United States;
Antistaminici H1 - H2
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
AquADEK
University of Colorado, Denver
2007 Phase 1/Phase 2 NCT01018303 United States;
AquADEKs-2
University of Colorado, Denver
2013 Phase 2 NCT01859390 United States;
Arginine
Children's Hospital of Philadelphia
2013 - NCT01852448 United States;
Aridol or Osmohale
Pharmaxis Pharmaceuticals Limited
- Phase 3 EUCTR2007-001412-23-DE Germany;Ireland;United Kingdom;
Arikayce™
Insmed Incorporated
2009 Phase 2 NCT03905642 Belgium;Hungary;Macedonia, The Former Yugoslav Republic of;North Macedonia;Poland;Serbia;Slovakia;Ukraine;
2008 Phase 1/Phase 2 NCT00558844 United States;
Ataluren
PTC THERAPEUTICS, INC.
2010 - EUCTR2010-019692-30-IT Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC Therapeutics
2015 Phase 3 NCT02456103 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 NCT02107859 Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2010 Phase 3 NCT01140451 Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 Phase 3 NCT00803205 Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2007 Phase 2 NCT00458341 Belgium;France;Israel;
2005 Phase 2 NCT00237380 Israel;
PTC Therapeutics, Inc
2011 Phase 3 EUCTR2010-019692-30-GB Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019692-30-ES Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-019692-30-DE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2010 - EUCTR2010-019692-30-SE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 - EUCTR2010-019692-30-NL Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 - EUCTR2010-019692-30-BE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-BE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC Therapeutics, Inc.
2016 Phase 3 EUCTR2014-005355-83-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-GR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-FR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005449-35-FR Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2015 Phase 3 EUCTR2013-004581-34-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-GR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005449-35-SE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-IT Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-ES Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-DE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-BE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-004581-34-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
University of Alabama at Birmingham
2017 Phase 4 NCT03256968 United States;
Ataluren (PTC124®)
PTC Therapeutics
2014 Phase 3 NCT02139306 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Atorvastatin
NHS Lothian
2010 Phase 4 EUCTR2010-022042-24-GB United Kingdom;
2010 Phase 4 EUCTR2010-022040-20-GB United Kingdom;
University of Edinburgh
2010 Phase 4 NCT01299181 United Kingdom;
Atropina
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
Augmentin
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Aurexis® (tefibazumab)
Bristol-Myers Squibb
2005 Phase 2 NCT00198289 United States;
Avian polyclonal IgY antibody against PA
MUKOVISZIDOSE E.V.
2012 Phase 3 EUCTR2011-000801-39-IT Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
Mukoviszidose Institute gGmbH
2014 Phase 3 EUCTR2011-000801-39-HU Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2014 Phase 3 EUCTR2011-000801-39-ES Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2014 Phase 3 EUCTR2011-000801-39-AT Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2013 Phase 3 EUCTR2011-000801-39-IE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2012 Phase 3 EUCTR2011-000801-39-SE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2012 Phase 3 EUCTR2011-000801-39-BE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2011 Phase 3 EUCTR2011-000801-39-DE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
Azithromycin
Assistance Publique Hopitaux De Marseille
2015 Phase 3 NCT02531984 -
Bonnie Ramsey
2014 Phase 3 NCT02054156 United States;
Hospices Civils de Lyon
2014 - NCT02803944 France;
Instituto de Investigacion Sanitaria La Fe
2006 - NCT01463371 Spain;
Seattle Children's Hospital
2016 Phase 4 NCT02677701 United States;
St. Michael's Hospital, Toronto
2006 Phase 2 NCT00298922 Canada;
The University of Queensland
2012 Phase 3 NCT01270074 Australia;New Zealand;
University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)
2012 Phase 4 NCT03045198 -
University of Colorado, Denver
2014 - NCT02372383 United States;
Azithromycin 250 mg tablets
CF Therapeutics Development Network Coordinating Center
2007 Phase 4 NCT00431964 Canada;United States;
Azithromycin 500 mg film-coated tablet
university medical center utrecht
2018 Phase 4 EUCTR2016-001440-18-NL Netherlands;
Aztreonam
Gilead Sciences Inc
2008 - EUCTR2007-004277-26-IT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Liverpool Heart & Chest Hospital
2016 Phase 4 EUCTR2016-002832-34-GB United Kingdom;
Liverpool Heart and Chest Hospital NHS Foundation Trust
2017 Phase 4 NCT02894684 United Kingdom;
Aztreonam Lysine for Inhalation
Gilead Sciences
2003 - NCT00499720 Puerto Rico;United States;
Aztreonam for Inhalation (AI)
Gilead Sciences
2003 Phase 2 NCT01055847 United States;
Aztreonam for Inhalation Solution
Gilead Sciences, Inc.
2012 Phase 2 EUCTR2011-001255-36-BE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001362-18-DE France;Germany;Italy;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-NL Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-IE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-DE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-AT Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2011 Phase 2 EUCTR2011-001255-36-ES Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- Phase 3 EUCTR2011-001362-18-FR France;Germany;Italy;Poland;Spain;United States;
- Phase 2 EUCTR2011-001255-36-FR Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- - EUCTR2011-001362-18-Outside-EU/EEA United States;
- - EUCTR2011-001255-36-Outside-EU/EEA United States;
Aztreonam for Inhalation Solution (AZLI)
Gilead Sciences
2011 Phase 2 NCT01375049 Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2008 Phase 3 NCT00757237 Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Aztreonam lysine
Gilead Sciences
2009 - NCT00989807 Canada;
Gilead Sciences Inc
2010 - EUCTR2007-004277-26-AT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-004277-26-GB Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-FR Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-ES Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-BE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-PT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-NL Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DK Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Aztreonam lysine for inhalation
Novartis Pharmaceuticals
2010 - NCT01460836 -
Aztreonam solución para inhalación
Gilead Sciences, Inc.
2012 Phase 3 EUCTR2011-001362-18-ES France;Germany;Italy;Poland;Spain;United States;
Aztreonan lysine
Gilead Sciences Inc
2008 - EUCTR2007-004277-26-IT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
BAY 85-8501
Bayer HealthCare AG
2013 Phase 2 EUCTR2012-004491-18-IT Italy;United Kingdom;
2013 Phase 2 EUCTR2012-004491-18-GB Italy;Spain;United Kingdom;
2013 - EUCTR2012-004491-18-ES Spain;United Kingdom;
BAY q 3939
Bayer HealthCare AG
2007 - EUCTR2007-002912-24-DE Germany;
BAY63-2521
Bayer AG
2015 Phase 2 EUCTR2013-004595-35-BE Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2014 Phase 2 EUCTR2013-004595-35-GB Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2014 Phase 2 EUCTR2013-004595-35-DE Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
Bayer HealthCare AG
2015 Phase 2 EUCTR2013-004595-35-NL Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States;
BAY85-8501
Bayer
2013 Phase 2 NCT01818544 France;Germany;Italy;Spain;United Kingdom;
BAYQ3939
Bayer AG
2014 Phase 3 EUCTR2013-004659-19-BG Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Bayer AG
2014 Phase 3 EUCTR2013-004659-19-NL Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-LT Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-DE Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-CZ Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-AT Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Bayer Healthcare AG, D-51368 Leverkusen, Germany
2014 Phase 3 EUCTR2013-004659-19-SK Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-PT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-LV Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
BAYq3939
BAYER HEALTHCARE AG
2013 Phase 3 EUCTR2011-004208-39-IT Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
Bayer HealthCare AG
2014 Phase 3 EUCTR2011-004208-39-SK Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2014 - EUCTR2011-004208-39-LV Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-GB Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-FR Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-ES Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-DE Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 - EUCTR2011-004208-39-DK Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2009 Phase 2 EUCTR2009-009869-34-ES Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-SE Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-GB Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-DE Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008314-40-SE Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-008314-40-DK Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-008314-40-DE Denmark;Germany;Sweden;United Kingdom;
Bayer Healthcare AG
2009 - EUCTR2008-008314-40-GB Denmark;Germany;Sweden;United Kingdom;
BCG TICE Vaccine
Johns Hopkins University
2021 Phase 2 NCT04884308 United States;
BH4
Augusta University
2011 Phase 2 NCT01772758 United States;
BI 1265162
Boehringer Ingelheim
2019 Phase 2 NCT04059094 Belgium;Canada;France;Germany;Spain;Sweden;United Kingdom;United States;
BI 1265162 10 µg
Boehringer Ingelheim
2019 Phase 2 EUCTR2019-000261-21-SE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim France
2019 Phase 2 EUCTR2019-000261-21-FR Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Limited
2019 Phase 2 EUCTR2019-000261-21-IE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000261-21-GB Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2019 Phase 2 EUCTR2019-000261-21-DE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim, S.A.
2019 Phase 2 EUCTR2019-000261-21-ES Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2019 Phase 2 EUCTR2019-000261-21-BE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1265162 100 µg
Boehringer Ingelheim
2019 Phase 2 EUCTR2019-000261-21-SE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim France
2019 Phase 2 EUCTR2019-000261-21-FR Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Limited
2019 Phase 2 EUCTR2019-000261-21-IE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000261-21-GB Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2019 Phase 2 EUCTR2019-000261-21-DE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim, S.A.
2019 Phase 2 EUCTR2019-000261-21-ES Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2019 Phase 2 EUCTR2019-000261-21-BE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1265162 25 µg
Boehringer Ingelheim
2019 Phase 2 EUCTR2019-000261-21-SE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim France
2019 Phase 2 EUCTR2019-000261-21-FR Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Limited
2019 Phase 2 EUCTR2019-000261-21-IE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000261-21-GB Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2019 Phase 2 EUCTR2019-000261-21-DE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim, S.A.
2019 Phase 2 EUCTR2019-000261-21-ES Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2019 Phase 2 EUCTR2019-000261-21-BE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1265162 50 µg
Boehringer Ingelheim
2019 Phase 2 EUCTR2019-000261-21-SE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim France
2019 Phase 2 EUCTR2019-000261-21-FR Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Limited
2019 Phase 2 EUCTR2019-000261-21-IE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000261-21-GB Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2019 Phase 2 EUCTR2019-000261-21-DE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
Boehringer Ingelheim, S.A.
2019 Phase 2 EUCTR2019-000261-21-ES Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2019 Phase 2 EUCTR2019-000261-21-BE Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1323495
Boehringer Ingelheim
2021 Phase 1 NCT04656275 Germany;United Kingdom;
BI 443651
Boehringer Ingelheim
2017 Phase 1 NCT02976519 Germany;United Kingdom;
BIIL 283 BS (Amelubent)
Boehringer Ingelheim
2003 Phase 2 NCT00060801 United States;
BIIL 284 BS, high dose
Boehringer Ingelheim
2002 Phase 1 NCT02269189 -
BIIL 284 BS, high dose, adult patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BIIL 284 BS, high dose, pediatric patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BIIL 284 BS, low dose
Boehringer Ingelheim
2002 Phase 1 NCT02269189 -
BIIL 284 BS, low dose, adult patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BIIL 284 BS, low dose, pediatric patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BIIL 284 BS, medium dose, adult patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BIIL 284 BS, medium dose, pediatric patients
Boehringer Ingelheim
2001 Phase 1 NCT02265679 -
BLF
Alaxia SAS
2015 Phase 1 NCT02598999 France;
BRAMICIL - 100 MG/ 2 ML SOLUZIONE INIETTABILE 10 FIALE DA 2 ML
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML
ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
- Phase 4 EUCTR2014-001401-41-IT Italy;Netherlands;
BRAMITOB*NEBUL 28F 300MG/4ML
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
2011 - EUCTR2011-001821-26-IT Italy;
BRAMITOB*NEBUL 56F 300MG/4ML
AZIENDA OSPEDALIERA MEYER
2011 - EUCTR2011-006171-19-IT Italy;
BX004-A
BiomX, Inc.
2021 Phase 1/Phase 2 NCT05010577 -
Bactrim
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Balance
Hacettepe University
2019 - NCT03902236 Turkey;
University of Alabama at Birmingham
2008 - NCT01759342 United States;
Benralizumab
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
AstraZeneca
2021 Phase 3 NCT05006573 Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
AstraZeneca AB
2021 Phase 3 EUCTR2020-004068-24-DK Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
2021 Phase 3 EUCTR2020-004068-24-DE Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Viet Nam;
Beta-Adrenergic cocktail
Richard Barry Moss
2015 - NCT02310789 United States;
Bethkis
Mylan Inc.
2015 - NCT02449031 United States;
Biaxin ( clarithromycin)
Wake Forest University
2000 Phase 2 NCT00205634 United States;
Bio-25 probiotic
Sheba Medical Center
2010 - NCT01201434 -
Bisphosphonate treatment
Gilles Boire
2001 Phase 4 NCT01882400 Canada;
Blood draw
Emory University
2015 - NCT02589444 United States;
Blood draw.
University of Florida
2007 - NCT01851642 United States;
Blood or Saliva Sample Collection
Children's Hospital of Philadelphia
2013 - NCT01852448 United States;
Blood sample
Hopital Foch
2016 - NCT02850692 France;
Blood sampling for determination of serum Zn
University Hospital, Ghent
2004 - NCT00221559 Belgium;
Blood test
Assistance Publique - Hôpitaux de Paris
2018 - NCT03492567 France;
Boost VHC
Virginia Commonwealth University
2022 - NCT03931252 United States;
Boots High Strength Garlic Odour Controlled
University of Nottingham
2005 Phase 2 EUCTR2005-000311-98-GB United Kingdom;
Bramitob
Erasmus University Medical Centre
2012 - EUCTR2012-002503-17-NL Netherlands;
Haga Hospital
2014 - EUCTR2013-004488-30-NL Netherlands;
Bramitob 300mg/4ml Nebuliser Solution
Bramitob® administered by PARI LC® PLUS nebulizer
Chiesi Farmaceutici S.p.A.
2010 Phase 1 NCT01116089 Czech Republic;Czechia;Moldova, Republic of;Russian Federation;Slovakia;
Bramitob® administered by PARI eFlow® rapid electronic nebulizer
Chiesi Farmaceutici S.p.A.
2010 Phase 1 NCT01116089 Czech Republic;Czechia;Moldova, Republic of;Russian Federation;Slovakia;
Brensocatib
Fernandez C
2021 Phase 3 JPRN-jRCT2031210048 Australia;Canada;Germany;Japan;New Zealand;Taiwan;United States;
INSMED INCORPORATED
2021 Phase 3 EUCTR2020-003688-25-IT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Insmed Incorporated
2021 Phase 3 EUCTR2020-003688-25-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-LT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-IE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2 NCT05090904 United States;
2020 Phase 3 NCT04594369 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Broccoli sprouts
University Hospitals Cleveland Medical Center
2011 - NCT01315665 United States;
Bronchial mucus collection
University Hospital, Grenoble
2021 - NCT04687319 -
Bronchitol
PHARMAXIS LTD
2014 Phase 3 EUCTR2013-005357-79-SK Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
Pharmaxis Limited
2016 Phase 3 EUCTR2013-005357-79-SE Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;European Union;Greece;Hungary;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2013-005357-79-GR Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2013-005357-79-BG Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005357-79-IT Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005357-79-HU Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005357-79-CZ Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005357-79-BE Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Pharmaxis Ltd.
2014 - EUCTR2012-002699-14-NL Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;
2014 - EUCTR2012-002699-14-IT Argentina;Belgium;Canada;Italy;Netherlands;United Kingdom;
2013 Phase 2 EUCTR2012-002699-14-GB Argentina;Belgium;Canada;France;Italy;Netherlands;United Kingdom;
2013 - EUCTR2012-002699-14-BE Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
- Phase 2 EUCTR2012-002699-14-FR Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Bronchoscopy with BAL
National Center for Research Resources (NCRR)
2001 - NCT00023465 United States;
Bucelipase alfa
Biovitrum AB
2008 - EUCTR2007-004063-21-NL Netherlands;
Budesonide-formoterol single inhaler
Hospital General de Requena
2004 - NCT00728715 Spain;
Burlulipase
Nordmark Arzneimittel GmbH & Co. KG
2013 Phase 1/Phase 2 NCT01710644 United States;
C01CA04 - Dopamina
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
CAYSTON aztreonam 75 mg powder and solvent for nebuliser solution
GILEAD SCIENCES INC.
2012 Phase 3 EUCTR2011-001362-18-IT France;Germany;Italy;Spain;United States;
CB-280
Calithera Biosciences, Inc
2020 Phase 1 NCT04279769 Canada;United States;
CEFTAZIDIMA PENTAIDRATO
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
CEFTAZIDIME PENTAHYDRATE
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
CF patients with a G551D mutation and treated with Ivacaftor
Assistance Publique - Hôpitaux de Paris
2014 - NCT02194881 France;
CFTR Modulators
Children's Hospital Medical Center, Cincinnati
2022 - NCT04580368 -
Societe Francaise de la Mucoviscidose
2020 - NCT04301856 France;
Universidad Europea de Madrid
2020 - NCT04415268 Spain;
CFTR potentiator
Novartis Pharma AG
2021 Phase 2 EUCTR2019-002840-26-DE China;Germany;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002840-26-GB China;Germany;Spain;United Kingdom;
CHF 6333
Chiesi Farmaceutici S.p.A.
2019 Phase 1 NCT04010799 Germany;
CHF6333 (Part 1 - SAD)
Chiesi Farmaceutici S.p.A.
2016 Phase 1 NCT03056326 Belgium;
CHF6333 (Part 2 - MAD)
Chiesi Farmaceutici S.p.A.
2016 Phase 1 NCT03056326 Belgium;
CIPROFLOXACIN HYDROCHLORIDE
AZIENDA OSPEDALIERA MEYER
2011 - EUCTR2011-006171-19-IT Italy;
Aradigm Corporation
2010 Phase 2 EUCTR2009-014412-35-DE Germany;United Kingdom;
2010 - EUCTR2009-014412-35-GB Germany;United Kingdom;
CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE
COP:TRIN Region Hovedstaden (Gentofte hospital)
2017 Phase 4 EUCTR2015-003399-58-DK Denmark;
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
CIPROFLOXACINA CLORIDRATO
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
CIPROXIN - 500 MG COMPRESSE RIVESTITE 14 COMPRESSE
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
CIPROXIN*6CPR RIV
AZIENDA OSPEDALIERA MEYER
2011 - EUCTR2011-006171-19-IT Italy;
CLORURO SODICO
ADELAIDA LAMAS FERREIRO
2009 - EUCTR2008-001284-11-ES Spain;
COLIMICINA - 1000000 U/4 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 4 ML
AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER
2016 Phase 3 EUCTR2015-003881-96-IT Italy;
COLIMYCINE inhalation
Poitiers University Hospital
2011 Phase 1 NCT01537614 France;
COLIMYCINE injectable
Poitiers University Hospital
2011 Phase 1 NCT01537614 France;
COLISTIMETATO SODICO
AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER
2016 Phase 3 EUCTR2015-003881-96-IT Italy;
COLISTIMETHATE SODIUM
Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
2014 Phase 4 EUCTR2013-004295-35-AT Austria;
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
COLISTIMETHATE SODIUM (A COMPONENT)
CUB - Hôpital Erasme
2014 - EUCTR2013-004987-80-BE Belgium;
COLISTIN MESILATE SODIUM
AZIENDA OSPEDALIERA MEYER
2011 - EUCTR2011-006171-19-IT Italy;
COLISTINEB 2MUI
CUB - Hôpital Erasme
2014 - EUCTR2013-004987-80-BE Belgium;
COVID-19 Vaccine (ChAdOx1-S [recombinant])
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant])
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 Vaccine Moderna dispersion for injection
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 mRNA vaccine (nucleoside-modified)
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 mRNA vaccine Moderna (CX-024414)
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 vaccine (Ad26.COV2-S [recombinant])
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19)
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
CPX
FDA Office of Orphan Products Development
1997 Phase 1 NCT00004428 -
CR002 Liquid API
CSL Behring
2011 Phase 1 NCT01347190 Bulgaria;Hungary;Poland;United Kingdom;
CRC3357, ZK-355322, Leukoton
Celtaxsys Inc.
2016 Phase 2 EUCTR2015-002677-38-IT Belgium;France;Germany;Italy;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-GB Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-DE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-BE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
CREON
AbbVie
2021 Phase 4 NCT05069597 United States;
2020 Phase 4 NCT04315311 United States;
2012 - NCT01652157 United States;
CREON 10000 Capsules
EURAND SPA
2010 - EUCTR2009-012842-21-IT Bulgaria;Germany;Hungary;Italy;United Kingdom;
CREON IR
Abbott Laboratories GmbH
2015 - EUCTR2014-004519-35-HU Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-GB Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-CZ Czech Republic;Hungary;Spain;United Kingdom;
CREON N 25000
Abbott Laboratories GmbH
2013 - EUCTR2013-002819-10-HU Hungary;Russian Federation;Spain;
CSL787
CSL Behring
2020 Phase 1 NCT04643587 United Kingdom;
CTX-4430
Celtaxsys Inc.
2016 Phase 2 EUCTR2015-002677-38-IT Belgium;France;Germany;Italy;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-GB Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-DE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002677-38-BE Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
Celtaxsys, Inc.
2015 Phase 2 NCT02443688 Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
2013 Phase 1 NCT01944735 United Kingdom;
CYC202
CHRU de Brest
2015 Phase 2 EUCTR2015-002911-13-FR France;
CYCLO[L-ALANYL-L-SERYL-L-ISOLEUCYL-L-PROLYL-L-PROLYL-L-GLUTAMINYL-L-LYSYL-L-TYROSYL-D-PROLYL-L-PROLYL-(2S)-2-AMINODECANOYL-L-ALPHA-GLUTAMYL-L-THREONYL]
Santhera Pharmaceuticals (Switzerland) Ltd
2018 Phase 1;Phase 2 EUCTR2018-002550-71-DE Germany;
Calcium carbonate
University of North Carolina
1998 - NCT00004489 United States;
Calfactant
University of Pittsburgh
2008 - NCT00628134 United States;
Cavosonstat
Nivalis Therapeutics, Inc.
2016 Phase 2 NCT02724527 United States;
2016 Phase 1 NCT02934139 United States;
2015 Phase 2 NCT02589236 United States;
Cayston
Gilead Sciences, Inc.
2012 Phase 3 EUCTR2011-001362-18-ES France;Germany;Italy;Poland;Spain;United States;
Gilead Sciences Inc
2010 - EUCTR2007-004277-26-AT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-004277-26-GB Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
- - EUCTR2007-004277-26-Outside-EU/EEA United States;
Gilead Sciences, Inc.
2018 Phase 3 EUCTR2016-002749-42-NL Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2016-002749-42-GR Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-IT Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-GB Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-FR Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-ES Austria;Belgium;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-DK Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-DE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-BE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002749-42-AT Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2012 Phase 2 EUCTR2011-001255-36-BE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001362-18-DE France;Germany;Italy;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-NL Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-IE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-DE Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2012 - EUCTR2011-001255-36-AT Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
2011 Phase 2 EUCTR2011-001255-36-ES Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- Phase 3 EUCTR2016-002749-42-IE Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2011-001362-18-FR France;Germany;Italy;Poland;Spain;United States;
- Phase 2 EUCTR2011-001255-36-FR Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
- - EUCTR2015-000398-11-Outside-EU/EEA United States;
- - EUCTR2015-000397-36-Outside-EU/EEA Canada;
- - EUCTR2015-000396-26-Outside-EU/EEA United States;
- - EUCTR2015-000395-97-Outside-EU/EEA Australia;Canada;United States;
- - EUCTR2011-001362-18-Outside-EU/EEA United States;
- - EUCTR2011-001255-36-Outside-EU/EEA United States;
- - EUCTR2009-011740-19-Outside-EU/EEA Canada;United States;
Liverpool Heart & Chest Hospital
2016 Phase 4 EUCTR2016-002832-34-GB United Kingdom;
Mylan Inc.
2015 - NCT02449031 United States;
Cayston 75 mg Pulver und Lösungsmittel zur Herstellung einer Lösung für einen Vernebler
Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
2014 Phase 4 EUCTR2013-004295-35-AT Austria;
Cayston Aztreonam 75 mg powder and solvent for nebuliser solution
GILEAD SCIENCES INC.
2012 - EUCTR2011-001255-36-IT Austria;Germany;Ireland;Italy;Netherlands;Spain;United States;
Ceftaroline
Children's Hospital Medical Center, Cincinnati
2017 Phase 4 NCT03771313 United States;
Ceftazidim Fresenius Kabi 2000 mg poeder voor oplossing voor injectie of infusie
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
Ceftazidime
Association Nationale pour le Traitement à Domicile de l'Insuffisance Respiratoire
2001 Phase 4 NCT00333385 France;
Imperial College London
2010 Phase 4 NCT01044719 United Kingdom;
Imperial College, London
2009 - EUCTR2009-014042-28-GB United Kingdom;
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
University College Cork
2015 - NCT02526004 Ireland;
University Ghent
2016 - NCT02840136 Belgium;
University Hospitals Bristol NHS Foundation Trust
2016 Phase 4 EUCTR2009-012575-10-SE Sweden;United Kingdom;
2009 Phase 4 EUCTR2009-012575-10-GB Sweden;United Kingdom;
Ceftazidime and tobramycin
University of North Carolina, Chapel Hill
2004 Phase 1 NCT00823238 United States;
Ceftazidime/avibactam
University of Southern California
2015 Phase 4 NCT02504827 United States;
Ceftolozane/Tazobactam
Joseph L. Kuti, PharmD
2015 Phase 4 NCT02421120 United States;
Cefuroxim
Västra Götalandsregionen
2021 Phase 4 EUCTR2019-003501-10-DK Denmark;Norway;Sweden;
2020 Phase 4 EUCTR2019-003501-10-SE Denmark;Norway;Sweden;
Cephalexin
University of British Columbia
2020 Phase 3 NCT04553419 Canada;
Cftr Modulators
Indiana University
2019 - NCT04206436 United States;
Chlorhexidine Gluconate
University of North Carolina, Chapel Hill
2018 Phase 2 NCT03489629 United States;
Chlorhexidine gluconate oral rinse
University of North Carolina, Chapel Hill
2011 Phase 2 NCT01349192 United States;
Chlorhexidine solution wipes
University of North Carolina, Chapel Hill
2011 Phase 2 NCT01349192 United States;
Chloride
Milton S. Hershey Medical Center
2018 - NCT03367494 United States;
Cholecalciferol
Children's Hospital of Philadelphia
2008 Phase 3 NCT00762918 United States;
Emory University
2011 Phase 3 NCT01426256 United States;
Shanghai Pulmonary Hospital, Shanghai, China
2015 Phase 4 NCT02507843 China;
University of North Carolina
1998 - NCT00004489 United States;
Cholecalciferol (Vitamin D3)
University of Pittsburgh
2010 - NCT01222273 United States;
Cholecalciferol (vitaminD3)
Heba Omara
2018 Phase 2/Phase 3 NCT04411901 Egypt;
Cholecalciferol Pill
Hospital Infantil de Mexico Federico Gomez
2022 Phase 4 NCT05276960 Mexico;
Choline Chloride
University Hospital Tuebingen
2014 - NCT03312140 -
Choline supplementation
University of British Columbia
2007 - NCT00686361 Canada;
Chronic Antioxidant
Augusta University
2015 - NCT02690064 United States;
Cipro (Ciprofloxacin, BAYQ3939)
Bayer
2016 - NCT02555059 Japan;
Cipro Inhale
Bayer HealthCare AG
2009 Phase 2 EUCTR2009-009869-34-ES Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-SE Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-GB Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-DE Germany;Spain;Sweden;United Kingdom;
Ciprofloxacin
AZIENDA OSPEDALIERA MEYER
2008 - EUCTR2008-006502-42-IT Italy;
Bayer
2016 - NCT02661438 United States;
Bayer HealthCare AG
2009 Phase 2 EUCTR2009-009869-34-ES Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-SE Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-GB Germany;Spain;Sweden;United Kingdom;
2009 - EUCTR2009-009869-34-DE Germany;Spain;Sweden;United Kingdom;
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
University Hospitals Bristol NHS Foundation Trust
2016 Phase 4 EUCTR2009-012575-10-SE Sweden;United Kingdom;
2009 Phase 4 EUCTR2009-012575-10-GB Sweden;United Kingdom;
Vertex Pharmaceuticals Incorporated
2014 Phase 1 NCT02015507 -
2013 Phase 1 NCT01768663 United States;
Ciprofloxacin (BAYQ3939) dry powder for inhalation
Bayer
2014 Phase 3 NCT02106832 Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Czechia;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Ciprofloxacin (Cipro Inhale, BAYQ3939)
Bayer
2008 Phase 2 NCT00645788 Australia;Canada;Denmark;Germany;Israel;Norway;Sweden;United Kingdom;United States;
Ciprofloxacin (Cipro, BAYQ3939)
Bayer
2009 Phase 2 NCT00930982 Australia;Germany;Spain;Sweden;United Kingdom;United States;
2009 Phase 1 NCT00910351 United States;
Ciprofloxacin (ciproxin)
Belfast City Hospital Trust
2005 Phase 4 EUCTR2005-003837-42-GB United Kingdom;
Ciprofloxacin DPI
BAYER HEALTHCARE AG
2013 Phase 3 EUCTR2011-004208-39-IT Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
Bayer AG
2014 Phase 3 EUCTR2013-004659-19-BG Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Bayer AG
2014 Phase 3 EUCTR2013-004659-19-NL Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-LT Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-DE Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-CZ Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-AT Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Bayer HealthCare AG
2014 Phase 3 EUCTR2011-004208-39-SK Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2014 - EUCTR2011-004208-39-LV Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-GB Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-FR Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-ES Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2011-004208-39-DE Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 - EUCTR2011-004208-39-DK Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
Bayer Healthcare AG, D-51368 Leverkusen, Germany
2014 Phase 3 EUCTR2013-004659-19-SK Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-PT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
2014 Phase 3 EUCTR2013-004659-19-LV Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Ciprofloxacin DPI (BAYQ3939)
Bayer
2013 Phase 3 NCT01764841 Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
Ciprofloxacin Inhale
Bayer HealthCare AG
2009 - EUCTR2008-008314-40-SE Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-008314-40-DK Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-008314-40-DE Denmark;Germany;Sweden;United Kingdom;
Bayer Healthcare AG
2009 - EUCTR2008-008314-40-GB Denmark;Germany;Sweden;United Kingdom;
Ciprofloxacin dispersion for inhalation
Aradigm Corporation
2014 Phase 3 NCT02104245 Australia;Canada;Former Serbia and Montenegro;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 NCT01515007 Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;New Zealand;Poland;Romania;South Africa;Spain;Taiwan;United Kingdom;United States;
Ciprofloxacin for Inhalation
Aradigm Corporation
2010 Phase 2 NCT00889967 Canada;Germany;United Kingdom;United States;
2010 Phase 2 EUCTR2009-014412-35-DE Germany;United Kingdom;
2010 - EUCTR2009-014412-35-GB Germany;United Kingdom;
Ciproxin
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Ciproxin Suspension
Southampton University Hospital Trust
2008 - EUCTR2008-001769-27-GB United Kingdom;
Clarithromycin
Chinese University of Hong Kong
2020 - NCT04658277 Hong Kong;
Claritromycin 500mg film coated tablets
university medical center utrecht
2018 Phase 4 EUCTR2016-001440-18-NL Netherlands;
Cobamamide
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
2010 - EUCTR2010-020516-11-IT Italy;
Colistimethat-Natrium
University of Jena
2009 - EUCTR2008-007877-19-DE Germany;
Colistimethate
Novartis Pharmaceuticals
2013 Phase 4 NCT01844778 Germany;Ireland;Spain;Switzerland;United Kingdom;
Colistimethate 75 mg inhaled two times daily
Dartmouth-Hitchcock Medical Center
2014 - NCT02113397 United States;
Colistimethate Sodium
Zambon SpA
2017 Phase 3 NCT03093974 Australia;Belgium;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Colistimethate sodium
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-DK Belgium;Denmark;
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
Profile Pharma Ltd
2010 - EUCTR2008-005045-34-IE Ireland;United Kingdom;
2008 Phase 3 EUCTR2008-005045-34-GB Ireland;Russian Federation;Ukraine;United Kingdom;
University of Colorado, Denver
2013 - NCT02288429 United States;
Zambon SpA
2018 Phase 3 NCT03460704 Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
Colistimethate sodium (BAN, USAN), Colistimethatum natricum, Colistin sodium methanesulfonate
Forest Laboratories UK Ltd.
2011 - EUCTR2011-000192-13-PL Germany;Poland;Ukraine;United Kingdom;
2011 - EUCTR2011-000192-13-GB Germany;Poland;United Kingdom;
2011 - EUCTR2011-000192-13-DE Germany;Poland;Ukraine;United Kingdom;
Colistimethate sodium (promixin)
Aarhus University Hospital, Department of Respiratory Medicine
2015 Phase 2 EUCTR2015-003662-87-DK Denmark;
Colistin
AZIENDA OSPEDALIERA MEYER
2008 - EUCTR2008-006502-42-IT Italy;
National Jewish Health
2016 Phase 4 NCT02918409 United States;
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
University Hospital Tuebingen
2014 Phase 3 NCT03341741 -
University of Jena
2009 Phase 2 NCT01035853 Germany;
Colistin CF
University of Jena
2009 - EUCTR2008-007877-19-DE Germany;
Colistin Forest - Trockenstechampullen mit Lösungsmittel
Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
2014 Phase 4 EUCTR2013-004295-35-AT Austria;
Colobreathe
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-DK Belgium;Denmark;
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
Forest Laboratories UK Ltd.
2011 - EUCTR2011-000192-13-PL Germany;Poland;Ukraine;United Kingdom;
2011 - EUCTR2011-000192-13-GB Germany;Poland;United Kingdom;
2011 - EUCTR2011-000192-13-DE Germany;Poland;Ukraine;United Kingdom;
Colomycin
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-DK Belgium;Denmark;
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
The Leeds Teaching Hospitals NHS Trust
2015 - NCT02489955 United Kingdom;
Comirnaty concentrate for dispersion for injection
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
Compound 1a
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Continuous Glucose Monitoring
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Continuous Glucose Monitoring System (CGMS)
University Hospital, Strasbourg, France
2008 - NCT00476281 France;
Continuous glucose monitor (CGM)
Jagdeesh Ullal
2021 Phase 4 NCT04533646 United States;
Continuous infusion Cefepime
The Alfred
2012 Phase 4 NCT01667094 Australia;
Continuous infusion Ceftazidime
The Alfred
2012 Phase 4 NCT01667094 Australia;
Continuous infusion Meropenem
The Alfred
2012 Phase 4 NCT01667094 Australia;
Continuous infusion Piperacillin tazobactam
The Alfred
2012 Phase 4 NCT01667094 Australia;
Continuous infusion Ticarcillin-clavulanate
The Alfred
2012 Phase 4 NCT01667094 Australia;
Control
University Hospital Southampton NHS Foundation Trust.
2011 Phase 2 NCT02295566 United Kingdom;
Control Group Isotonic Saline
University of Washington, the Collaborative Health Studies Coordinating Center
2015 Phase 2/Phase 3 NCT02950883 Australia;Belgium;Canada;Denmark;France;Italy;Netherlands;Spain;United States;
Control multivitamin
University of Colorado, Denver
2013 Phase 2 NCT01859390 United States;
Creon 10.000, hårde enterokapsler
Terese Katzenstein
2020 Phase 4 EUCTR2019-004940-31-DK Denmark;
Creon 10000
Solvay Pharmaceuticals GmbH
2008 - EUCTR2007-004004-12-BG Bulgaria;
Creon 25.000, hårde enterokapsler
Terese Katzenstein
2020 Phase 4 EUCTR2019-004940-31-DK Denmark;
Creon 25000
Abbott Laboratories GmbH
2013 - EUCTR2013-002819-10-HU Hungary;Russian Federation;Spain;
Solvay Pharmaceuticals GmbH
2008 - EUCTR2007-004004-12-BG Bulgaria;
Creon 40.000, hårde enterokapsler
Terese Katzenstein
2020 Phase 4 EUCTR2019-004940-31-DK Denmark;
Creon IR
Abbott
2015 Phase 2 NCT02415959 Czech Republic;Hungary;Poland;Spain;
Creon N
Abbott
2014 Phase 3 NCT02137382 Hungary;Russian Federation;Spain;
Creon®
Abbott
2014 Phase 3 NCT02137382 Hungary;Russian Federation;Spain;
Creon® (DR/GR)
Abbott
2015 Phase 2 NCT02415959 Czech Republic;Hungary;Poland;Spain;
Creon® 25,000
Abbott Laboratories GmbH
2015 - EUCTR2014-004519-35-HU Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-GB Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-CZ Czech Republic;Hungary;Spain;United Kingdom;
Crestor
University of Liverpool
2014 Phase 2 EUCTR2014-002387-32-GB United Kingdom;
Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm
University Medical Centre Utrecht
2014 Phase 2 EUCTR2014-000817-30-NL Netherlands;
Cystagon
University of LIverpool
2019 Phase 1;Phase 2 EUCTR2017-001259-29-GB United Kingdom;
Cystagon (cysteamine bitartrate) immediate-release capsules
University of Aberdeen
2014 Phase 1;Phase 2 EUCTR2014-000284-40-GB United Kingdom;
Cysteamine
NovaBiotics Ltd.
2016 Phase 2 NCT03000348 Italy;United Kingdom;United States;
University of Aberdeen
2014 Phase 1/Phase 2 NCT02212431 United Kingdom;
Cysteamine bitartrate
NovaBiotics, Ltd
2017 Phase 2 EUCTR2015-004986-99-IT Italy;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004986-99-GB Italy;Netherlands;United Kingdom;United States;
University of LIverpool
2019 Phase 1;Phase 2 EUCTR2017-001259-29-GB United Kingdom;
Cysteamine bitartrate (Cystagon)
European Institute for Cystic Fibrosis Research (IERFC)
2013 - EUCTR2013-001258-82-IT Italy;
Cystic Fibrosis Ready to Use Supplemental Food
Washington University School of Medicine
2018 Phase 1/Phase 2 NCT03462056 United States;
D-a-tocopheryl PEG 1000 succinate
ORPHAN
2007 - EUCTR2007-001007-38-FR France;
D6-25-hydroxyvitamin D3
University of Washington
2017 Phase 1 NCT03104855 United States;
DCI 1020
Digestive Care, Inc.
2009 - NCT00663975 United States;
DEPELESTAT
DEBIOPHARM S.A.
2005 - EUCTR2004-002341-12-IT Belgium;Germany;Italy;United Kingdom;
DORIPENEM HYDRATE
Johnson & Johnson Pharmaceutical Research & Development L.L.C
- - EUCTR2015-001225-16-Outside-EU/EEA United States;
DP Mannitol
Pharmaxis Ltd
2004 Phase 2 EUCTR2004-001888-21-GB United Kingdom;
DTPA
University of Pittsburgh
2007 - NCT00541190 United States;
DX-890
DEBIOPHARM S.A.
2005 - EUCTR2004-002341-12-IT Belgium;Germany;Italy;United Kingdom;
De-activated smart device
Vertex Pharmaceuticals Incorporated
2016 Phase 4 NCT02823470 Canada;United States;
Decolonization
State University of New York - Upstate Medical University
2011 - NCT01229553 United States;
Denosumab
University of Texas Southwestern Medical Center
2022 Phase 4 NCT03921060 United States;
Denufosol Tetrasodium (INS37217) Inhalation Solution
Merck Sharp & Dohme Corp.
2008 Phase 3 NCT00625612 Australia;Canada;New Zealand;United States;
Denufosol tetrasodium (INS37217)
Merck Sharp & Dohme Corp.
2005 Phase 2 NCT00130182 United States;
2005 Phase 2 NCT00103714 United States;
2003 Phase 2 NCT00056147 United States;
Denufosol tetrasodium (INS37217) Inhalation Solution
Merck Sharp & Dohme Corp.
2007 Phase 2 NCT00425165 United States;
2006 Phase 3 NCT00357279 Canada;United States;
2001 Phase 1/Phase 2 NCT00034515 United States;
Denufosol tetrasodium Inhalation Solution
Merck Sharp & Dohme Corp.
2010 Phase 2 NCT01181622 United States;
2009 Phase 3 NCT00846781 Australia;Canada;New Zealand;United States;
Depelestat
Debiopharm SA
2005 Phase 2 EUCTR2004-002341-12-GB Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-DE Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-BE Belgium;Germany;Italy;United Kingdom;
Detoxifying agents for antineoplastic treatment
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
2010 - EUCTR2010-020516-11-IT Italy;
Deuterated Ivacaftor
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
Dexamethasone
ISTITUTO GIANNINA GASLINI
2008 - EUCTR2007-001782-15-IT Italy;
Dexamethasone sodium phosphate 250 mg/10 ml solution
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
2011 - EUCTR2011-000130-11-IT Italy;
Diet
Hospital de Clinicas de Porto Alegre
2016 - NCT03205904 Brazil;
Digitoxin
National Jewish Health
2010 Phase 2 NCT00782288 United States;
Docosahexaenoic acid
Hospices Civils de Lyon
2010 Phase 2 NCT02690857 -
Docosahexaenoic acid (DHA)
University of Massachusetts, Worcester
2003 - NCT00530244 United States;
Docosahexaenoic acid administration: 50 mg/kg/day during 12 months
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
2011 - NCT01783613 Spain;
Docosahexanoic Acid Supplement
Vanderbilt University
2013 Phase 2 NCT00924547 United States;
Dornase alfa
David Nichols, MD
2020 - NCT04378153 United States;
Genentech, Inc.
2008 Phase 4 NCT00680316 United States;
2007 Phase 4 NCT00434278 United States;
University of Jena
- Phase 3 EUCTR2007-001548-36-DE Germany;
Dornase alfa (Pulmozyme)
University of Jena
2007 Phase 3 NCT00534079 Germany;
Dornase alfa [Pulmozyme®]
Genentech, Inc.
2012 Phase 4 NCT01712334 United States;
Dornase alpha
Pharmaxis
2005 Phase 2 NCT00117208 United Kingdom;
University of Oklahoma
2006 - NCT00671723 United States;
Doxycyclin
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Doxycycline
Johns Hopkins University
2012 Phase 2 NCT01594827 United States;
University of Alabama at Birmingham
2008 - NCT01112059 United States;
University of Southern California
2008 Phase 4 NCT01323101 United States;
Dry powder tobramycin
University Medical Center Groningen
2013 - EUCTR2012-004437-16-NL Netherlands;
- Phase 2 EUCTR2016-005014-21-NL Netherlands;
Dual Energy X-ray Absorptiometry (DEXA)
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
2006 - NCT00287430 -
Dulaglutide 0.75Mg/0.5Ml Inj Pen
University of Pennsylvania
2021 Phase 2 NCT04731272 United States;
Duramycin, 2622U90
AOP Orphan Pharmaceuticals AG
2006 Phase 2;Phase 3 EUCTR2005-005594-29-SK Czech Republic;Hungary;Slovakia;
2006 - EUCTR2005-005594-29-HU Czech Republic;Hungary;
2006 - EUCTR2005-005594-29-CZ Czech Republic;Hungary;
2006 - EUCTR2005-004344-30-HU Hungary;
2005 - EUCTR2005-004344-30-AT Austria;Hungary;
ECGC
Hadassah Medical Organization
2011 - NCT00889434 Israel;
EGCG + Tocotrienol
Hadassah Medical Organization
2011 - NCT00889434 Israel;
ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
ELX (VX-445)/TEZ (VX-661)/IVA (VX-770)
VERTEX PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2020-003170-44-IT Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2020-003170-44-CZ Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-NL Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-FR Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-BE Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
ELX / 40mg TEZ / 60mg IVA
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
ELX /50 mg TEZ /75 mg IVA FDC
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
ELX-02
Eloxx Pharmaceuticals Inc
2019 Phase 2 EUCTR2018-000966-12-DE Australia;Germany;Israel;
Eloxx Pharmaceuticals, Inc.
2019 Phase 2 NCT04135495 Canada;United States;
2019 Phase 2 NCT04126473 Australia;Germany;Israel;
ELX/25 mg TEZ/37.5 mg IVA
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
ELX/25 mg TEZ/37.5 mg IVA fixed dose combination
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
ELX/50 mg TEZ /75 mg IVA FDC
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
ELX/50 mg TEZ/75 mg IVA fixed dose combination
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2021-001628-16-ES Australia;Belgium;Canada;Spain;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2021-001628-16-BE Australia;Belgium;Canada;Spain;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
ELX/50mg TEZ /75mg IVA
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
ELX/TEZ/IVA
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 NCT05274269 -
2022 Phase 3 NCT05153317 United States;
2022 Phase 3 NCT05111145 Australia;Spain;
2022 Phase 3 EUCTR2021-000712-31-SE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-DE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 NCT05076149 Australia;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2021 Phase 3 NCT05033080 Czechia;Germany;United Kingdom;United States;
2021 Phase 3 NCT04969224 Australia;Belgium;Canada;Spain;
2021 Phase 3 NCT04599465 Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
2021 Phase 3 NCT04545515 Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2021-000694-85-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NO Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-GR Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
2021 - NCT04702360 -
2020 Phase 3 NCT04537793 Australia;Canada;Germany;United Kingdom;United States;
2020 Phase 3 NCT04362761 Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 NCT04353817 Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 NCT04183790 Australia;Canada;Ireland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 - NCT04058210 -
2019 Phase 3 NCT04105972 Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 NCT04058366 Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 NCT04058353 Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 NCT04043806 Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-CZ Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
EMEA/H/C/000125
European Institute for Cystic Fibrosis Research (IERFC)
2013 - EUCTR2013-001258-82-IT Italy;
EPI-hNE4 DX-890
Debiopharm SA
2005 Phase 2 EUCTR2004-002341-12-GB Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-DE Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-BE Belgium;Germany;Italy;United Kingdom;
ETD001 multiple once daily doses
Enterprise Therapeutics Ltd
2021 Phase 1 NCT04926701 United Kingdom;
ETD001 multiple twice daily doses
Enterprise Therapeutics Ltd
2021 Phase 1 NCT04926701 United Kingdom;
ETD001 single dose
Enterprise Therapeutics Ltd
2021 Phase 1 NCT04926701 United Kingdom;
EU Orphan Designation Number EU/3/02/120
AOP Orphan Pharmaceuticals AG
2006 - EUCTR2005-004344-30-HU Hungary;
2005 - EUCTR2005-004344-30-AT Austria;Hungary;
EUR-1008
Aptalis Pharma US Inc.
2013 - EUCTR2009-012842-21-HU Bulgaria;Germany;Hungary;Italy;United Kingdom;
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-DE Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-BG Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
EUR-1008 (APT-1008)
Forest Laboratories
2010 Phase 4 NCT01131507 United States;
2010 Phase 4 NCT01100606 United States;
2006 Phase 3 NCT00981214 United States;
2006 Phase 3 NCT00297167 United States;
EUR-1008 25,000 Units
Aptalis Pharma
2012 Phase 3 NCT01641393 Belgium;Bulgaria;France;Germany;Italy;Poland;United Kingdom;
EZ-2053
Neovii Biotech
2005 Phase 3 NCT00105183 Australia;Austria;Canada;United States;
Elasomeran
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
Elexacaftor
VERTEX PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2020-003170-44-IT Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
2019 Phase 3 EUCTR2019-000833-37-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
2021 Phase 3 EUCTR2021-001628-16-ES Australia;Belgium;Canada;Spain;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-003170-44-CZ Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-001827-11-IE Australia;Canada;Ireland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001695-38-GB Australia;Canada;Ireland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-001628-16-BE Australia;Belgium;Canada;Spain;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-NL Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-FR Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-BE Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-001827-11-GB Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2019-000833-37-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-001695-38-IE Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Elexacaftor-tezacaftor-ivacaftor exposure
Jennifer Taylor-Cousar
2019 - NCT04056702 United States;
Elexacaftor/tezacaftor/ivacaftor
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-000712-31-SE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-DE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NO Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-GR Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-CZ Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Engineerd Protein Inhibitor of human Neutrophil Elastase
Debiopharm SA
2005 Phase 2 EUCTR2004-002341-12-GB Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-DE Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-BE Belgium;Germany;Italy;United Kingdom;
Engineered Protein Inhibitor of human Neutrophil Elastase
Debiopharm SA
2005 Phase 2 EUCTR2004-002341-12-GB Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-DE Belgium;Germany;Italy;United Kingdom;
2005 - EUCTR2004-002341-12-BE Belgium;Germany;Italy;United Kingdom;
Ensure High Protein
Virginia Commonwealth University
2022 - NCT03931252 United States;
Ensure plus
Texas A&M University
2011 - NCT01494909 United States;
Ergocalciferol (vitamin D2)
Atlanta VA Medical Center
2006 - NCT00450073 United States;
Esomeprazole
Biovitrum AB
2008 - EUCTR2007-004063-21-NL Netherlands;
Columbia University
2008 Phase 2 NCT01983774 United States;
Essential amino acid intake + Leucine vs total AA supplement
Texas A&M University
2008 - NCT01172301 United States;
Estradiol
Emory University
2019 Phase 4 NCT03724955 United States;
Ethambutol
University of Colorado, Denver
2014 - NCT02372383 United States;
Exercise
University of Kansas Medical Center
2022 Phase 2 NCT05239611 United States;
Exhaled Nitric Oxide
The Hospital for Sick Children
2010 - NCT01155115 Canada;
F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)
University Hospital, Strasbourg, France
2020 Phase 4 NCT04381429 France;
FDG-PET
National Center for Research Resources (NCRR)
2001 - NCT00023465 United States;
FDL169
Flatley Discovery Lab LLC
2018 Phase 1/Phase 2 NCT03756922 United Kingdom;
2018 Phase 1 NCT03527095 United Kingdom;
2017 Phase 1 NCT03424252 United Kingdom;
2017 Phase 1 NCT03093714 Australia;Czechia;Germany;United Kingdom;
2016 Phase 1/Phase 2 NCT02767297 United Kingdom;
2015 Phase 1 NCT02680418 United Kingdom;
2015 Phase 1 NCT02359357 United Kingdom;
FDL176
Flatley Discovery Lab LLC
2018 Phase 1/Phase 2 NCT03756922 United Kingdom;
2017 Phase 1 NCT03173573 Australia;
FDL176 & FDL169 coadministration
Flatley Discovery Lab LLC
2018 Phase 1 NCT03516331 United Kingdom;
FLUCLOXACILLIN SODIUM
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
FORLAX 4 g, poudre pour solution buvable en sachet
CHU de Bordeaux
2020 Phase 2 EUCTR2019-004958-29-FR France;
FTI, AZLI
Gilead Sciences
2008 Phase 2 NCT00794586 United States;
Fasenra
AstraZeneca AB
2021 Phase 3 EUCTR2020-004068-24-DK Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
2021 Phase 3 EUCTR2020-004068-24-DE Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Viet Nam;
Fenretinide
Elias Matouk
2014 Phase 1 NCT02141958 Canada;
Ferinject
University of Oxford / Clinical Trials and Research Governance
2018 Phase 4 EUCTR2018-002366-39-GB United Kingdom;
Ferric carboxymaltose
University of Oxford
2019 Phase 4 NCT03632525 United Kingdom;
University of Oxford / Clinical Trials and Research Governance
2018 Phase 4 EUCTR2018-002366-39-GB United Kingdom;
Ferrous sulfate
Dartmouth-Hitchcock Medical Center
2011 - NCT01755455 United States;
Finely ground flaxseed powder
University of Pennsylvania
2012 Phase 1 NCT02014181 United States;
Fish oil
Nestlé
2016 - NCT02646995 Switzerland;
Flucloxacillin 250mg/5ml Sugar-Free Powder for Oral Solution
Alder Hey Children's NHS Foundation Trust
2016 Phase 4 EUCTR2016-002578-11-GB United Kingdom;
Flucloxicillin
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
Flumist®
McGill University Health Center
2013 - NCT01885169 Canada;
Fluticasone
Royal Brompton & Harefield NHS Foundation Trust
2001 - NCT00220259 United Kingdom;
Fortum
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
Frequently Sampled Oral Glucose Tolerance Test and CGM
University Hospitals Cleveland Medical Center
2019 - NCT03961516 United States;
Fucidin Tablets
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Fusidin
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
G1117337
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002181-42-DE Germany;
G914167
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
G957389
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-NL Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-GB Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-ES Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-BE Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002837-31-CZ Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-IE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-GB Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-DE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-BE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
GIP
University of Pennsylvania
2013 - NCT01851694 United States;
GLP-1
University of Pennsylvania
2013 - NCT01851694 United States;
GLPG1837
Galapagos NV
2016 Phase 2 EUCTR2015-003292-30-NL Belgium;Netherlands;
2016 Phase 2 EUCTR2015-003292-30-BE Belgium;Netherlands;
2016 Phase 2 EUCTR2015-003291-77-IE Australia;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2015-003291-77-GB Australia;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2015-003291-77-DE Australia;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2015-003291-77-CZ Australia;Czech Republic;Germany;Ireland;United Kingdom;
GLPG1837 dose 1
Galapagos NV
2016 Phase 2 NCT02707562 Australia;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 NCT02690519 Belgium;Netherlands;
GLPG1837 dose 2
Galapagos NV
2016 Phase 2 NCT02707562 Australia;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 NCT02690519 Belgium;Netherlands;
GLPG1837 dose 3
Galapagos NV
2016 Phase 2 NCT02707562 Australia;Czech Republic;Germany;Ireland;United Kingdom;
GLPG2222
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
2018 Phase 1 NCT03540524 Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
2017 Phase 2 NCT03119649 Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-NL Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-GB Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-ES Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004477-40-BE Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002837-31-CZ Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-IE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-GB Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-DE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
2016 Phase 2 EUCTR2016-002837-31-BE Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
GLPG2222 150 mg q.d.
Galapagos NV
2017 Phase 2 NCT03045523 Australia;Belgium;Czechia;Germany;Ireland;United Kingdom;
GLPG2222 300 mg q.d.
Galapagos NV
2017 Phase 2 NCT03045523 Australia;Belgium;Czechia;Germany;Ireland;United Kingdom;
GLPG2451 dose regimen A
Galapagos NV
2018 Phase 1 NCT03540524 Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
GLPG2451 dose regimen B
Galapagos NV
2018 Phase 1 NCT03540524 Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
GLPG2737
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
2018 Phase 1 NCT03540524 Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
2017 Phase 2 NCT03474042 Germany;
2017 Phase 2 EUCTR2017-002181-42-DE Germany;
GLPG2737 single dose
Galapagos NV
2017 Phase 1 NCT03450720 Belgium;
GLPG3067
Galapagos NV
2018 Phase 2 EUCTR2018-000098-61-GB Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
GLPG3067 single dose
Galapagos NV
2018 Phase 1 NCT03589313 Belgium;
GLUTATHIONE SODIUM
Aarhus University Hospital
2014 Phase 2 EUCTR2013-005481-19-DK Denmark;
GLYPRESSINE 1 mg/5 mL, poudre et solvant pour solution injectable (I.V.)
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2021 Phase 3 EUCTR2020-005931-58-FR France;
GS-5737
Gilead Sciences
2013 Phase 1 NCT01840735 United States;
2012 Phase 1 NCT01793649 United States;
GS-5745
Gilead Sciences, Inc.
2016 Phase 2 EUCTR2015-002192-23-ES Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002192-23-DE Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002192-23-BE Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
GS-9411
Gilead Sciences
2009 Phase 1 NCT01025713 Australia;
2009 Phase 1 NCT00999531 Australia;
2009 Phase 1 NCT00951522 Australia;
2008 Phase 1 NCT00800579 Australia;
GSH (Glutathione)
Mukoviszidose Institut gGmbH i. G.
2006 - EUCTR2005-003870-88-DE Germany;
Galicaftor
AbbVie
2021 Phase 2 NCT04853368 Australia;Belgium;Czechia;Germany;Hungary;Netherlands;New Zealand;Slovakia;
AbbVie Deutschland
2019 Phase 2 EUCTR2019-000750-63-NL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-HU Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-GB Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-FR Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000750-63-BE Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2020 Phase 2 EUCTR2019-000750-63-PL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
Gallium nitrate
Chris Goss
2021 Phase 1 NCT04294043 United States;
University of Washington
2016 Phase 2 NCT02354859 United States;
Genistein (Unconjugated Isoflavones 100)
Children's Hospital of Philadelphia
2003 Phase 1/Phase 2 NCT00590538 United States;
Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm
University Medical Centre Utrecht
2014 Phase 2 EUCTR2014-000817-30-NL Netherlands;
Gentamicin
Assistance Publique - Hôpitaux de Paris
2003 Phase 2 NCT00376428 France;
Gernebcin
University of Jena
2008 - EUCTR2008-000164-17-DE Germany;
Ghrelin
Papworth Hospital
2010 - NCT00763477 United Kingdom;
Giving DHA-rich supplement
University Hospital, Ghent
2007 Phase 2 NCT00221546 Belgium;
Glargine
Federico II University
2006 Phase 4 NCT00483769 Italy;
Glargine insulin
University of Minnesota - Clinical and Translational Science Institute
2003 Phase 3 NCT00222521 United States;
Glucose
Children's Hospital of Philadelphia
2013 - NCT01852448 United States;
Christoph Saner
2015 - NCT02569229 Switzerland;
Emory University
2014 - NCT02202876 United States;
Hospices Civils de Lyon
2009 - NCT02723968 -
Imperial College London
2009 - NCT01091025 United Kingdom;
Katie Larson Ode
2019 - NCT03650712 United States;
Liverpool Heart and Chest Hospital NHS Foundation Trust
2011 - NCT03644199 United Kingdom;
Mayo Clinic
2021 - NCT04579939 United States;
National Center for Research Resources (NCRR)
2001 - NCT00014768 United States;
Royal Brompton & Harefield NHS Foundation Trust
2013 - NCT01883037 United Kingdom;
Yale University
2015 Early Phase 1 NCT02398383 United States;
Glutamine
Emory University
2010 Phase 2 NCT01051999 United States;
Glutathione
AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI
2009 - EUCTR2008-005080-33-IT Italy;
Glycine
Instituto Nacional de Enfermedades Respiratorias
2012 Phase 2 NCT01417481 Mexico;
Glycine Buffer
University Hospitals Cleveland Medical Center
2018 Phase 1/Phase 2 NCT03617718 United States;
GlycosBio Nutritional Supplement
GlycosBio, Inc.
2018 - NCT04966897 United States;
Gold
The Alfred
2016 - NCT02717650 Australia;
Growth Hormone Stimulation Test
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
Growth hormone
University of Utah
2001 Phase 2 NCT00016445 United States;
H02 - Corticosteroidi Sistemici
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
HEPARIN SODIUM
Vectura Limited
2008 - EUCTR2007-006276-11-IE Ireland;Italy;
2008 - EUCTR2007-006276-11-GB Ireland;Italy;United Kingdom;
- Phase 2 EUCTR2007-006276-11-PL Ireland;Italy;Poland;United Kingdom;
HFNT during exercise
The Leeds Teaching Hospitals NHS Trust
2019 - NCT03965832 United Kingdom;
HGPIV diagnosis test
Hospices Civils de Lyon
2009 - NCT02723968 -
HMSCs
Marilyn Glassberg
2016 Phase 1 NCT02625246 United States;
HOMAR-IR diagnosis test
Hospices Civils de Lyon
2009 - NCT02723968 -
HP 129Xe
Thunder Bay Regional Research Institute
2019 Early Phase 1 NCT02748798 Canada;
HP 3He
Thunder Bay Regional Research Institute
2019 Early Phase 1 NCT02748798 Canada;
Heparin 25mg inhalation powder, hard capsule
VECTURA LIMITED
2010 - EUCTR2007-006276-11-IT Ireland;Italy;
Vectura Limited
2008 - EUCTR2007-006276-11-IE Ireland;Italy;
2008 - EUCTR2007-006276-11-GB Ireland;Italy;United Kingdom;
- Phase 2 EUCTR2007-006276-11-PL Ireland;Italy;Poland;United Kingdom;
Heracillin
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
High dose of budesonide
Hospital General de Requena
2004 - NCT00728715 Spain;
High flow nasal oxygen cannula
St. Michael's Hospital, Toronto
2014 - NCT02262871 Canada;
High-Dose Vitamin D3
Emory University
2015 - NCT02589444 United States;
History and physical exam.
University of Florida
2007 - NCT01851642 United States;
Home Oral Glucose Tolerance Test kit
Great Ormond Street Hospital for Children NHS Foundation Trust
2015 - NCT02703155 United Kingdom;
Human recombinant growth hormone
National Center for Research Resources (NCRR)
2000 Phase 3 NCT00005112 United States;
Hyaluronan
Ospedale Civile Ca' Foncello
2009 - NCT01658449 Italy;
Hydrocortisone
Birmingham Children's Hospital NHS Foundation Trust
2012 - EUCTR2011-005790-23-GB United Kingdom;
Hydroxychloroquine
Vanderbilt University
2006 Phase 1 NCT00311883 United States;
Hyperglycemic Clamp with concurrent GIP infusion
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Hyperglycemic clamp with concurrent GLP-1 infusion
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Hyperpolarized Helium-3
University of Massachusetts, Worcester
2008 - NCT00846573 United States;
Hyperpolarized Helium-3 MRI of the chest
University of Virginia
2011 - NCT02163681 United States;
Hyperpolarized Xe129
Mario Castro, MD, MPH
2020 Phase 1 NCT04624490 United States;
Hyperpolarized Xenon
Children's Hospital Medical Center, Cincinnati
2016 - NCT02848560 United States;
Hyperpolarized Xenon 129
Children's Hospital Medical Center, Cincinnati
2020 Phase 4 NCT04467957 -
Hyperpolarized Xenon gas
Children's Hospital Medical Center, Cincinnati
2018 - NCT03593434 United States;
University of North Carolina, Chapel Hill
2018 Early Phase 1 NCT03482960 United States;
Hyperpolarized xenon-129
The University of Nottingham
- Phase 2 EUCTR2019-003052-36-GB United Kingdom;
Hypertonic Saline
Parion Sciences
2015 Phase 2 NCT02343445 United States;
The Hospital for Sick Children
2011 Phase 2 NCT02276898 Canada;
2006 Phase 2 NCT00721071 Canada;
2006 Phase 1 NCT00753987 Canada;
Tim Corcoran
2017 Phase 1 NCT02947126 United States;
University of North Carolina, Chapel Hill
2009 - NCT01031706 United States;
University of Oklahoma
2006 - NCT00671723 United States;
Hypertonic Saline (HS)
CF Therapeutics Development Network Coordinating Center
2009 - NCT00709280 Canada;United States;
University of Washington, the Collaborative Health Studies Coordinating Center
2015 - NCT02378467 Canada;United States;
Hypertonic Saline (HS), 4mL
Heidelberg University
2012 Phase 2 NCT01619657 Germany;
Hypertonic bicarbonate
Joseph Pilewski
2014 Phase 1 NCT03391414 United States;
Hypertonic saline
Adelaida Lamas Ferreiro
2009 Phase 4 NCT01377792 Spain;
Erasmus MC
2018 Phase 3 EUCTR2015-004143-39-IT Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2017 Phase 3 EUCTR2015-004143-39-DK Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-NL Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-BE Australia;Belgium;Denmark;Netherlands;Spain;United States;
- Phase 3 EUCTR2015-004143-39-FR Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
Joseph Zabner
2011 Phase 1/Phase 2 NCT01355796 United States;
Royal Prince Alfred Hospital, Sydney, Australia
2000 Phase 3 NCT00271310 -
The Hospital for Sick Children
2008 - NCT00700050 Canada;
Hypertonic saline ()
University of Pittsburgh
2010 Phase 1 NCT01223183 United States;
Hypertonic saline () and isotonic saline ()
The Hospital for Sick Children
2008 Phase 3 NCT00635141 Canada;
Hypertonic saline -
The Alfred
2007 Phase 3 NCT00484263 Australia;
Hypertonic saline solution
University Hospital Ghent
2007 - EUCTR2007-002707-40-BE Belgium;
ICS+LABA
Shanghai Pulmonary Hospital, Shanghai, China
2011 Phase 4 NCT02782312 China;
IDPM
Pharmaxis Pharmaceuticals Limited
2009 Phase 3 EUCTR2008-002740-42-FR Belgium;France;Germany;Netherlands;
2009 - EUCTR2008-002740-42-NL Belgium;France;Germany;Netherlands;
2009 - EUCTR2008-002740-42-BE Belgium;France;Germany;Netherlands;
2008 - EUCTR2008-002740-42-DE Belgium;France;Germany;Netherlands;
2007 - EUCTR2007-001412-23-IE Ireland;United Kingdom;
- Phase 3 EUCTR2007-001412-23-DE Germany;Ireland;United Kingdom;
IDPM: Inhaled Dry Powder Mannitol
Pharmaxis Ltd
2009 - EUCTR2008-008228-34-GB United Kingdom;
Pharmaxis Pharmaceuticals Limited
2009 - EUCTR2007-001412-23-GB Ireland;United Kingdom;
Pharmaxis UK Limited
2007 Phase 3 EUCTR2006-004078-28-GB United Kingdom;
IGE025
Novartis Pharma Services AG
2008 - EUCTR2007-006648-23-DE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
INCRELEX*SC 1FL 4ML 10MG/ML
AZIENDA OSPEDALIERA DI PARMA
2011 - EUCTR2011-002719-27-IT Italy;
INDUSIL*OS GTT FL 30MG+FL 15ML
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
2010 - EUCTR2010-020516-11-IT Italy;
INOmax 400ppm mol/mol inhalation gas
Southampton University Hopsitals NHS Trust
2011 - EUCTR2010-023529-39-GB United Kingdom;
INS1007
INSMED INCORPORATED
2021 Phase 3 EUCTR2020-003688-25-IT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-IT Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
Insmed Incorporated
2021 Phase 3 EUCTR2020-003688-25-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-LT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-IE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-003688-25-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-003688-25-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2017-002533-32-BE Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-SE Australia;Belgium;Bulgaria;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-PL Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-NL Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-GB Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-ES Australia;Belgium;Bulgaria;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-DK Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-DE Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002533-32-BG Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
INS1007 10 mg oral tablet
Insmed Incorporated
2017 Phase 2 NCT03218917 Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
INS1007 25 mg oral tablet
Insmed Incorporated
2017 Phase 2 NCT03218917 Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
IONIS-ENaCRx
Ionis Pharmaceuticals, Inc.
2018 Phase 1 NCT03647228 Germany;United Kingdom;
IV amikacin
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV ceftazidime
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV glucose tolerance test
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
IV meropenem
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV piperacillin-tazobactam
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV ticarcillin-clavulanate
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV tobramycin
Seattle Children's Hospital
2004 - NCT00153634 United States;
IV vancomycin hydrochloride
Savara Inc.
2011 Phase 1 NCT01537666 Australia;
IVA
Vertex Pharmaceuticals Incorporated
2019 Phase 2 NCT03911713 Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 3 NCT03691779 Australia;Ireland;United Kingdom;United States;
2018 Phase 3 NCT03601637 Canada;United States;
2018 Phase 3 NCT03537651 Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 NCT03525574 Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 NCT03447262 Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 2 NCT03625466 Germany;
2016 Phase 2 NCT02971839 United States;
2016 Phase 2 NCT02951182 Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;United Kingdom;United States;
2016 Phase 1 NCT03486236 United Kingdom;
IVACAFTOR 59,
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
Ibuprofen
FDA Office of Orphan Products Development
1996 - NCT00004440 -
Ramsey, Bonnie, MD
2004 - NCT00219895 United States;
University Hospitals Cleveland Medical Center
2007 - NCT00531882 United States;
Icenticaftor
Novartis Pharma AG
2021 Phase 2 EUCTR2019-002840-26-DE China;Germany;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002840-26-GB China;Germany;Spain;United Kingdom;
IgY
Mukoviszidose Institut gGmbH
2011 Phase 3 NCT01455675 Austria;Belgium;Germany;Hungary;Ireland;Italy;Poland;Spain;Sweden;
Impact
Alcresta Therapeutics, Inc.
2016 - NCT02750501 United States;
Impact-Nutridrink
University Hospital, Motol
2013 Phase 4 NCT02048592 Czech Republic;
Indirect Calorimetry
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
Indium
University of Pittsburgh
2007 - NCT00541190 United States;
Indium-DTPA
Tim Corcoran
2017 Phase 1 NCT02947126 United States;
Influenza vaccination
Assistance Publique - Hôpitaux de Paris
2009 Phase 4 NCT01499914 France;
Inhaled AR-501
Aridis Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03669614 United States;
Inhaled Mannitol
Pharmaxis
2013 Phase 2 NCT01883531 United Kingdom;
Inhaled Reduced Glutathione
Serafino A. Marsico
2010 Phase 3 NCT01450267 Italy;
Inhaled SNSP113
Synspira, Inc.
2017 Phase 1 NCT03309358 United Kingdom;
Inhaled Sodium Pyruvate
University of Minnesota - Clinical and Translational Science Institute
2006 Phase 1 NCT00332215 United States;
Inhaled Vancomycin
Johns Hopkins University
2012 Phase 2 NCT01594827 United States;
Inhaled dry powder mannitol
Pharmaxis Pharmaceuticals Limited
2007 - EUCTR2007-001412-23-IE Ireland;United Kingdom;
- Phase 3 EUCTR2007-001412-23-DE Germany;Ireland;United Kingdom;
Inhaled hypertonic saline ()
Tim Corcoran
2013 Phase 1 NCT01887197 United States;
University of Pittsburgh
2014 Phase 1 NCT02141191 United States;
Inhaled hypertonic saline (HS)
CF Therapeutics Development Network Coordinating Center
2007 - NCT00546663 Canada;United States;
Inhaled mannitol
Pharmaxis
2014 Phase 3 NCT02134353 Argentina;Australia;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Israel;Italy;Mexico;New Zealand;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
2008 Phase 3 NCT00630812 Argentina;Belgium;Canada;France;Germany;Netherlands;United States;
2004 Phase 2 NCT00455130 Australia;New Zealand;
Inhaled tobramycin
Seattle Children's Hospital
2016 Phase 4 NCT02677701 United States;
University of North Carolina, Chapel Hill
2004 Phase 1 NCT00823238 United States;
Initiation of CFTR Modulator
Children's Hospital Medical Center, Cincinnati
2020 Phase 4 NCT04467957 -
2020 Phase 4 NCT04259970 Canada;United States;
Insulin
Fondazione per la ricerca sulla Fibrosi Cistica
2005 Phase 3 NCT00687466 Italy;
Jagdeesh Ullal
2021 Phase 4 NCT04533646 United States;
National Center for Research Resources (NCRR)
2001 - NCT00014768 United States;
Insulin Asparte
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2001 Phase 3 NCT00072904 Canada;United States;
Insulin Pump
University of Texas Southwestern Medical Center
2006 - NCT00287456 United States;
Insulin detemir [rDNA origin] injection
Nationwide Children's Hospital
2008 Phase 2/Phase 3 NCT00639626 United States;
Insulin glargine
ISTITUTO GIANNINA GASLINI
2005 - EUCTR2005-002135-27-IT Italy;
Insuline humaine recombinante
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2006 - EUCTR2006-001254-27-FR France;
Interferon gamma-1b
InterMune
2002 Phase 1/Phase 2 NCT00043342 United States;
2001 Phase 1/Phase 2 NCT00043316 United States;
Intermittent, short infusion Cefepime
The Alfred
2012 Phase 4 NCT01667094 Australia;
Intermittent, short infusion Ceftazidime
The Alfred
2012 Phase 4 NCT01667094 Australia;
Intermittent, short infusion Meropenem
The Alfred
2012 Phase 4 NCT01667094 Australia;
Intermittent, short infusion Piperacillin tazobactam
The Alfred
2012 Phase 4 NCT01667094 Australia;
Intermittent, short infusion Ticarcillin-clavulanate
The Alfred
2012 Phase 4 NCT01667094 Australia;
Inulin
Emory University
2020 Phase 4 NCT04118010 United States;
Isotonic Saline
Tim Corcoran
2017 Phase 1 NCT02947126 United States;
Isotonic Saline (IS)
CF Therapeutics Development Network Coordinating Center
2009 - NCT00709280 Canada;United States;
University of Washington, the Collaborative Health Studies Coordinating Center
2015 - NCT02378467 Canada;United States;
Isotonic Saline (IS), 4mL
Heidelberg University
2012 Phase 2 NCT01619657 Germany;
Isotonic saline
Erasmus MC
2018 Phase 3 EUCTR2015-004143-39-IT Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2017 Phase 3 EUCTR2015-004143-39-DK Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-NL Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-BE Australia;Belgium;Denmark;Netherlands;Spain;United States;
- Phase 3 EUCTR2015-004143-39-FR Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
University of Jena
2007 Phase 3 NCT00534079 Germany;
University of Pittsburgh
2010 Phase 1 NCT01223183 United States;
2008 - NCT00628134 United States;
Itraconazole
Novartis Pharmaceuticals
2008 Phase 4 NCT00787917 Belgium;Germany;Italy;Netherlands;United Kingdom;
Ottawa Hospital Research Institute
2007 Phase 4 NCT00528190 Canada;
Vertex Pharmaceuticals Incorporated
2013 Phase 1 NCT01768663 United States;
Itraconazole/voriconazole
Rennes University Hospital
2014 Phase 2 NCT01576315 France;United Kingdom;
Ivacaftor
Children's Hospital of Philadelphia
2019 - NCT03783286 United States;
Eloxx Pharmaceuticals Inc
2019 Phase 2 EUCTR2018-000966-12-DE Australia;Germany;Israel;
Eloxx Pharmaceuticals, Inc.
2019 Phase 2 NCT04135495 Canada;United States;
Medical University of South Carolina
2016 Phase 3 NCT02934698 -
Richard Barry Moss
2015 - NCT02310789 United States;
The Alfred
2014 Phase 4 NCT01937325 Australia;
University of California, San Francisco
2013 - NCT01784419 United States;
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2019 Phase 2 EUCTR2018-003970-28-NL Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-GB Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 3 NCT03277196 Australia;Canada;Germany;Ireland;United Kingdom;United States;
2017 Phase 3 NCT03068312 Israel;
2016 Phase 3 NCT02742519 Australia;Canada;United Kingdom;
2016 Phase 3 NCT02725567 Australia;Canada;Ireland;United Kingdom;United States;
2016 Phase 2 NCT02951195 United States;
2016 Phase 1 NCT03029455 United Kingdom;
2015 Phase 3 NCT02390219 United States;
2015 - NCT02445053 Italy;Netherlands;United Kingdom;
2014 Phase 2 NCT02070744 United States;
2014 Phase 1 NCT02015507 -
2013 Phase 3 NCT01946412 Canada;United Kingdom;United States;
2013 Phase 3 NCT01897233 Canada;United States;
2013 Phase 3 NCT01707290 Belgium;France;Ireland;United Kingdom;United States;
2013 Phase 3 NCT01705145 Canada;United Kingdom;United States;
2013 Phase 1 NCT01910415 Netherlands;
2013 Phase 1 NCT01899105 United States;
2013 Phase 1 NCT01768663 United States;
2012 Phase 3 NCT01614470 Belgium;France;United States;
2012 Phase 3 NCT01614457 Ireland;United Kingdom;United States;
2012 Phase 2 NCT01685801 United States;
2012 Phase 2 NCT01531673 Canada;Germany;United Kingdom;United States;
2011 Phase 2 NCT01262352 Canada;Ireland;United Kingdom;United States;
2010 Phase 3 NCT01117012 Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 Phase 3 EUCTR2009-012997-11-GB Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 Phase 2 NCT01225211 Australia;Belgium;France;Germany;Ireland;New Zealand;United Kingdom;United States;
2010 - EUCTR2010-020546-96-GB Canada;United Kingdom;United States;
2010 - EUCTR2009-012997-11-IE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2009-012997-11-DE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2009-012997-11-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 NCT00909727 Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 NCT00909532 Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-007479-26-GB Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-007416-15-GB Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 2 NCT00953706 United States;
2009 - EUCTR2008-007479-26-IE Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 - EUCTR2008-007479-26-DE Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 - EUCTR2008-007416-15-IE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- - EUCTR2008-007416-15-DE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
university medical center utrecht
2018 Phase 4 EUCTR2016-001440-18-NL Netherlands;
Ivacaftor (proposed INN)
Vertex Pharmaceuticals Incorporated
- - EUCTR2009-010261-23-Outside-EU/EEA United States;
Ivacaftor 125mg tablet
Vertex Pharmaceuticals Incorporated
2014 Phase 3 EUCTR2013-000604-41-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-IT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 - EUCTR2013-000604-41-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-SE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-GB Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003990-24-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003989-40-NL Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IT Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-DE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
Ivacaftor 150 mg or
Vertex Pharmaceuticals Incorporated
2007 Phase 2 NCT00457821 Canada;Germany;United States;
Ivacaftor 25 mg/
Vertex Pharmaceuticals Incorporated
2007 Phase 2 NCT00457821 Canada;Germany;United States;
Ivacaftor 75 mg/
Vertex Pharmaceuticals Incorporated
2007 Phase 2 NCT00457821 Canada;Germany;United States;
Ivacaftor Exposed
Vertex Pharmaceuticals Incorporated
2013 - NCT01863238 United States;
Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Sonya Heltshe
2020 - NCT04509050 United States;
Ivacaftor+lumacaftor
Assistance Publique - Hôpitaux de Paris
2016 - NCT03475381 France;
Ivacaftor/Ataluren
University of Alabama at Birmingham
2017 Phase 4 NCT03256799 United States;
Ivacaftor/Kalydeco
University Medical Centre Utrecht
2014 Phase 2 EUCTR2014-000817-30-NL Netherlands;
Ivacaftor/Trikafta
University of Alabama at Birmingham
2018 Phase 4 NCT03624101 United States;
J01GB01
University Medical Center Groningen
2013 - EUCTR2012-004437-16-NL Netherlands;
- Phase 2 EUCTR2016-005014-21-NL Netherlands;
JBT-101
CORBUS PHARMACEUTICALS, INC
2018 Phase 2 EUCTR2017-003723-29-IT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Corbus Pharmaceuticals, Inc.
2020 Phase 2;Phase 3 EUCTR2020-001762-11-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2020-001762-11-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003723-29-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003723-29-NL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-SK Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-PT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-GR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002581-23-DE Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
2015 Phase 2 EUCTR2015-002581-23-GB Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
2015 Phase 2 EUCTR2015-002581-23-FR Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
2015 Phase 2 EUCTR2015-002581-23-BE Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2017-003723-29-FR Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
JBT-101 (lenabasum)
Corbus Pharmaceuticals Inc.
2015 Phase 2 NCT02465450 Belgium;France;Germany;Italy;Poland;United Kingdom;United States;
KB001
KaloBios Pharmaceuticals
2008 Phase 1/Phase 2 NCT00638365 United States;
KB001-A
KaloBios Pharmaceuticals
2012 Phase 2 NCT01695343 Australia;Israel;New Zealand;United States;
KREON 25000
Aptalis Pharma US Inc.
2013 - EUCTR2009-012842-21-HU Bulgaria;Germany;Hungary;Italy;United Kingdom;
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-DE Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-BG Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
Axcan Pharma Inc.
- - EUCTR2010-019267-11-DE Germany;
KREON N 25000
Abbott Laboratories GmbH
2013 - EUCTR2013-002819-10-ES Hungary;Russian Federation;Spain;
KREON de Liberación Inmediata
Abbott Laboratories GmbH
2015 Phase 2 EUCTR2014-004519-35-ES Czech Republic;Hungary;Spain;United Kingdom;
Kaftrio
Haga Teaching Hospital
2021 Phase 4 EUCTR2020-005224-12-NL Netherlands;
Royal College of Surgeons, Ireland
2020 Phase 4 NCT04602468 Ireland;United Kingdom;
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
Kalydeco
Eloxx Pharmaceuticals Inc
2019 Phase 2 EUCTR2018-000966-12-DE Australia;Germany;Israel;
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-PL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2016-004479-35-GB Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2017-001379-21-GB Canada;Germany;Ireland;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001997-16-IE Canada;Germany;Ireland;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001267-39-GB Australia;Canada;France;United Kingdom;
2016 Phase 3 EUCTR2014-004838-25-DE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-AT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004788-18-BE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-BE Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-SE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-NL Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IT Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-GB Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-ES Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DK Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-NL Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-IT Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-GB Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-DE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004787-37-ES Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-DE Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-AT Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 - EUCTR2014-004827-29-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2014 Phase 2 EUCTR2010-020413-90-GB Australia;Belgium;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2010-020413-90-IE Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
2013 Phase 3 EUCTR2012-000386-20-GB Canada;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000389-39-GB Belgium;France;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000389-39-BE Belgium;France;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000388-26-BE Belgium;France;United States;
2012 - EUCTR2012-000387-19-GB United Kingdom;United States;
2011 - EUCTR2010-020413-90-DE Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
2011 - EUCTR2010-020413-90-BE Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
2010 Phase 3 EUCTR2009-012997-11-GB Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2009-012997-11-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-001379-21-IE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2017-001379-21-DE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001997-16-GB Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001997-16-DE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001267-39-FR Australia;Canada;France;United Kingdom;
- Phase 2 EUCTR2017-000673-37-Outside-EU/EEA United States;
- Phase 2 EUCTR2017-000672-28-Outside-EU/EEA United States;
Kalydeco 150 mg film-c
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Kalydeco 150 mg film-coated tablets
VERTEX PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2019-000833-37-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-IT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2021-001628-16-ES Australia;Belgium;Canada;Spain;
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-001827-11-IE Australia;Canada;Ireland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004652-38-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001735-31-GB Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000833-37-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001695-38-GB Australia;Canada;Ireland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004134-29-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-NL Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-GB Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-DE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-BE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-IE Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-GB Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-ES Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-000126-55-NL Netherlands;
2017 Phase 3 EUCTR2017-000540-18-DE France;Germany;United States;
2017 Phase 2 EUCTR2017-000797-11-NL Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-NL Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-GB Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-ES Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-DE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-BE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-AT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000454-36-DK Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-001628-16-BE Australia;Belgium;Canada;Spain;
- Phase 3 EUCTR2019-001827-11-GB Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2019-001735-31-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2019-000833-37-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-001695-38-IE Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-004133-82-DE Australia;Germany;Ireland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-004132-11-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000540-18-FR France;Germany;United States;
Ketone Monoester
University of Alabama at Birmingham
2021 - NCT04938726 -
Kineret
Ruprecht-Karls-University Heidelberg, Medical Faculty
- Phase 2 EUCTR2016-004786-80-DE Germany;
Klacid
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Kreon 25 000
Abbott Laboratories GmbH
2015 Phase 2 EUCTR2014-004519-35-ES Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-HU Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-GB Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-CZ Czech Republic;Hungary;Spain;United Kingdom;
Aptalis Pharma US Inc.
2013 - EUCTR2009-012842-21-HU Bulgaria;Germany;Hungary;Italy;United Kingdom;
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-DE Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-BG Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
Kreon 25,000 Units
Aptalis Pharma
2012 Phase 3 NCT01641393 Belgium;Bulgaria;France;Germany;Italy;Poland;United Kingdom;
Kreon 25000
Abbott Laboratories GmbH
2013 - EUCTR2013-002819-10-ES Hungary;Russian Federation;Spain;
Kreon® 25,000
Abbott Laboratories GmbH
2015 Phase 2 EUCTR2014-004519-35-ES Czech Republic;Hungary;Spain;United Kingdom;
Forest Laboratories
2011 Phase 4 NCT01327703 Germany;Poland;
L-Glutamine
University of Nottingham
2008 Phase 4 EUCTR2007-006204-37-GB United Kingdom;
L-Lysine N acetylcysteinate
LABORATOIRES SMB S.A.
2010 - EUCTR2010-018454-13-IT Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine N-acetylcysteinate
LABORATOIRES SMB S.A.
2010 - EUCTR2010-018454-13-IT Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine- N-acetylcysteinate
Laboratoires SMB S.A.
2010 Phase 3 EUCTR2010-018454-13-ES Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine-N-acetyl-L-cysteinate
Laboratoires SMB S.A.
- Phase 3 EUCTR2010-018454-13-BE Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine-N-acetylcysteinate
Laboratoires SMB S.A.
2010 Phase 3 EUCTR2010-018454-13-FR Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018454-13-DK Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-HU Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-GB Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-DE Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-CZ Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-alanine
Emory University
2010 Phase 2 NCT01051999 United States;
L-arginine
The Hospital for Sick Children
2006 Phase 2 NCT00405665 Canada;
LABA/LAMA
Shanghai Pulmonary Hospital, Shanghai, China
2020 Phase 4 NCT04509661 -
LANTUS*SC 5CAR3ML100UI/ML
ISTITUTO GIANNINA GASLINI
2005 - EUCTR2005-002135-27-IT Italy;
LAU-7b
Laurent Pharmaceuticals Inc.
2018 Phase 2 NCT03265288 Australia;Canada;United States;
LEVOFLOXACIN HEMIHYDRATE
Medical University of Vienna
2020 Phase 4 EUCTR2019-000955-16-AT Austria;
LIPASA
ANTHERA Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2016-002851-92-ES Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
LIPASE
ANTHERA Pharmaceuticals, Inc.
2017 Phase 3 EUCTR2017-000571-85-LT Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-HU Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-GB Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000571-85-ES Hungary;Israel;Lithuania;Poland;Spain;United States;
2016 Phase 4 EUCTR2016-002851-92-CZ Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
2016 Phase 3 EUCTR2016-002851-92-HU Canada;Hungary;Israel;Spain;United States;
2016 Phase 3 EUCTR2015-002739-17-CZ Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-HU Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-ES Canada;Czech Republic;Hungary;Israel;Spain;United States;
- Phase 3 EUCTR2017-000571-85-PL Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-002851-92-PL Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
LU 70274
Nordmark Arzneimittel GmbH
2006 - EUCTR2006-005180-25-DE Germany;
LUM
Vertex Pharmaceuticals Incorporated
2018 Phase 3 NCT03601637 Canada;United States;
2018 Phase 2 NCT03625466 Germany;
LUM/IVA
Vertex Pharmaceuticals Incorporated
2020 Phase 3 NCT04235140 Canada;United States;
2017 Phase 3 NCT03125395 Canada;United States;
2017 Phase 2 NCT03061331 Netherlands;
2016 Phase 4 NCT02875366 Australia;United Kingdom;
2016 Phase 4 NCT02823470 Canada;United States;
2016 Phase 3 NCT02797132 Canada;United States;
2015 Phase 3 NCT02544451 Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
LUM/IVA fixed-dose combination
Vertex Pharmaceuticals Incorporated
2018 Phase 2 EUCTR2017-003761-99-DE Germany;
2016 Phase 2 EUCTR2016-001585-29-NL Netherlands;
Lactic acid producing organisms
UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
2009 - EUCTR2009-015875-28-IT Italy;
2009 - EUCTR2009-011289-27-IT Italy;
Lactizole nebulization
Medical Universtity of Lodz
2019 - NCT04058340 Poland;
Lactobacillus reuteri
Azienda Policlinico Umberto I
2009 Phase 4 NCT01737983 Italy;
Lactobacillus rhamnosus
Cantonal Hospital of St. Gallen
2013 - NCT01837355 Switzerland;
Lactobacillus rhamnosus GG
Federico II University
2010 Phase 3 NCT01956916 Italy;
2009 Phase 3 NCT01961661 Italy;
Lansoprazole
Arkansas Children's Hospital Research Institute
2006 Phase 1 NCT00458614 United States;
Lantus 100 units/ml solution for injection in a cartridge
HagaZiekenhuis, pulmonary department
2012 - EUCTR2011-001916-69-NL Netherlands;
Lantus® 100 Units/ml solution for injection in a vial. Lantus® 100 Units/ml solution for injection in a cartridge. Lantus® 100 Units/ml solution for injection in a pre-filled pen
St George's, University of London
2008 - EUCTR2007-004956-35-GB United Kingdom;
Lefamulin
Nabriva Therapeutics AG
2022 Phase 1 NCT05225805 -
Lenabasum
CORBUS PHARMACEUTICALS, INC
2018 Phase 2 EUCTR2017-003723-29-IT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Corbus Pharmaceuticals Inc.
2017 Phase 2 NCT03451045 Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Corbus Pharmaceuticals, Inc.
2020 Phase 2;Phase 3 EUCTR2020-001762-11-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2020-001762-11-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003723-29-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-SK Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-GR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2017-003723-29-FR Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Leucine
National Center for Research Resources (NCRR)
2001 - NCT00014768 United States;
Levemir 100 U/ml solution for injection in a cartridge, Levemir 100 U/ml solution for injection in a pre-filled pen
St George's, University of London
2008 - EUCTR2007-004956-35-GB United Kingdom;
Levemir FlexPen
Liverpool Heart and Chest Hospital NHS Trust
2013 - EUCTR2012-002880-86-GB United Kingdom;
Levemir Penfill
Sheffield Children's NHS Trust
2006 Phase 4 EUCTR2005-002997-31-GB United Kingdom;
Levemir insulin
University of Minnesota
2015 Phase 2/Phase 3 NCT02496780 United States;
Levofloxacin
Mpex Pharmaceuticals, Inc.
2008 - EUCTR2008-001728-30-NL Germany;Netherlands;
2008 - EUCTR2008-001728-30-DE Germany;Netherlands;
Levofloxacin Kabi
Medical University of Vienna
2020 Phase 4 EUCTR2019-000955-16-AT Austria;
Levofloxacin hemihydrate
Mpex Pharmaceuticals, Inc.
2011 Phase 3 EUCTR2010-019634-26-GB Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-IE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-DE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
- Phase 3 EUCTR2010-019634-26-FR France;Germany;Ireland;United Kingdom;
Linez
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Linezolid
University of Texas Southwestern Medical Center
2010 Phase 2 NCT00625703 United States;
Linoleic acid supplementation
Karolinska Institutet
2021 - NCT04531410 Italy;Norway;Poland;Sweden;
Lipase CLEC
Altus Pharmaceuticals Inc
2007 Phase 3 EUCTR2007-000171-41-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000171-41-PL Italy;Poland;Slovakia;
Altus Pharmaceuticals Inc.
2007 Phase 3 EUCTR2007-000178-21-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000178-21-PL Italy;Poland;Slovakia;
Lipase Lip2 from Yarrowia lipolytica
AzurRx
2020 Phase 2 EUCTR2018-003831-31-ES Hungary;Poland;Spain;
AzurRx SAS
- Phase 2 EUCTR2018-003831-31-PL Hungary;Poland;Spain;Turkey;
Lipitor
NHS Lothian
2010 Phase 4 EUCTR2010-022042-24-GB United Kingdom;
2010 Phase 4 EUCTR2010-022040-20-GB United Kingdom;
Liposomal Amikacin
INSMED INCORPORATED
2012 - EUCTR2011-000443-24-IT Australia;Austria;Belgium;Bulgaria;Canada;Denmark;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Spain;Sweden;United Kingdom;
Liposomal Amikacin (Arikace TM)
Insmed Incorporated
2011 Phase 3 EUCTR2011-000443-24-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
Liposomal Amikacin (Arikace™)
INSMED INCORPORATED
2011 - EUCTR2011-000441-20-IT Austria;Bulgaria;Canada;Denmark;Greece;Hungary;Ireland;Italy;Netherlands;Spain;United Kingdom;
Insmed Incorporated
2013 - EUCTR2011-000443-24-NL Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000443-24-PL Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000443-24-BE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-000441-20-BE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000443-24-SE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-000443-24-DK Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-000441-20-NL Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2012 - EUCTR2011-000441-20-IE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-DK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-BG Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-000443-24-SK Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-000443-24-GB Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2011-000443-24-FR Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2011 - EUCTR2011-000443-24-IE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000443-24-HU Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000443-24-GR Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2011 - EUCTR2011-000443-24-DE Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;
2011 - EUCTR2011-000443-24-BG Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
2011 - EUCTR2011-000443-24-AT Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2011-000442-38-ES Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-000442-38-BG Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-000441-20-SK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-HU Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-GR Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2011 - EUCTR2011-000441-20-GB Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-DE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-AT Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
- Phase 3 EUCTR2011-000442-38-PL Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
Transave, Inc.
2007 Phase 2 EUCTR2006-006980-22-SK Belgium;Hungary;Poland;Slovakia;
2007 - EUCTR2006-006980-22-HU Belgium;Hungary;
2007 - EUCTR2006-006980-22-BE Belgium;Hungary;
- Phase 2 EUCTR2006-006980-22-PL Belgium;Hungary;Poland;Slovakia;
Liposomal amikacin for inhalation
Insmed Incorporated
2012 Phase 3 NCT01316276 Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2012 Phase 3 NCT01315691 -
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
Insmed Incorporated
2012 Phase 3 NCT01315678 Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
Liposomal amphotericin B (Ambisome®)
Poitiers University Hospital
2014 Phase 2 NCT02273661 France;
Liprotamasa
ANTHERA Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2016-002851-92-ES Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
Liprotamase
ANTHERA Pharmaceuticals, Inc.
2017 Phase 3 EUCTR2017-000571-85-LT Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-HU Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-GB Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000571-85-ES Hungary;Israel;Lithuania;Poland;Spain;United States;
2016 Phase 4 EUCTR2016-002851-92-CZ Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
2016 Phase 3 EUCTR2016-002851-92-HU Canada;Hungary;Israel;Spain;United States;
2016 Phase 3 EUCTR2015-002739-17-CZ Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-HU Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-ES Canada;Czech Republic;Hungary;Israel;Spain;United States;
- Phase 3 EUCTR2017-000571-85-PL Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-002851-92-PL Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
Anthera Pharmaceuticals
2017 Phase 3 NCT03051490 Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2016 Phase 4 NCT02823964 Czech Republic;Czechia;Hungary;Israel;Poland;Spain;United States;
2015 Phase 3 NCT02279498 Canada;Czech Republic;Czechia;Hungary;Israel;Poland;Spain;United States;
2007 Phase 3 NCT00449904 United States;
2007 Phase 3 NCT00449878 United States;
2004 Phase 2 NCT00095732 United States;
Liprotamase Powder for Oral Solution
Anthera Pharmaceuticals
2016 Phase 3 NCT02734810 United States;
Loestrin (norethindrone acetate and ethinyl estradiol)
University of Texas Southwestern Medical Center
2014 Early Phase 1 NCT02036879 United States;
Lonodelestat
Santhera Pharmaceuticals (Switzerland) Ltd
2018 Phase 1;Phase 2 EUCTR2018-002550-71-DE Germany;
Losartan
University of Kansas Medical Center
2022 Early Phase 1 NCT03435939 United States;
University of Miami
2017 Phase 2 NCT03206788 United States;
Lubiprostone
University of Arkansas
2008 - NCT00706004 United States;
Lucinactant first
University of North Carolina, Chapel Hill
2008 Phase 2 NCT00934362 United States;
Lumacaftor
Vertex Pharmaceuticals Incorporated
2015 Phase 3 NCT02390219 United States;
2013 Phase 3 NCT01897233 Canada;United States;
2013 Phase 1 NCT01910415 Netherlands;
2013 Phase 1 NCT01899105 United States;
2013 Phase 1 NCT01768663 United States;
2010 Phase 2 NCT01225211 Australia;Belgium;France;Germany;Ireland;New Zealand;United Kingdom;United States;
Lumacaftor / ivacaftor
Vertex Pharmaceuticals Incorporated
2018 Phase 2 EUCTR2017-003761-99-DE Germany;
Lumacaftor Plus Ivacaftor Combination
Vertex Pharmaceuticals Incorporated
2013 Phase 3 NCT01931839 Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 NCT01807949 Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 NCT01807923 Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
Lumacaftor plus Ivacaftor
Hannover Medical School
2016 - NCT02807415 Germany;
Lumacaftor, Ivacaftor Drug Combination
Carmel Medical Center
2016 - NCT04623879 -
Lumacaftor-Ivacaftor treatment
University Hospital, Strasbourg, France
2016 - NCT03512119 France;
Lumacaftor-ivacaftor
Massachusetts General Hospital
2018 - NCT02653027 -
2016 - NCT02858843 -
Lumacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
2014 Phase 2 EUCTR2010-020413-90-GB Australia;Belgium;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2010-020413-90-IE Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
2011 - EUCTR2010-020413-90-DE Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
2011 - EUCTR2010-020413-90-BE Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
Lumacaftor/ivacaftor
Vertex Pharmaceuticals Incorporated
2016 Phase 4 EUCTR2016-000066-34-GB Australia;United Kingdom;
- Phase 3 EUCTR2017-001309-34-Outside-EU/EEA United States;
- Phase 3 EUCTR2017-001078-41-Outside-EU/EEA Canada;United States;
Lumacaftor/ivacaftor 100mg/125mg tablets
Vertex Pharmaceuticals Incorporated
2016 Phase 3 EUCTR2015-001644-11-GB Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-FR Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DK Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-BE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-SE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-GB Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-DK Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-DE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-BE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2015-001644-11-SE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2015-000543-16-FR Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
Lumacaftor/ivacaftor 200mg/
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
Lumacaftor/ivacaftor 200mg/125mg tablets
Vertex Pharmaceuticals Inc.
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2016 Phase 3 EUCTR2015-001644-11-GB Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-FR Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DK Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-BE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-IT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 - EUCTR2013-000604-41-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-SE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-GB Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003990-24-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003989-40-NL Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IT Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-DE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2015-001644-11-SE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
Lumacaftor/ivacaftor 200mg/83mg tablet
Vertex Pharmaceuticals Incorporated
2014 Phase 3 EUCTR2013-000604-41-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-IT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 - EUCTR2013-000604-41-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-SE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-GB Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003990-24-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003989-40-NL Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IT Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-DE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
Lung Clearance Index
The Hospital for Sick Children
2015 Phase 2 NCT02740868 Canada;
University of North Carolina, Chapel Hill
2015 Early Phase 1 NCT03497117 United States;
Lym-X-Sorb powder
Avanti Polar Lipids, Inc.
2007 Phase 2 NCT00406536 United States;
Lysomucil
University Hospital Ghent
2009 - EUCTR2008-008317-20-BE Belgium;
MAG-DHA
SCF Pharma
2015 Phase 2 NCT02518672 Canada;
MEDI-563
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
AstraZeneca AB
2021 Phase 3 EUCTR2020-004068-24-DK Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
2021 Phase 3 EUCTR2020-004068-24-DE Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Viet Nam;
MEROPENEM TRIHYDRATE
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
MINOCYCLINE HYDROCHLORIDE
AOU Meyer
2013 Phase 3 EUCTR2013-000219-25-IT Italy;
MOLI 1901
AOP ORPHAN PHARMACEUTICALS
2008 - EUCTR2006-006693-24-IT Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
MP-376
Horizon Pharma USA, Inc.
2008 Phase 2 NCT00677365 Germany;Netherlands;United States;
Mpex Pharmaceuticals, Inc.
2011 Phase 3 EUCTR2010-019634-26-GB Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-IE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2011 - EUCTR2010-019634-26-DE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
2008 - EUCTR2008-001728-30-NL Germany;Netherlands;
2008 - EUCTR2008-001728-30-DE Germany;Netherlands;
- Phase 3 EUCTR2010-019634-26-FR France;Germany;Ireland;United Kingdom;
MP-376 (Levofloxacin Solution for Inhalation)
Horizon Pharma USA, Inc.
2011 Phase 3 NCT01270347 France;Germany;Ireland;Israel;United Kingdom;United States;
MP-376 (Levofloxacin solution for Inhalation)
Horizon Pharma USA, Inc.
2010 Phase 3 NCT01180634 Australia;Canada;Israel;New Zealand;United States;
2009 Phase 1 NCT00840333 United States;
2007 Phase 1 NCT00503490 United States;
MRI with PFP
University of North Carolina, Chapel Hill
2015 Early Phase 1 NCT03497117 United States;
MRT5005
Translate Bio, Inc.
2018 Phase 1/Phase 2 NCT03375047 United States;
MS1819
AzurRx BioPharma, Inc.
2020 Phase 2 NCT04375878 Poland;United States;
MS1819-SD
AzurRx
2020 Phase 2 EUCTR2018-003831-31-ES Hungary;Poland;Spain;
2019 Phase 2 EUCTR2018-003831-31-HU Hungary;Poland;Spain;
AzurRx BioPharma, Inc.
2019 Phase 2 NCT03746483 Poland;United States;
AzurRx SAS
2019 Phase 2 NCT04302662 Hungary;Turkey;
- Phase 2 EUCTR2018-003831-31-PL Hungary;Poland;Spain;Turkey;
MSI-1995
Genaera Corporation
2005 Phase 2 EUCTR2004-004334-13-IE Ireland;
MTT
Pharmaxis Pharmaceuticals Limited
2009 Phase 3 EUCTR2008-002740-42-FR Belgium;France;Germany;Netherlands;
2009 - EUCTR2008-002740-42-NL Belgium;France;Germany;Netherlands;
2009 - EUCTR2008-002740-42-BE Belgium;France;Germany;Netherlands;
2008 - EUCTR2008-002740-42-DE Belgium;France;Germany;Netherlands;
Macroduct sweat stimulator
Richard Barry Moss
2015 - NCT02310789 United States;
Magnetic Resonance Imaging
The Hospital for Sick Children
2015 Phase 2 NCT02740868 Canada;
Mannite
University Children’s Hospital Tuebingen
2009 Phase 2 NCT01309178 Germany;
Mannitol
Pharmaxis
2008 Phase 1 NCT00792714 Australia;United Kingdom;
2007 Phase 3 NCT00446680 Australia;Ireland;United Kingdom;
2005 Phase 2 NCT00251056 Argentina;Canada;
Pharmaxis Ltd.
2014 - EUCTR2012-002699-14-NL Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;
2014 - EUCTR2012-002699-14-IT Argentina;Belgium;Canada;Italy;Netherlands;United Kingdom;
2013 Phase 2 EUCTR2012-002699-14-GB Argentina;Belgium;Canada;France;Italy;Netherlands;United Kingdom;
2013 - EUCTR2012-002699-14-BE Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
- Phase 2 EUCTR2012-002699-14-FR Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Mannitol + pulmozyme
Pharmaxis
2005 Phase 2 NCT00117208 United Kingdom;
Mannitol inhalation powder
Tim Corcoran
2013 Phase 1 NCT01887197 United States;
Manuka honey sinus rinse
Swansea University
2019 - NCT04589897 United Kingdom;
Matched isoglycemic clamp
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Medical Grade Oxygen
Hal C Charles
2012 Phase 1 NCT01731015 United States;
Melphalan
Federal State Budgetary Institution, Pulmonology Scientific Research Institute
2018 Phase 2 NCT04278040 Russian Federation;
Menadiol sodium diphosphate
Barts and the London NHS Trust
2006 Phase 3 EUCTR2006-000945-20-GB United Kingdom;
Meropenem
Imperial College London
2010 Phase 4 NCT01044719 United Kingdom;
Imperial College, London
2009 - EUCTR2009-014042-28-GB United Kingdom;
Joseph Kuti
2012 Phase 4 NCT01429259 United States;
University Ghent
2016 - NCT02840136 Belgium;
Meropenem Fresenius Kabi 1 g poeder voor oplossing voor injectie of infusie
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
Meropenem Infusion
St. Michael's Hospital, Toronto
2010 - NCT01158937 Canada;
Mesenchymal Stem Cells
Erica Roesch
2016 Phase 1 NCT02866721 United States;
Metformin Hydrochloride
University of Kansas Medical Center
2022 Phase 2 NCT04530383 United States;
Metformine HCL 500 PCH
Staf Longziekten
2009 - EUCTR2009-009875-37-NL Netherlands;
Miglustat
Actelion
2008 Phase 2 NCT00742092 Belgium;
2007 Phase 2 NCT00537602 Spain;
Actelion Pharmaceuticals Ltd
2008 - EUCTR2008-002352-20-BE Belgium;
2007 - EUCTR2006-002049-35-ES Spain;
Assistance Publique - Hôpitaux de Paris
2015 Phase 2/Phase 3 NCT02325362 France;
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2009 Phase 2 NCT00945347 Belgium;
Minocycline
University of North Carolina, Chapel Hill
2018 Phase 2 NCT03489629 United States;
2011 Phase 2 NCT01349192 United States;
Modified Oral Glucose Tolerance Test (50g 4-hours)
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Modified lipid formulation
Nestlé
2016 - NCT02646995 Switzerland;
Molgramostim
Savara Inc.
2015 Phase 1 NCT02468908 United Kingdom;
Molgramostim nebulizer solution
Savara Inc.
2019 Phase 2 NCT03597347 United States;
Moli 1901 (2622U90, duramycin)
AOP Orphan Pharmaceuticals AG
2007 Phase 2;Phase 3 EUCTR2006-006693-24-FR Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
Moli1901
AOP Orphan Pharmaceuticals AG
2007 Phase 2 NCT00671736 Austria;
2006 Phase 2;Phase 3 EUCTR2005-005594-29-SK Czech Republic;Hungary;Slovakia;
2006 - EUCTR2005-005594-29-HU Czech Republic;Hungary;
2006 - EUCTR2005-005594-29-CZ Czech Republic;Hungary;
Moli1901 (2622U90, duramycin)
AOP Orphan Pharmaceuticals AG
2008 Phase 2;Phase 3 EUCTR2006-006693-24-ES Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
2008 - EUCTR2006-006693-24-CZ Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
2007 Phase 2;Phase 3 EUCTR2006-006693-24-DE Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
2007 - EUCTR2006-006693-24-SE Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
2007 - EUCTR2006-006693-24-HU Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
2007 - EUCTR2006-006693-24-AT Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
2006 - EUCTR2005-004344-30-HU Hungary;
2005 - EUCTR2005-004344-30-AT Austria;Hungary;
- Phase 2 EUCTR2006-006693-24-PL Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
Moxifloxacin hydrochloride
Vertex Pharmaceuticals Incorporated
2013 Phase 1 NCT01910415 Netherlands;
Mucoid exopolysaccharide P. aeruginosa immune globulin IV
National Center for Research Resources (NCRR)
1995 Phase 2 NCT00004747 -
Mucolysin
Aarhus University Hospital
2016 Phase 2 EUCTR2016-000354-35-DK Denmark;
2014 Phase 2 EUCTR2013-005481-19-DK Denmark;
Mucomyst
Aarhus University Hospital
2014 Phase 2 EUCTR2013-005481-19-DK Denmark;
Multienzymes (lipase, protease etc.)
ALTUS PHARMACEUTICALS INC
2007 - EUCTR2007-000178-21-IT Italy;
2007 - EUCTR2007-000171-41-IT Italy;
EURAND SPA
2010 - EUCTR2009-012842-21-IT Bulgaria;Germany;Hungary;Italy;United Kingdom;
Mupirocin
University of North Carolina, Chapel Hill
2018 Phase 2 NCT03489629 United States;
2011 Phase 2 NCT01349192 United States;
Mupirocin Intranasal Creme
Johns Hopkins University
2012 Phase 2 NCT01594827 United States;
N-(5-hydroxy-2,4- bis(trimethylsilyl)phenyl)-4-oxo- 1,4-dihydroquinoline-3-carboxamide
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
N-acetylcystein
Rigshospitalet
2010 Phase 4 EUCTR2007-001401-15-DK Denmark;
N-acetylcysteine
Qilu Hospital of Shandong University
2014 - NCT02088216 China;
University Hospital Ghent
2009 - EUCTR2008-008317-20-BE Belgium;
N-acetylcysteine (NAC)
Stanford University
2008 Phase 2 NCT00809094 United States;
N6022
Nivalis Therapeutics, Inc.
2014 Phase 1 NCT01746784 United States;
N91115
Nivalis Therapeutics, Inc.
2015 Phase 1 NCT02275936 United States;
2014 Phase 1 NCT02227888 United States;
NAL
LABORATOIRES SMB S.A.
2010 - EUCTR2010-018454-13-IT Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
Laboratoires SMB S.A.
2010 Phase 3 EUCTR2010-018454-13-FR Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018454-13-ES Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018454-13-DK Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-HU Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-GB Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-DE Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-CZ Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
- Phase 3 EUCTR2010-018454-13-BE Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
NEB/01-07
Laboratoire Erempharma
2008 - EUCTR2007-003868-22-FR France;
NEBCINE
CHRU de Lille
- Phase 2 EUCTR2014-003882-10-FR France;
NO
Southampton University Hopsitals NHS Trust
2011 - EUCTR2010-023529-39-GB United Kingdom;
NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
2020 Phase 2;Phase 3 EUCTR2019-004511-31-IT Czech Republic;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
NOXAFIL - 40 mg/ml oral suspension
Bambino Gesù Children's Hospital
- Phase 2;Phase 3 EUCTR2019-004511-31-IE Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
NOXAFIL - oral suspension 40 mg/ml
Bambino Gesù Children's Hospital
2022 Phase 2;Phase 3 EUCTR2019-004511-31-NL Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
2022 Phase 2;Phase 3 EUCTR2019-004511-31-DE Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
2021 Phase 2;Phase 3 EUCTR2019-004511-31-PT Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
2021 Phase 2;Phase 3 EUCTR2019-004511-31-GR Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
- Phase 2;Phase 3 EUCTR2019-004511-31-FR Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
Bambino Gesù Children´s Hospital
2022 Phase 2;Phase 3 EUCTR2019-004511-31-ES Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
NR
Virginia Commonwealth University
2020 - NCT04166396 United States;
NaCl
University of North Carolina
2001 Phase 2 NCT00274391 United States;
NaCl/Inhalation solution
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
NaCl/inhalation solution
Vertex Pharmaceuticals Inc.
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
Nacystelyn
LABORATOIRES SMB S.A.
2010 - EUCTR2010-018454-13-IT Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
Nacystelyn®
Laboratoires SMB S.A.
2010 Phase 3 EUCTR2010-018454-13-FR Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018454-13-ES Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018454-13-DK Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-HU Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-GB Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-DE Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
2010 - EUCTR2010-018454-13-CZ Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
- Phase 3 EUCTR2010-018454-13-BE Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
Nasal Aztreonam
Virginia Commonwealth University
2017 Phase 2 NCT02730793 United States;
Navocaftor
AbbVie
2021 Phase 2 NCT04853368 Australia;Belgium;Czechia;Germany;Hungary;Netherlands;New Zealand;Slovakia;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-005805-25-NL Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
2021 Phase 2 EUCTR2020-005805-25-HU Hungary;
2021 Phase 2 EUCTR2020-005805-25-BE Belgium;Hungary;Netherlands;
Nebcin
University Hospital, Lille
2017 Phase 3 NCT03066453 France;
Nebcin (tobramycin)
The Univeristy of Nottingham
2010 Phase 4 EUCTR2010-023030-23-GB United Kingdom;
Nebcinal
EREMPHARMA SAS
- Phase 1 EUCTR2010-023533-34-FR France;
Erempharma SAS
2009 - EUCTR2009-013660-39-FR France;
Nebcinal Tobi
Erempharma
2010 - NCT01288170 France;
Nebulization of Amikacin during NIV (RR: 15 cycles/minute)
University Hospital St Luc, Brussels
2014 - NCT02084043 Belgium;Switzerland;
Nebulization of Amikacin during NIV (RR: 25 cycles/minute)
University Hospital St Luc, Brussels
2014 - NCT02084043 Belgium;Switzerland;
Nebulization tobramycin
University Medical Center Groningen
- Phase 2 EUCTR2016-005014-21-NL Netherlands;
Nexium 20
Biovitrum AB
2008 - EUCTR2007-004063-21-NL Netherlands;
Nitric Oxide
Southampton University Hopsitals NHS Trust
2011 - EUCTR2010-023529-39-GB United Kingdom;
University Hospital Southampton NHS Foundation Trust.
2011 Phase 2 NCT02295566 United Kingdom;
Nitric Oxide 160 ppm
Novoteris, LLC
2017 Phase 2 NCT02498535 Canada;United States;
Nitric Oxide for Inhalation
Mallinckrodt
2004 Phase 1/Phase 2 NCT00570349 United States;
Nitrogen
Mallinckrodt
2004 Phase 1/Phase 2 NCT00570349 United States;
Nocturnal oxygen , nocturnal bi-level positive pressure ventilation
Bayside Health
2003 Phase 1/Phase 2 NCT00157183 Australia;
Non invasive ventilation
Karolinska University Hospital
2016 - NCT02684552 Sweden;
None
AstraZeneca AB
2009 - EUCTR2008-001530-27-GB Denmark;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-001530-27-DK Denmark;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-001530-27-SE Denmark;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-001530-27-DE Denmark;Germany;Sweden;United Kingdom;
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
University of Nottingham
2008 Phase 4 EUCTR2007-006204-37-GB United Kingdom;
None assigned
Aradigm Corporation
2010 Phase 2 EUCTR2009-014412-35-DE Germany;United Kingdom;
2010 - EUCTR2009-014412-35-GB Germany;United Kingdom;
Noninvasive ventilation
St. Michael's Hospital, Toronto
2014 - NCT02262871 Canada;
Normal Saline
University of Washington
2016 Phase 2 NCT02354859 United States;
Normal saline
Nivalis Therapeutics, Inc.
2014 Phase 1 NCT01746784 United States;
Qilu Hospital of Shandong University
2014 Phase 4 NCT02081963 China;
Translate Bio, Inc.
2018 Phase 1/Phase 2 NCT03375047 United States;
University Hospital, Ghent
2010 Phase 4 NCT00996424 Belgium;
Normal saline IV, salt tablets
Bayside Health
2004 Phase 2/Phase 3 NCT00163852 Australia;
Normal saline solution
University Hospital Ghent
2007 - EUCTR2007-002707-40-BE Belgium;
Normal saline:
University of Oklahoma
2006 - NCT00671723 United States;
Norvir 100 mg film-coated tablets
university medical center utrecht
2018 Phase 4 EUCTR2016-001440-18-NL Netherlands;
Novo Rapid
Papworth Hospital NHS Foundation Trust
2005 Phase 4 EUCTR2004-005019-28-GB United Kingdom;
Novo Rapid Insulin (Novonordisk)
Hadassah Medical Organization
2010 - NCT01149005 Israel;
NovoNorm
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2006 - EUCTR2006-001254-27-FR France;
NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen.
St George's, University of London
2008 - EUCTR2007-004956-35-GB United Kingdom;
NovoRapid Aspartate
Papworth Hospital NHS Foundation Trust
2005 Phase 4 EUCTR2004-005019-28-GB United Kingdom;
Novolog insulin
University of Minnesota
2015 Phase 2/Phase 3 NCT02496780 United States;
Novorapid / humalog short acting insulin
Hadassah Medical Organization
2010 - NCT01149005 Israel;
Noxafil
MSD
2012 - EUCTR2012-003140-68-GB United Kingdom;
Noxafil - oral suspension 40 mg/ml
Bambino Gesù Children's Hospital
- Phase 2;Phase 3 EUCTR2019-004511-31-GB Czech Republic;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
Noxafil 100 mg Tablets Gastro-Resistant
Bambino Gesù Children's Hospital
- Phase 2;Phase 3 EUCTR2019-004511-31-IE Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
Noxafil®
Karolinska University Hospital, Stockholm CF center
2018 Phase 2 EUCTR2018-002579-16-SE Sweden;
Nutridrink-Impact
University Hospital, Motol
2013 Phase 4 NCT02048592 Czech Republic;
Nutropin AQ
University of Massachusetts, Worcester
2008 Phase 1 NCT00803179 United States;
University of Texas Southwestern Medical Center
2000 Phase 2/Phase 3 NCT00256555 -
Nutropin AQ [somatropin (DNA origin) injection]
Genentech, Inc.
2003 Phase 2 NCT00079742 United States;
OGT 918
Actelion Pharmaceuticals Ltd
2007 - EUCTR2006-002049-35-ES Spain;
OSCN-
Alaxia SAS
2015 Phase 1 NCT02598999 France;
Oleic acid supplementation
Karolinska Institutet
2021 - NCT04531410 Italy;Norway;Poland;Sweden;
OligoG (60 mg/ml)
AlgiPharma AS
2011 Phase 2 EUCTR2010-023090-19-GB Ireland;United Kingdom;
2011 - EUCTR2010-023090-19-IE Ireland;United Kingdom;
OligoG CF-5/20
AlgiPharma AS
2011 Phase 1/Phase 2 NCT01465529 Ireland;United Kingdom;
2009 Phase 1 NCT00970346 United Kingdom;
OligoG CF-5/20 -
AlgiPharma AS
2020 Phase 2 EUCTR2018-000378-30-GB Austria;Germany;Ireland;Poland;United Kingdom;
- Phase 2 EUCTR2018-000378-30-IE Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF-5/20, 17,5 mg, Hartkapsel mit Pulver zur Inhalation
AlgiPharma AS
2020 Phase 2 EUCTR2018-000378-30-DE Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF/20 -
AlgiPharma AS
2020 Phase 2 EUCTR2018-000378-30-GB Austria;Germany;Ireland;Poland;United Kingdom;
- Phase 2 EUCTR2018-000378-30-IE Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF/20, 27,5 mg, Hartkapsel mit Pulver zur Inhalation
AlgiPharma AS
2020 Phase 2 EUCTR2018-000378-30-DE Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF/20, 37,5 mg, Hartkapsel mit Pulver zur Inhalation
AlgiPharma AS
2020 Phase 2 EUCTR2018-000378-30-DE Austria;Germany;Ireland;Poland;United Kingdom;
OligoG DPI
AlgiPharma AS
2019 Phase 2 NCT03822455 Australia;
OligoG Dry powder for inhalation
AlgiPharma AS
2020 Phase 2/Phase 3 NCT03698448 Germany;
OligoG-CF5/20, Alginate oligosaccharide (G-block) fragment
AlgiPharma AS
2011 Phase 2 EUCTR2010-023090-19-GB Ireland;United Kingdom;
Oligomer of Sodium Alginate
Algipharma AS
2014 Phase 2 EUCTR2014-002125-35-DE Germany;
2014 Phase 2 EUCTR2014-000844-13-SE Denmark;Germany;Sweden;
2014 Phase 2 EUCTR2014-000844-13-DK Denmark;Germany;Sweden;
Omadacycline Injection [Nuzyra]
Paul Beringer
2021 Phase 4 NCT04460586 United States;
Omadacycline Oral Tablet [Nuzyra]
Paul Beringer
2021 Phase 4 NCT04460586 United States;
Omalizumab
NOVARTIS FARMA
2009 - EUCTR2007-006648-23-IT Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Novartis Pharma Services AG
2009 - EUCTR2007-006648-23-GB Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-006648-23-DE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-006648-23-BE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Novartis Pharmaceuticals
2008 Phase 4 NCT00787917 Belgium;Germany;Italy;Netherlands;United Kingdom;
Omega 3 Premium
Hôpital Universitaire Des Enfants Reine Fabiola (H.U.D.E.R.F.)
2008 - EUCTR2006-004155-38-BE Belgium;
Omega-3 triglycerides
Queen Fabiola Children's University Hospital
2008 Phase 3 NCT00959010 Belgium;
Omeprazole 40mg Capsule
Children's Hospital of Philadelphia
2018 Phase 2 NCT03551691 United States;
Once-daily insulin detemir
Sydney Children's Hospitals Network
2010 Phase 3 NCT01100892 Australia;United States;
Oral Aztreonam
Virginia Commonwealth University
2017 Phase 2 NCT02730793 United States;
Oral Glucose Tolerance Test
University of Texas Southwestern Medical Center
2006 - NCT00287456 United States;
Oral Glucose Tolerance test (75g 2-hour)
Liverpool Heart and Chest Hospital NHS Foundation Trust
2013 - NCT01975259 United Kingdom;
Oral Glucose tolerance test
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
Oral Glutathione
University of Minnesota
2017 Phase 2 NCT03020719 United States;
Oral ciprofloxacin
Seattle Children's Hospital
2004 Phase 2 NCT00097773 United States;
Oral ciprofloxacin plus inhaled colistin
Universitaire Ziekenhuizen Leuven
2001 Phase 4 NCT01400750 Belgium;
Oral reduced l-glutathione
Clark Bishop
2011 - NCT02029521 Italy;
Oral roflumilast
The University of Hong Kong
2018 Phase 2 NCT03428334 Hong Kong;
Orkambi
Antwerp University Hospital
2018 Phase 4 EUCTR2018-001573-24-BE Belgium;
Assistance Publique - Hôpitaux de Paris
2019 - NCT03894657 France;
Children's Hospital of Philadelphia
2019 - NCT03795363 United States;
Parion Sciences
2016 Phase 2 NCT02709109 France;Ireland;United Kingdom;United States;
University Hospital, Antwerp
2018 Phase 4 NCT03956589 Belgium;
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incoporated
2017 Phase 4 EUCTR2016-004996-33-ES Australia;Canada;Spain;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
2016 Phase 4 EUCTR2016-000066-34-GB Australia;United Kingdom;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
Orkambi 100 mg/125 mg film-coated tablets
Vertex Pharmaceuticals Incorporated
2018 Phase 2 EUCTR2017-003761-99-DE Germany;
Orkambi 200 mg/125 mg film-coated tablets
Vertex Pharmaceuticals Incorporated
2016 Phase 2 EUCTR2016-001585-29-NL Netherlands;
Orkambi: contains lumacaftor and ivacaftor
Orkambi®
ASSISTANC-PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
- Phase 4 EUCTR2018-002624-16-FR France;
Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/
University of Pennsylvania
2014 Phase 1 NCT02144246 United States;
Oseltamivir
Inserm
2009 - EUCTR2009-016662-90-FR France;
Other non-sponsor pancreatic enzyme replacement therapy
AbbVie
2012 - NCT01652157 United States;
Other respiratory system products
DEBIOPHARM S.A.
2005 - EUCTR2004-002341-12-IT Belgium;Germany;Italy;United Kingdom;
Oxygen
Assistance Publique - Hôpitaux de Paris
2012 - NCT01586728 France;
Karolinska University Hospital
2016 - NCT02684552 Sweden;
P-1037
Parion Sciences
2015 Phase 2 NCT02343445 United States;
PAAG15
Synspira Therapeutics, Inc.
2019 Phase 2 EUCTR2019-003178-25-HU Hungary;
PANCREASE MT
Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
- - EUCTR2015-001219-11-Outside-EU/EEA Canada;United States;
PANCREASLIPASE
Aptalis Pharma US Inc.
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
PANCREATIN (PAncreas Powder)
Abbott Laboratories GmbH
2015 - EUCTR2014-004519-35-GB Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-CZ Czech Republic;Hungary;Spain;United Kingdom;
PANCREATIN (Pancreas Powder)
Abbott Laboratories GmbH
2015 - EUCTR2014-004519-35-HU Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-GB Czech Republic;Hungary;Spain;United Kingdom;
2015 - EUCTR2014-004519-35-CZ Czech Republic;Hungary;Spain;United Kingdom;
PANCREATINA
Abbott Laboratories GmbH
2013 - EUCTR2013-002819-10-ES Hungary;Russian Federation;Spain;
PANCREATINA (Páncreas Polvo)
Abbott Laboratories GmbH
2015 Phase 2 EUCTR2014-004519-35-ES Czech Republic;Hungary;Spain;United Kingdom;
PANCREAZE
AbbVie
2012 - NCT01652157 United States;
PANCREAZE®
ANTHERA Pharmaceuticals, Inc.
2017 Phase 3 EUCTR2017-000571-85-LT Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-HU Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-GB Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000571-85-ES Hungary;Israel;Lithuania;Poland;Spain;United States;
2016 Phase 3 EUCTR2015-002739-17-CZ Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-HU Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-ES Canada;Czech Republic;Hungary;Israel;Spain;United States;
- Phase 3 EUCTR2017-000571-85-PL Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
PANCRECARB® (pancrelipase)
Digestive Care, Inc.
2007 Phase 3 NCT00432861 United States;
PANZYTRAT 25000
Axcan Pharma Inc.
- - EUCTR2010-019267-11-DE Germany;
PARI eFlow nebulizer system
Savara Inc.
2019 Phase 2 NCT03597347 United States;
PBI4050
Liminal BioSciences Ltd.
2017 Phase 2 NCT02955888 Canada;
PC945
Pulmocide Ltd
2019 Phase 2 NCT03870841 United Kingdom;
2018 Phase 2 EUCTR2018-000243-87-GB United Kingdom;
PERTZYE
AbbVie
2012 - NCT01652157 United States;
PFP
University of North Carolina, Chapel Hill
2018 Early Phase 1 NCT03482960 United States;
2015 Early Phase 1 NCT03489590 United States;
PFP and SF6 Human Lung Coil
Thunder Bay Regional Research Institute
2019 Early Phase 1 NCT02748798 Canada;
PFT
Indiana University
2018 - NCT03579173 United States;
PGM169/GL67A
Imperial College
2012 Phase 2 EUCTR2011-004761-33-GB United Kingdom;
2008 - EUCTR2007-004050-85-GB United Kingdom;
Imperial College London
2012 Phase 2 NCT01621867 United Kingdom;
2008 Phase 1/Phase 2 NCT00789867 United Kingdom;
PIPERACILLIN SODIUM
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
PL 0010/0211
Southampton University Hospital Trust
2008 - EUCTR2008-001769-27-GB United Kingdom;
PO azithromycin
Seattle Children's Hospital
2004 - NCT00153634 United States;
PO ciprofloxacin
Seattle Children's Hospital
2004 - NCT00153634 United States;
POL6014
Santhera Pharmaceuticals
2018 Phase 1/Phase 2 NCT03748199 Germany;
Santhera Pharmaceuticals (Switzerland) Ltd
2018 Phase 1;Phase 2 EUCTR2018-002550-71-DE Germany;
2017 Phase 1;Phase 2 EUCTR2016-005110-22-DE Germany;
POL7080
Polyphor Ltd.
2014 Phase 2 EUCTR2013-002202-31-DE Germany;Spain;United Kingdom;
2013 Phase 2 NCT02096315 Spain;United Kingdom;
2013 Phase 2 EUCTR2013-002202-31-GB Germany;Spain;United Kingdom;
2013 - EUCTR2013-002202-31-ES Germany;Spain;United Kingdom;
PPI treatment
University of Colorado, Denver
2017 - NCT02769637 United States;
PREFOLIC*30CPR GASTROR
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
2010 - EUCTR2010-020516-11-IT Italy;
PROMIXIN*NEBUL 30MONOD 1MUI
AZIENDA OSPEDALIERA MEYER
2011 - EUCTR2011-006171-19-IT Italy;
PROTEASA
ANTHERA Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2016-002851-92-ES Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
PROTEASE
ANTHERA Pharmaceuticals, Inc.
2017 Phase 3 EUCTR2017-000571-85-LT Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-HU Hungary;Israel;Lithuania;Poland;Spain;United States;
2017 Phase 3 EUCTR2017-000571-85-GB Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000571-85-ES Hungary;Israel;Lithuania;Poland;Spain;United States;
2016 Phase 4 EUCTR2016-002851-92-CZ Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
2016 Phase 3 EUCTR2016-002851-92-HU Canada;Hungary;Israel;Spain;United States;
2016 Phase 3 EUCTR2015-002739-17-CZ Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-HU Canada;Czech Republic;Hungary;Israel;Spain;United States;
2015 Phase 3 EUCTR2015-002739-17-ES Canada;Czech Republic;Hungary;Israel;Spain;United States;
- Phase 3 EUCTR2017-000571-85-PL Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2016-002851-92-PL Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
PTC-0161480
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC-124
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC-C124
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC124
PTC THERAPEUTICS, INC.
2010 - EUCTR2010-019692-30-IT Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-IT Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC Therapeutics
2006 Phase 2 NCT00351078 Israel;
2005 Phase 2 NCT00234663 United States;
PTC Therapeutics, Inc
2011 Phase 3 EUCTR2010-019692-30-GB Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019692-30-ES Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-019692-30-DE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2010 - EUCTR2010-019692-30-SE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 - EUCTR2010-019692-30-NL Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 - EUCTR2010-019692-30-BE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-BE Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC Therapeutics, Inc.
2016 Phase 3 EUCTR2014-005355-83-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-GR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005355-83-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-FR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005355-83-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005449-35-FR Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2015 Phase 3 EUCTR2013-004581-34-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-GR Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004581-34-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005449-35-SE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-IT Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-ES Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-DE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-005449-35-BE Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
2014 Phase 3 EUCTR2013-004581-34-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004581-34-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2007 - EUCTR2007-000724-40-BE Belgium;
PTI-428
Proteostasis Therapeutics
2017 Phase 1;Phase 2 EUCTR2016-001214-24-DK Canada;Czech Republic;Denmark;France;Germany;Italy;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2016-001214-24-DE Canada;Czech Republic;Denmark;France;Germany;Italy;United Kingdom;United States;
Proteostasis Therapeutics, Inc.
2018 Phase 2 NCT03591094 United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1/Phase 2 NCT03500263 United Kingdom;
2017 Phase 1/Phase 2 NCT03251092 Australia;Belgium;Canada;Denmark;France;Germany;New Zealand;United Kingdom;United States;
2017 Phase 1 NCT03258424 United Kingdom;
2016 Phase 1/Phase 2 NCT02718495 Canada;Czechia;Denmark;France;Germany;United Kingdom;United States;
PTI-801
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1/Phase 2 NCT03500263 United Kingdom;
2017 Phase 1/Phase 2 NCT03251092 Australia;Belgium;Canada;Denmark;France;Germany;New Zealand;United Kingdom;United States;
2017 Phase 1 NCT03140527 Canada;Denmark;Germany;Portugal;Sweden;United States;
PTI-808
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1/Phase 2 NCT03500263 United Kingdom;
2017 Phase 1/Phase 2 NCT03251092 Australia;Belgium;Canada;Denmark;France;Germany;New Zealand;United Kingdom;United States;
2017 Phase 1 NCT03140527 Canada;Denmark;Germany;Portugal;Sweden;United States;
PUR118
Pulmatrix Inc.
2012 Phase 1 NCT01543191 United Kingdom;
Pancreas Powder
Aptalis Pharma US Inc.
2013 - EUCTR2009-012842-21-HU Bulgaria;Germany;Hungary;Italy;United Kingdom;
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-DE Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-BG Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
Axcan Pharma Inc.
- - EUCTR2010-019267-11-DE Germany;
Pancrease MT 10.5, or MT 21
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008 Phase 3 NCT00662675 Canada;United States;
Pancreatin
Abbott Products
2012 Phase 3 NCT01747330 Russian Federation;
McNeil Consumer and Specialty Pharmaceuticals
- Phase 2 EUCTR2005-001438-34-BE Belgium;
Pancrelipase
AbbVie
2019 Phase 4 NCT03924947 Spain;United States;
Digestive Care, Inc.
2008 Phase 4 NCT00744250 United States;
University of Colorado, Denver
2014 - NCT02372383 United States;
Pancrelipase Delayed Release
Solvay Pharmaceuticals
2009 Phase 3 NCT00775528 United States;
2008 Phase 3 NCT00690820 United States;
2007 Phase 3 NCT00510484 Hungary;Israel;South Africa;Spain;United States;
Pancrelipase Delayed Release Capsule
Solvay Pharmaceuticals GmbH
2008 - EUCTR2007-004004-12-BG Bulgaria;
Pancrelipase Microtablets
McNeil Consumer and Specialty Pharmaceuticals
- Phase 2 EUCTR2005-001438-34-BE Belgium;
Pancrelipase microtablets
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
2005 Phase 2 NCT00217204 Belgium;Netherlands;
Pancrelipase with bicarbonate
National Center for Research Resources (NCRR)
1999 - NCT00006063 -
Pancrelipase/Pancreas Powder
Solvay Pharmaceuticals GmbH
2008 - EUCTR2007-004004-12-BG Bulgaria;
Pankreatin
Terese Katzenstein
2020 Phase 4 EUCTR2019-004940-31-DK Denmark;
Panzytrat® 25,000
Forest Laboratories
2011 Phase 4 NCT01327703 Germany;Poland;
Panzytrat® ok
McNeil Consumer and Specialty Pharmaceuticals
- Phase 2 EUCTR2005-001438-34-BE Belgium;
Perfluorinated gas/oxygen mixture
Hal C Charles
2009 Phase 1 NCT01710449 United States;
Perform three multiple breath nitrogen washout tests (N2-MBW-test)
Universitair Ziekenhuis Brussel
2017 - NCT02950116 Belgium;
Physiologic serum nebulized nasally
Virginie ESCABASSE
2017 Phase 3 NCT02888730 France;
Physiological solution
Serafino A. Marsico
2010 Phase 3 NCT01450267 Italy;
Physiotherapy, exercise, percutaneous gastrostomy feeds
Bayside Health
2001 - NCT00164021 Australia;
Pilocarpine
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2017 - NCT03584841 Belgium;
Pilocarpine Iontophoresis
Emory University
2022 - NCT04732195 United States;
Pilocarpine Nitrate
Richard Barry Moss
2015 - NCT02310789 United States;
Pilocarpine microneedle patch
Emory University
2022 - NCT04732195 United States;
Pioglitazone
Paul Beringer
2008 Phase 1 NCT00719381 United States;
University Hospitals Cleveland Medical Center
2007 - NCT00531882 United States;
2006 - NCT00322868 United States;
Piperacillin sodium , tazobactam sodium
COP:TRIN Region Hovedstaden (Gentofte hospital)
2017 Phase 4 EUCTR2015-003399-58-DK Denmark;
Piperacillin with Tazobactam (tazocin)
Aarhus University Hospital, Department of Respiratory Medicine
2015 Phase 2 EUCTR2015-003662-87-DK Denmark;
Piperacillin-tazobactam combination product
University Ghent
2016 - NCT02840136 Belgium;
West Virginia University
2012 Phase 4 NCT01694069 United States;
Piperacillin/Tazobactam
COP:TRIN Region Hovedstaden (Gentofte hospital)
2017 Phase 4 EUCTR2015-003399-58-DK Denmark;
Piperacillin/Tazobactam Kabi - Fresenius Kabi Austria
Medical University of Vienna
2020 Phase 4 EUCTR2019-000955-16-AT Austria;
Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
Plerixafor mobilization of autologous CD117 stem cells
University of Colorado, Denver
2013 Phase 1 NCT01916577 United States;
Polyethylene Glycol 3350
St. Louis University
2019 Phase 4 NCT04210427 United States;
Porcine (pig) PERT
Anthera Pharmaceuticals
2015 Phase 3 NCT02279498 Canada;Czech Republic;Czechia;Hungary;Israel;Poland;Spain;United States;
Porcine PERT
Anthera Pharmaceuticals
2017 Phase 3 NCT03051490 Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
AzurRx BioPharma, Inc.
2020 Phase 2 NCT04375878 Poland;United States;
2019 Phase 2 NCT03746483 Poland;United States;
Posaconazole
Bambino Gesù Children's Hospital
2022 Phase 2;Phase 3 EUCTR2019-004511-31-DE Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
Bayside Health
2018 - NCT03421366 Australia;
MSD
2012 - EUCTR2012-003140-68-GB United Kingdom;
Posaconazole 100 MG [Noxafil]
Bambino Gesù Hospital and Research Institute
2021 Phase 2/Phase 3 NCT04966234 Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Switzerland;United Kingdom;
Posaconazole 40 MG/ML
Bambino Gesù Hospital and Research Institute
2021 Phase 2/Phase 3 NCT04966234 Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Switzerland;United Kingdom;
Positive expiratory pressure
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2015 - NCT02535130 Belgium;
Prednisolone
Birmingham Children's Hospital NHS Foundation Trust
2012 - EUCTR2011-005790-23-GB United Kingdom;
Prednisone
The Hospital for Sick Children
2017 Phase 3 NCT03070522 Canada;
Prograft capsules
Hopital Erasme - Chest service
2009 - EUCTR2009-014050-15-BE Belgium;
Prolastin (drug)
Université de Sherbrooke
2004 Phase 2 NCT02010411 Canada;
Promixin
ZAMBON SPA
2020 Phase 3 EUCTR2016-004558-13-IT Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
Promixin 1 million International Units (IU) Powder for Nebuliser Solution
Profile Pharma Ltd
2010 - EUCTR2008-005045-34-IE Ireland;United Kingdom;
2008 Phase 3 EUCTR2008-005045-34-GB Ireland;Russian Federation;Ukraine;United Kingdom;
Promixin, 1 million International Units (IU) Powder for Nebuliser Solution
Zambon S.p.A.
2020 Phase 3 EUCTR2016-004558-13-PT Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
2020 Phase 3 EUCTR2016-004558-13-GR Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
2020 Phase 3 EUCTR2016-004558-13-DE Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
2017 Phase 3 EUCTR2016-004558-13-PL Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
2017 Phase 3 EUCTR2016-004558-13-FR Canada;France;Poland;United States;
Promixin,1 millón de Unidades Internacionales,polvo para solución para inhalación por nebulizador
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-001565-33-ES Germany;Ireland;Spain;Switzerland;United Kingdom;
Promixin/Tadim
ZAMBON SPA
2017 Phase 3 EUCTR2015-002743-33-IT Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Zambon S.p.A.
2018 Phase 3 EUCTR2015-002743-33-NL Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2015-002743-33-GR Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2015-002743-33-PT Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2015-002743-33-GB Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2015-002743-33-ES Belgium;Germany;Italy;Portugal;Spain;United Kingdom;
2017 Phase 3 EUCTR2015-002743-33-DE Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Protease
Altus Pharmaceuticals Inc
2007 Phase 3 EUCTR2007-000171-41-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000171-41-PL Italy;Poland;Slovakia;
Altus Pharmaceuticals Inc.
2007 Phase 3 EUCTR2007-000178-21-SK Italy;Slovakia;
- Phase 3 EUCTR2007-000178-21-PL Italy;Poland;Slovakia;
PsAer IgY
MUKOVISZIDOSE E.V.
2012 Phase 3 EUCTR2011-000801-39-IT Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
Mukoviszidose Institute gGmbH
2014 Phase 3 EUCTR2011-000801-39-HU Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2014 Phase 3 EUCTR2011-000801-39-ES Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2014 Phase 3 EUCTR2011-000801-39-AT Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2013 Phase 3 EUCTR2011-000801-39-IE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2012 Phase 3 EUCTR2011-000801-39-SE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2012 Phase 3 EUCTR2011-000801-39-BE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
2011 Phase 3 EUCTR2011-000801-39-DE Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
Pulmaquin®
Aradigm Corporation
2015 Phase 3 EUCTR2013-005366-19-PL Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005366-19-FR Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005348-28-PL Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-RO Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-IT Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-HU Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-GB Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005366-19-ES Australia;Canada;France;Germany;Hungary;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-RO Australia;Canada;Georgia;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-LV Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-IT Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-IE Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-HU Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-GB Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-005348-28-ES Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
Pulmonary Function Testing
The Hospital for Sick Children
2010 - NCT01155115 Canada;
Pulmonary function testing.
University of Florida
2007 - NCT01851642 United States;
Pulmozyme
F. Hoffmann-La Roche AG
- Phase 4 EUCTR2015-003537-99-Outside-EU/EEA United States;
University Hospital, Tours
2009 Phase 4 NCT00843817 France;
University of Jena
2005 Phase 3 NCT00265434 Germany;
- Phase 3 EUCTR2007-001548-36-DE Germany;
Pulmozyme (Dornase alpha)
ErasmusMC - Sophia Children's Hospital
- - EUCTR2007-000935-25-NL Netherlands;
Pulmozyme (dornase alfa)
Pharmaxis Ltd
2004 Phase 2 EUCTR2004-001888-21-GB United Kingdom;
University of Vermont
2006 Phase 2 NCT00416182 United States;
Pulmozyme single use ampule
Milton S. Hershey Medical Center
2013 Phase 3 NCT01155752 United States;
Pulmozyme®
AO GENERIUM
2017 Phase 3 NCT04468100 Russian Federation;
QAU145
Novartis Pharmaceuticals
2007 Phase 2 NCT00506792 United States;
QBW251
Novartis Pharma AG
2021 Phase 2 EUCTR2019-002840-26-DE China;Germany;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002840-26-GB China;Germany;Spain;United Kingdom;
Novartis Pharma Services AG
2015 - EUCTR2011-005085-37-FR Belgium;France;Germany;Ireland;United Kingdom;United States;
2015 - EUCTR2011-005085-37-BE Belgium;France;Ireland;United Kingdom;United States;
2014 Phase 1;Phase 2 EUCTR2011-005085-37-DE Belgium;France;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2011-005085-37-IE Belgium;France;Ireland;United Kingdom;United States;
2012 Phase 1;Phase 2 EUCTR2011-005085-37-GB Belgium;France;Germany;Ireland;Netherlands;Romania;United Kingdom;United States;
Novartis Pharmaceuticals
2012 Phase 1/Phase 2 NCT02190604 Belgium;France;Germany;Ireland;Netherlands;Romania;United Kingdom;United States;
QBW276
Novartis Pharmaceuticals
2017 Phase 1/Phase 2 NCT02566044 Germany;United Kingdom;United States;
QBW276 1500mcg
Novartis Pharma AG
2017 Phase 1;Phase 2 EUCTR2014-004915-35-DE Germany;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2014-004915-35-GB Germany;United Kingdom;United States;
QBW276 300mcg
Novartis Pharma AG
2017 Phase 1;Phase 2 EUCTR2014-004915-35-DE Germany;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2014-004915-35-GB Germany;United Kingdom;United States;
QBW276 Succinate
Novartis Pharma AG
2017 Phase 1;Phase 2 EUCTR2014-004915-35-DE Germany;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2014-004915-35-GB Germany;United Kingdom;United States;
QR-010
ProQR Therapeutics
2015 Phase 1/Phase 2 NCT02532764 Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2015 Phase 1 NCT02564354 Belgium;France;United States;
Quercetin
University of Alabama at Birmingham
2010 Phase 2 NCT01348204 United States;
R03AC02
University Medical Centre Utrecht
2014 Phase 2 EUCTR2014-000057-37-NL Netherlands;
R03CC02
University Medical Centre Utrecht
2014 Phase 2 EUCTR2014-000057-37-NL Netherlands;
R05C B01
Rigshospitalet
2010 Phase 4 EUCTR2007-001401-15-DK Denmark;
RELiZORB (immobilized lipase) cartridge
Alcresta Therapeutics, Inc.
2016 - NCT02750501 United States;
RPL554
Verona Pharma plc
2017 Phase 2 NCT02919995 United Kingdom;
2017 Phase 2 EUCTR2015-004263-36-DE Germany;United Kingdom;
2016 Phase 2 EUCTR2015-004263-36-GB Germany;United Kingdom;
RPS 2505
PTC Therapeutics, Inc
2010 Phase 3 EUCTR2010-019692-30-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-GB Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-003924-52-FR Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-SE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-NL Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-003924-52-DE Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Radiolabelled OligoG CF-5/20 DPI
Bio-Images Research Ltd
2014 Phase 2 NCT01991028 United Kingdom;
Radiolabelled OligoG CF-5/20 Dry Powder for Inhalation (DPI)
AlgiPharma AS
2014 Phase 2 EUCTR2013-003774-27-GB United Kingdom;
Radiolabelled OligoG CF-5/20 Solution
Bio-Images Research Ltd
2014 Phase 2 NCT01991028 United Kingdom;
Radiolabelled OligoG CF-5/20 Solution for Nebulisation
AlgiPharma AS
2014 Phase 2 EUCTR2013-003774-27-GB United Kingdom;
Rapeglinide
Papworth Hospital NHS Foundation Trust
2005 Phase 4 EUCTR2004-005019-28-GB United Kingdom;
Ravicti high dose
National Jewish Health
2018 Phase 1/Phase 2 NCT02323100 United States;
Ravicti low dose
National Jewish Health
2018 Phase 1/Phase 2 NCT02323100 United States;
Recombiant human Desoxyribonuclease ( rhDNase)
University of Jena
- Phase 3 EUCTR2007-001548-36-DE Germany;
Recombinant Human DNase (Pulmozyme)
Nationwide Children's Hospital
2005 Phase 2 NCT00179998 United States;
Recombinant human IGF-1
Stony Brook University
2008 Phase 1 NCT00566241 United States;
Recombinant humanized monoclonal antibody omalizumab to IgE
Novartis Pharma Services AG
2009 - EUCTR2007-006648-23-NL Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Recombinant truncated SPINT2 protease inhibitor
Aerovance Inc
2005 Phase 1;Phase 2 EUCTR2005-000313-35-GB United Kingdom;
Red Blood Cell Zn
Indiana University
2019 - NCT04302428 United States;
Reduced glutathione
Mukoviszidose Institut gGmbH i. G.
2006 - EUCTR2005-003870-88-DE Germany;
Reduced glutathione sodium salt
Mukoviszidose Institut gGmbH
2007 Phase 2 NCT00506688 Germany;
Repaglinide
Arbelaez, Ana Maria
2006 - NCT00763412 United States;
Mukoviszidose Institut gGmbH
2001 Phase 3 NCT00662714 Austria;France;Germany;Italy;
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2001 Phase 3 NCT00072904 Canada;United States;
Repaglinide and Insulin
Children's Hospital of Philadelphia
2005 - NCT00231192 United States;
Reparixin
IST. DI RICERCHE FARMACOLOG. M. NEGRI
2010 - EUCTR2009-013340-36-IT Italy;
Resunab, ajulemic acid, anabasum
Corbus Pharmaceuticals, Inc.
2020 Phase 2;Phase 3 EUCTR2020-001762-11-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2020-001762-11-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003723-29-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2019 Phase 2 EUCTR2017-003723-29-NL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-SK Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-PT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-GR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2017-003723-29-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-001762-11-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2017-003723-29-FR Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Resveratrol
Virginia Commonwealth University
2020 - NCT04166396 United States;
RhBSSL
Biovitrum AB
2008 - EUCTR2007-004063-21-NL Netherlands;
Swedish Orphan Biovitrum
2008 Phase 2 NCT00743483 Netherlands;Poland;
RhDNAse
Pharmaxis Ltd
2004 Phase 2 EUCTR2004-001888-21-GB United Kingdom;
The Hospital for Sick Children
2008 Phase 4 NCT00557089 Canada;
Rifampin
AOU Meyer
2013 Phase 3 EUCTR2013-000219-25-IT Italy;
Johns Hopkins University
2020 Phase 4 NCT02547116 United States;
2012 Phase 2 NCT01594827 United States;
University of Colorado, Denver
2014 - NCT02372383 United States;
University of North Carolina, Chapel Hill
2011 Phase 2 NCT01349192 United States;
Vertex Pharmaceuticals Incorporated
2013 Phase 1 NCT01768663 United States;
2009 Phase 1 NCT01018368 United States;
Rimactan
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Riociguat (Adempas, BAY63-2521)
Bayer
2014 Phase 2 NCT02170025 Belgium;Canada;France;Germany;Greece;Italy;Netherlands;United Kingdom;United States;
Roflumilast
Assiut University
2019 Early Phase 1 NCT04090294 -
Prince of Songkla University
2015 Phase 3 NCT04122547 Thailand;
University of Sao Paulo General Hospital
2019 Phase 2 NCT03988816 Brazil;
Roflumilast Oral Tablet
The University of Hong Kong
2020 Phase 2 NCT04322929 Hong Kong;
Roscovitine
University Hospital, Brest
2016 Phase 2 NCT02649751 France;
Rosuvastatin calcium
University of Liverpool
2014 Phase 2 EUCTR2014-002387-32-GB United Kingdom;
Roxithromycin
First Affiliated Hospital of Guangxi Medical University
2009 - ChiCTR-TRC-13003979 China;
Répaglinide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2006 - EUCTR2006-001254-27-FR France;
S-1226
SolAeroMed Inc.
2019 Phase 2 NCT03903913 Canada;
SB-656933 Tablets
GlaxoSmithKline Research & Development Limited
2010 - EUCTR2010-018738-27-DE Germany;
SB-656933-AAA
GlaxoSmithKline Research & Development Limited
2010 - EUCTR2010-018738-27-DE Germany;
SB656933
GlaxoSmithKline
2009 Phase 2 NCT00903201 Canada;France;Germany;Israel;United States;
2008 Phase 1 NCT00605761 United States;
SE10599
University of Nottingham
2005 Phase 2 EUCTR2005-000311-98-GB United Kingdom;
SIN ASIGNAR
ANTHERA Pharmaceuticals, Inc.
2016 Phase 3 EUCTR2016-002851-92-ES Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
SLIT Amikacin
Transave, Inc
2005 - EUCTR2005-004389-17-HU Hungary;
SLIT(TM) Amikacin
Transave, Inc.
2005 - EUCTR2005-004899-21-BE Belgium;
SNSP113
Synspira Therapeutics, Inc.
2019 Phase 2 EUCTR2019-003178-25-HU Hungary;
SODIUM BICARBONATE BP
Fundació Parc Taulí
2017 Phase 2 EUCTR2016-004033-25-ES Spain;
SODIUM CHLORIDE PH. EUR.
Erasmus MC
- Phase 3 EUCTR2015-004143-39-FR Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
SODIUM CHLORIDE SOLUTION
Erasmus MC
2018 Phase 3 EUCTR2015-004143-39-IT Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2017 Phase 3 EUCTR2015-004143-39-DK Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-NL Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
2016 Phase 3 EUCTR2015-004143-39-BE Australia;Belgium;Denmark;Netherlands;Spain;United States;
SPI-1005 Ebselen 200mg Capsule x1
Sound Pharmaceuticals, Incorporated
2017 Phase 2 NCT02819856 United States;
SPI-1005 Ebselen 200mg Capsule x2
Sound Pharmaceuticals, Incorporated
2017 Phase 2 NCT02819856 United States;
SPI-1005 Ebselen 200mg Capsule x3
Sound Pharmaceuticals, Incorporated
2017 Phase 2 NCT02819856 United States;
SPX-101
SPYRYX BIOSCIENCES, INC.
2017 Phase 2 EUCTR2016-005230-30-IT Australia;Canada;France;Italy;Portugal;United Kingdom;
Spyryx Biosciences, Inc.
2017 Phase 2 NCT03229252 Canada;France;Italy;Portugal;United Kingdom;
2017 Phase 2 EUCTR2016-005230-30-PT Australia;Canada;France;Italy;Portugal;United Kingdom;
2017 Phase 2 EUCTR2016-005230-30-GB Australia;Canada;France;Italy;Portugal;United Kingdom;
2017 Phase 1 NCT03056989 Canada;
STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE ( W / V)
Erasmus MC
2017 Phase 3 EUCTR2015-004143-39-ES Australia;Denmark;Netherlands;Spain;United States;
SUB185183
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
Salbutamol
UMC Utrecht
2015 Phase 2 EUCTR2015-001317-28-NL Netherlands;
University of British Columbia
2018 - NCT03522831 Canada;
Salbutamol-ratiopharm® N metered-dose aerosol inhaler
ZAMBON SPA
2020 Phase 3 EUCTR2016-004558-13-IT Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
Salbutamol-ratiopharm® N metereddose aerosol inhaler
ZAMBON SPA
2020 Phase 3 EUCTR2016-004558-13-IT Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
Salbutamolo
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-004068-24-IT Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
Saline
AlgiPharma AS
2011 Phase 1/Phase 2 NCT01465529 Ireland;United Kingdom;
Joseph Zabner
2013 Phase 1/Phase 2 NCT00928135 United States;
Lakshmi Durairaj
2017 Phase 1 NCT03078088 United States;
Parion Sciences
2016 Phase 2 NCT02709109 France;Ireland;United Kingdom;United States;
Saline Solution
Zambon SpA
2018 Phase 3 NCT03460704 Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
2017 Phase 3 NCT03093974 Australia;Belgium;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Saline inhalation solution
Medical Center Alkmaar
2016 Phase 2/Phase 3 NCT02657473 Netherlands;
Salmeterol
National Center for Research Resources (NCRR)
2000 - NCT00005110 United States;
Saxagliptin
Ram Weiss
2015 - NCT02239458 Israel;
2014 - NCT02148978 Israel;
Serum Zn
Indiana University
2019 - NCT04302428 United States;
Short-acting Insulin (Actrapid)
Mukoviszidose Institut gGmbH
2001 Phase 3 NCT00662714 Austria;France;Germany;Italy;
Sildenafil
Children's Hospital Medical Center, Cincinnati
2012 Phase 1/Phase 2 NCT01194232 United States;
National Jewish Health
2015 Phase 2 NCT01132482 United States;
2015 Phase 1/Phase 2 NCT02626182 United States;
2008 Phase 1/Phase 2 NCT00659529 United States;
Sildenafil (Acute-1 hour)
Augusta University
2014 Phase 2 NCT02057458 United States;
Sildenafil (Subchronic-4 weeks)
Augusta University
2014 Phase 2 NCT02057458 United States;
Sildenafil 40mg oral capsule
National Jewish Health
2019 Phase 2/Phase 3 NCT04039087 United States;
Simvastatin
University Hospitals Cleveland Medical Center
2007 - NCT00531882 United States;
University of British Columbia
2010 Phase 1/Phase 2 NCT01092572 Canada;
Simvastatin treatment for 28 days
Akron Children's Hospital
2004 Phase 1 NCT00255242 United States;
Sitagliptin
Emory University
2010 Phase 3 NCT00967798 Canada;United States;
Nemours Children's Clinic
2012 Phase 1 NCT01721382 United States;
University of British Columbia
2010 Phase 2 NCT01257464 Canada;
University of Pennsylvania
2013 - NCT01879228 United States;
SmartPill Motility System & PillCam Patency Capsule
St. Louis University
2019 Phase 4 NCT04210427 United States;
Snack beverage
Institut de Recherches Cliniques de Montreal
2019 - NCT03710538 Canada;
Sodium (R)-8-methyl-2-(3-methylbenzofuran-2-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)ethoxy)quinoline-4-ca
Proteostasis Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2017-003319-21-GB Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-DE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-003319-21-BE Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
Sodium 4-Phenylbutyrate
Children's Hospital of Philadelphia
2003 Phase 1/Phase 2 NCT00590538 United States;
Sodium 4-Phenylbutyrate (4PBA)
Children's Hospital of Philadelphia
2001 Phase 1/Phase 2 NCT00016744 United States;
Sodium Pyruvate in Sodium Chloride Solution
Emphycorp
2006 Phase 1 NCT00308243 United States;
Sodium bicarbonate
University of Pittsburgh
2002 Phase 1 NCT00177645 United States;
Sodium chloride
Joseph Pilewski
2014 Phase 1 NCT03391414 United States;
Sodium chloride ()
University of North Carolina, Chapel Hill
2009 Phase 1 NCT01094704 United States;
Sodium chloride 0,
University of Jena
2010 - NCT01086839 Germany;
Sodium nitrite
Schmidhofer, Mark, MD
2016 Phase 1/Phase 2 NCT02694393 United States;
Soluble fiber supplementation
Institut de Recherches Cliniques de Montreal
2016 - NCT02810691 Canada;
Somalgen
Genaera Corporation
2005 Phase 2 EUCTR2004-004334-13-IE Ireland;
Sperti Del Sol Lamp
Atlanta VA Medical Center
2006 - NCT00450073 United States;
Spiriva Respimat 2.5 mcg
Boehringer Ingelheim
2010 Phase 3 EUCTR2010-019802-17-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim España, S.A
2010 - EUCTR2010-019802-17-ES Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France
2010 - EUCTR2010-019802-17-PT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Limited
2010 - EUCTR2010-019802-17-IE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019802-17-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2010 - EUCTR2010-019802-17-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2010 - EUCTR2010-019802-17-AT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH&Co KG
2010 Phase 3 EUCTR2010-019802-17-SK Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2010 Phase 3 EUCTR2010-019802-17-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Spiriva Respimat 2.5 microgram, solution for inhalation
BOEHRINGER ING.
2010 - EUCTR2010-019802-17-IT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2009 - EUCTR2008-001156-43-IT Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim
2010 Phase 3 EUCTR2010-019802-17-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim España, S.A
2010 - EUCTR2010-019802-17-ES Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France
2010 - EUCTR2010-019802-17-PT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-001156-43-FR Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim Limited
2010 - EUCTR2010-019802-17-IE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019802-17-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2008 - EUCTR2008-001156-43-GB Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2010 - EUCTR2010-019802-17-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co.KG
2008 - EUCTR2008-001156-43-DE Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim Pharmaceuticals, Inc.
2009 - EUCTR2008-001156-43-PT Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2010 - EUCTR2010-019802-17-HU Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-AT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH&Co KG
2010 Phase 3 EUCTR2010-019802-17-SK Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
Boehringer Ingelheim bv
2009 - EUCTR2008-001156-43-NL Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2010 Phase 3 EUCTR2010-019802-17-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2008 - EUCTR2008-001156-43-BE Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Spirometry
National Center for Research Resources (NCRR)
2001 - NCT00023465 United States;
Sporanox 10 mg/ml Oral Solution
CHU de Rennes (Rennes University Hospital Centre)
2012 - EUCTR2011-005799-41-GB United Kingdom;
Sputum
University of Miami
2010 - NCT02198079 United States;
Sputum Collection
The Hospital for Sick Children
2010 - NCT01155115 Canada;
Ss-Adrenergic cocktail
Richard Barry Moss
2015 - NCT02310789 United States;
Standard Care
Liverpool Heart and Chest Hospital NHS Foundation Trust
2017 Phase 4 NCT02894684 United Kingdom;
Standard Dose YPT-01
Yale University
2021 Phase 1/Phase 2 NCT04684641 United States;
Standard Formula
Laboratorios Ordesa
2012 - NCT02128984 Peru;Spain;
Standard Nutritional Supplement + PERT
GlycosBio, Inc.
2018 - NCT04966897 United States;
Standard formula (Enfamil)
University of Massachusetts, Worcester
2003 - NCT00530244 United States;
Standard of care IV antibiotic(s)
Chris Goss
2016 Phase 4 NCT02781610 Canada;United States;
Standard oxygen therapy/RA
The Leeds Teaching Hospitals NHS Trust
2019 - NCT03965832 United Kingdom;
Standard sinus rinse
Swansea University
2019 - NCT04589897 United Kingdom;
Standardized turmeric root extract
Ramsey, Bonnie, MD
2005 Phase 1 NCT00219882 United States;
Study medication, azithromycin
Rigshospitalet, Denmark
2008 Phase 4 NCT00411736 Denmark;Norway;Sweden;
Sulfato de amikacina
Insmed Incorporated
2011 Phase 3 EUCTR2011-000443-24-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2011-000441-20-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
Supplementation with vitamin D2/D3
Karolinska Institutet
2010 Phase 2 NCT01321905 Sweden;
Symbiotic Formula with DHA and antioxidants
Laboratorios Ordesa
2012 - NCT02128984 Peru;Spain;
Symdeko
University of Alabama at Birmingham
2019 Early Phase 1 NCT03587961 United States;
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
Symdeko/Trikafta
University of Alabama at Birmingham
2018 Phase 4 NCT03624101 United States;
Symkevi
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
Symkevi 100mg/150mg Film-coated tablets
VERTEX PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001735-31-GB Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
- Phase 3 EUCTR2019-001735-31-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
Synrinse
University of Washington
2017 Phase 1/Phase 2 NCT03154541 United States;
T 100 PARI
PARI GmbH
- Phase 1 EUCTR2005-004103-10-PL Germany;Poland;
T100
PARI Pharma GmbH
- Phase 1 EUCTR2010-023235-41-PL Poland;
T100 PARI
PARI GmbH
2007 - EUCTR2007-000959-33-DE Germany;
PARI Pharma GmbH
2006 - EUCTR2005-004103-10-DE Germany;
TAD 600
AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI
2009 - EUCTR2008-005080-33-IT Italy;
Mukoviszidose Institut gGmbH i. G.
2006 - EUCTR2005-003870-88-DE Germany;
TAZOBACTAM SODIUM
Ghent University
2016 Phase 4 EUCTR2016-000398-19-BE Belgium;
TBD
AbbVie Deutschland
2019 Phase 2 EUCTR2019-000750-63-NL Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
TBM100
NOVARTIS PHARMA SERVICES AG
2016 Phase 2 EUCTR2015-003040-39-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Novartis Pharma GmbH
2008 - EUCTR2007-004507-36-DE Germany;
Novartis Pharma Services AG
2017 Phase 2 EUCTR2015-003040-39-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-IE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-GB Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-BE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2010 - EUCTR2009-016590-15-DE Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;
2009 - EUCTR2009-016590-15-HU Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
- Phase 4 EUCTR2011-002000-32-FR Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Pharmaceuticals
2013 Phase 4 NCT01775137 Argentina;Australia;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
2012 Phase 4 NCT01519661 Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TBM100C
NOVARTIS FARMA
2012 - EUCTR2011-002000-32-IT Argentina;Australia;Brazil;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Farmaceutica S. A
2011 Phase 4 EUCTR2011-002000-32-ES Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-003532-23-ES Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2013 - EUCTR2012-001565-33-ES Germany;Ireland;Spain;Switzerland;United Kingdom;
Novartis Pharma GmbH
2014 Phase 4 EUCTR2014-001204-21-DE Germany;
Novartis Pharma Services AG
2015 - EUCTR2012-001565-33-IE Germany;Ireland;Spain;Switzerland;United Kingdom;
2013 Phase 4 EUCTR2012-001565-33-GB Germany;Ireland;Spain;Switzerland;United Kingdom;
2013 - EUCTR2012-003532-23-DE Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2013 - EUCTR2012-001565-33-DE Germany;Ireland;Spain;Switzerland;United Kingdom;
2012 - EUCTR2012-003532-23-HU Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2011 Phase 3 EUCTR2005-003772-37-IE Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2011 - EUCTR2011-002000-32-HU Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2011 - EUCTR2011-002000-32-DE Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2010 - EUCTR2009-016734-26-LV Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-LT Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-EE Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-BG Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-LV Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-LT Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-EE Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-BG Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-LV Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-LT Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-EE Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-BG Bulgaria;Estonia;Latvia;Lithuania;
2008 Phase 3 EUCTR2005-003772-37-GR Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2007 - EUCTR2005-003772-37-HU Germany;Greece;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-003772-37-GB Germany;Greece;Hungary;Italy;Spain;United Kingdom;
TEZ
Vertex Pharmaceuticals Incorporated
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 3 NCT03691779 Australia;Ireland;United Kingdom;United States;
2018 Phase 3 NCT03537651 Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 NCT03525574 Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 NCT03447262 Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2016 Phase 2 NCT02951182 Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;United Kingdom;United States;
2016 Phase 1 NCT03486236 United Kingdom;
TEZ/150 mg IVA FDC
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
TEZ/IVA
Vertex Pharmaceuticals Incorporated
2019 Phase 2 NCT03912233 Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 3 NCT03559062 Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 1/Phase 2 NCT03768089 Netherlands;United Kingdom;
2017 Phase 2 NCT03224351 Ireland;Israel;United Kingdom;United States;
2017 Phase 1/Phase 2 NCT03227471 Australia;Belgium;Netherlands;United States;
2016 Phase 3 NCT02953314 Canada;United States;
2015 Phase 3 NCT02565914 Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
THA
Children's Hospital of Philadelphia
2006 Phase 4 NCT00572975 United States;
TIOTROPIUM BROMIDE MONOHYDRATE
Boehringer Ingelheim
2010 Phase 3 EUCTR2010-019802-17-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim España, S.A
2010 - EUCTR2010-019802-17-ES Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France
2010 - EUCTR2010-019802-17-PT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Limited
2010 - EUCTR2010-019802-17-IE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019802-17-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2010 - EUCTR2010-019802-17-HU Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-AT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH&Co KG
2010 Phase 3 EUCTR2010-019802-17-SK Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2010 Phase 3 EUCTR2010-019802-17-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
TIP
Chiron Corporation Ltd
2006 - EUCTR2005-003772-37-ES Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Novartis Pharma Services AG
2005 - EUCTR2005-002035-28-LT Lithuania;
- - EUCTR2005-003772-37-DE Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Novartis Pharmaceuticals
2017 Phase 2 NCT02712983 Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
TIP (Tobramycin inhalation powder)
Novartis Farmaceutica S. A
2011 Phase 4 EUCTR2011-002000-32-ES Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Pharma Services AG
2011 - EUCTR2011-002000-32-HU Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2010 - EUCTR2009-016734-26-LV Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-LT Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-EE Bulgaria;Estonia;Latvia;Lithuania;
2010 - EUCTR2009-016734-26-BG Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-LV Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-LT Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-EE Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-004764-39-BG Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-LV Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-LT Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-EE Bulgaria;Estonia;Latvia;Lithuania;
2009 - EUCTR2008-002318-22-BG Bulgaria;Estonia;Latvia;Lithuania;
- Phase 4 EUCTR2011-002000-32-FR Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TIS (Tobramycin Inhalation Solution)
Horizon Pharma USA, Inc.
2011 Phase 3 NCT01270347 France;Germany;Ireland;Israel;United Kingdom;United States;
TIS or TIP
Novartis Pharmaceuticals
2015 Phase 4 NCT02248922 Germany;
TNSE
ECUPHARMA S.R.L.
2007 - EUCTR2007-003628-39-IT Italy;
TOBI
CHRU de Lille
- Phase 2 EUCTR2014-003882-10-FR France;
Gilead Sciences Inc
2010 - EUCTR2007-004277-26-AT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-004277-26-GB Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-FR Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-ES Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-BE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-PT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-NL Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DK Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
- - EUCTR2007-004277-26-Outside-EU/EEA United States;
Mpex Pharmaceuticals, Inc.
2011 - EUCTR2010-019634-26-IE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
Novartis Pharma Services AG
2011 Phase 3 EUCTR2005-003772-37-IE Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2005-003772-37-GR Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2007 - EUCTR2005-003772-37-HU Germany;Greece;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-003772-37-GB Germany;Greece;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2005-003772-37-DE Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Novartis Pharmaceuticals
2010 Phase 3 NCT01082367 Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;United States;
PARI GmbH
- Phase 1 EUCTR2005-004103-10-PL Germany;Poland;
St. Michael's Hospital, Toronto
2014 Phase 1 NCT02212587 Canada;
Universitaire Ziekenhuizen Leuven
2001 Phase 4 NCT01400750 Belgium;
TOBI (tobramycin)
Pari Pharma GmbH
2013 Phase 1 NCT01953367 Germany;
TOBI 300 mg / 5 mL nebuliser solution
Novartis Pharma Services AG
2013 - EUCTR2009-016590-15-PL Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;United States;
2009 - EUCTR2009-016590-15-HU Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
TOBI 300 mg/5 ml Lösung für einen
Mpex Pharmaceuticals, Inc.
2011 - EUCTR2010-019634-26-DE Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
TOBI 300 mg/5 ml Lösung für einen Vernebler
Novartis Pharma Services AG
2010 - EUCTR2009-016590-15-DE Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;
TOBI 300 mg/5 ml Nebuliser Solution
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
TOBI 300 mg/5 ml solución para inhalación por nebulizador
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-001565-33-ES Germany;Ireland;Spain;Switzerland;United Kingdom;
TOBI 300 mg/5 ml, solution pour inhalation par nébuliseur
Mpex Pharmaceuticals, Inc.
- Phase 3 EUCTR2010-019634-26-FR France;Germany;Ireland;United Kingdom;
TOBI 300mg/ 5ml solución para inhalación con nebulizador
Insmed Incorporated
2011 Phase 3 EUCTR2011-000441-20-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
TOBI 300mg/5mL Nebuliser Solution
Chiron Corporation Ltd
2006 - EUCTR2005-003772-37-ES Germany;Greece;Hungary;Italy;Spain;United Kingdom;
TOBI 300mg/5mL nebuliser solution
Novartis Pharma Services AG
2010 Phase 3 EUCTR2009-016590-15-FR France;Germany;Greece;Hungary;Italy;Poland;
2010 - EUCTR2009-016590-15-GR France;Germany;Greece;Hungary;Italy;Poland;
TOBI 300mg/5ml Nebuliser solution
Insmed Incorporated
2012 Phase 3 EUCTR2011-000441-20-BE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-NL Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2012 - EUCTR2011-000441-20-IE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-DK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-000441-20-BG Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-SK Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-HU Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-GR Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
2011 - EUCTR2011-000441-20-GB Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-DE Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
2011 - EUCTR2011-000441-20-AT Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
TOBI PODHALER
Novartis Farmaceutica S. A
2011 Phase 4 EUCTR2011-002000-32-ES Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI PODHALER - 28 MG POLVERE PER INALAZIONE CAPSULA RIGIDA USO INALATORIO BLISTER(ALU/ALU) 56 CAPSULE + 1 INALATORE
NOVARTIS PHARMA SERVICES AG
2016 Phase 2 EUCTR2015-003040-39-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
TOBI PODHALER*448CPS 28MG+10IN
NOVARTIS FARMA
2013 - EUCTR2012-003532-23-IT Argentina;Australia;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI Podhaler
Mylan Inc.
2015 - NCT02449031 United States;
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-003532-23-ES Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2013 - EUCTR2012-001565-33-ES Germany;Ireland;Spain;Switzerland;United Kingdom;
Novartis Pharma GmbH
2014 Phase 4 EUCTR2014-001204-21-DE Germany;
Novartis Pharma Services AG
2017 Phase 2 EUCTR2015-003040-39-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-IE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-GB Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-BE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2015 - EUCTR2012-001565-33-IE Germany;Ireland;Spain;Switzerland;United Kingdom;
2013 Phase 4 EUCTR2012-001565-33-GB Germany;Ireland;Spain;Switzerland;United Kingdom;
2013 - EUCTR2012-003532-23-DE Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2013 - EUCTR2012-001565-33-DE Germany;Ireland;Spain;Switzerland;United Kingdom;
2012 - EUCTR2012-003532-23-HU Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
- Phase 4 EUCTR2011-002000-32-FR Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Pharmaceuticals Corporation
- Phase 4 EUCTR2016-004318-82-Outside-EU/EEA United States;
- Phase 4 EUCTR2016-001840-20-Outside-EU/EEA United States;
TOBI Podhaler 28 mg Hartkapseln mit Pulver zur Inhalation
Novartis Pharma Services AG
2011 - EUCTR2011-002000-32-DE Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI Podhaler 28 mg inhalációs por, kemény kapszula
Novartis Pharma Services AG
2011 - EUCTR2011-002000-32-HU Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI*NEBUL 56F 1D 300MG/5ML
AZIENDA OSPEDALIERA MEYER
2008 - EUCTR2008-006502-42-IT Italy;
Gilead Sciences Inc
2008 - EUCTR2007-004277-26-IT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
NOVARTIS FARMA
2011 - EUCTR2009-016590-15-IT Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
TOBI®
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-DK Belgium;Denmark;
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
Gilead Sciences, Inc.
- - EUCTR2015-000398-11-Outside-EU/EEA United States;
PARI GmbH
2007 - EUCTR2007-000959-33-DE Germany;
PARI Pharma GmbH
2006 - EUCTR2005-004103-10-DE Germany;
- Phase 1 EUCTR2010-023235-41-PL Poland;
TOBI™ Podhaler™ 112 mg inhaled twice daily
Dartmouth-Hitchcock Medical Center
2014 - NCT02113397 United States;
TOBRAMICINA SOLFATO
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
TOBRAMYCIN SULFATE
Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
2014 Phase 4 EUCTR2013-004295-35-AT Austria;
St. Vincent's University Hospital
2016 Phase 4 EUCTR2016-001785-29-IE Ireland;
TOTTIZIM - 1 G/10 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO ENDOVENOSO 1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 10 ML
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
TR02
Transave, Inc
2005 - EUCTR2005-004389-17-HU Hungary;
Transave, Inc.
2005 - EUCTR2005-004899-21-BE Belgium;
Ta1
SciClone Pharmaceuticals Limited Ltd
2019 Phase 2 EUCTR2019-001441-40-IT Italy;
Tacrolimus and MMF
University Hospital, Limoges
2009 Phase 4 NCT00975663 Belgium;France;
Tacrolimus capsules
Hopital Erasme - Chest service
2009 - EUCTR2009-014050-15-BE Belgium;
Tacrolimus prolonged-release hard capsules
Hopital Erasme - Chest service
2009 - EUCTR2009-014050-15-BE Belgium;
Tad
Aarhus University Hospital
2014 Phase 2 EUCTR2013-005481-19-DK Denmark;
Talniflumate
Genaera Corporation
2005 Phase 2 EUCTR2004-004334-13-IE Ireland;
Tauroursodeoxycholic acid
Children's Hospital Medical Center, Cincinnati
1997 - NCT00004441 Italy;United States;
Technetium Sulfur Colloid
Tim Corcoran
2017 Phase 1 NCT02947126 United States;
Tedizolid IV
University of Southern California
2015 Phase 4 NCT02444234 United States;
Tedizolid PO
University of Southern California
2015 Phase 4 NCT02444234 United States;
Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.
Neupharma Srl
2019 Phase 1 NCT04176328 Italy;
Telavancin Injection
Joseph L. Kuti, PharmD
2017 Phase 4 NCT03172793 United States;
Terlipressin acetate
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2021 Phase 3 EUCTR2020-005931-58-FR France;
Tezacaftor
VERTEX PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2020-003170-44-IT Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
2021 Phase 3 EUCTR2021-001628-16-ES Australia;Belgium;Canada;Spain;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-003170-44-CZ Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 2 NCT02951195 United States;
2016 Phase 1 NCT03029455 United Kingdom;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-001628-16-BE Australia;Belgium;Canada;Spain;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-NL Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-FR Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-003170-44-BE Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Tezacaftor (TEZ)
VERTEX PHARMACEUTICALS INCORPORATED
2017 Phase 2 EUCTR2016-000454-36-IT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-000454-36-NL Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-GB Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-ES Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-DE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-BE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-AT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000454-36-DK Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Tezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
2017 Phase 3 NCT03150719 France;Germany;United States;
2016 Phase 2 NCT02730208 Australia;
2016 Phase 2 NCT02508207 United States;
2015 Phase 3 NCT02412111 Australia;Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
Tezacaftor/Ivacaftor + Ivacaftor
Nottingham University Hospitals NHS Trust
2019 Phase 2 NCT04006873 United Kingdom;
Tezacaftor/Ivacaftor 100mg/
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
Tezacaftor/Ivacaftor/100mg/
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-004133-82-IE Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-GB Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-ES Australia;Germany;Ireland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-004133-82-DE Australia;Germany;Ireland;Spain;United Kingdom;United States;
Tezacaftor/ivacaftor
Vertex Pharmaceuticals Incorporated
2017 - NCT03278314 -
Tezacaftor/ivacaftor 100mg/
VERTEX PHARMACEUTICALS INCORPORATED
2017 Phase 2 EUCTR2016-000454-36-IT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-000126-55-NL Netherlands;
2017 Phase 3 EUCTR2017-000540-18-DE France;Germany;United States;
2017 Phase 2 EUCTR2017-000797-11-NL Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-000454-36-NL Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-GB Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-ES Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-DE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-BE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-AT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000454-36-DK Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-000540-18-FR France;Germany;United States;
Tham
Lakshmi Durairaj
2017 Phase 1 NCT03078088 United States;
The gut mycobiota and microbiota profile
University Hospital, Bordeaux
2018 - NCT03565692 France;
The lung mycobiota and microbiota profile
University Hospital, Bordeaux
2018 - NCT03565692 France;
Theophylline
The First Affiliated Hospital of Guangzhou Medical University
2012 Phase 4 NCT01684683 China;
The first affiliated hospital of Guangzhou Medical University
2012 - ChiCTR-TRC-12002470 China;
Thymosin alpha 1
SciClone Pharmaceuticals Limited Ltd
2019 Phase 2 EUCTR2019-001441-40-IT Italy;
Tigerase®
AO GENERIUM
2017 Phase 3 NCT04468100 Russian Federation;
Tiotropium Bromide (monohydrate)
Boehringer Ingelheim Pharma GmbH & Co. KG
2010 - EUCTR2010-019802-17-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Tiotropium Respimat
Boehringer Ingelheim
2010 Phase 3 EUCTR2010-019802-17-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim España, S.A
2010 - EUCTR2010-019802-17-ES Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim France
2010 - EUCTR2010-019802-17-PT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim Limited
2010 - EUCTR2010-019802-17-IE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
2010 - EUCTR2010-019802-17-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2010 - EUCTR2010-019802-17-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Boehringer Ingelheim RCV GmbH & Co KG
2010 - EUCTR2010-019802-17-HU Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-019802-17-AT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
Boehringer Ingelheim RCV GmbH&Co KG
2010 Phase 3 EUCTR2010-019802-17-SK Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2010 Phase 3 EUCTR2010-019802-17-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Tiotropium Respimat 1.25 microgram solution for inhalation
Boehringer Ingelheim France
2008 Phase 2 EUCTR2008-001156-43-FR Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim Limited
2008 - EUCTR2008-001156-43-GB Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim Pharmaceuticals, Inc.
2009 - EUCTR2008-001156-43-PT Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Boehringer Ingelheim bv
2009 - EUCTR2008-001156-43-NL Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
SCS Boehringer Ingelheim Comm.V
2008 - EUCTR2008-001156-43-BE Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium Respimat 1.25 microgram, solution for inhalation
Boehringer Ingelheim Pharma GmbH & Co.KG
2008 - EUCTR2008-001156-43-DE Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium Respimat 1.25 micrograms solution for inhalation
BOEHRINGER ING.
2009 - EUCTR2008-001156-43-IT Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium Respimat® inhaler
Boehringer Ingelheim
2010 Phase 3 NCT01179347 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Tiotropium bromide
BOEHRINGER ING.
2010 - EUCTR2010-019802-17-IT Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
2009 - EUCTR2008-001156-43-IT Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium bromide 5 mcg
Boehringer Ingelheim
2008 Phase 2 NCT00737100 Australia;Belgium;France;Germany;Italy;Netherlands;New Zealand;Portugal;Russian Federation;United Kingdom;United States;
Tiotropium bromide high
Boehringer Ingelheim
2006 Phase 1 NCT02172534 -
Tiotropium bromide low
Boehringer Ingelheim
2006 Phase 1 NCT02172534 -
Tiotropium bromide medium
Boehringer Ingelheim
2006 Phase 1 NCT02172534 -
Tiotropium bromide monohydrate
Boehringer Ingelheim Pharma GmbH & Co.KG
2008 - EUCTR2008-001156-43-DE Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium bromide-low dose-2.5mcg
Boehringer Ingelheim
2008 Phase 2 NCT00737100 Australia;Belgium;France;Germany;Italy;Netherlands;New Zealand;Portugal;Russian Federation;United Kingdom;United States;
Tobacco
University Hospital, Toulouse
2019 - NCT04437641 France;
University of Alabama at Birmingham
2021 - NCT04777344 United States;
Tobi
EREMPHARMA SAS
- Phase 1 EUCTR2010-023533-34-FR France;
Erempharma SAS
2009 - EUCTR2009-013660-39-FR France;
INSMED INCORPORATED
2011 - EUCTR2011-000441-20-IT Austria;Bulgaria;Canada;Denmark;Greece;Hungary;Ireland;Italy;Netherlands;Spain;United Kingdom;
Novartis Pharma GmbH
2008 - EUCTR2007-004507-36-DE Germany;
Tobi 300 mg/5 ml Nebuliser Solution
Leeds Teaching Hospitals NHS Trust
2007 - EUCTR2007-005346-20-GB United Kingdom;
Mpex Pharmaceuticals, Inc.
2011 Phase 3 EUCTR2010-019634-26-GB Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
Tobi 300mg/5ml Nebuliser solution.
Chiesi Farmaceutici S.p.A
2009 Phase 3 EUCTR2006-006215-68-FR Czech Republic;France;Germany;Hungary;Spain;
2008 Phase 3 EUCTR2006-006215-68-CZ Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-HU Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-DE Czech Republic;France;Germany;Hungary;Spain;
Tobi 300mg/5ml Solución para inhalación por nebulizador.
Chiesi Farmaceutici S.p.A
2008 Phase 3 EUCTR2006-006215-68-ES Czech Republic;France;Germany;Hungary;Spain;
Tobi Inhalant Product
University Hospital, Lille
2017 Phase 3 NCT03066453 France;
Tobi Nebcinal
Erempharma
2010 - NCT01288170 France;
Tobi Podhaler
Mylan Inc.
2018 Phase 4 NCT03502070 United States;
Novartis Pharmaceuticals
2014 Phase 4 NCT02178540 United States;
Tobramcyin
The Univeristy of Nottingham
2010 Phase 4 EUCTR2010-023030-23-GB United Kingdom;
Tobramicina
Chiesi Farmaceutici S.p.A
2008 Phase 3 EUCTR2006-006215-68-ES Czech Republic;France;Germany;Hungary;Spain;
Insmed Incorporated
2011 Phase 3 EUCTR2011-000441-20-ES Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
Tobramicina polvere inalatoria
NOVARTIS PHARMA SERVICES AG
2016 Phase 2 EUCTR2015-003040-39-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Tobramicyn
UNIVERSITY OF LIVERPOOL
- Phase 4 EUCTR2009-012575-10-IT Italy;Sweden;United Kingdom;
Tobramycin
AZIENDA OSPEDALIERA MEYER
2008 - EUCTR2008-006502-42-IT Italy;
Chiesi Farmaceutici S.p.A
2009 Phase 3 EUCTR2006-006215-68-FR Czech Republic;France;Germany;Hungary;Spain;
2008 Phase 3 EUCTR2006-006215-68-ES Czech Republic;France;Germany;Hungary;Spain;
2008 Phase 3 EUCTR2006-006215-68-CZ Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-HU Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-DE Czech Republic;France;Germany;Hungary;Spain;
Chiesi Farmaceutici S.p.A.
2009 Phase 3 NCT01111383 France;Poland;Ukraine;
Erempharma
2011 Phase 1/Phase 2 NCT01337219 France;
FDA Office of Orphan Products Development
1995 Phase 3 NCT00004829 -
Forest Laboratories UK Ltd
2005 - EUCTR2004-003675-36-DK Belgium;Denmark;
2005 - EUCTR2004-003675-36-BE Belgium;Denmark;
2005 - EUCTR2004-003675-36-AT Austria;Belgium;Denmark;
Gilead Sciences Inc
2010 - EUCTR2007-004277-26-AT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-004277-26-GB Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-FR Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-ES Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-004277-26-BE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-PT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-NL Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IT Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-IE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DK Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004277-26-DE Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Imperial College London
2010 Phase 4 NCT01044719 United Kingdom;
Imperial College, London
2009 - EUCTR2009-014042-28-GB United Kingdom;
Leeds Teaching Hospitals NHS Trust
2007 - EUCTR2007-005346-20-GB United Kingdom;
NOVARTIS FARMA
2013 - EUCTR2012-003532-23-IT Argentina;Australia;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
National Jewish Health
2016 Phase 4 NCT02918409 United States;
Novartis
2008 Phase 3 NCT00634192 Germany;
2006 Phase 1 NCT00420836 -
2006 Phase 1 NCT00399945 United Kingdom;
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-003532-23-ES Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Pharma GmbH
2008 - EUCTR2007-004507-36-DE Germany;
Novartis Pharma Services AG
2013 - EUCTR2012-003532-23-DE Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2013 - EUCTR2009-016590-15-PL Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;United States;
2012 - EUCTR2012-003532-23-HU Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2011 - EUCTR2011-002000-32-DE Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
2010 Phase 3 EUCTR2009-016590-15-FR France;Germany;Greece;Hungary;Italy;Poland;
2010 - EUCTR2009-016590-15-GR France;Germany;Greece;Hungary;Italy;Poland;
2010 - EUCTR2009-016590-15-DE Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;
2009 - EUCTR2009-016590-15-HU Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
The Leeds Teaching Hospitals NHS Trust
2015 - NCT02489955 United Kingdom;
University College Cork
2015 - NCT02526004 Ireland;
University Hospitals Bristol NHS Foundation Trust
2016 Phase 4 EUCTR2009-012575-10-SE Sweden;United Kingdom;
2009 Phase 4 EUCTR2009-012575-10-GB Sweden;United Kingdom;
University Medical Center Groningen
2019 Phase 1/Phase 2 NCT03485456 Netherlands;
University Medical Centre Groningen
2013 Phase 1/Phase 2 NCT02035488 Netherlands;
University of Jena
2008 - EUCTR2008-000164-17-DE Germany;
University of Milan
2012 Phase 4 NCT01608555 Italy;
University of Nottingham
2011 Phase 4 NCT01207245 United Kingdom;
Tobramycin (Gernebcin®)
University of Jena
2008 Phase 2 NCT00774072 Germany;
Tobramycin / Bramitob
Chiesi Farmaceutici S.p.A.
2009 Phase 3 NCT00885365 Czech Republic;Czechia;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
Tobramycin / TOBI
Chiesi Farmaceutici S.p.A.
2009 Phase 3 NCT00885365 Czech Republic;Czechia;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
Tobramycin 100 PARI
PARI GmbH
2007 - EUCTR2007-000959-33-DE Germany;
- Phase 1 EUCTR2005-004103-10-PL Germany;Poland;
PARI Pharma GmbH
2006 - EUCTR2005-004103-10-DE Germany;
Tobramycin Inhalation Powder
Chiron Corporation Ltd
2006 - EUCTR2005-003772-37-ES Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Novartis
2005 Phase 3 NCT00125346 Argentina;Brazil;Bulgaria;Canada;Chile;Former Serbia and Montenegro;Lithuania;Mexico;United States;
Novartis Pharma Services AG
2005 - EUCTR2005-002035-28-LT Lithuania;
- - EUCTR2005-003772-37-DE Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Novartis Pharmaceuticals
2014 Phase 4 NCT02015663 United States;
2013 Phase 4 NCT01844778 Germany;Ireland;Spain;Switzerland;United Kingdom;
2009 Phase 3 NCT00918957 Bulgaria;Egypt;Estonia;India;Latvia;Lithuania;Romania;Russian Federation;South Africa;
2006 Phase 3 NCT00388505 Australia;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Spain;United Kingdom;United States;
Tobramycin Inhalation Powder (TIP)
Novartis Pharma Services AG
2011 Phase 3 EUCTR2005-003772-37-IE Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2008 Phase 3 EUCTR2005-003772-37-GR Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
2007 - EUCTR2005-003772-37-HU Germany;Greece;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-003772-37-GB Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Tobramycin Inhalation Powder TIP delivered by the T-326 Inhaler
CHIRON CORPORATION LIMITED
2006 - EUCTR2005-003772-37-IT Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Tobramycin Inhalation Solution (TIS)
Gilead Sciences
2008 Phase 3 NCT00757237 Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Tobramycin Powder
University Hospital Tuebingen
2014 Phase 3 NCT03341741 -
Tobramycin Solution for Inhalation
Novartis Pharmaceuticals
2006 Phase 3 NCT00388505 Australia;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Spain;United Kingdom;United States;
Tobramycin Steri-Neb 300 mg/5 ml, inhalation solution
Noordwest Ziekenhuisgroep
2016 Phase 2;Phase 3 EUCTR2016-000166-35-NL Netherlands;
Tobramycin dry powder
University Medical Center Groningen
2013 - EUCTR2012-004437-16-NL Netherlands;
Tobramycin for Inhalation
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2000 Phase 2 NCT00006280 United States;
Tobramycin inhalation powder
NOVARTIS FARMA
2012 - EUCTR2011-002000-32-IT Argentina;Australia;Brazil;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
Novartis Pharma Services AG
2017 Phase 2 EUCTR2015-003040-39-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-IE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-GB Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 2 EUCTR2015-003040-39-BE Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Novartis Pharmaceuticals
2010 Phase 3 NCT01069705 Bulgaria;Estonia;Latvia;Lithuania;Romania;Russian Federation;South Africa;
2009 Phase 3 NCT00982930 Estonia;Russian Federation;
Tobramycin inhalation solution
Gilead Sciences
2012 Phase 3 NCT01641822 United States;
Medical Center Alkmaar
2016 Phase 2/Phase 3 NCT02657473 Netherlands;
Novartis Pharmaceuticals
2013 Phase 4 NCT01844778 Germany;Ireland;Spain;Switzerland;United Kingdom;
Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
Insmed Incorporated
2012 Phase 3 NCT01315678 Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
Tobramycin injection 40mg/1ml
The Univeristy of Nottingham
2010 Phase 4 EUCTR2010-023030-23-GB United Kingdom;
Tobramycin nebulized nasally
Virginie ESCABASSE
2017 Phase 3 NCT02888730 France;
Tobramycin solution for inhalation
Bonnie Ramsey
2014 Phase 3 NCT02054156 United States;
Novartis
2003 Phase 3 NCT00391976 -
Novartis Pharmaceuticals
2010 - NCT01460836 -
Tobramycin solution for inhalation (TOBI)
Seattle Children's Hospital
2004 Phase 2 NCT00097773 United States;
Tobramycine
Erempharma SAS
2009 - EUCTR2009-013660-39-FR France;
Novartis Pharma Services AG
2005 - EUCTR2005-002035-28-LT Lithuania;
Tobramycinum
PARI GmbH
- Phase 1 EUCTR2005-004103-10-PL Germany;Poland;
PARI Pharma GmbH
- Phase 1 EUCTR2010-023235-41-PL Poland;
Tobrineb/Bramitob
Chiesi Farmaceutici S.p.A
2009 Phase 3 EUCTR2006-006215-68-FR Czech Republic;France;Germany;Hungary;Spain;
2008 Phase 3 EUCTR2006-006215-68-ES Czech Republic;France;Germany;Hungary;Spain;
2008 Phase 3 EUCTR2006-006215-68-CZ Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-HU Czech Republic;France;Germany;Hungary;Spain;
2008 - EUCTR2006-006215-68-DE Czech Republic;France;Germany;Hungary;Spain;
Tozinameran
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
Treatment
Johns Hopkins All Children's Hospital
2016 Phase 2 NCT02613884 United States;
Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor
Charite University, Berlin, Germany
2018 - NCT04732910 Germany;
Treatment with polyethylene glycol (Macrogol 4000)
University Hospital, Bordeaux
2020 Phase 2 NCT04458129 -
Trifakta
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Trikafta
Emory University
2019 Phase 2 NCT03506061 United States;
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Trimethoprim Sulfamethoxazole (TMP/SMX)
University of North Carolina, Chapel Hill
2018 Phase 2 NCT03489629 United States;
Trimethoprim and Sulfamethoxazole
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Trimethoprim-sulfamethoxazole
AOU Meyer
2013 Phase 3 EUCTR2013-000219-25-IT Italy;
Trimethoprim/Sulfamethoxazole
University of North Carolina, Chapel Hill
2011 Phase 2 NCT01349192 United States;
Trimethoprim/Sulfamethoxazole (TMP/SMX)
Johns Hopkins University
2012 Phase 2 NCT01594827 United States;
Trimetoprim
Vãstre Gõtalandsregionen, Sweden
2021 Phase 4 EUCTR2019-003501-10-NO Denmark;Norway;Sweden;
Västra Götalandsregionen
2021 Phase 4 EUCTR2019-003501-10-DK Denmark;Norway;Sweden;
2020 Phase 4 EUCTR2019-003501-10-SE Denmark;Norway;Sweden;
Triple combination therapy
National Jewish Health
2019 - NCT04038710 United States;
ULTRESA
AbbVie
2012 - NCT01652157 United States;
Ultrase® MT12
Forest Laboratories
2009 Phase 3 NCT00880100 United States;
Ultrase® MT20
Forest Laboratories
2007 Phase 3 NCT00513682 United States;
2006 Phase 3 NCT00408317 United States;
Unconjugated Isoflavones 100 (PTI G-4660, Genistein)
Children's Hospital of Philadelphia
2001 Phase 1/Phase 2 NCT00016744 United States;
Uridine
FDA Office of Orphan Products Development
1996 - NCT00004705 -
Urinary collect
University Hospital, Strasbourg, France
2008 - NCT00476281 France;
Urinary levels of PIIINP as a marker of changes in renal function
Nantes University Hospital
2012 - NCT01572194 France;
Ursodiol
Children's Hospital Medical Center, Cincinnati
1997 - NCT00004441 Italy;United States;
National Center for Research Resources (NCRR)
1995 Phase 2 NCT00004315 United States;
V-Fend
CHU de Rennes (Rennes University Hospital Centre)
2012 - EUCTR2011-005799-41-GB United Kingdom;
VFEND 40 mg/ml powder for oral suspension
CHU de Rennes (Rennes University Hospital Centre)
2012 - EUCTR2011-005799-41-GB United Kingdom;
VITAMIN E - TGPS
ORPHAN
2007 - EUCTR2007-001007-38-FR France;
VR496
VECTURA LIMITED
2010 - EUCTR2007-006276-11-IT Ireland;Italy;
VRT-813077
Vertex Pharmaceuticals Incorporated
2010 Phase 3 EUCTR2009-012997-11-FR Czech Republic;France;Germany;Ireland;United Kingdom;
- - EUCTR2009-010261-23-Outside-EU/EEA United States;
VRT-826809
Vertex Pharmaceuticals Incorporated
2009 - EUCTR2008-006446-25-NL Belgium;Germany;Netherlands;
2009 - EUCTR2008-006446-25-DE Belgium;Germany;Netherlands;
2009 - EUCTR2008-006446-25-BE Belgium;Germany;Netherlands;
VRT-893661
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002968-40-PL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2016-004479-35-PL Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-GB Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-FR Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DK Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-BE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-004827-29-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 - EUCTR2014-004827-29-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-004479-35-IE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
VRT-893661 VRT-0893661
Vertex Pharmaceuticals Incorporated
2016 Phase 3 EUCTR2014-004838-25-DE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-AT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004788-18-BE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-BE Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-SE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-NL Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IT Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-GB Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-ES Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DK Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-NL Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-IT Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-GB Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-DE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004787-37-ES Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-DE Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-AT Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
VX-121
Vertex Pharmaceuticals Incorporated
2019 Phase 2 NCT03912233 Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-000126-55-NL Netherlands;
2018 Phase 1/Phase 2 NCT03768089 Netherlands;United Kingdom;
VX-121/TEZ/D-IVA
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-000712-31-SE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-DE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 NCT05076149 Australia;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2021 Phase 3 NCT05033080 Czechia;Germany;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NO Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-GR Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-CZ Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
VX-121/tezacaftor/deutivacaftor
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-000712-31-SE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-DE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NO Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-GR Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-CZ Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
VX-152
Vertex Pharmaceuticals Incorporated
2016 Phase 2 NCT02951195 United States;
VX-371
Parion Sciences
2016 Phase 2 NCT02709109 France;Ireland;United Kingdom;United States;
VX-371 in hypertonic saline
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
VX-371 in saline
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
VX-440
VERTEX PHARMACEUTICALS INCORPORATED
2017 Phase 2 EUCTR2016-000454-36-IT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2016-000454-36-NL Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-GB Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-ES Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-DE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-BE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-AT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 NCT02951182 Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000454-36-DK Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 1 NCT03486236 United Kingdom;
VX-445
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 NCT03691779 Australia;Ireland;United Kingdom;United States;
2018 Phase 3 NCT03525574 Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000797-11-NL Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 1/Phase 2 NCT03227471 Australia;Belgium;Netherlands;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-445 / TEZ / IVA
Vertex Pharmaceuticals Incorporated
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
VX-445 / TEZ / IVA FDC
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2019-001827-11-IE Australia;Canada;Ireland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001695-38-GB Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2019-001827-11-GB Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-001695-38-IE Australia;Canada;Ireland;United Kingdom;United States;
VX-445 /50 mg TEZ/75 mg IVA FDC
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
VX-445 /TEZ/IVA
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2018-004652-38-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
VX-445/50 mg TEZ /75 mg IVA FDC
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-445/50mg TEZ /75mg IVA FDC
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
VX-445/TEZ/IVA
VERTEX PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2019-000833-37-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
2020 Phase 3 EUCTR2019-000833-37-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001735-31-GB Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000833-37-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001695-38-GB Australia;Canada;Ireland;United Kingdom;United States;
2018 Phase 3 NCT03525548 Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 NCT03525444 Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2019-001735-31-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2019-000833-37-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-001695-38-IE Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-561
Vertex Pharmaceuticals Incorporated
2019 Phase 2 NCT03912233 Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 NCT03911713 Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-NL Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-GB Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-DE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-BE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
2017 Phase 2 NCT03224351 Ireland;Israel;United Kingdom;United States;
2017 Phase 1/Phase 2 NCT03227471 Australia;Belgium;Netherlands;United States;
2016 Phase 2 NCT02971839 United States;
VX-561 (CTP-656)
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
VX-659
Vertex Pharmaceuticals Incorporated
2018 Phase 3 NCT03447262 Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 2 NCT03224351 Ireland;Israel;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
2016 Phase 1 NCT03029455 United Kingdom;
VX-659/ TEZ/IVA
Vertex Pharmaceuticals Incorporated
2019 Phase 3 EUCTR2017-004134-29-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
VX-659/TEZ/IVA
Vertex Pharmaceuticals Incorporated
2018 Phase 3 NCT03633526 United States;
2018 Phase 3 NCT03460990 Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 NCT03447249 Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-IE Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-GB Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-ES Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-004133-82-DE Australia;Germany;Ireland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-004132-11-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
VX-659/Tezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
2019 Phase 3 EUCTR2017-004134-29-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-IE Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-GB Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-ES Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-004133-82-DE Australia;Germany;Ireland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-004132-11-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
VX-661
VERTEX PHARMACEUTICALS INCORPORATED
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2018-004652-38-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-NL Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-GB Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000184-89-BE Belgium;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2014 Phase 2 NCT02070744 United States;
2014 Phase 1 NCT02015507 -
2012 Phase 2 NCT01531673 Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-661 / VX-770
VERTEX PHARMACEUTICALS INCORPORATED
2019 Phase 3 EUCTR2018-002835-76-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2020 Phase 3 EUCTR2018-002835-76-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-001735-31-GB Australia;Belgium;Germany;United Kingdom;
2019 Phase 3 EUCTR2018-002835-76-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002835-76-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2019-001735-31-BE Australia;Belgium;Germany;United Kingdom;
- Phase 3 EUCTR2018-002835-76-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-002835-76-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
VX-661 Plus Ivacaftor Combination
Vertex Pharmaceuticals Incorporated
2015 Phase 3 NCT02347657 Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
VX-661 plus ivacaftor combination
Vertex Pharmaceuticals Incorporated
2015 Phase 3 NCT02516410 Australia;Austria;Canada;France;Israel;Spain;United States;
VX-661, VRT-893661
Vertex Pharmaceuticals Incorporated
2013 Phase 2 EUCTR2011-003821-93-DE Canada;Germany;United Kingdom;United States;
2012 Phase 2 EUCTR2011-003821-93-GB Canada;Germany;United Kingdom;United States;
VX-661/Ivacaftor
Vertex Pharmaceuticals Incorporated
2015 Phase 3 NCT02392234 Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
VX-661/VX-770
VERTEX PHARMACEUTICALS INCORPORATED
2017 Phase 2 EUCTR2016-000454-36-IT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2019 Phase 2 EUCTR2018-002496-18-PT Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-NL Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-GB Germany;Netherlands;Portugal;United Kingdom;United States;
2019 Phase 2 EUCTR2018-002496-18-DE Germany;Netherlands;Portugal;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2018-000126-55-NL Netherlands;
2017 Phase 3 EUCTR2017-000540-18-DE France;Germany;United States;
2017 Phase 2 EUCTR2017-000797-11-NL Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2017-000797-11-BE Australia;Belgium;Netherlands;United States;
2017 Phase 2 EUCTR2016-003585-11-GB Ireland;Israel;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-NL Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-GB Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-ES Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-DE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-BE Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000454-36-AT Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-DE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-AT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004788-18-BE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000454-36-DK Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-BE Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-SE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-NL Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IT Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-GB Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-ES Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DK Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-NL Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-IT Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-GB Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-DE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004787-37-ES Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-DE Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-AT Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 - EUCTR2014-004827-29-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-000540-18-FR France;Germany;United States;
VX-661/VX-770 (TEZ/IVA)
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-004133-82-IE Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-GB Australia;Germany;Ireland;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004133-82-ES Australia;Germany;Ireland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2017-004133-82-DE Australia;Germany;Ireland;Spain;United Kingdom;United States;
VX-661/ivacaftor (VX-770) 100mg/
Vertex Pharmaceuticals Incorporated
2016 Phase 3 EUCTR2014-004827-29-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 - EUCTR2014-004827-29-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
VX-661/ivacaftor 100 mg/
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002968-40-PL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2016-004479-35-PL Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-GB Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-FR Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DK Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-BE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
- Phase 3 EUCTR2017-002968-40-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-004479-35-IE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
VX-661/ivacaftor 100mg/
Vertex Pharmaceuticals Incorporated
2016 Phase 3 EUCTR2014-004838-25-DE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-AT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004788-18-BE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-BE Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-SE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-NL Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IT Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-GB Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-ES Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DK Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-NL Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-IT Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-GB Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-DE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004787-37-ES Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-DE Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-AT Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
VX-661/ivacaftor 50 mg/
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002968-40-PL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2016-004479-35-PL Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-GB Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-FR Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DK Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-BE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
- Phase 3 EUCTR2017-002968-40-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-004479-35-IE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
VX-77
Vertex Pharmaceuticals Incorporated
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
VX-770
VERTEX PHARMACEUTICALS INCORPORATED
2021 Phase 3 EUCTR2021-000694-85-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-IT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2022 Phase 3 EUCTR2021-005320-38-ES Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
2022 Phase 3 EUCTR2021-000712-31-SE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-PT Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000712-31-DE Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
2022 Phase 3 EUCTR2021-000694-85-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-001628-16-ES Australia;Belgium;Canada;Spain;
2021 Phase 3 EUCTR2021-000694-85-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NO Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-GR Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000694-85-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004885-21-ES Belgium;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-004885-21-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
2021 Phase 3 EUCTR2020-002251-38-DE Germany;United Kingdom;United States;
2021 Phase 3 EUCTR2020-001404-42-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2021 Phase 3 EUCTR2020-001404-42-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2020-001404-42-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-NL Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-GB Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DK Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003554-86-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-GB Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-DE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-003455-11-BE Australia;Belgium;Germany;United Kingdom;
2020 Phase 3 EUCTR2019-001827-11-IE Australia;Canada;Ireland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000833-37-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004652-38-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000833-37-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004652-38-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-001695-38-GB Australia;Canada;Ireland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000185-11-AT Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004134-29-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-NL Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-GB Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-DE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2019 Phase 2 EUCTR2018-003970-28-BE Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-NL Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-CZ Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000185-11-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-SE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000183-28-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004134-29-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-IE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-GB Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-ES Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DK Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004132-11-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-001379-21-GB Canada;Germany;Ireland;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001997-16-IE Canada;Germany;Ireland;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001267-39-GB Australia;Canada;France;United Kingdom;
2015 Phase 3 NCT02514473 Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-000386-20-GB Canada;United Kingdom;United States;
2013 Phase 3 EUCTR2012-000204-15-GB Canada;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000389-39-GB Belgium;France;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000389-39-BE Belgium;France;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000388-26-BE Belgium;France;United States;
2012 - EUCTR2012-000387-19-GB United Kingdom;United States;
2011 - NCT01381289 -
2010 Phase 2 NCT01161537 United States;
2010 Phase 1 NCT01216046 United States;
2010 Phase 1 NCT01208285 Czech Republic;Slovakia;
2010 Phase 1 NCT01153542 United States;
2010 Phase 1 NCT01060566 United States;
2009 Phase 1 NCT01018368 United States;
- Phase 3 EUCTR2021-005320-38-PT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-NL Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-DE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-BE Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-005320-38-AT Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
- Phase 3 EUCTR2021-001628-16-BE Australia;Belgium;Canada;Spain;
- Phase 3 EUCTR2021-000712-31-IE Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000712-31-CZ Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2021-000694-85-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004885-21-NL Belgium;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-004885-21-BE Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
- Phase 3 EUCTR2020-002239-31-DE Australia;Canada;Germany;United Kingdom;United States;
- Phase 3 EUCTR2020-001404-42-FR Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2020-001404-42-DE Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-001827-11-GB Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2019-000833-37-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-004652-38-DE Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2018-001695-38-IE Australia;Canada;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-SE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000185-11-DE Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2018-000183-28-FR Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2017-004132-11-PL Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-001379-21-IE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2017-001379-21-DE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001997-16-GB Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001997-16-DE Canada;Germany;Ireland;United Kingdom;United States;
- Phase 3 EUCTR2015-001267-39-FR Australia;Canada;France;United Kingdom;
- Phase 2 EUCTR2017-000673-37-Outside-EU/EEA United States;
- Phase 2 EUCTR2017-000672-28-Outside-EU/EEA United States;
- - EUCTR2009-010261-23-Outside-EU/EEA United States;
VX-770, VRT-8130077
Vertex Pharmaceuticals Incorporated
2010 Phase 3 EUCTR2009-012997-11-FR Czech Republic;France;Germany;Ireland;United Kingdom;
VX-770, VRT-813077
Vertex Pharmaceuticals Incorporated
2018 Phase 3 EUCTR2017-002968-40-PL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002968-40-BE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2016-004479-35-PL Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-GB Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-FR Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DK Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-DE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-004479-35-BE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-004838-25-DE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004838-25-AT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004827-29-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-004788-18-BE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IT Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-IE Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004838-25-BE Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-SE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-NL Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IT Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-IE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-GB Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-ES Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DK Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004837-13-DE Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-SE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-IE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004827-29-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-NL Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-IT Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-GB Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004788-18-DE Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004787-37-ES Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-DE Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 Phase 3 EUCTR2014-004787-37-AT Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
2015 - EUCTR2014-004827-29-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2014 Phase 2 EUCTR2010-020413-90-GB Australia;Belgium;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2010-020413-90-IE Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
2013 Phase 2 EUCTR2011-003821-93-DE Canada;Germany;United Kingdom;United States;
2012 Phase 2 EUCTR2011-003821-93-GB Canada;Germany;United Kingdom;United States;
2011 - EUCTR2010-020413-90-DE Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
2011 - EUCTR2010-020413-90-BE Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
2010 Phase 3 EUCTR2009-012997-11-GB Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2010-020546-96-GB Canada;United Kingdom;United States;
2010 - EUCTR2009-012997-11-IE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2009-012997-11-DE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2010 - EUCTR2009-012997-11-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-007479-26-GB Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-007479-26-FR France;Germany;Ireland;United Kingdom;
2009 Phase 3 EUCTR2008-007416-15-GB Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-007416-15-FR Czech Republic;France;Germany;Ireland;United Kingdom;
2009 - EUCTR2008-007479-26-IE Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 - EUCTR2008-007479-26-DE Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
2009 - EUCTR2008-007416-15-IE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
2009 - EUCTR2008-007416-15-CZ Czech Republic;France;Germany;Ireland;United Kingdom;
2007 - EUCTR2007-002657-23-DE Germany;
- Phase 3 EUCTR2017-002968-40-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2017-002968-40-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2016-004479-35-IE Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
- - EUCTR2008-007416-15-DE Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
VX-809
Vertex Pharmaceuticals Incorporated
2015 Phase 3 NCT02514473 Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2010 Phase 1 NCT01216046 United States;
2009 Phase 2 NCT00865904 Belgium;Canada;Germany;Netherlands;United States;
2009 - EUCTR2008-006446-25-NL Belgium;Germany;Netherlands;
2009 - EUCTR2008-006446-25-DE Belgium;Germany;Netherlands;
2009 - EUCTR2008-006446-25-BE Belgium;Germany;Netherlands;
VX-809 & VX-770
Vertex Pharmaceuticals Incorporated
2009 Phase 1 NCT00966602 Netherlands;
VX-809 / VX-770
Vertex Pharmaceuticals Incorporated
2018 Phase 2 EUCTR2017-003761-99-DE Germany;
2016 Phase 3 EUCTR2015-001644-11-GB Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-FR Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DK Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-DE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001644-11-BE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-SE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-GB Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-DK Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-DE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000543-16-BE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-NL Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-000604-41-IT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 - EUCTR2013-000604-41-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2013-000604-41-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-DK Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003990-24-BE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-SE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-GB Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003989-40-CZ Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-IE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2013-000604-41-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003990-24-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003990-24-AT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
2013 - EUCTR2012-003989-40-NL Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IT Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-IE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
2013 - EUCTR2012-003989-40-DE Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2015-001644-11-SE Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2015-000543-16-FR Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
VX-809, VRT-826809
Vertex Pharmaceuticals Incorporated
2014 Phase 2 EUCTR2010-020413-90-GB Australia;Belgium;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2010-020413-90-IE Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
2011 - EUCTR2010-020413-90-DE Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
2011 - EUCTR2010-020413-90-BE Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
VX-809/VX-770
Vertex Pharmaceuticals Inc.
2016 Phase 2 EUCTR2015-004841-13-IE Czech Republic;France;Ireland;United Kingdom;United States;
- Phase 2 EUCTR2015-004841-13-FR Czech Republic;France;Ireland;United Kingdom;United States;
Vertex Pharmaceuticals Incorporated
2017 Phase 2 EUCTR2015-004841-13-CZ Czech Republic;France;Ireland;United Kingdom;United States;
2016 Phase 4 EUCTR2016-000066-34-GB Australia;United Kingdom;
2014 Phase 2 EUCTR2010-020413-90-GB Australia;Belgium;Germany;Ireland;United Kingdom;United States;
2014 - EUCTR2010-020413-90-IE Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
2011 - EUCTR2010-020413-90-DE Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
2011 - EUCTR2010-020413-90-BE Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
- Phase 3 EUCTR2017-001309-34-Outside-EU/EEA United States;
- Phase 3 EUCTR2017-001078-41-Outside-EU/EEA Canada;United States;
Vertex Pharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-004841-13-GB Czech Republic;France;Ireland;United Kingdom;United States;
Vaccin grippal pandémique H1N1
Inserm
2009 - EUCTR2009-016662-90-FR France;
Vaccination with vaccine against hepatitis A and B
Karolinska University Hospital
2015 - NCT02605538 Sweden;
Valganciclovir [Valcyte]
Hoffmann-La Roche
2004 Phase 1 NCT00377741 United States;
Vancomycin
Case Western Reserve University
2012 Phase 1 NCT01509339 United States;
Vancomycin hydrochloride inhalation powder
Savara Inc.
2013 Phase 2 NCT01746095 United States;
Vancomycin inhalation powder
Savara Inc.
2017 Phase 3 NCT03181932 Canada;United States;
Vantobra (tobramycin)
Pari Pharma GmbH
2013 Phase 1 NCT01953367 Germany;
Vardenafil
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2011 Phase 2 NCT01002534 Belgium;
Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S
Medical University of Innsbruck, University Clinic for Pediatrics III
- Phase 4 EUCTR2021-003277-55-AT Austria;Canada;European Union;Ireland;United Kingdom;United States;
Ventolin® Evohaler
ZAMBON SPA
2017 Phase 3 EUCTR2015-002743-33-IT Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Ventolin¿ Evohaler¿
ZAMBON SPA
2017 Phase 3 EUCTR2015-002743-33-IT Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Vfend
Leeds Teaching Hospital NHS Trust
2007 Phase 4 EUCTR2006-006362-41-GB United Kingdom;
Vitamin D
Hadassah Medical Organization
2014 - NCT02043717 Israel;
Vitamin D Oil
Emory University
2013 Phase 4 NCT01880346 United States;
Vitamin D Powder
Emory University
2013 Phase 4 NCT01880346 United States;
Vitamin D3
Atlanta VA Medical Center
2006 - NCT00450073 United States;
Emory University
2020 Phase 4 NCT04118010 United States;
2008 - NCT00788138 United States;
University of Southern California
2019 - NCT03734744 United States;
Vitamin K supplementation, dose #1
Institut de Recherches Cliniques de Montreal
2020 - NCT04496921 Canada;
Vitamin K supplementation, dose #2
Institut de Recherches Cliniques de Montreal
2020 - NCT04496921 Canada;
Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1
University of British Columbia
2007 - NCT01070446 Canada;
Voriconazole
CHU de Rennes (Rennes University Hospital Centre)
2012 - EUCTR2011-005799-41-GB United Kingdom;
WATER FOR INJECTIONS, EP
Fundació Parc Taulí
2017 Phase 2 EUCTR2016-004033-25-ES Spain;
Whole body Protein Turnover
University of Texas Southwestern Medical Center
2006 - NCT00287456 United States;
Whole body Protein Turnover Study
University of Texas Southwestern Medical Center
2006 - NCT00287430 -
Whole body protein turnover
University of Texas Southwestern Medical Center
2006 - NCT00287443 United States;
Xenon
Children's Hospital Medical Center, Cincinnati
2021 - NCT04793867 United States;
Papworth Hospital NHS Foundation Trust
2016 - NCT02912637 United Kingdom;
Xenon-129
The Hospital for Sick Children
2015 Phase 2 NCT02740868 Canada;
Xolair
Novartis Pharma Services AG
2009 Phase 4 EUCTR2007-006648-23-IE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
2009 - EUCTR2007-006648-23-NL Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
2009 - EUCTR2007-006648-23-GB Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-006648-23-BE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Xolair 150 mg Pulver und Injektionslösung zur Herstellung einer Injektionslösung
Novartis Pharma Services AG
2008 - EUCTR2007-006648-23-DE Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Xylitol
Joseph Zabner
2013 Phase 1/Phase 2 NCT00928135 United States;
2011 Phase 1/Phase 2 NCT01355796 United States;
ZENPEP
AbbVie
2012 - NCT01652157 United States;
EURAND SPA
2010 - EUCTR2009-012842-21-IT Bulgaria;Germany;Hungary;Italy;United Kingdom;
ZITHOMAX 40 mg/ml ENFANTS
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
- Phase 3 EUCTR2014-003023-22-FR France;
Zadaxin
SciClone Pharmaceuticals Limited Ltd
2019 Phase 2 EUCTR2019-001441-40-IT Italy;
Zavesca
Actelion Pharmaceuticals Ltd
2008 - EUCTR2008-002352-20-BE Belgium;
2007 - EUCTR2006-002049-35-ES Spain;
Zenpep
Aptalis Pharma US Inc.
2013 - EUCTR2009-012842-21-HU Bulgaria;Germany;Hungary;Italy;United Kingdom;
2012 Phase 3 EUCTR2009-012842-21-BE Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
2011 - EUCTR2009-012842-21-BG Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-012842-21-GB Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
Zinc acetate (20mg/d)
Cystic Fibrosis Foundation Therapeutics
2004 - NCT00104494 United States;
Zitromax
Copenhagen CF-centre
2009 Phase 4 EUCTR2006-003275-12-NO Denmark;Norway;Sweden;
2007 Phase 4 EUCTR2006-003275-12-DK Denmark;
- Phase 4 EUCTR2006-003275-12-SE Denmark;Norway;Sweden;
Zoledronic acid
Papworth Hospital NHS Foundation Trust
2013 Phase 4 NCT01702415 United Kingdom;
chlorhexidine gluconate liquid skin cleanser
Johns Hopkins University
2012 Phase 2 NCT01594827 United States;
normal saline (control)
Mukoviszidose Institut gGmbH
2007 Phase 2 NCT00506688 Germany;
saline
Johns Hopkins University
2007 Phase 2 NCT01293084 -
w/v sodium chloride solution
Merck Sharp & Dohme Corp.
2010 Phase 2 NCT01181622 United States;